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Abstract  
The potential relationship between hypovitaminosis D and non-skeletal health 
outcomes is a growing public health concern.  There is suggestion of a 
relationship between 25-hydroxyvitamin D (25(OH)D) and brain function, with 
equivocal epidemiological evidence for an association with common mental 
disorders (CMD) and cognitive function.  The aim of the thesis was to 
investigate the association of 25(OH)D with CMDs and cognitive function in 
mid-adulthood.  
Observational and genetic studies were used to gain better insight into the 
causal nature of the relationship between 25(OH)D and cognitive function.  
During observational studies, the association of 25(OH)D with CMDs and 
cognitive function was assessed in the 1958 British birth cohort (1958BC).  A 
genetic study investigated the potential for a gene-environment interaction 
(GxE) by APOE ε4 on cognitive function using participants from the 1958BC.  
This GxE study was replicated in an older European cohort.  The causal 
relationship between 25(OH)D and cognitive function was assessed using a 
Mendelian randomisation (MR) approach in a meta-analyses using participants 
from nine European cohorts.   
Using observational data from 1958BC, there was evidence that both low and 
high 25(OH)D concentrations were associated with increased risk of CMDs and 
lower memory function.  There was also evidence of a GxE interaction for 
memory function; where increasing 25(OH)D concentrations may be particularly 
beneficial for those with APOE ε4 genotype.  However, results from a MR study 
provided no evidence for 25(OH)D concentrations acting as a causal factor for 
cognitive performance in mid- to later-life.  Since there was evidence of a non-
linear observational association, the MR study may have been underpowered to 
detect small causal effects at the extremes of the 25(OH)D distribution.   
Overall, there is some evidence of a potential non-linear association of 25(OH)D 
with CMDs and cognitive function.  However the causal nature of this 
relationship requires confirmation from large long-term randomised controlled 
trials. 
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 Introduction Chapter 1
1.1 Motivation  
Promising investigations into the potential effect of modifiable exposures on 
mental health and cognitive function throughout the life-course has motivated 
work for this thesis: Vitamin D, common mental disorders and cognition: 
Insights from observational and genetic epidemiology.  The prospect of a true 
casual effect between vitamin D status and these outcomes could have long 
term implications by providing an easily modifiable, safe and cheap way to 
improve human well-being. 
There has been a significant move towards promoting mental health and 
campaigning to reduce stigma and discrimination associated with mental ill-
health.  In 2013, member states participating in the 66th World Health Assembly 
adopted the World Health Organisation’s (WHO) comprehensive Mental Health 
Action Plan1 which emphasises the importance of mental health and specifies 
targets to be reached by 2020.  Further efforts to promote mental health include 
the establishment of World Mental Health Day in 1992 by the World Federation 
for Mental Health2 and Mental Health Awareness week in 2002 by the UK 
organisation, Mental Health Foundation.  Despite these endeavours, mental 
disorders remain both poorly diagnosed and poorly treated (1).  Common 
mental disorders (CMD), such as depression and anxiety affect a large 
percentage of the adult UK population (9).  Research into the mechanisms and 
potential risk factors for CMDs could lead to significant improvements in the 
understanding of the disorder, the quality of life of individuals and may benefit 
the wider society.  
The other topic explored involves cognitive function.  Generally, an individual’s 
cognitive ability develops from birth, stabilises in adulthood and declines with 
increasing age.  The prediction of an increasing global population and 
concurrent shift towards an older demographic highlights the need for the 
examination of factors related to healthy ageing (10).  Through the identification 
of modifiable exposures that could either maximise cognitive function or delay 
                                            
1
 http://www.who.int/mental_health/en/index.html 
2
 http://www.wfmh.com/index.html 
15 
 
the onset of cognitive decline, the quality of life of older adults could be 
improved and consequent economic and social benefits could ensue. 
Further details on mental health and cognitive function including definition, risk 
factors and public health importance are given later in this chapter.  Also 
presented is the biological plausibility of vitamin D playing a causal role in 
mental health and cognitive function.  However, it is important first to provide an 
overview of vitamin D; its discovery, how it is metabolised, factors that can 
influence vitamin D status and the vitamin D concentration thresholds used to 
define deficiency and toxicity.  
1.2 Vitamin D 
1.2.1 Discovery of vitamin D 
In the early 19th century, an adequate diet was considered to consist of 
appropriate amounts of protein (12%), minerals (5%), fat (10-30%) and 
carbohydrate (remaining %) (11).  This view of adequacy began to change with 
the finding that consumption of certain foods prevented disease for example, 
consumption of lime to prevent scurvy (11).  The realisation that food contained 
another vital factor relevant for health led to a rapid growth in experimental 
models.  E.V. McCollum and his team are credited as one of the first to identify 
these vital amines or vitamins with the discovery of vitamin A and the B vitamins 
(12). 
Unravelling the cause of the paediatric bone disease, rickets, led to the 
discovery of vitamin D (11).  At the end of the 19th century, rickets, also known 
as the English disease, was at epidemic proportions.  Rickets was found to 
affect children living in sunlight-deprived industrial cities as opposed to those 
living in rural areas or in sunnier climates (13).  Sir Edward Mellanby began to 
explore diet-related explanations for rickets.  He found that children with rickets 
could be treated with cod liver oil.  Subsequent work conducted by Mellanby 
and McCollum identified the antirachitic substance in cod liver oil as vitamin D, 
which became known as an essential nutrient (11).  
16 
 
During the same period, Mellanby discovered that rickets could also be treated 
by exposure to sunlight or mercury lamps (11).  Furthermore, it was found that 
food irradiated with ultraviolet B (UVB) can be antirachitic (13).  The link 
between sunlight and rickets coupled with extensive research carried out in the 
1970s contributed to the understanding of the dual sources of vitamin D, helping 
to clarify that the nutrient is in fact a hormone precursor that can be produced in 
the body rather than a vitamin (13).   
Research into the health effects of vitamin D continues to date.  Some 
remaining challenges in vitamin D epidemiology include determining causative 
relationships with non-skeletal diseases/disorders and establishing effective 
thresholds for identifying deficiency and population groups at risk.   
1.2.2 Metabolism of vitamin D 
Since the first discovery of vitamin D, there has been extensive research into 
the identification and description of the compound and its metabolic pathway.  
The term vitamin D refers to a group secosteroids i.e. a molecule similar in 
structure to a steroid but with a broken ring (the 9,10 carbon-carbon bond of 
ring B is broken in vitamin D) (14).  Humans obtain vitamin D mainly through 
synthesis in the skin following exposure to sunlight and to a lesser extent 
through dietary sources (15).  There are two main forms of the vitamin D 
nutrient, vitamin D3 and vitamin D2 (Figure 1.1). 
Vitamin D3 (cholecalciferol), is derived from 7-dehydrocholesterol in the skin 
following exposure to UVB radiation of wavelengths 290-315nm (16).  Vitamin 
D3 can also be obtained from a limited number of dietary sources such as, oily 
fish like, salmon, tuna, sardines and mackerel, egg yolk and fortified foods.  
Vitamin D2 (ergocalciferol) is produced by the UV irradiation of ergosterol from 
yeast and can occur naturally in some types of mushrooms for example, 
shiitake (17).  Both nutrient forms can also be obtained in supplement form. 
Vitamin D3 and D2 both result in an increase of an individual’s nutritional status 
and they follow the same metabolic pathway.  However, small structural 
differences in the side chains of vitamin D3 and D2 (Figure 1.1) inspired further 
17 
 
research into their comparative effectiveness.  A recent review has 
demonstrated that despite some evidence implying that vitamin D3 is more 
effective in raising and maintaining an individual’s nutritional status than D2, this 
does not occur across all studies (18).  For the purposes of the thesis, the term, 
vitamin D will be used to represent D2 or D3 unless specified.   
The metabolism of vitamin D is illustrated in Figure 1.1.  Following skin 
exposure to UVB radiation, 7-dehydrocholesterol, present in cells of the dermis 
and epidermis, is converted to pre-vitamin D3 and subsequently to vitamin D3.  
Excessive sunlight exposure degrades pre-vitamin D3 into inactive substances 
(17).  Due to its lipophilic nature, vitamin D requires a protein carrier for 
transport in circulation and can potentially be taken up by adipose tissue via 
lipoprotein lipase (19).  Dietary sources of vitamin D are incorporated into 
chylomicrons (which are involved in the transport of dietary lipids) when they 
enter the circulation. 
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Figure 1.1: Vitamin D metabolism 
Taken from Holick, 2007(17) 
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Once in circulation, vitamin D binds to the vitamin D-binding protein (VDBP) and 
is transported mainly to the liver where it undergoes its first hydroxylation.  
Here, vitamin D is converted to 25-hydroxyvitamin D (25(OH)D) by the enzyme 
25-hydroxylase.  The conversion of vitamin D to 25(OH)D is dependent on 
vitamin D intake and 25(OH)D concentrations via a negative feedback system 
(20, 21).  25(OH)D is the major circulating form of vitamin D that is used to 
determine vitamin D status.  This is a good measure of vitamin D nutritional 
status as it takes into account sun exposure and dietary sources and has an 
half-life of approximately 15 days (19, 20).  
In order for the metabolite to become biologically active, 25(OH)D travels to the 
kidney and some other organs where it is hydroxylated by the enzyme 
25(OH)D-1α-hydroxylase.  This hydroxylation produces the biologically active 
hormone, 1,25-dihydroxyvitamin (1,25(OH)2D, also known as calcitriol).  The 
production of 1,25(OH)2D is tightly regulated and has a serum half-life of 10 to 
20 hours (19).  Renal regulation of 1,25(OH)2D  comprises many factors and is 
involved in the maintenance of calcium homeostasis.  Increased serum 
phosphorous, calcium and fibroblast growth factor 23 inhibit the production of 
1,25(OH)2D while parathyroid hormone (PTH) enhances production (17).  PTH 
is secreted when serum calcium levels are low.  This increase in PTH triggers 
production of 1,25(OH)2D  which enables  calcium resorption in the kidney.  
Additionally, when serum calcium levels are low, 1,25(OH)2D increases 
absorption of calcium in the small intestine and encourages osteoblasts to 
mobilise calcium and phosphate from the bone to maintain normocalcemia (22). 
The role of 1,25(OH)2D in calcium homeostasis and bone health is well 
established.  However, the far-reaching biological effects of 1,25(OH)2D  are 
only beginning to be understood.  The diverse biological actions of the hormone 
1,25(OH)2D can occur following binding with nuclear vitamin D receptors (VDR).  
The VDR is a transcription factor i.e. a protein that binds to specific DNA 
sequences that can control gene expression (23).  The VDR can recognise a 
specific DNA sequence, in this case, the vitamin D response element (VDRE) 
thereby targeting distinctive genes.  Once 1,25(OH)2D binds to the VDR, a 
heterodimer structure between VDR and a retinoid-X receptor (RXR), which is 
part of the family of nuclear receptors, is formed.  This VDR/RXR structure will 
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then bind to VDRE in the regulatory region of a vitamin D target gene (24).  This 
process will trigger the expression of the target gene which facilitates the 
formation of proteins with tissue-specific functions. 
Catabolism of excess 25(OH)D and 1,25(OH)2D is mediated by the enzyme 24-
hydroxylase where they are converted to water-soluble inactive substance 
calcitroic  acid, and excreted in the bile (17, 20).   
1.2.3 Factors influencing vitamin D status  
There are a variety of factors from environmental to genetic that can influence 
an individual’s vitamin D status.   
As mentioned, one of the main sources of vitamin D is sunlight. Therefore, it is 
no surprise that factors affecting UVB exposure influence vitamin D status.  One 
element that affects UVB radiation is the solar zenith angle (SZA).  The SZA is 
the angle at which the sun penetrates the earth’s atmosphere (21).  A small 
SZA will result in increased UV radiation.  Latitude, time of day and seasonality 
all effect the SZA (25).  As expected, in the northern hemisphere, UVB radiation 
is most effective at mid-day in the summer (25).  Thus, in the UK, 25(OH)D 
levels are lowest during late winter and highest during late summer (26).  
Furthermore, it has been suggested that the SZA is smaller in latitudes below 
approximately 350˚ north (27).  Consequently, cutaneous production of vitamin 
D has the potential to be produced all year round in these areas for example, 
Miami, Florida (250) and Abu Dhabi (240).  It was also noted that above 
latitudes of 350˚ north for example, areas of Boston (420) and Norway (610), 
UVB radiation is insufficient to stimulate vitamin D synthesis during the winter 
months (27).  Pollution and heavy cloud cover can diminish the number of UVB 
rays that reach the earth’s surface thereby reducing the skin’s ability to produce 
vitamin D (25).   
Individual determinates of vitamin D status range from lifestyle factors, ageing, 
and ethnicity amongst others.  As a person ages, skin thickness decreases (25).  
This results in a reduction of 7-dehydrocholesterol in the epidermis thereby 
reducing the ability to produce pre-vitamin D (28).  Additionally, application of 
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sunscreen to the skin blocks UVB rays, preventing the synthesis of vitamin D 
(29).  Colour of the skin also plays a role in determining vitamin D status.  
Melanin is a substance that acts as a natural sunscreen and gives skin its 
pigmentation (25).  Studies have shown that individuals with darker skin and 
more melanin produce less vitamin D compared with individuals with lighter skin 
(30).   
Obesity has been associated with lower vitamin D status (31, 32).  A recent bi-
directional Mendelian randomisation study suggested that a higher body mass 
index (BMI) leads to reduced 25(OH)D concentrations while the effect of lower 
25(OH)D concentrations on higher BMI is likely to be small (33).  This 
relationship may be a result of  adipose sequestration of vitamin D from 
circulation, resulting in a reduction of circulating 25(OH)D (34).   
Factors such as working conditions and cultural practices can have an effect on 
vitamin D status.  For example, those working in outdoor activities will have 
greater exposure to sunlight compared to those working indoors (35).  Use of 
clothing to cover the skin can limit the amount of skin available for vitamin D 
production.  For instance, a study conducted in the Lebanon, found that the 
majority of women who wore veils had 25(OH)D concentrations of less than 
12.5nmol/l (36).  Dietary factors such as consumption of oily fish and 
supplements can also influence an individual’s vitamin D status (26).   
A genetic influence on vitamin D status has been shown.  Study estimates of 
the heritability of vitamin D status range from 29% (Framingham Offspring 
Study (37)), 43% (Twins UK study (38)) to 80% (German Asthma Study (39)).  
The discovery of genetic variants associated with the metabolism of vitamin D 
has escalated in the past several years.  These will be discussed further in 
Chapter 4. There is also a hypothesised association between 25(OH)D and 
Apolipoprotein ε4 alleles (40, 41) which is detailed in Chapter 7. 
The environmental and individual factors discussed in this section may act 
independently or interact to initiate or maintain deficient, optimal or toxic 
concentrations of 25(OH)D.  
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1.2.4 Vitamin D deficiency and toxicity 
The classical characteristics of severe vitamin D deficiency are stunted growth, 
defective bone mineralisation and muscle weakness.  These can manifest as 
rickets (in children) and osteomalacia (in adults) (42).  Deficiency symptoms are 
the result of the actions of 1,25(OH)2D to maintain calcium homoeostasis 
(detailed in section 1.2.2).  When 1,25(OH)2D is severely reduced, calcium 
absorption from the intestine is decreased.  The resulting hypocalcaemia can 
trigger calcium mobilisation from bones and result in adverse skeletal, muscular 
and dental outcomes.  
Toxicity symptoms include hypercalcaemia and calcification of soft tissue (19).  
Toxicity does not occur through intake from sunlight, but can occur via 
excessive dietary intake or supplement sources of vitamin D.  The mechanism 
of vitamin D toxicity remains elusive.  However, it has been suggested that 
excessive vitamin D intake increases plasma concentrations of 25(OH)D which 
exceed the VDBP capacity.  Therefore, synthesis to 1,25(OH)2D does not 
occur, resulting in unregulated, free 25(OH)D entering the cell and directly 
binding to VDR where it can have a direct effect on gene expression (19).  
Inappropriately high levels of free 1,25(OH)2D may also result in increased 
intestinal calcium absorption and bone resorption (43). 
Determining the exact threshold of 25(OH)D concentrations needed for health 
has been heavily debated.  One position, taken by the Institute of Medicine 
(IOM), is to set the threshold based on evidence for bone health.  Consensus 
has been reached that everyone should have 25(OH)D above 25nmol/l (42), 
with the IOM reporting an increased risk of bone disease below 30nmol/l when 
calcium intake is adequate (44).  The IOM continues to reason that the 
threshold should be at least 50nmol/l which would be sufficient to maintain bone 
health of 97.5% of the population (44). 
The second position in this debate states that the threshold should be increased 
to at least 75-100nmol/l based on new evidence of the association between 
vitamin D and non-skeletal disease (45).  In 2009, the Rank Forum on Vitamin 
D declared that before recommendations on 25(OH)D thresholds are confirmed, 
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optimal vitamin D requirements for non-skeletal health outcomes should be 
established (42).  
There is consensus that levels greater than 250nmol/l can lead to 
hypercalcemia (19, 46).  The IOM toxicity threshold is 125-150nmol/l.  This was 
based on evidence that individuals maintain plasma concentrations of 125-
150nmol/l following maximal sun exposure and some adverse health outcomes 
were reported at concentrations below 125nmol/l (44).  
With these thresholds in mind, the IOM set the Recommended Dietary 
Allowance (RDA) based on the maintenance of 25(OH)D concentrations at 
50nmol/L (44).  RDA, assuming minimum sun exposure, for males and females 
aged 9-70 years was set as 600 IU/day (15 µg/day) and 800 IU/day (20 µg/day) 
for those aged >70 years.  Tolerable Upper Intake Level (UL) was estimated to 
be 4,000 IU/day (100 µg/day) for ages >9 years.   
Public health efforts to maintain the population’s “optimal” vitamin D status 
prompted fortification of food with vitamin D.  In 1940, the Department of Health 
UK included cod liver oil and dried fortified milk in its Welfare Food Scheme 
(47).  Voluntary fortification of cereals and evaporated milk followed (48).  
However, reported cases of hypercalcaemia in infants and children led to a 
sharp reduction in these fortification efforts. The association between excessive 
vitamin D fortification and hypercalcaemia was refuted in a review conducted in 
1967  (49).  Currently, in the UK, vitamin D fortification of margarine (7.05-8.82 
μg/100g) and infant formula is mandatory (50, 51).  
More research to clarify the association between vitamin D and non-skeletal 
health is required to conclude this debate.   
1.2.5 Public health importance of vitamin D  
Due to the lack of a universal agreement of the thresholds of 25(OH)D status, 
prevalence of vitamin D deficiency varies depending on what cut-points are 
used.  Nevertheless, low serum 25(OH)D concentrations are extremely 
prevalent in the UK and worldwide (17, 42).   
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It has been estimated that at least 10% of UK adults have 25(OH)D 
concentrations below 25nmol/l (Figure 1.2) (42).  25(OH)D concentrations have 
been found to be particularly low in both younger and older adults (52) (Figure 
1.2).  Children from ethnic minorities residing in the UK were also at risk of 
lower 25(OH)D concentrations (53).  Results from a longitudinal study 
conducted in Southampton, UK, showed that maternal vitamin D insufficiency 
(i.e. 25-50nmol/l 25(OH)D) was common during pregnancy and associated with 
poor bone health in children (54).  Furthermore, the Health for England survey 
carried out in 2005 observed that the majority of adults aged ≥65 years (57% of 
women and 49% men) had 25(OH)D concentrations of less than 50nmol/l  (55).   
Reduced 25(OH)D concentrations have been associated with a myriad of 
adverse health outcomes including autoimmune, cardiovascular and infectious 
disease (56).  Therefore, low 25(OH)D status constitutes a public health 
problem which has been largely attributed to modern lifestyle behaviours, 
characterised by increasing obesity, indoor working and proficient use of 
suncover (26, 35).   
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Figure 1.2: Prevalence of 25(OH)D <25nmol/l in the UK 
 British Asians are defined as those of South Asian origin (Pakistani, Indian and Bangladeshi. F: free-living; I: institutionalised. Light grey 
bars are males and dark grey bars are females. Taken from Lanham-New, 2011 (42)
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1.3 Common mental disorder 
1.3.1 Definition of common mental disorder 
The term “mental health” can be used in a number of ways.  Mental well-being 
is a subjective concept involving perceptions of autonomy, and fulfilment of an 
individual’s intellectual and emotional potential.  According to the WHO, mental 
health is not just the absence of a disorder.  It is: 
 “A state of complete physical, mental and social well-being, and not 
merely the absence of disease” (57)  
Similarly, mental ill-health is not solely an absence of good mental health.  
Psychological distress is a common and normal reaction to some situations 
such as adverse life events.  Reactions may become abnormal if they last a 
long time, are severe and have a damaging  effect on individuals or others (1).   
Research for the thesis was limited to CMDs, also known as adult neurotic 
disorders (1), encompassing conditions that: 
 “…cause appreciable emotional distress and interfere with daily 
function, but do not usually affect insight or cognition” (9) 
These disorders include depression, anxiety, phobias, and obsessive 
compulsive disorders.  CMDs are usually diagnosed based on the presence of 
symptoms (Box 1.1).  Symptoms of CMDs generally exist on a continuum 
whereby some individuals may be below the diagnostic threshold but are at very 
high risk of developing a disorder.  Additionally, CMDs do not always present in 
discrete groups of symptoms for example, the presence of mixed anxiety 
depression is common. 
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1.3.2 Prevalence and treatment of common mental disorder  
Mental and behavioural disorders are a leading cause of disability and disease 
burden worldwide (58).  They affect people in all regions, in all societies and 
across all stages of the life-course.  Globally, approximately 450 million 
individuals suffer from mental and behavioural disorders in their lifetime (59).  
The WHO found depression to be the leading cause of disability as measured 
by Years Lived with Disability (YLDs) and the second cause of Disability 
Adjusted Life Years (DALYs) for people aged 15-44 years (60).  
In 2007, prevalence of CMDs in England was assessed using the Clinical 
Interview Schedule-Revised (CIS-R) (9).  This study observed that 15.1% of 
adults aged 16 years or over had significant neurotic symptoms (CIS-R score 
≥12), whereby 7.5% of these had severe symptoms (CIS-R >17) requiring 
treatment.  Additional investigation of specific disorders found that 16.2% of 
adults met the diagnostic criteria for a least one CMD.  This is higher than the 
Box 1.1 Example symptoms of CMDs (1) 
 Low mood 
 Fatigue 
 Irritability 
 Poor concentration 
 Impaired sleep 
 Impaired appetite 
 Impaired libido 
 Low self-esteem 
 Feeling of worthlessness 
 Suicidal ideas 
 Palpitations 
 Trembling 
 Feeling of unreality 
 Fear of dying 
 Repetitive and compulsive thoughts and actions 
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overall CIS-R as it is possible to meet the threshold for some types of CMD 
without having a total CIS-R score of 12.  More than half of those with CMDs 
had mixed anxiety and depressive disorder (9%), 4.4% had generalised anxiety 
disorder, 2.3% depression and less than 1.5% met the diagnostic criteria for the 
remaining categories (9).  Women and those aged 45-54 years were found to 
be most likely to have a CIS-R score of ≥12 (9).  
In a US study, the median age of onset of an anxiety disorder (as measured by 
the Diagnostic and Statistical Manual IV (DSM-IV)) was 11 years and mood 
disorder 30 years, with later onsets usually consisting of co-morbid conditions 
(61).  Although CMDs can affect individuals at any time point, it has been shown 
that those in mid-adulthood were more likely to present with significant 
symptoms of CMDs (9). 
CMDs, particularly depression and anxiety, can have a lifelong course 
consisting of relapse and remission.  For example, a national longitudinal 
survey found that 51% of women and 49% of men who had a CMD at baseline 
still had the disorder 18 months later (62).  Factors that contributed to recovery 
included lower baseline symptom score, higher socioeconomic position, higher 
social support and less adverse life events (1). 
The treatment of mental and behavioural disorders has evolved through time 
(59).  Historically, individuals with mental illness were isolated from society and 
confined to asylums.  As the medical model of mental illness developed, 
individuals were treated with newly identified drugs.  Insights into the social 
components of mental health has contributed to the way in which disorders are 
treated today (59).   
There is considerable variation in severity and type of CMDs, therefore 
treatment can be difficult.  The most common treatment in primary care is 
psychotropic medication, however the National Institute of Health and Care 
Excellence (NICE) recommend the use of other psychological treatments such 
as cognitive behavioural therapy or counselling in combination with medication 
(63).  Although the vast majority of cases of CMDs that are diagnosed by 
general practitioners (GPs) are treated in primary care, many individuals do not 
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seek treatment.  This could be due to under-recognition for mild disorders 
and/or the avoidance of individual patients to report their symptoms (1, 63).   
The WHO’s comprehensive mental health action plan 2013-2020 adopted 
during the 66th World Health Assembly outlined a number of new directions for 
the treatment of mental illness (64).  These plans include movement away from 
a medical model of mental illness to the provision of community based care 
while addressing social determinants of mental health (64). 
In order to reduce the burden of CMDs in the population, the multidimensional 
and interactive risk factors need to be addressed.  
1.3.3 Risk factors for common mental disorders 
There are numerous factors that can interact to maintain mental health or 
influence mental ill health.  These factors can be on the structural (e.g. access 
to healthcare), community (e.g. social networks) and individual level (e.g. 
psychological factors) (1).  Figure 1.3, from the Foresight report, Mental Health: 
Future Challenges, illustrates the complexity of these mechanisms (1).  Further 
details on the complex and inter-linking biological, psychological, social and 
lifestyle factors related to CMDs will be discussed in this section.  
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Figure 1.3: Factors associated with mental health 
Taken from Foresight report, 2008 (1) 
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Biological factors 
Significant advances in neuroscience have amplified our understanding of the 
brain.  The brain is an extremely complex organ that integrates genetic, 
biochemical and molecular information with information from the outside world.  
The main cells of the brain include neurons, which send and receive 
information, and neuroglia which protect neurons.  Each neuron communicates 
with others via specialised chemicals (neurotransmitters) through structures 
(synapses).  Synaptic connections can be created and remodelled to change 
the structure of the brain throughout the life-course (65).  Mental and 
behavioural processes are the result of the development of circuits between 
neurons (59).  Biological mechanisms for CMDs are not fully understood, 
however, there are a number of proposed models.  They include the disruption 
or deficiency of a group of neurotransmitters called catecholamines (dopamine, 
noradrenaline and serotonin) (66), disruption of hormonal function for example, 
the stress hormone cortisol (67) and changes in the function of the immune and 
central nervous system (66, 68).  
Psychological factors 
Childhood and adolescence are sensitive times for the development of 
emotional disorders (59).  Many CMDs in adulthood begin in childhood.  For 
example, internalising and externalising disorders at ages 7, 11 and 16 years 
have been associated with a higher risk for mid-life anxiety and affective 
disorders (69).  Early life factors such as major psychological stressors and 
trauma can influence CMDs in later life (70).  Furthermore, the relationship 
between a child and their parents or caregivers is an essential determinant of 
mental and behavioural development (71).  Individuals are more likely to 
engage in behaviours where they are rewarded and learn how to cope with 
stressful life events through this caregiver interaction.  Thus, a disorder can be 
viewed as maladaptive behaviour that has been learned (59).  Cognitive 
functioning may also have a role in CMDs (section 1.4.3), with one study 
suggesting that higher childhood cognitive ability is associated with fewer 
symptoms of anxiety and depression in adulthood (72). 
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Social factors 
Socioeconomic factors including poverty, unemployment and low education 
have also been associated with CMDs (61).  Longitudinal studies of British 
participants have shown that socioeconomic position (SEP) in childhood and 
adulthood can influence depression and anxiety in mid-life (73, 74).  This 
relationship is complex as it remains unknown if poverty is the cause of a 
disorder or if those with a disorder will drift into poverty (59).   
Lifestyle factors 
Health-related behaviours throughout life also influence the onset and course of 
a CMD.  For example, the use of substances such as tobacco and alcohol has 
been associated with CMDs.  Epidemiological studies have identified that both 
non-drinkers and harmful drinkers have higher levels of CMDs compared with 
moderate drinkers (75-78).  Additionally, those with a mental disorder are 
approximately twice as likely to smoke compared to those without a disorder 
(79).  Nicotine is an addictive substance that has an effect on the brain, 
therefore it remains unknown whether those with a CMD smoke more to 
alleviate their symptoms or if smoking causes a CMD (59). 
Physical inactivity is another important factor in CMDs.  A study of British 
individuals found a consistent association between physical activity in 
adolescence and psychological well-being in adulthood (80).  Furthermore, 
literature reviews provide evidence that exercise appears to be beneficial in the 
treatment of CMDs in combination with other medication (81, 82).  A link 
between CMDs and obesity has been suggested by a meta-analysis conducted 
in 2010 (83), with further studies suggesting that a U-shaped trend exists 
between BMI and depression (84).  CMDs may cause obesity via changes in 
eating behaviour or reduced physical activity; conversely, obesity may cause 
CMDs for example through a negative body image.   
Good nutrition is essential for the maintenance of both physical and mental 
health.  A number of specific nutrients have been associated with mental health.  
For example, low maternal folate status during early pregnancy has been 
associated with a higher risk of emotional problems in childhood (85).  Dietary 
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folate has also been associated with depressive symptoms in middle-aged men 
(86) and poor thiamine status has been associated with higher odds of 
depressive symptoms (87, 88).  Despite some evidence, the causal association 
between specific nutrients and CMDs remain equivocal.  A recent meta-analysis 
suggested that a diet consistent with high intakes of fruit, vegetables, fish and 
whole grains may be associated with a reduced depression risk (89).  
There are a multitude of interlinking risk factors affecting CMDs, of which only a 
few have been discussed in this section.  CMDs can occur in the absence of 
stressful and negative life events, however, they are more likely to present 
following an incident (66).  Genetics (90), emotional reactivity, presence of 
chronic illness (91, 92), low self-esteem (93), poverty, work stress (94), poor 
interpersonal relationships, family history, gender, age, marital status, 
unemployment and social cohesiveness (91, 95, 96) are some of the other 
factors related to onset and progression of CMDs. 
1.3.4 Public health importance 
If people with CMDs are untreated they are more likely to experience long-term 
disability and premature mortality (97).  CMDs can have a large impact on 
individuals, families and communities.  Individuals suffer the symptoms of a 
CMD and are often unable to participate in work and leisure activities while 
families often bear the burden of care via both emotional and financial support.   
The high prevalence of CMD means the cumulative cost to society is great, for 
example, causing one fifth of days to be lost from work (98).  Therefore, 
research into novel approaches for prevention and/or treatment is essential.  
1.4 Cognition 
The second outcome to be investigated is cognitive function.  The process of 
normal ageing is not well characterised and differences in cognitive function in 
mid-life may reflect some pre-clinical features of later-life pathological conditions 
(99).  Therefore, cognitive disorders at older ages are mentioned briefly in this 
section. 
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1.4.1 Definition of cognition 
Cognition refers to mental processing.  Through these processes, the brain 
acquires, stores, transforms and applies information.  Cognitive processes 
include various mechanisms such as attention, perception, language, 
organisation, problem solving, memory and decision-making amongst others 
(100) and are often organised into specific domains.  Examples of cognitive 
domains include, executive function (i.e. the ability to plan, solve problems, shift 
focus and perform abstract reasoning), memory (i.e. ability to learn and recall 
information) or visuospatial ability (i.e. comprehension and effective 
manipulation of nonverbal information) amongst others.  
Traditionally, cognitive function has been studied in the distinct fields of 
cognitive development and cognitive ageing, however cognitive changes can 
occur throughout the whole lifespan (101).  Cognitive function is a dynamic 
process which can be influenced by many genetic, environmental, social and 
biological interactions throughout the lifespan (102).  
In their 2006 paper, Craik and Bialystok proposed a framework consisting of 
representations, control and their interaction to describe cognition throughout 
the lifespan (101).  Representations consist of crystallized schemas for 
example, acquired knowledge or experience and vocabulary.  Control consists 
of fluid operations such as memory, name-finding, complex decision making 
and speed of processing.  The general assumption is that representation (or 
crystallised pragmatics) increases during childhood and remains stable in later 
life whereas control (or fluid mechanics) increase during childhood, reach a 
threshold in early-adulthood and decline with increasing age (101, 103).  These 
life-course changes are depicted in Figure 1.4.   
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Figure 1.4: Cognitive function throughout the lifespan 
Adapted from Craik, 2006 (101) 
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Determining the age at which normal age-related cognitive decline begins 
remains complex.  It is difficult to separate the effects of normal ageing and 
pathological processes on cognitive function.  Furthermore, there are 
differences in findings from longitudinal and cross-sectional studies.  
Longitudinal studies tend to find little evidence for age-related decline before the 
age of 60 years, whereas cross-sectional studies find linear declines across the 
lifespan starting in young adulthood (104, 105) (Figure 1.5).  Cross-sectional 
studies may overestimate the age at which cognitive decline occurs due to 
cohort differences (i.e. differences in cultural factors, economic conditions etc.).  
On the other hand, longitudinal studies may underestimate the age at which 
cognitive decline occurs due to practice effects (i.e. the influence of past 
experience of taking a test) and attrition (105).  Therefore, it is plausible that 
age-related cognitive decline can emerge in mid-life, before the age of 60 years. 
1.4.2 Cognitive disorders in later life 
Cognitive ability varies widely among middle aged and older people, with 
maintained function at one extreme and dementia at the other (106, 107).  
Cognitive impairment is evident when decline is greater than what is expected 
for age and education level (108).  Although a clinical definition for cognitive 
impairment is still being debated, a score of 0.5 on the clinical dementia rating 
scale, or stage 3 on the global deterioration scale for ageing and dementia, has 
been used in the past.  Individuals with the amnestic sub-type of impairment 
(i.e. problems with memory) have a higher risk of progression to Alzheimer’s 
disease (AD) (108).  There are a number of different types of dementia, 
including mixed dementia.  It has been estimated that approximately 50-70% of 
all cases of dementia are the result of Alzheimer’s disease and this number may 
increase with age (109).  Other types of dementia include vascular dementia, 
frontotemporal dementia and dementia with Lewy bodies, affecting various 
aspects of cognitive function (110).  
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Figure 1.5: Cross-sectional and longitudinal estimates of age-relates change in cognitive function 
A: Cross-sectional data from the Seattle Longitudinal Study. B: Seven year longitudinal data from the same study. Taken from Hedden, 
2004 (105) 
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1.4.3 Factors influencing cognition function 
As with CMDs, there are numerous interacting factors that influence cognitive 
function, some of which will be discussed in this section.   
During normal senescence, natural reductions in brain tissue volume and other 
anatomical changes contribute to the decline in cognitive function (105).  
However there are several factors throughout the lifespan including genetic, 
environmental, socioeconomic and biological which may affect brain structure 
and function and influence an individual’s cognitive ability at any time point. 
Since the brain remains plastic throughout the life-course (65), it is no surprise 
that health, social and environmental factors in early life can have a dramatic 
effect on outcomes in later life (111).  Cognitive ability in childhood has been 
shown to be a strong predictor of cognitive ability in adulthood (112).  Childhood 
cognitive ability has also been associated with a myriad of health and social 
outcomes in later life including socioeconomic position (SEP), educational 
attainment, health behaviours, and emotional status (111) which in turn can 
influence cognitive function in mid- to later life.  Further studies have 
demonstrated an association of lower childhood SEP with poorer cognitive 
function in adulthood (113, 114).  Another study suggested an indirect effect of 
childhood SEP on cognitive function via its effect on later measures of SEP 
(115).  Additionally, SEP in adulthood as well as educational attainment 
throughout the life-course has been found to influence cognitive function in 
adulthood (113, 116-119).  Early adverse conditions have been shown to 
influence cognitive ability in childhood and adolescence and in some cases are 
associated with cognitive ability in mid-life (120).   
Mental health status may be associated with cognitive function (121), with some 
evidence for an association of depression with dementia, particularly AD and 
vascular dementia (122).  However, CMDs and cognitive impairment often co-
occur making the causal direction difficult to determine.  In a recent paper 
Richards et al propose three possible explanations for the association between 
affective disorders (for example, depression and anxiety) and cognitive 
impairment (123).  Firstly, affective disorders may directly cause cognitive 
39 
 
impairment; secondly, affective disorders are the result of an emotional 
response to cognitive impairment; thirdly, affective disorders may share similar 
neuropathological pathways to cognitive impairment.  Depression can often lead 
to increased levels of glucocorticoid (also released in the presence of chronic 
stress) production which in turn could cause hippocampal atrophy (associated 
with memory loss).  On the other hand, cognitive impairment with damage to the 
frontostriatal brain or with hippocampal atrophy may result in depression (124).  
One study suggested that depressive symptoms were associated with memory 
decline amongst an older population (121). However, a study conducted in a 
relatively younger population (60-64 years) found no inverse association 
between symptoms of affective disorder and cognitive test scores (123), 
implying that associations may be more likely amongst older populations.  
Another study found that social integration protected against memory decline 
(125). 
In their review, Hughes and Ganguli identified factors from low birth weight and 
fetal under nutrition to obesity and occupation as potential modifiable risk 
factors for cognitive impairment in later life (126).  Smoking has been 
associated with faster declines in verbal memory and with slower processing 
speed (127).  Furthermore, passive smoking has been associated with higher 
odds of cognitive impairment (128).  The relationship between alcohol 
consumption and cognitive function is more complex.  Compared with 
abstinence, alcohol consumption in older adults has been associated with better 
cognitive ability (129).  Furthermore, alcohol consumption has been associated 
with a slower memory decline from 43 to 53 years in men but with a more rapid 
decline in processing speed in women (130).  Other risk factors that may affect 
cognitive function in mid to later life include, vascular health, for example, high 
blood pressure (126, 131, 132), obesity  (133) and physical fitness (134).   
Physical function and cognitive function are associated, however the direction of 
their relationship remains unknown (135).  Physical exercise as well as leisure-
time activity may be beneficial to memory in mid-life, however their mechanisms 
could involve several different pathways (136). 
Nutrition has been associated with cognitive function.  For example, iron 
deficiency anaemia had been negatively associated with cognitive performance 
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in childhood (137) and vitamin B-12 serum concentrations positively associated 
with cognitive function in adults (138).  There is evidence that high fish 
consumption is associated with reduced cognitive decline in later life (139), 
however evidence from a randomised controlled trail with omega-3 long chain 
polyunsaturated fatty acids did not support this (140).  An animal study has 
shown a diet rich in antioxidants may delay cognitive ageing  (141).  In addition 
to single nutrients, healthy dietary patterns have been implicated in slower 
declines in cognitive function.  For example, adherence to the Mediterranean 
diet was associated with slower cognitive decline and a reduced risk of 
Alzheimer’s disease (142) and diets with high intakes of fruit and vegetables, 
complex carbohydrates and cereal in early mid-life may be protective of verbal 
memory decline from mid- to later-life (143).  However, it remains unknown if a 
nutritional deficit is the cause or consequence of reduced cognitive function 
(144).   
Genetic factors may also play a significant role in determining an individual’s 
cognitive ability.  For example, mutations of apolipoprotein E alleles have been 
shown to be associated with cognitive performance (145) and are strong 
predictors of Alzheimer’s disease (146-148).  The association between 
apolipoprotein E and cognitive function will be discussed further in Chapter 7. 
1.4.4 Public health importance  
Global populations are predicted to increase in number and shift towards an 
older demographic (10).  Therefore, there is a growing interest in understanding 
the factors that lead to healthy ageing.  Poor cognitive function is linked with a 
higher risk of dementia, disability and consequently institutionalisation and 
mortality (149, 150).  The WHO estimated that 35.6 million people globally have 
dementia, with this number projected to double every 20 years (151).  The 
Alzheimer’s society 2012 estimates suggest 800,000 people in the UK had a 
form of dementia (152).  Furthermore, in a study conducted using data from the 
Cognitive Function and Ageing Study II in 2011, 670,000 adults aged ≥65 years 
were estimated to have dementia (153).  According to the WHO, the social and 
economic implications of dementia cost 1.24% of gross domestic product in 
high-income countries (151).  It is difficult to estimate the public health impact of 
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reduced cognitive function in mid-life, before the onset of cognitive disorders.  
According to Fries’ compression of morbidity hypothesis,  if the age of onset of 
cognitive decline can be postponed to a shorter period before the time of death 
(154), quality of life of individuals could be significantly improved.  While most 
interventions to target a decline in cognitive ability are aimed at people aged 60 
and over, there is some evidence to suggest that decline may occur prior to this, 
highlighting the need for early intervention. 
1.5 Rationale 
The importance of maintaining mental health and cognitive ability has been 
emphasised during this chapter.  Vitamin D has been a candidate in the effort to 
understand how novel modifiable exposures may influence these outcomes. 
Evidence is accumulating in support of a biologically plausible relationship 
between vitamin D and the brain.  Not only has 1,25(OH)2D  been shown to 
pass the blood-brain barrier (155), but recent data has also demonstrated the 
presence of vitamin D metabolites (156) and enzymes for bioactivation (1α-
hydroxylases, 25-hydroxylases) (157-159) and catabolism (24-hydroxylase) 
(160) in the central nervous system.  This supports the potential existence of 
localised metabolic pathways for 1,25(OH)2D in the brain.  The additional 
finding of VDR in various areas of the human brain, including in key behaviour 
regulation sites (amygdala, cortex and cerebellum), has contributed to the 
suggestion that 1,25(OH) 2D has neurosteroid properties (158, 161-164). 
1,25(OH)2D has many potential roles in the neuroendocrine system.  This 
hormone has been shown to play a role in brain development (160, 162, 165-
167), neuroprotection (168-172), have immunosuppressant effects (163, 173, 
174) and anti-depressant or behavioural modification functions (175-177).  
1,25(OH)2D  may influence cognitive function via its impact on vascular health 
i.e. through influencing blood pressure (178, 179), stroke (180) or diabetes 
(179, 181).  1,25(OH)2D has also been shown to aid in the prevention and 
clearance of amyloid-β plaques seen in AD (182, 183) and can protect against 
glucocorticoid-induced apoptosis in the hippocampal cells which is often the 
result of depressive disorders (168). 
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In addition to experimental studies, epidemiologic studies have been carried out 
to assess the association between vitamin D and CMDs and between vitamin D 
and cognitive performance.  Although results remain equivocal, two meta-
analyses have demonstrated an inverse association between 25(OH)D and 
depression (184) and cognitive performance (185).  Examination of previous 
epidemiologic studies will be included in Chapters 5 and 6.   
In this thesis, investigation of the association between vitamin D status CMDs 
and cognitive function will employ methods of observational and genetic 
epidemiology.  The use of these various study designs will provide additional 
insight into the relationship between vitamin D status, CMDs and cognitive 
function.  The aims are outlined in the next chapter.  
1.6 Summary 
 The maintenance of mental health and cognitive function are important 
public health issues 
 Many factors from childhood and adulthood influence mental health and 
cognitive function in mid-life 
 Vitamin D status has been associated with a variety of potential health 
outcomes and is affected by several environmental, lifestyle and genetic 
factors.  Low concentrations of 25-hydroxyvitamin D is widespread 
 Experimental and epidemiological evidence suggests an association 
between vitamin D, mental health and cognitive function 
 This thesis endeavours to address the question: how is vitamin D status 
associated with common mental disorder and cognitive function in mid-
life 
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1.7 Plan of thesis 
 Chapter 2 will outline the overall aim and specify the study objectives  
 Chapters 3 and 4 will discuss the different methodological approaches 
and data used to address the aim  
 Chapters 5 and 6 will describe the work and results from the 
observational study of vitamin D, common mental disorders and cognitive 
function 
 Chapters 7 and 8 will explore the use of genetic information to 
understand the role of vitamin D, using cognitive function as an example   
 Chapter 9 will present a final discussion and overview of the research 
Papers published in peer-reviewed journals directly related to work in this thesis 
are provided in Appendix 1, including:  
Paper I 
Maddock J, Berry DJ, Geoffroy MC, Power C, Hyppönen E. 25-Vitamin D and 
common mental disorders in mid-life: Cross-sectional and prospective findings. 
Clinical Nutrition 2013; 32(5): 758-764. 
Paper II 
Maddock J, Geoffroy MC, Power C, Hyppönen E. 25-Hydroxyvitamin D and 
cognitive performance in mid-life. British Journal of Nutrition 2014; 111(5):904-
914. 
Paper III 
Maddock J, Cavadino C, Power C, Hyppönen E. 25-Hydroxyvitamin D, APOE 
ε4 genotype and cognitive function: Findings from the 1958 British birth cohort.  
Submitted 2014.  
Paper IV 
Alfred T, Ben-Shlomo Y, Cooper R, Hardy R, Deary IJ, Elliott J, Harris SE, 
Hyppönen E, Kivimaki M, Kumari M, Maddock J, Power C, Starr JM, Kuh D, 
Day IN; HALCyon Study Team. Genetic variants influencing biomarkers of 
nutrition are not associated with cognitive capability in middle-aged and older 
adults. Journal of Nutrition 2013; 143(5):606-612. 
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First author oral and poster presentations are:  
 Maddock J, A Cavadino, Power C, Hyppönen E et al. Investigating the 
effect of vitamin D status on cognitive function using a Mendelian 
randomisation approach. Oral presentation at Vitamin D and Human 
Health, April 2014.  Recipient of Young Investigator Award  
 Maddock J, Geoffroy MC, Power C, Hyppönen E. 25-Hydroxyvitamin D 
and cognitive performance in mid-life. Poster presentation at UCL 
Graduate school open day, March 2014 
 Maddock J, Geoffroy MC, Power C, Hyppönen E. 25-Hydroxyvitamin D 
and cognitive performance in mid-life. Poster presentation at UCL 
Institute of Child Health open day, November 2013 
 Maddock J, Berry DJ, Geoffroy MC, Power C, Hyppönen E. 25-
Hydroxyvitamin D and common mental disorders in mid-life. Poster 
presentation at International Congress of Nutrition,  September 2013 
 Maddock J, Geoffroy MC, Power C, Hyppönen E. 25-Hydroxyvitamin D 
and cognitive performance in mid-life. Poster presentation at 
International Congress of Nutrition,  September 2013 
 Maddock J, Berry DJ, Geoffroy MC, Power C, Hyppönen E. Symptoms 
of common mental disorders and vitamin D: Findings from the 1958 
British birth cohort. Poster presentation at UCL Graduate school open 
day, March 2012 
 Maddock J, Berry DJ, Geoffroy MC, Power C, Hyppönen E. Symptoms 
of common mental disorders and vitamin D: Findings from the 1958 
British birth cohort. Poster presentation at UCL Institute of Child Health 
open day, November 2011.  Recipient of 2nd place prize 
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 Aims and objectives  Chapter 2
The overall aim of this thesis is to determine whether and the extent to which 
25-hydroxyvitamin D concentrations affect common mental disorders and 
cognitive function.  Using methods from both observational and genetic 
epidemiology and data collected mainly from a large nationwide cohort study, 
the 1958 British birth cohort, the aim will be achieved by: 
I. Examining the cross-sectional and prospective association between 25-
hydroxyvitamin D and prevalence of common mental disorders and 
determining the extent to which it may be explained by vitamin D related 
lifestyle factors 
II. Examining the prospective association between 25(OH)D and cognitive 
function in mid-life 
III. Evaluating the interaction between 25(OH)D and APOE ε4 genotype in 
relation to the association between 25(OH)D and cognitive function using 
a gene-environment interaction analysis  
IV. Evaluating the relationship between 25(OH)D and cognition using the 
genetic indicators for lifelong 25(OH)D status in a Mendelian 
randomisation analysis 
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 Methodological approaches Chapter 3
3.1 Introduction 
Since the 19th century, the discipline of epidemiology has been used to study 
why and how often health problems occur in different groups of people (186).  
Epidemiological methods can be credited with the successful identification of 
the source of a devastating cholera break in London in 1854, providing 
evidence for the association between smoking and lung cancer in 1950 and 
identifying the fetal origins of adult disease, amongst many others (186).  
Investigations into the aetiology of diseases and disorders have been greatly 
advanced by the advent of the human genome project coupled with advances in 
molecular biology and genetic technology.  Epidemiology has responded to 
these advances by integrating genetic knowledge into the discipline (187). 
Both observational and genetic epidemiology were used to address the aims as 
outlined in Chapter 2.  The use of both approaches endeavours to triangulate 
evidence to facilitate greater understanding and increase confidence in the 
findings.  Details on the strengths and limitations of observational and genetic 
epidemiology and how they were used to address the aims of the thesis are 
described in this chapter.  
3.2 Observational epidemiology 
Experimental studies, particularly randomised, double-blind controlled trials 
(RCT), are considered the gold standard of research.  They involve 
randomisation of a population into groups, for example, one which receives 
treatment (or exposure) and another which does not.  In theory, by using this 
approach, any variation in the outcome of interest can be attributed to the 
treatment (188).  However, due to ethical and financial limitations these are not 
always feasible.  Therefore, other methods are required to examine 
associations between risk factors and disease. 
Observational epidemiology involves non-experimental studies, for example, 
cohort, case-control and cross-sectional studies.  In these, the investigator 
observes an exposure and outcome in a population without exerting any 
47 
 
influence (188).  Observational epidemiology has led to many successful public 
health interventions for example, folic acid fortification in flour to reduce neural 
tube defect in the US (189).  Conversely, there have been many high profile 
failures, for example, while observational results suggested that vitamin E was 
protective for cardiovascular disease and beta-carotene for cancer, evidence 
from RCTs does not support these claims (190). 
A good quality observational study needs to be well-designed, powerful and 
reliable.  Random sampling from the population is the ideal and sufficient 
numbers of participants need to be included to ensure adequate power (i.e. the 
probability that the study will be able to detect a true effect (191)).  The reliability 
of a study is determined by its ability to reproduce the same results if it is 
repeated a number of times (192). 
Valid causal inferences from observational studies can be difficult to make.  
Spurious associations and inaccurate estimates may result from chance 
random error, systematic bias or confounding.  While random error cannot be 
completely eliminated, it can be minimised through well-designed studies.  
Certain systematic bias such as measurement error (i.e. the difference in 
measures of outcomes or exposures and their true value (193)) can be 
minimised through using valid, quality instruments to assess relevant variables.  
Furthermore, selection bias (i.e. when there is a difference between those 
included and those not included), can affect the representativeness of the study 
sample. 
One of the most likely explanations for past failures of observational 
epidemiology is confounding (3).  Confounders are factors that correlate with 
both the exposure and outcome and may explain all or part of the measure of 
an association (194), for example, season is associated with both vitamin D 
status and depression.  Some confounding can be minimised by using statistical 
methods however, it is difficult to account for all possible factors that may 
confound the relationship between the exposure and outcome.   
Well-designed cohort studies can facilitate the optimal use of observational 
epidemiological methods.  These studies often contribute rich and detailed data 
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on exposures, outcome and potential confounders that have been collected in a 
large number of participants throughout their lifespan.  Therefore, an in-depth, 
longitudinal examination between the exposure and outcome can be conducted.  
This thesis uses cross-sectional and prospective study designs.  A cross-
sectional study involves the examination of an exposure and outcome at one 
time point.  While these studies are useful to investigate the presence of an 
association between an exposure and outcome, the timing of events and 
inference of causality remains difficult (188).  Prospective studies are 
longitudinal in design.  These studies record exposures and identify an outcome 
in the future, providing a temporal dimension to the association (195). 
Observational epidemiology was used to address aims I and II on the cross-
sectional and prospective associations of 25-hydroxyvitamin D (25(OH)D) with 
outcomes of interest (Chapter 2). 
3.3 Genetic epidemiology 
Genetic epidemiology was used to complement findings from observational 
epidemiology.  The two genetic epidemiological methods of gene-environment 
interaction and Mendelian randomisation (MR) are described in this section.  
3.3.1 Gene-environment interaction 
There is a general consensus that the vast majority of disease is due to 
complex relationships between genetic and environmental factors.  While many 
studies have focused on investigating either genetic or environmental 
determinants, the interaction between genotypes and environmental exposures 
on complex health outcomes is becoming more evident (196). 
David J Hunter described the rationale for the study of gene-environment 
interactions (GxE) in 2005 (197).  Firstly, GxE may achieve a better estimate of 
the population-attributable risk for both genetic and environmental risk factors 
by accounting for their joint interactions.  Secondly, GxE may strengthen the 
associations between environmental factors and diseases by examining 
genetically susceptible individuals.  Thirdly, GxE may aid in dissecting disease 
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mechanisms and finally, results from GxE may offer tailored preventative 
advice.  
Figure 3.1 demonstrates the growing interest in this field through illustrating the 
PubMed search results since 1990.  GxE studies have produced new and 
important findings, for example, it has been suggested that the risk of cognitive 
decline is particularly high in APOE ε4 carriers who have untreated 
hypertension (198, 199).  However, GxE findings do not always replicate, as 
demonstrated in a meta-analyses in 2009 examining the interaction between 
the serotonin transporter gene with stressful life events on the risk of depression 
(200).  The study of GxE requires information on both elements of the 
relationship.  While description of the genetic side may be relatively accurate, 
depending on genotyping techniques (197), a precise depiction of the 
environment aspect may be more difficult, due to, for example, measurement 
issues or other interactive environmental factors (201).  Another issue common 
in many GxE studies is statistical power.  It is thought that the sample size 
required to detect an interaction is at least four times the sample size that is 
needed to evaluate the main effect of each of the variables (197, 202). 
Chapter 7 displays a GxE analyses which investigated a differential effect of an 
environmental exposure on a health outcome depending on the presence of 
genetic variants in unrelated individuals (197, 203). Figure 3.2 illustrates the 
concept of this interaction or conditional independence (203). 
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Figure 3.1: PubMed search results for gene-environment interaction between 1990 and 2012 
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Figure 3.2: Theoretical gene-environment interaction on a health-related outcome 
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3.3.2 Mendelian randomisation 
MR analysis is presented during Chapter 8 to support observational findings. A 
glossary of genetic terms used can be found in Appendix 2.1. 
MR is a method of genetic epidemiology that has been developed with the aim 
of overcoming some of the limitations of observational epidemiology (187).  MR 
is based on an application of the method of instrumental variables (IV) 
commonly used in econometrics (3).  The instrument is a variable that affects 
an outcome only through its ability to proxy an exposure.  The aim of IV analysis 
is to estimate the causal effect of an exposure on an outcome.  MR uses 
genetic variants as an IV.  
MR can (in theory) overcome the issues of confounding and reverse causality 
that can be problematic for observational approaches.  Genetic variants are 
transmitted from parents to offspring at random during meiosis.  Therefore, 
factors that may confound the association between a modifiable exposure and 
outcome should be distributed evenly amongst those with and without the 
genetic variant, thus MR has been referred to as “nature’s randomised trial”, 
(Figure 3.3) (204, 205).  Furthermore, since the genetic variant of interest is 
assigned prior to the appearance of outcome, the possibility of reverse causality 
is minimised (3). 
In order to be effective, genetic variants must influence the exposure (in this 
case 25(OH)D status).  If 25(OH)D concentrations are causally associated with 
cognitive function, genetic variants that proxy 25(OH)D concentrations should 
also be associated with cognitive function (205-207). 
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Figure 3.3: Comparison of design of MR studies with RCT 
Taken from Davey-Smith, 2005 (205) 
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MR is subject to a number of limitations (3) and in order to be effective, the 
genetic variant must meet certain assumptions (Figure 3.4): 
I. The genetic variant must be associated with the exposure  
II. The genetic variant must be independent of confounding factors typically 
associated with findings from observational data 
III. The genetic variant must not independently influence the outcome 
While the association between the genetic variant and 25(OH)D concentration 
can be tested statistically, it is more difficult to test the other assumptions (206).  
There are a number of factors that may result in spurious results from MR 
analysis (3, 206):   
I. Population stratification  
The genotype is not randomly allocated in the population. There may be 
systematic differences in allele frequencies between subpopulations, for 
example, due to non-random mating between groups.  This can result in 
confounded associations that may be specific to only one population. 
II. Pleiotropy  
The genetic variant results in multiple biological outcomes.  This is an issue if 
the resulting biological alterations affect the outcome through an independent 
mechanism. 
III. Canalisation (or developmental compensation) 
Developmental compensation may occur when environmental or other genetic 
factors offset the effects of the genetic variant.  This will reduce the association 
noted between the genotype and exposure.   
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Figure 3.4: Assumptions of MR; illustrated by 25(OH)D and cognitive function 
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MR studies require large sample sizes partly due to the very small amount of 
variation in the exposure explained by genetic instruments (3).  For example, a 
previous study found only 0.56% of the variation of 25(OH)D concentrations 
was explained by a combined genetic sore (207).  Furthermore, an illustrative 
power calculation suggested that approximately 80,000 participants are 
required to establish a causal effect of vitamin D on blood  pressure using a 
combined genetic sore (207).  It is assumed that similarly large sample sizes 
are essential for the examination of the causal association between 25(OH)D 
and cognitive function.  Therefore, a collaborative approach from other 
appropriate cohorts (Chapter 4) was taken.  
Genetic epidemiology was used to address aims III and IV to further investigate 
the relationship between 25(OH)D and cognitive function (Chapter 2). 
3.4 Statistical methods 
This section gives an overview of the statistical methods applied in subsequent 
chapters.  All statistical analyses were conducted using STATA version 12 
(208). 
3.4.1 Statistical methods for observational study 
Systematic review 
Two systematic reviews were conducted to identify, assess and compile primary 
evidence for the association of 25(OH)D with CMDs and cognitive function 
(Chapters 5 and 6).  PubMed, which is an online version of Index Medicus 
produced by the US National Library of Medicine, was used to identify studies of 
interest.  Search results were supplemented with relevant studies from review 
articles not captured by the PubMed search.  Although methods of a systematic 
review were applied (209), there were some limitations.  Quality of study 
appraisal may have been comprised since only one person conducted the 
review.  Furthermore, results were restricted to studies in the English language, 
for which full test was available via online or University College London library 
and a formal assessment of publication bias was not conduced.   
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Descriptive statistics 
Distributions of all main variables were examined using histograms and 
normality was assessed visually and using quantile-quantile (Q-Q) plots.  A Q-Q 
plot examines how close the distribution of a variable is to a normal distribution.  
If continuous variables were found to be skewed, a natural logarithmic (ln) 
transformation was applied to improve approximation of a normal distribution.  
For example, 25(OH)D concentrations in all chapters were found to be slightly 
left skewed, therefore a natural logarithmic transformation was applied when 
25(OH)D was used as an outcome.  Where appropriate, tabulations of important 
covariates are displayed in relevant chapters.  Pearson’s chi-square tests were 
used to determine significant differences between categorical variables (210).  
Logistic and linear regression was applied to assess the association between 
covariates and outcomes as relevant. 
Logistic regression models 
Logistic regression was used to investigate the association between an 
exposure and a binary outcome in observational studies, for example, 
examining the association between 25(OH)D concentrations and presence of 
CMDs in Chapter 5.  The estimate is expressed in terms of an odds ratio (OR).  
This describes the odds of having the outcome for every unit increase in the 
exposure.  The 95% confidence interval (CI) is estimated and a Wald test is 
used to determine whether there is a significant association between the 
exposure and outcome (211).  Potential confounding factors can be included in 
these models to examine whether there is an independent association between 
the exposure and outcome.  
Linear regression models 
Linear regression was used to investigate the association between an exposure 
and a continuous outcome, for example, examining the association between 
25(OH)D and cognitive function in Chapter 6.  The best-fitting straight line 
between the exposure and outcome is estimated using the method of least 
squares i.e. the values that minimise the sum of the squared vertical distance 
from the line.  The estimate is expressed in terms of a regression coefficient.  
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95% CI are estimated and t-tests are applied to determine whether there is a 
significant association.  In order to meet the underlying assumptions of linear 
regression, the outcome should be normally distributed.  The distance between 
the observed values and corresponding point on the fitted line (i.e. residuals) 
should also be normally distributed.  When the exposure is continuous, the 
regression coefficient is the increase/decrease in the outcome due to a unit 
increase in the exposure.  
The effects of categorical exposures with more than two levels are estimated by 
creating proxy, indicator variables (212).  These indicator variables are used to 
sort data into mutually exclusive categories whereby each category takes a 
particular value.  A baseline group (usually coded as 0) is chosen to which the 
other groups (coded as 1, 2, 3 etc.) are to be compared.  Each regression 
coefficient for non-baseline groups equal the differences in the mean outcome, 
compared to the baseline group.  Evaluating the presence of a dose-response 
relationship, whereby the effect of the exposure increases (or decreases) in a 
systematic manner, is tested using a trend test.  Here, the regression 
coefficient, known as the linear effect, is assumed to be constant and reflects 
the common change in log odds from one categorical level to the next across 
the entire range of the exposure (191).  As for logistic regression, potential 
confounding factors can be included to examine whether there is an 
independent association between the exposure and outcome. 
Non-linear regression models 
As implied by the name, linear regression models allow a straight line to be 
fitted.  In some cases, the relationship between the exposure and outcome may 
not be linear; therefore a polynomial curve can be examined.  Non-linearity or 
curvature can be assessed by including a squared term of the exposure in the 
regression model (213).  Non-linear regression models were assessed in 
observational studies.  
Predicted values 
Predicted values can be estimated after running either linear or logistic 
regression models.  Predicted values give an estimate of the outcome for a 
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particular value of the exposure, based on the regression model.  Predicted 
values were estimated and used to construct graphs in Chapters 5 and 6.   
Interaction  
When the effects of an exposure on an outcome vary by another factor, there is 
an interaction.  Interaction can be assessed by including the multiplicative term 
of the two parameters (214).  For example, Chapter 6 examined whether the 
association between 25(OH)D and cognitive function varied for men and 
women.  Where there was evidence for interaction, results were stratified.  More 
complex interaction models were assessed in genetic studies, which will be 
described in the next section. 
Missing Data 
Missing data can be the result of attrition or item non-response.  Attrition is 
common in longitudinal studies and involves a reduction in the numbers of 
participants in the study.  Attrition could be due to participant mortality, refusal 
or inability to establish contact with the individual (215).  Attrition may lead to 
bias and a reduction in the generalisability of the results if the reason for non-
participation is not random.  For example, in the 1958 British birth cohort 
(1958BC, which was used throughout this thesis) attrition to age 45 years was 
mostly through unavoidable loss, however, those with poor reading or maths 
score, with externalising or internalising behaviours and shorter stature were 
moderately under-represented (216).  Therefore, inverse probability weighting 
was used in observational studies (Chapters 5 and 6) to correct for potential 
bias due to attrition. 
Sample weights for Chapters 5 and 6 were derived from previously identified 
variables that are underrepresented in the 1958BC (i.e. maths score at 7 and 11 
years, externalising and internalising disorder at 7 and 11 years, gender, 
socioeconomic position (SEP), marital status and ability to pay household bills 
in the 1958BC).  Weights were then be calculated in relation to the surviving 
cohort at 50 years (n=17,091) and used to adjust for selection bias during 
specified regression analyses. 
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Missing data can also be the result of a participant’s non-response to particular 
items in the study.  There are several different reasons for missing data which 
are outlined in Box 3.1.  Missing data due to item non-response can lead to a 
reduction in the precision of estimates that result from the inevitably smaller 
sample size of complete case analysis (2). 
 
 
 
 
 
 
 
Multiple imputation was used in the observational studies (Chapters 5 and 6) to 
account for missing covariates.  For multiple imputation to be valid, the missing 
covariates should be MAR or MCAR.  During imputation multiple copies of the 
dataset (n=10 in this case) are generated and missing values are replaced by 
imputed values using the chained equation method (MICE).  As a single 
imputation does not account for the uncertainty in calculating missing values, 
imputed values are sampled from the predicted distribution based on the 
observed data.  Following this, the model of interest, for example, linear 
regression models, is fitted to each imputed dataset.  Results are combined and 
standard errors are calculated using Rubin’s rules (217) which account for the 
variability in results between imputed datasets.  
The associations of 25(OH)D with CMDs and 25(OH)D with cognitive function  
in observational studies, were assessed using complete, imputed and weighted 
datasets.  The estimates obtained in each method were found to be broadly 
similar (see results in Chapter 5 and 6).  Therefore, imputed regression results 
Box 3.1 Missing Data mechanisms (2)  
 Missing completely at random (MCAR): There is no systematic 
difference between the missing value and observed values  
 Missing at random (MAR): The difference between the missing 
value and the observed value may be explained by differences in the 
observed measurements.  Therefore, missing data is unrelated to 
the unobserved value itself after controlling for other variables in the 
analyses   
 Missing not at random (MNAR): The missing values are 
dependent on unseen observations.  Therefore, even after the 
observed data are taken into account, systematic differences 
between missing and observed values remain  
61 
 
are presented with completed and weighted results displayed in Appendices 3 
and 4. 
Additional and sensitivity analyses 
In addition to the main analyses, Chapter 5 explored the possibility of reverse 
causality by using linear regression models where naturally log-transformed 
25(OH)D is used as the outcome and CMDs as the exposure.  Chapter 5 also 
assessed the association between 25(OH)D and different levels of severity of 
depressive symptoms by using different cut-offs for depressive symptoms in 
prospective analysis.  
In Chapter 6, the association between 25(OH)D and cognitive function was 
additionally adjusted for the use of any nutritional supplement.  This sensitivity 
analysis examines if other nutrients may play a role the in the association 
between 25(OH)D and cognitive function.  
3.4.2 Statistical methods for genetic study 
Linear, logistic and non-linear regression models described in section 3.4.1 
were also applied to genetic studies (section 3.4.1).  This section gives an 
overview of the statistics used in GxE and MR analyses.  
Gene-environment interaction 
Effect modification (or interaction, section 3.4.1.) is an important factor to 
consider when investigating the association between an exposure and outcome 
and is the main focus of Chapter 7.  In Chapter 7, effect modification by APOE 
ε4 was examined from the most complex models, which tests for interaction 
between APOE ε4 and the quadratic term of 25(OH)D (i.e. 25(OH)D2).  In order 
to determine the most appropriate model, APOE ε4 interaction was assessed in 
three ways:  
1) Three way interaction between 25(OH)D, APOE ε4 and 25(OH)D2 
2) Two way interaction between 25(OH)D and APOE ε4, adjusting for 
25(OH)D2 
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3) Two way interaction between 25(OH)D and APOE ε4 
The most appropriate interaction model was chosen by omitting the highest 
level term which did not make a significant contribution to the model (judged by 
p-value >0.05). 
Mendelian randomisation 
There are three main steps for the MR analyses used in Chapter 8: 
I. Genetic variant association with exposure (i.e. 25(OH)D) 
II. Genetic variant association with outcome (i.e. cognitive function) 
III. IV ratio calculation 
Linear regression models are used to assess the change in naturally log-
transformed 25(OH)D according to the average increase in the number of effect 
alleles in the genetic variants.  Linear regression models are also applied when 
the association between genetic variants with global and memory cognitive 
function is examined.   
In order to estimate the causal effect of 25(OH)D on cognitive function, the IV 
ratio method is used (3).  This MR estimate can be conceptualised as a ratio of 
two estimates i.e. the coefficient for the association between the genetic variant 
and 25(OH)D, and the coefficient from the linear regression of the genetic 
variant on cognitive function (218).  The Wald or ratio estimator of the average 
causal effect for a one unit difference in X (i.e. 25(OH)D) on Y (i.e. cognitive 
function) is defined as  ̂   ̂  ⁄  where  ̂   and   ̂   are the coefficients from 
linear regressions of Y on Z and X on Z (i.e. genetic variant) respectively 
(Figure 3.5). The IV ratio is defined as:     
   
   
. 
The variance of the IV ratio is estimated using the delta method, assuming that 
the covariance is close to zero (219): 
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63 
 
 
Figure 3.5: IV ratio estimation; illustrated by 25(OH)D and cognitive function 
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The IV ratio should be directly comparable with the more formal 2-stage least 
squares method (220).  The advantage of using the IV ratio was demonstrated 
by Pierce and Burgess using simulated data sets (218).  They found that there 
was no loss of statistical power or bias for the MR estimate when exposure data 
were available for only subset of participants, providing a good quality IV was 
used.  
MR instrument validation  
There are a variety of assumptions that underlie MR studies (outlined in section 
3.3.2).  These state that the selected genetic variant should be linearly 
associated with the exposure of interest, be independent of confounding factors 
and must not be associated directly with the outcome of interest. 
The strength of the genetic variant as an instrument for MR studies can be 
estimated from the adjusted R2 which describes the proportion of variation in 
the exposure (i.e. 25(OH)D) explained by the genetic variant, adjusted for the 
number of parameters in the linear regression model.  The F-statistic for the 
genetic variant can also be used to indicate the strength of the genetic variant 
as an instrument in MR analysis.  The F-statistic should ideally be greater than 
10 in order for an instrument to be considered strong enough to use (221).  The 
F-statistic can be calculated using the following formula:  
2
2
( 1 )
=  
(1 )
R n k
F
R k
 
 , 
where k is the number of instruments (or variables) and n is the sample size 
(Rice 1995).  The F-statistic was calculated from the average of the weighted 
adjusted R2 in each study. 
Mendel’s law (222) implies that the genetic variant will be independent of any 
confounding factors.  Therefore, the effect of the genetic variant association 
with 25(OH)D when adjusted for the social, lifestyle and dietary covariates that 
could potentially confound the relationship between 25(OH)D and cognitive 
function is examined using linear regression models.  Logistic regression 
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models are used to examine the direct association of the genetic variant with 
the dichotomised social, lifestyle and dietary variables.  These models were 
adjusted for 25(OH)D with the assumption that controlling for the modifiable 
exposure should not affect the association if pleiotropy exists.  The genetic 
variant associations with the potential confounding factors were also corrected 
for multiple testing. 
Meta-analyses 
Meta-analyses were conducted in order to increase power of the MR analyses.  
In a meta-analysis, the effect size for each study is calculated.  The consistency 
between each individual effect size is assessed to obtain a summary score 
(223).  In order to calculate this summary effect, each study included in the 
meta-analysis is assigned a weight which is related to its precision.  Studies 
with a larger sample size tend to be more precise and hence are assigned a 
larger weight (223). 
A meta-analysis can be conducted in two ways (224).  The first is a fixed-effect 
meta-analysis.  This model assumes there is one true effect size underlying all 
the studies in the analysis and the difference observed between each individual 
study is due to sampling error.  A random effects meta-analysis assumes that 
the true effect may vary from study to study as the sample populations differ for 
example, when the participants differ in age (224). 
Heterogeneity is the term used to describe the difference between each 
individual effect sizes between included studies.  While variation can be due to 
random error or be indicative of an underlying true difference between the 
studies, heterogeneity refers to the variation in true effect sizes (223).  The 
statistical significance of heterogeneity between the studies can be tested using 
the Q statistic.  The I2 is a descriptive statistic that reflects the proportion of 
observed variance.  If the I2 is near zero, then almost all observed variance is 
spurious, if the I2 is large, then reasons for heterogeneity should be 
investigated.  If the Q statistic indicated significant heterogeneity at the alpha 
level of 0.05, a random effects meta-analysis was run, otherwise fixed models 
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were used.  Sensitivity analyses conducted in Chapter 8, compared models 
using both random and fixed effects meta-analysis.  
Meta-regression was used to determine the sources of heterogeneity among 
the different study cohorts included in the observational meta-analyses of 
Chapter 8 (225).  The potential source of heterogeneity for inclusion in meta-
regression such as age and country were chosen a priori.  
3.5 Summary  
 Observational and genetic epidemiology are the two approaches that will 
be used  
 Observational epidemiology can give insight into associations between 
environmental exposures and health outcomes however reverse 
causality and confounding can be problematic 
 Exploration of gene-environment interactions can help to disentangle 
observed associations between an environmental exposure and health 
outcome and assess how associations are affected by genotype 
 Mendelian randomisation is an approach that utilises a genetic variant, 
related to an environmental exposure as a proxy to estimate the causal 
association between an environmental exposure and health outcome 
 The use of both observational and genetic epidemiological approaches 
will enable the development of a hierarchy of evidence from cross-
sectional observational studies that can describe evidence of a 
relationship, to a Mendelian randomisation analysis that has the potential 
to reflect causal associations.  Using these various methods enables 
triangulation of results to increase confidence in the findings 
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 Data Chapter 4
4.1 Introduction 
Data for the thesis were collected using participants from cohort studies.  These 
cohort studies involve a group of people who share a common condition or 
experience, for example, all born in the same year.  Many cohort studies collect 
longitudinal data on a variety of topics including health, social and economic 
affairs.  This study design was chosen based on its ability to contribute rich, 
detailed information to address the aims of the thesis. 
Data were predominately collected using participants from the 1958 British birth 
cohort (1958BC).  Data from eight additional cohorts were used to increase 
power of genetic epidemiology analyses as discussed in Chapter 3.  Ethical 
approval for the 1958BC was outlined in the acknowledgments.  All participants 
from the other cohorts provided informed consent, and ethical approval was 
granted by local research ethics committees.   
During this chapter, I will describe participants of the 1958BC, the measures of 
exposure and outcomes used and discuss the genetic variants applied.  The 
final section will give an overview of the participants and variables of the 
additional cohorts that were used.  
4.2 1958 British birth cohort 
4.2.1  Participants 
The 1958BC, also known as the National Child Development Study (NCDS), is 
an on-going, multidisciplinary study.  The 1958BC is the second oldest 
nationwide cohort after the 1946 National Survey of Health and Development3  
The aim of the 1958BC is to monitor social, behavioural, educational and 
physical outcomes as well as to collect information regarding economic 
circumstances, employment and health behaviour (226). 
                                            
3
 http://www.nshd.mrc.ac.uk/ 
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The 1958BC originally began as the Perinatal Mortality Study (PMS).  This 
study aimed to investigate still-birth and infant mortality.  Mothers of babies born 
in one week in March 1958 in England, Scotland and Wales (approximately 
17,415) were interviewed by mid-wives, who completed questionnaires with 
reference to medical records (227).  To date, the cohort has been followed up 
ten times; at ages 7, 11, 16, 23, 33, 42, 46, 50, including a biomedical survey at 
45 years and NCDS9 which began in the summer of 2013 (55 years).  However, 
data from NCDS9 was not available at the time of this thesis.  Table 4.1 gives 
the target and achieved sample at each sweep in addition to the main sources 
of information at each time point (228).  
During the childhood sweeps at NCDS1-3, immigrants that were born during the 
survey week in March 1958 were added to the study (n=920) (227, 229).  
Individuals who participated in any of the childhood sweeps were contacted and 
followed up for NCDS4-8 (229).  Deaths were confirmed through receipt of 
death certification or notification to the study team (216).  At the 45 year survey, 
ethical approval was obtained from the South East Multi-centre Research Ethics 
Committee (ref. 01/1/44).  During the biomedical survey, self-completed 
questionnaires, blood and saliva samples were administered and a home 
interview was conducted by a research nurse.  
Data collected in the 1958BC has led to a multitude of studies describing the 
health and socioeconomic characteristics of the participants.  The longitudinal 
design facilities investigation of disease progression and enables the 
identification of potential risk factors.  Some selected findings from the 1958BC 
include; the effect of family, social circumstances and smoking on perinatal 
mortality (230), that children of obese and overweight parents have a higher risk 
of obesity (231) and that children’s relationship with both their mother and father 
predicted mental health problems in adulthood (71).  The 1958BC can be 
compared with earlier and later born cohorts to examine changing patterns of 
diseases.  For example, one study comparing the 1958BC with the 1946 birth 
cohort found that individuals born in 1958 were no heavier in childhood than 
those born in 1946 but they were taller and grew faster (232).  Furthermore, by 
mid adulthood, participants in the 1958BC had a higher BMI and higher 
prevalence of obesity compared with the older cohort (232). 
69 
 
Table 4.1: 1958BC sweep information 
  PMS NCDS1 NCDS2 NCDS3 NCDS4 NCDS5 NCDS6 NCDS7 Biomedical NCDS8 
  1958 1965 1969 1974 1981 1991 2000 2004 2003 2008 
Age (y) Birth 7 11 16 23 33 42 46 45 50 
Source Parents Parents Parents Parents Subject Subject Subject Subject Medical Subject 
 Medical School School School Census Partner   Subject  
  Tests Tests Tests  Children     
  Medical Medical Medical       
    Subject       
    Census       
Target (n) 17,638 17,370 16,880 16,929 16,713 16,389 16,194 16,072 11,971 16,014 
Achieved (n) 17,415 15,425 15,337 14,654 12,537 11,469 11,419 9,534 9,377 9,790 
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In order to generalise findings from the 1958BC to the current British population, 
the study sample needs to be representative.  As with all cohort studies, sample 
attrition has occurred in the 1958BC.  For example, those with a lower social 
class at birth, lower mathematics score at 7 years and with internalising and 
externalising behaviours at 7 years were found to be under-represented in the 
45 year survey (Chapter 3) (216).  Although immigrants were included during 
the childhood studies, the majority of participants of the 1958BC are from a 
white European population, which was representative of the population at the 
time (216).  Therefore, the 1958BC does not capture the ethnic diversity of 
today’s society.  Despite this potential bias, a study examining participants of 
the 33 year (NCDS5) survey found that they are broadly representative of the 
general white British population in terms of several socioeconomic 
characteristics (233).  Similarly, participants of the 45 year biomedical survey 
were shown to broadly represent those born in Britain in 1958 and resemble the 
white British population (216). 
4.2.2 Exposure 
Serum vitamin D, or 25-hydroxyvitamin D (25(OH)D) is the main exposure 
variable used.  Information regarding the background, intake, metabolism and 
thresholds of 25(OH)D is detailed in Chapter 1. 
Non-fasting blood samples were collected from 88% of participants in the 
1958BC during the biomedical survey.  97% of these consented to the creation 
of immortalised cell lines (234).  The venous blood sample was obtained during 
the 45 year biomedical survey.  These blood samples were collected into 
Sarstedt evacuated tubes without anticoagulant and sent by regular mail to the 
central laboratory (235).  25(OH)D assessment was performed on n=7,591 
participants in the Royal Victoria Infirmary (Newcastle upon Tyne, Tyne 
Hospitals National Health Service Trust, Newcastle upon Tyne UK) (235).  An 
automated application of Immunodiagnostic Systems Ltd. (IDS) enzyme 
immunoassay (EIA) was used to obtain serum 25(OH)D measurements.  The 
application was evaluated in the central laboratory on a BEP2000 
programmable microtiter plate analyser (Dade-Behring, Marburg, Germany) 
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with sensitivity of 5.0nmol/l, linearity ≤155nmol/l and intra-assay Coefficient of 
Variation (CV) 5.5-7.2% (235). 
Variations between 25(OH)D assays reduces between-study comparisons.  Due 
to problems relating to these variations, there was a need for a rigorous internal 
quality-assurance scheme for 25(OH)D assays that led to the establishment of 
the International Vitamin D External Quality Assessment Scheme (DEQAS) in 
1989  (236).  The primary aim of DEQAS is to  
“monitor the performance of individual laboratories…also used to assess 
the performance of the methods used”  (236) 
Laboratories that participate in DEQAS are sent five quarterly samples of 
human serum.  These samples are analysed to give an All-Laboratory Trimmed 
Mean (ALTM).  Laboratories receive a certificate if 80% of these results are 
within 30% of the DEQAS ALTM (236).  The use of the ALTM has been 
criticised.  The ALTM has been used as a good surrogate for values obtained 
by the gas chromatography-mass spectrometry method (237).  However, as 
more methods are being used and developed, ALTM can no longer be regarded 
as the true value.  In this instance, while passing the DEQAS may mean the 
method is relatively accurate compared with other laboratories, it may not 
represent the true value of 25(OH)D.  With this in mind, more procedures to 
improve assay comparability are being explored.  In 2010, a serum based 
reference material was proposed and it is hoped that this can be used in the 
future to produce valid 25(OH)D measurements (238). 
25(OH)D measurements in the 1958BC were standardised according to the 
DEQAS reference (235). 
4.2.3 Outcomes 
Common mental disorders (CMD) 
CMDs were assessed in the 45 year biomedical survey and the 50 year sweep 
of the 1958BC.  The Clinical Interview Schedule Revised (CIS-R) used to 
assess CMDs at 45 years (239, 240) was administered by a survey nurse using 
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computer assisted personal interviewing (CAPI).  The CIS-R is a standardised 
semi-structured questionnaire, assessing symptoms of CMDs in the previous 
week.  The CIS-R usually contains 14 sections, however only 9 were 
administered at 45 years (listed in Table 4.2) due to time constraints (241). 
Each section of the CIS-R assessed a group of symptoms related to a CMD 
(see Table 4.3).  For the purposes of this thesis, depressive, anxiety, panic and 
phobia symptoms were examined.  Filter questions were used to establish the 
presence of symptoms of a particular CMD in the past month.  Positive 
response to these led to further questions based on symptoms in the past week.  
For each symptom, scores range from 0 to 4, with a higher score indicating 
more frequent and severe symptoms.  Symptom scores were computed for 
each disorder.  To create a binary variable for each CMD, a score of ≥2 on each 
scale was defined as clinically relevant, where ≥2 indicated presence of the 
CMD and <2 symptoms indicated no CMD (98). 
Good reliability and validity for the CIS-R has been reported (240).  
Standardisation aims to transform clinical judgements of presence of CMDs into 
rules.  Therefore, any systematic bias that may present due to between-
observer variation of CMDs is reduced by the standardisation of the CIS-R 
questionnaire.  Furthermore, the validity of the results from the CIS-R increased 
through limiting assessment to symptoms in the previous week with the 
assumption that recall for psychological symptoms become weaker over a 
longer period.  Two reliability studies conducted in London, UK and Santiago, 
Chile reported no difference in the CIS-R results between lay interviews and 
trained psychiatrists (240).  The CIS-R has been also used in the Adult 
Psychiatric Morbidity Survey in England (9) and the EMPIRIC study (242). 
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Table 4.2: Symptoms of CMDs measured by CIS-R at 45 years in 1958BC 
Included in biomedical survey Not included in biomedical survey 
Depression Worry 
Anxiety Obsessions 
Panic Somatic symptoms 
Phobias Compulsions 
Depressive ideas Worry about physical health 
Fatigue  
Sleep problems  
Irritability  
Concentration/forgetfulness  
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Table 4.3: CMD symptoms assessed using CIS-R at 45 years in 1958BC 
Depressive symptoms 
Have you had a spell of feeling depressed in the past month 
Have you been able to enjoy things as much as you usually do 
In the past week have you felt depressed 
In the past week have you been able to enjoy things as much as usual 
On how many days in the past week have you felt depressed or unable to take an interest 
in things 
Have you felt depressed/unable to take interest in things for more than 3 hours in total on 
any day in the past week 
What sort of things made you feel depressed in the past week 
In the past week when you were depressed did you become happier when something nice 
happened 
How long have you been feeling depressed 
Anxiety symptoms 
Have you been feeling anxious or nervous in the past month 
In the past month did you ever find your muscles felt tense 
Have you felt anxious when there was no real danger 
Was this brought on by a phobia about some specific situation or did you feel generally 
anxious 
On how many of the past 7 days have you felt generally anxious 
In the past week how unpleasant has your anxiety been 
When you’ve been anxious have you had any of the symptoms shown on this card & which 
of these symptoms have you had 
Have you felt anxious for more than 3 hours in any day in the past week 
How long have you had these feelings of general anxiety 
Panic symptoms 
In past month did your anxiety get so bad that you thought you might collapse or lose 
control 
How often has this happened in the last week 
In the past week, how unpleasant have these feelings of panic been 
Did this panic last for longer than 10 minutes 
Are you relatively free of anxiety between these panics 
Is the panic always brought on by same thing 
How long have you been having these feelings of panic 
Phobia symptoms 
Have you avoided anything because it would have made you feel nervous or anxious even 
though there was no real danger 
Which of these situations made you the most anxious in the past month 
Which of these situations did you most avoid in the past month 
In the past week how many times have you felt anxious about this situation/thing 
In the past week on those occasions when you felt anxious did you have any of these 
symptoms  
Which of these symptoms did you have 
In the past week, have you avoided any situation because it would have made you feel 
anxious, even though there was no real danger 
How many times have you avoided such situations in the past seven days 
How long have you been having these feelings about these situations 
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During the 50 year survey, the Mental Health Inventory (MHI-5) was used to 
assess the presence of depressive symptoms in the past four weeks (versus 
CIS-R, which examines symptoms in the previous week) (243, 244).  
Participants completed the MHI-5 as part of a 16-page paper self-completion 
questionnaire which was mailed to them in advance of their interview (245).  
Box 4.1 illustrates the questions used.  Each item on the MHI-5 was scored on 
a 6-point scale ranging from ‘all of the time’ to ‘none of the time’.  To create an 
overall score, the responses to each item were summed.  Some of the items 
were reversed before summing to ensure that a high score indicated better 
mental health for example, item two, ‘felt calm and peaceful’.  The scores were 
then linearly transformed to a 0-100 scale with lower scores indicating worse 
mental health (246).  While MHI-5 was designed as a general mental health 
measure, several studies have shown that it is most appropriate for measuring 
depressive symptoms using a cut-off point of ≤52 (247-252). 
 
 
 
 
 
 
This short version of the MHI was compared with the 18-item MHI and the 30-
item version of the General Health Questionnaire (GHQ-30) and a 28-item 
Somatic Symptom Inventory (SSI-28).  The MHI-5 was found to be as good as 
the MHI-18 and the GHQ-30 and better than the SSI-28 at detecting major 
depression, affective disorders and anxiety disorders (based on Diagnostic 
Interview Schedule diagnosis) (244).  The MHI-5 has been used in the past to 
measure depressive symptoms in other population studies, for example, the 
Nurse’s Health study (249). 
Box 4.1: Mental Health Inventory-5 questions 
How much of the time during the last month have you: 
1. been very nervous person 
2. felt calm and peaceful 
3. felt downhearted and low 
4. been a happy person  
5. felt so down in the dumps that nothing cheers you up 
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Cognitive function 
In the 50 year survey of the 1958BC, cognitive function was assessed during a 
60 minute face to face interview in the participant’s home.  The test consisted of 
four memory and concentration tasks, where each task measured different 
aspects of cognitive function.  Figure 4.1 shows the domains assessed.  The 
interviewers also recorded any factors that might have influenced performance 
on cognitive tests (Table.4.4.)  The immediate word recall test examined how 
many words a participant could immediately recall from a list of 10 common 
words (Table 4.5.).  Participants had up to two minutes to recall as many words 
as possible.  
The delayed word list examined how many of these words the participants could 
recall after an interval of approximately 5 minutes, during which the other 
cognitive tests were conducted.  There were four word lists which were 
randomly assigned during these tasks (Table 4.5).  Additionally, while the lists 
were mainly read out by a computer voice; in 2% of cases the interviewer read 
out the lists at an equivalent pace to the computer.   
The animal naming task was used to assess verbal fluency.  This test measured 
how quickly the participants could name as many different words from a 
particular category, in this case, animals.  Participants had one minute to 
compete this task.  Repetitions, named animals (for example, Dumbo) and 
redundancies (for example, white cat, black cat) were excluded from the total 
score.  This test version was taken from the cognitive assessment section of the 
Cambridge Mental Disorders of the Elderly Examination (CAMDEX) (253).       
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Figure 4.1: Cognitive tests conducted at 50 years in 1958BC 
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Table 4.4: Factors affecting cognitive tests at 50 years in 1958BC 
Cognitive testing conditions Description 
Day and time of cognitive testing Weekday morning, weekday afternoon, weekday 
evening, weekend morning, weekend afternoon, 
or weekend evening 
Presence of others in the room yes, no 
Word list used* a, b, c, d 
Administration of word list computer or interviewer 
Other contextual factors affecting 
performance
† 
yes, no 
*Only relevant for immediate and delayed word recall test 
†
Includes: blind or poor eyesight; deaf or hard of hearing; too tired; Illness or physical 
impairment that affects the ability to perform; impaired concentration; very nervous or 
anxious; mental impairment; interruption or distraction; noisy environment; problems with 
the laptop; difficulty understanding English 
 
Table 4.5: Word lists for cognitive tests at 50 years in 1958BC 
Word list A Word list B Word list C Word list D 
Hotel Sky Woman Water 
River Ocean Rock Church 
Tree Flag Blood Doctor 
Skin Dollar Corner Palace 
Gold Wife Shoes Fire 
Market Machine Letter Garden 
Paper Home Girl Sea 
Child Earth House Village 
King College Valley Baby 
Book Butter Engine Table 
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Finally, the letter cancellation task (developed for the 1946 birth cohort (254)) 
assessed mental speed, attention and visual scanning.  This task involved a 
page with 125 upper case letters of the alphabet arranged randomly in 26 rows 
and 39 columns.  Participants were instructed to cross out as many target 
letters (P and W, 65 in total) as possible in one minute.  Participants are 
instructed to work across each row from left-to-right.  When the time is up, 
participants were asked to underline the last letter they reached.  The total 
number of letters searched i.e. the sum of all the items processed, regardless of 
accuracy, provided an assessment of processing speed.   
These cognitive measures have been used in other longitudinal studies (for 
example, the 1946 British birth cohort (255) and the English Longitudinal study 
of Ageing  (256)).  In order to increase comparability of the cognitive tests both 
within the 1958BC and with other studies, cognitive scores were standardised to 
z-scores whereby the mean was 0 and standard deviation was 1 using the 
following formula: 
  
    
 
, 
where z represents the standardised cognitive score, X is the unstandardized 
cognitive score, μ is the mean and σ is the standard deviation.  
4.2.4 Covariates 
Many demographic and lifestyle characteristics from the 1958BC were used.  
During this section I will give a brief overview of covariates.  The categorisation 
of each covariate will be described in relevant chapters. 
Demographic 
Ethnicity was self-reported at 42 years and grouped into two broad categories 
i.e. white and other, due to the small number of other ethnic groups in the 
cohort.  Region of residence was self-reported during the 46 year survey using 
computer assisted telephone interviewing.  Regions included North, Yorkshire 
and Humberside, East Midlands, East Anglia, south East, South West, West 
Midlands, North West, Wales, Scotland and Isle of Man and Channel Isles.  
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Socioeconomic position (SEP) in adulthood was assessed at 42 years (NCDS5) 
and defined using the Registrar General’s classification (257).  Educational 
attainment of cohort members was based on the highest qualification obtained 
by 42 years, or by 33 years if data was missing. 
Early life factors 
SEP in childhood was based on father’s occupation at the participant’s birth (or 
at 7 years if this data was missing) and categorised using the Registrar 
General’s classification (257).  Cognitive ability in childhood was assessed at 7, 
11 and 16 years from tests administered at school.  Mathematics ability at 7 
years was assessed using 10 problems with increasing levels of difficulty (range 
0-10) (258).  Arithmetic tests at 11 years (range 0-40) and 16 years (range 0-
31) were constructed specifically for use in the 1958 cohort by the National 
Foundation for Educational Research in England and Wales and Manchester 
University respectively.  Reading ability was assessed using the Southgate test 
at 7 years (range 0-30) (259) and an assessment similar to the Watts Vernon 
comprehension tests was constructed by the National Foundation for 
Educational Research in England and Wales at 11 and 16 years (range 0-35).  
A standardised test for general ability, consisting of verbal (range 0-40) and 
non-verbal components (range 0-40), was conducted when participants were 11 
years (260).  Pearson correlations between childhood tests ranged from 0.44 to 
0.78 (p<0.001 for all).  Tests were standardised for age at assessment to 
control for potential age-effects of cognitive ability, and averaged to obtain a 
summary score for childhood cognitive ability (261).  Missing data on one test 
were replaced by that individual’s mean standardised score on the other tests.  
Internalising and externalising behaviour was assessed at ages 7, 11 and 16 
years.  At 7 and 11 years, these behaviours were measured using the teacher-
rated Bristol Social Adjustment Guides which assess 12 different syndromes 
using 146 items (262).  Depression and withdrawal and were classified as 
internalising problems while anxiety, hostility and restlessness were indicative of 
externalising problems (69).  At 16 years, internalising and externalising 
problems were measured using the teacher version of the Rutter scales (263). 
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Physical status and lifestyles 
Menopausal status i.e. post-menopausal, pre-menopausal or peri-menopausal 
was obtained from questions regarding menstruation at 45 years during the 
biomedical survey.  Smoking and alcohol consumption were self-reported at 
ages 42 and 45 years respectively.  BMI was defined using the participants 
weight in kilograms divided by height measured in meters squared (kg/m2).  
Weight was measured using Tanita solar scales and height was measured with 
participants in light clothes and without shoes taken by a nurse at the 
participant’s home.  Frequency of physical activity was reported at 42 years. 
Vitamin D-related lifestyles 
Vitamin D-related lifestyles were all self-reported at 45 years (26).  These 
included the frequency of consumption of oily fish (such as salmon, trout, 
mackerel, sardines or fresh tuna), margarine and use of supplements containing 
cod liver, fish oil or vitamin D.  The amount of time spent outside during the past 
month and leisure time spent using the television (TV) or personal computer 
(PC) was also reported along with the frequency of suncover usage, blistering 
after sunburn, and seeking suntan.  Use of other dietary supplements i.e. pills 
powders, tablets or drops were reported at 45 years.  
4.2.5 Genetic data 
Information regarding the apolipoprotein E (APOE) gene and genetic variants 
related to 25(OH)D are required for Chapters 7 and 8.  8,018 participants from 
the 1958BC biomedical survey gave consent for DNA to be extracted from their 
blood samples.  The genetic variants used are single nucleotide polymorphisms 
(SNPs) (Box 4.2).  A glossary of genetic terms can be found in Appendix 2.1.  
The APOE and vitamin D-related SNPs are discussed separately below.  
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Apolipoprotein E  
APOE is a polymorphic gene consisting of three major alleles formed from two 
SNPs i.e. rs429358 and rs7412.  The SNPs possess an amino acid substitution 
of arginine to cysteine at positions 112 and 158 of the apolipoprotein E protein 
(264).  The common allelic forms are ε2, ε3 and ε4. Each individual possesses 
two APOE alleles, inheriting one from each parent.  Therefore, there are six 
possible APOE genotypes:  ε2/ε2, ε2/ε3 ε2/ε4 ε3/ε3 ε3/ε4 and ε4/ε4.  The APOE 
genotypes have varying frequencies in human populations.  APOE ε3 is the 
most commonly occurring form worldwide followed by ε4 (Table 4.6). 
Table 4.6: APOE allelic variation and worldwide frequencies 
 (40) 
 Nucleotide variation Amino acid variation Allele frequency* 
 rs7412 rs429358 158 112  
APOE ε2 T T Arginine Arginine 0 - 0.15 
APOE ε3 C T Cysteine   Arginine 0.55 - 0.91 
APOE ε4 C C Cysteine   Cysteine   0.05 - 0.41 
*Data from (264) 
In the 1958BC, APOE genotypes were obtained from the Illumina iSelect 
Metabochip genotyping array (265) from those who consented to genotyping 
during the biomedical survey (n=5,550).  The Metabochip is a custom 
genotyping array that can assay nearly 200,000 SNP markers (265).  
Box 4.2 Definition of single nucleotide polymorphism (SNP) 
A SNP refers to a sequence of DNA within a gene that differs 
between individuals (3).  Specifically, variation occurs when a 
single nucleotide i.e. adenine (A), guanine (G), thymine (T) or 
cytosine (C) differs between individuals.  Therefore, there is 
potentially more than one form of the gene consisting of a number 
of alleles (see Appendix 2.1).   
83 
 
Vitamin D-related genetic variants 
As mentioned in Chapter 1, previous research has suggested that there is a 
genetic influence on vitamin D status, with heritability estimates ranging from 29 
to 80% (37-39).  The identification of appropriate genetic proxies for 25(OH)D is 
essential for an MR study (3).  
The selection of vitamin D-related SNPs for Chapter 8 came primarily from two 
Genome-Wide Association (GWA) studies (5, 6).  One was carried out in the 
USA using 4,501 participants in the discovery phase and 2,221 in the replication 
analysis (6).  The other was carried out by SUNLIGHT consortium cohorts 
(Study of Underlying Genetic Determinants of Vitamin D and Highly Related 
Traits), which included participants from the 1958BC.  GWAS using the 
SUNLIGHT consortium consisted of 16,125 participants in the discovery stage 
and 17,871 in replication (5).  Both studies used participants from European 
ancestry.  Both studies identified three SNPs near genes involved in the 
metabolism of vitamin D i.e. 7-dehydrocholesterol reductase (DHCR7, 7-
dehydrocholesterol reductase), 25-hydroxylase (CYP2R1, cytochrome P450, 
family 2, subfamily R, polypeptide 1), vitamin D-binding protein (VDBP) (GC, 
group-specific component).  The SUNLIGHT meta-analysis also identified 
variants affecting the clearance of 25(OH)D i.e. CYP24A1 (cytochrome P450, 
family 24, subfamily A, polypeptide 1) (Figure 4.2 and Box 4.3). 
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Figure 4.2: Genetic variants on the vitamin D metabolic pathway 
Taken from Berry, 2012 (207) 
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Further work conducted in 2012 confirmed that these SNPs are appropriate 
instruments for MR studies using data from 6,877 participants from the 1958BC 
(207).  Additionally, DHCR7 and CYP2R1 have been used in a previous MR 
analysis to proxy 25(OH)D concentrations (33). 
There is evidence to suggest that VDBP (coded by GC) may affect the 
bioavailability of 25(OH)D (266).  CYP24A1 is regulated by other hormones, for 
example, parathyroid hormone.  Therefore the extent to which GC and 
CYP24A1 can proxy 25(OH)D concentrations is unclear.  Thus, DHCR7 and 
CYP2R1 will be used for MR analysis in Chapter 8. 
Genotyping participants for DHCR7 (rs12785878) and CYP2R1 (rs12794714) in 
the 1958BC came from two main resources utilising the 1958BC as sub-
samples for control populations in genome-wide studies: 
Box 4.3:  25(OH)D-related SNPs 
 DHCR7 produces the enzyme that catalyses the conversion of 
7-dehydrocholesterol in the skin to cholesterol.  This will result 
in the removal of pre-cholesterol from the vitamin D metabolism 
pathway, thus reducing the production of 25(OH)D (4).   
 CYP2R1 is involved in the hydroxylation of vitamin D by 25-
hydroxylase to produce 25(OH)D.  This gene was one of the 
top hits in both GWAS (5, 6).   
 GC codes VDBP which binds to 25(OH)D and transports it to 
target organs (7) 
 CYP24A1 catabolises 25(OH)D via the 24-hydroxylase into the 
water soluble calcitroic acid which is excreted in the bile (8) 
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1) Wellcome Trust Case Control Consortium (WTCCC) (267) 
The WTCCC genotyped 1,500 randomly selected participants of the 1958BC 
biomedical survey who had consented for DNA samples to be taken.  
Genotyping was conducted on Affymetrix Genechip 500K and Illumina Infinium 
550K chip (267).  During a second phase of the WTCCC (WTCCC 2), these 
subjects were re-genotyped along with an additional 1,500 individuals (n=3000) 
using the Affymetrix 6.0 and Illumina 1 (268). The genotyping calling algorithm 
was Chiamo (269).  Information from WTCCC 2 was used. 
In order to insure quality, genetically similar samples, those from non-European 
ancestry and those exceeding the heterozygosity thresholds were excluded.  
Further samples were excluded i.e. those with outlying allele intensities from a 
selection of SNPs compared with the larger sample, those with discordance 
with external genotypes and samples with gender discrepancy.  Definition of 
quality measures can be found in Appendix 2.1.  The minor allele frequency 
(MAF) refers to the frequency of the least common allele of the gene in a given 
population.  SNPs that had a MAF of <1% were excluded so that SNP 
differences in the sample could be captured.  Call rate indicates the amount of 
genotypes that were missing for each individual.  Individuals with a call rate of 
<0.97% were excluded to ensure good quality genotyping in the sample.  The 
Hardy-Weinberg equilibrium (HWE) tests if the alleles segregate randomly in 
the population following expected genotype frequencies.  Samples with a HWE 
p-value < 1e-20 were excluded.  
2) Type 1 Diabetes Genetics Consortium (T1DGC) (270) 
The T1DGC genotyped 2,596 randomly selected, consenting participants of the 
1958BC biomedical survey, exclusive of the WTCCC subjects.  Genotyping was 
conducted using the Illumina Infinium 550K (270). The genotyping calling 
algorithm was Illuminus (271). 
Samples that exceeded the call rate of 3%, exceeded the heterozygosity 
thresholds, had non-European ancestry and gender discrepancy were 
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excluded.  SNPs that had MAF <1% and HWE p-value <1e-7 were also 
excluded.   
The quality control measures aim to highlight potential issues with genotyping, 
duplicates, related individuals, and contaminated samples in both WTCCC2 and 
T1DGG and exclude individuals that don’t meet the standards (272).  Work 
conducted in a PhD thesis in 2012 provided further assurance of the suitability 
of genetic data from WTCCC2 and T1DGG for use in genetic studies (273). 
4.3 Additional cohorts  
As mentioned in the introduction, eight additional cohorts contributed data for 
Chapter 8.  One additional cohort (i.e. PIVUS) had information on APOE 
genotype and memory function, therefore this cohort was included in Chapter 
7.  Additional cohorts include: 
1) Austria Stroke Prevention Survey (ASPS) 
2) English Longitudinal Study of Ageing (ELSA) 
3) Epidemiologische Studie zu Chancen der Verhütung, Früherkennung 
und optimierten Therapie chronischer Erkrankungen in der älteren 
Bevölkerung (ESTHER) 
4) Helsinki Birth Cohort Study (HBCS) 
5) The Prospective Investigation of the Vasculature in Uppsala Seniors 
(PIVUS) – also contributing to Chapter 7 
6) The Tromsø Study (Tromsø) 
7) Uppsala Longitudinal Study of Adult Men (ULSAM) 
8) Whitehall II (WHII) 
Further details on the participants, exposure, outcome and genotyping are given 
in the remainder of this chapter.  Also presented is a comparison of the 1958BC 
with the eight additional cohorts.  
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ASPS 
Participants 
The ASPS is a prospective study on the effects of vascular risk factors on brain 
structure and function in cognitively normal inhabitants of Graz, Austria (274, 
275).  2,007 participants aged 45 to 86 years were recruited from the official 
community register and all participants were free of stroke and dementia.  
Individuals were excluded from the study if they had a history of 
neuropsychiatric disease.  Between 1991 and 1994, 509 participants randomly 
selected from the entire cohort underwent cognitive testing.  To enlarge the 
cohort with imaging  and neuropsychological assessments, an additional 567 
individuals were randomly selected in a second study between 1999 and 2003.  
Participants of the first and second panels were pooled, which resulted in a total 
of 1,076 individuals with blood and cognitive tests. 1,003 participants had 
information on at least one cognitive test and 829 participants had genotype 
information. 
Exposure 
Participants from this cohort did not have data on 25(OH)D concentrations.  
Outcome  
 Word association: Assessed during Bäumler’s Lern-und Gedächtnistest 
(LGT-3) (275) to measure verbal memory 
 Digit association: Assessed during LGT-3 to measure verbal memory 
 Story recall: Assessed during LGT-3 to measure verbal memory 
 Trail recall: Assessed during LGT-3 to measure visuospatial memory 
 Design recall: Assessed during LGT-3 to measure visuospatial memory 
 Wisconsin Card Sorting test: Used as a measure of conceptional 
reasoning. 
 The Alters–Konzentrations–Test: Used to test attention and speed  
 Trail Making Test B (TMT B):  Participants are asked to draw lines with a 
pencil between the numbers in the right order as fast as possible. The 
score is equal to the time in seconds. TMT B consists of digits and letters 
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1-A-2-B etc. to measure attention, processing speed and executive 
control 
 Digit span: Used to test attention and speed 
 Complex reaction time: Participants react selectively to a specific 
combination of a visual and acoustic signal by pressing a button as 
quickly as possible 
Genotyping 
Genotyping was done at the Human Genotyping Facility, Genetic Laboratory 
Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands, 
using the Illumina Human610-Quad BeadChip.  Participant-specific quality 
controls included filters for call rate (<98%), and high autosomal heterozygosity 
(FDR <1%).  Quality filters used a call rate >98%, a minor allele frequency 
>0.01 and a Hardy-Weinberg p>1x10-6. ASPS used the Markov Chain 
Haplotyping (MaCH) package (http://www.sph.umich.edu/csg/abecasis/MACH, 
version 1.0.15) for imputation to plus strand of NCBI build 36, HapMap release 
#22.  
ELSA 
Participants 
ELSA is an English based cohort consisting of men and women aged 50 years 
and over.  It is a follow-up study of respondents to the Government's Health 
Survey for England (HSE)4, an annual cross-sectional survey designed to be 
representative of the community-based population in England.  The main 
objective of ELSA is to collect longitudinal multidisciplinary data relating to 
health, disability, biological markers, well-being, social participation and 
economics.  ELSA began in 2002 and has been followed up every two years.  
The sample consists of individuals seen in HSE in 1998, 1999 or 2001.  11,391 
participants were interviewed for wave 1 (2002) in which cognitive testing was 
conducted (276).  6,219 participants had information on at least one cognitive 
test from wave 1.  8,780 participants were interviewed in wave 2 (2004), in 
                                            
4
 http://www.dh.gov.uk/ 
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which blood samples were taken for DNA analysis (276).  5,617 participants 
had genotype information.  
 Exposure 
Participants from this cohort did not have data on 25(OH)D concentrations.  
Outcome 
 Immediate word recall (277): Recall as many words as possible from a 
list of 10 common words read out by interviewer 
 Delayed word recall (277): Recall as many words as possible from a list 
of 10 common words read out by interviewer, following a short delay of 
approximately 5 minutes 
 Verbal fluency, animal naming  (278):  Measures how many words 
related to a category (in this case, types of animals) a participant can 
produce. Used to measure recall and executive control 
 Letter cancellation (254): Measures speed of processing.  Participants 
were instructed to cross out as many target letters (P and W, 65 in total) 
as possible in one minute. Used to measure speed of processing 
Genotyping 
DNA was extracted from blood samples using magnetic bead technology 
(Medical Solutions, Nottingham).  Genotyping was performed using the KASPar 
methodology.  The call rates and the concordance rates of the four SNPs were 
>98%, HWE values were p>0.08. 
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ESTHER 
Participants 
ESTHER is a population-based cohort study conducted in Saarland, Germany. 
The main aim of ESTHER is to contribute information for the prevention, early 
detection and treatment of chronic diseases.  A detailed characterization of this 
ongoing cohort study and the study population has been provided earlier (279, 
280).  Participants were recruited during health screening visits to their general 
practitioners. The baseline sample (2000-2002) included 9,949 participants 
aged between 50 and 74 years, in which blood samples for DNA and 25(OH)D 
were collected. 8,502 had genotype information and 9,581 had information on 
25(OH)D concentrations. 8,271 participants were included in the 5-year follow-
up (2005-2008) in which cognitive testing was conducted. 1,697 had information 
on at least one cognitive test.  
Exposure 
Baseline serum 25(O)D concentrations were measured with the DiaSorin-
Liason (Diasorin, Inc., Stillwater, USA) in 2006 and the IDS-iSYS 
(Immunodiagnostic Systems GmbH, Frankfurt Main, Germany) immunoassay in 
2010 for women and men, respectively.  Values for 25(OH)D were standardised 
with liquid chromatography tandem-mass spectrometry (LC-MS/MS) in the 
Department of Clinical Chemistry, Canisius Wilhelma Hospital, Nijmegen, The 
Netherlands (281).  
Outcome 
The Cognitive Telephone Screening Instrument (COGTEL) (282) was used to 
assess cognitive function.  
 Verbal short-term memory (283): Recall from a list of 8 word pairs 
following a short delay 
 Working memory (284): In reverse order, recall sequences of single-digit 
numbers which are presented at a 1 second rate   
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 Verbal fluency (285): Includes two tests, letter fluency i.e. producing as 
many words as possible beginning with a given letter within 60 seconds 
and category fluency i.e. producing as many different types of 
professions as possible within 70 seconds 
 Inductive reasoning (284): Involves the continuation of a mathematical 
sequence. 
 Verbal long-term memory (283): Recall from a list of 8 word pairs 
following a delay during which the other tests were conducted   
Genotyping 
Samples were genotyped using the TaqMan OpenArrayTM SNP Genotyping 
Platform (Applied Biosystems, Foster City, CA) according to the manufacturer’s 
instructions.  The overall call rate was 97.3%.  The genotyping concordance 
was 100% 
HBCS 
Participants 
The HBCS is a longitudinal study focused on the early origins of health and 
disease (286).  Information for this study was collected using data from the 
maternity hospital, clinical, school databases and other registries on people 
born in 1934-1944 in two hospitals in Helsinki Finland.  2,003 men and women 
participated in the clinical follow-up study (2001-2003) in which blood samples 
for DNA and 25(OH)D were obtained and cognitive testing was administered.  
Genetic data is available from 1,728 participants, 1,079 had information on 
25(OH)D concentrations and 1,054 participants had information on at least one 
cognitive test.   
Exposure 
Serum 25(OH)D concentrations were measured using the Chemiluminescent 
Microparticle Immuno Assay. 
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Outcome 
The HBCS uses CERAD (The Consortium to Establish a Registry for 
Alzheimer's disease) which consists of the following tests:  
 Verbal fluency, animal naming: Measures how many words related to a 
category (in this case, types of animals) a participant can produce   
 Immediate verbal recall: Recall as many words as possible from list of 10 
words in 90 seconds. 
 Delayed verbal recall: Recall as many words as possible from list of 10 
words after a delay 
 Verbal Learning: Participant is shown a list of 10 words 3 times then 
recalls as many words as possible. Total score is the number of correct 
words recalled. 
Genotyping 
DNA was extracted from blood samples and genotyping was performed with a 
modified Illumina 610k chip by the Wellcome Trust Sanger Institute, Cambridge, 
UK.  Genetically related individuals and those with gender discrepancies were 
excluded. After quality control procedures 1,720 samples remained for the 
analyses. SNPs were included in the analyses if they met the following 
conditions: call rate ≥ 0.95, minor allele frequency ≥ 0.01, and HWE test with P 
≥1x10-5. Genomic coverage was extended to ~2.5M common SNPs by 
imputation using the HapMap phase II CEU data (NCBI build 36 (UCSC hg18)) 
as the reference sample and MACH software. SNPs with low imputation quality 
(r-squared < 0.30), low minor allele frequency (MAF <0.01), or that diverged 
from HWE (1x10-5), were excluded from the analyses. 
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PIVUS 
Participants 
The PIVUS5 study includes men and women aged 70 years between 2001 and 
2004 in Uppsala, Sweden.  The primary aim of this study was to evaluate the 
usefulness of different measurements of endothelial function and other 
techniques to evaluate vascular function.  The baseline study consisted of 1,016 
participants in which blood samples were obtained for DNA and 25(OH)D 
concentrations. 989 participants had genetic data and 1,002 had information on 
25(OH)D concentrations.  Cognitive testing was conducted in the 5-year follow-
up (2006-2011, n=827). 799 individuals had information on at least one 
cognitive test.  
Exposure 
Serum 25(OH)D was measured at the department of Clinical Chemistry at 
Uppsala University Hospital using the DiaSorin-Liason immunoassay. CV for 
inter-assay analyses is 18.4% at a 25(OH)D level of 39.5 nmol/L and 11.7% at 
121.2 nmol/L. The intra-assay CV is 7.1% at 44.7 nmol/L and 3.6% at 120.0 
nmol/L.  
Outcome 
 Mini Mental State Examination (MMSE) (287): 30-point questionnaire 
used to screen for cognitive impairment 
 7 minute Screen test (288): Consists of (1) Benton temporal orientation 
i.e. measurement of orientation in time (2) enhanced cued recall i.e. 
identification and recall of 16 pictures immediately and after an interval 
with semantic cues if necessary (3) Clock drawing i.e. subject draws the 
face of a clock and places the hands on a fixed time (4) Verbal fluency 
i.e. participant names as many different animals as possible in one 
minute 
 TMT A 
 TMT B 
                                            
5
http://www.medsci.uu.se/pivus/ 
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Genotyping 
SNPs were genotyped as part of a larger study at the SNP technology platform 
at Uppsala University (http://www.genotyping.se/) on an Illumina BeadStation 
500GX using Infinium iSelect and Golden Gate assays from Illumina Inc (289).  
Genotyping calls were performed with Illumina BeadStudio or GenCall software. 
Samples with low call rate (<90 %), excess heterozygosity or cryptic 
relatedness were excluded from analyses. SNPs with a call rate less than 90%, 
or that failed HWE (exact p-value<1x10-6) were excluded from the study. 
Tromsø 
Participants 
Tromsø is a longitudinal population-based multi-purpose study focusing on 
lifestyle-related diseases in Norway.  It began in 1974 with 6,595 male 
participants.  Blood collection and DNA preparation was conducted in Tromsø 4 
(1994-1995, n=27,158) (290).  7,161 participants had 25(OH)D measures and 
12,029 had genetic data.  Cognitive tests were conducted in Tromsø 5 (2001, 
n=8,130).  5,267 individuals completed at least one cognitive test.   
Exposure 
Serum 25(OH)D concentrations were measured by an 
electrochemiluminescence immunoassay (ECLIA), using an automated clinical 
chemistry analyser (Modular E170, Roche Diagnostics®, Mannheim, Germany).  
The total analytical CV for the 25(OH)D assay was 7.3%. 
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Outcome 
 Finger tapping test  (291): Participant is asked to tap as many times as 
possible in 10 seconds with their index finger on a computer 
 Digit symbol coding test (284): Consists of rows containing blank 
squares, each paired with a randomly assigned number from one to nine, 
and a printed key about that pair, each number with a different nonsense 
symbol.  Participants consecutively fill-in as many as possible of the 
blank spaces with the corresponding symbol as quickly as possible for 90 
seconds 
 12 word memory test (291): Words were shown written on a board and 
pronounced. Participants had 2 minutes to recall the word 
Genotyping 
Genotyping was conducted by KBioscience (http://www.kbioscience.co.uk) 
using KASP (KBioScience Allele-Specific Polymorphism) SNP genotyping 
system. Two separate manual quality control checks were performed, and the 
data was also checked by specific software to determine that there are no 
incorrect call assignments, no samples too close or too far from the origin or 
any incorrect calls. The call rate for all the 4 SNPs was >98 % and the Hardy-
Weinberg equilibrium p value was p>0.01. 
ULSAM 
Participants 
ULSAM is a longitudinal study based on all men born between 1920 and 1924 
in Uppsala, Sweden.  The study began in 1970 when the men were 50 years 
(292).  The main aim of the study was to identify cardiovascular risk factors. 
Blood collection, DNA preparation and cognitive testing was conducted when 
participants were age 70 years (1991-1995 n=1,221). 1,124 participants had 
genetic data 1,194 had information on 25(OH)D concentrations and 999 had 
information on at least one cognitive test.  
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Exposure 
Serum 25(OH)D concentrations were determined with high-pressure liquid 
chromatography (HPLC) atmospheric pressure chemical ionization (APCI) mass 
spectrometry (MS) at Vitas, Oslo, Norway (www.vitas.no). HPLC was performed 
with a Hewlett Packard 1100 liquid chromatography (Agilent Technologies, Palo 
Alto CA, USA) interfaced by APCI to a Hewlett Packard mass spectrometer 
operated in single-ion monitoring mode (SIM). Recovery is 95%; the method is 
linear from 5-400 nmol/L and the limit of detection is 1-4 nmol/L. The CV for 
inter-assay analyses are 7.6% at 25(OH)D concentrations of 47.8 nmol/L and 
6.9% at 83.0 nmol/L. The intra-assay CV was 5.1% at 47.8 nmol/L and 6.1% at 
83.0 nmol/L. The assay is accredited by DEQAS. 
Outcome 
 MMSE (287): 30-point questionnaire used to screen for cognitive 
impairment 
 TMT A (293) 
 TMT B (293) 
Genotyping 
As for PIVUS,  SNPs were genotyped as part of a study of SNPs at the SNP 
technology platform at Uppsala University (http://www.genotyping.se/) on an 
Illumina BeadStation 500GX using Infinium iSelect and Golden Gate assays 
from Illumina Inc. Genotyping calls were performed with Illumina BeadStudio or 
GenCall software. Samples with low call rate (<90 %), excess heterozygosity or 
cryptic relatedness were excluded from analyses. SNPs with a call rate less 
than 90%, or that failed (exact P-value<1x10-6) were excluded from the study. 
WHII 
Participants 
WHII was established in 1985 with the aim of investigating the importance of 
socioeconomic difference in physical, mental illness and mortality in London-
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based offices of 20 Civil Service departments (294). DNA preparation and 
cognitive testing was conducted using information from phase 7 (2002-2004, 
n=6,967).  Genetic information was available for 5,067 participants and 6,362 
had information on at least one cognitive test.  
Exposure 
Participants from this cohort did not have data on 25(OH)D concentrations.  
Outcome 
 Memory test score (295): Recall in writing as many of the 20 two syllable 
words  in any order within two minutes 
 Alice-Heim 4 (296): Composed of a series of 65 verbal and mathematical 
reasoning items of increasing difficulty. It tests inductive reasoning, 
measuring the ability to identify patterns and infer principles and rules. 
Participants had 10 minutes to do this section 
 Mill Hill Score (297): Vocabulary was assessed using the multiple choice 
format consisting of a list of 33 stimulus words ordered by increasing 
difficulty and six response choices 
 Verbal fluency (phonemic) (298): Recall in writing as many words 
beginning with 's' as they could in one minute 
 Verbal fluency (semantic) (298): Recall in writing as many animal names 
as they could in one minute 
Genotyping 
DNA was extracted from blood samples using magnetic bead technology 
(Medical Solutions, Nottingham).  Genotyping was performed using the Illumina 
50K IBC CVD chip or KASPar methodology. The call rates and the concordance 
rates of the four SNPs were >98%. The HWE p values were p>0.07. 
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Overall, five cohorts had data on the exposure i.e. 25(OH)D concentrations 
(ESTHER, HBCS, PIVUS, Tromsø, and ULSAM).  All cohorts had data on the 
main outcome i.e. cognitive function.  In order to harmonise cognitive tests, 
each outcome was standardised to produce a mean of zero and a standard 
deviation of one through the following steps:  
1)  Standardise each individual cognitive test in each cohort:  
  
    
 
, 
where z represents the standardised cognitive score, X is the unstandardised 
cognitive score, μ is the mean and σ is the standard deviation.  
2) Obtain a summary score for both memory domain and global cognitive 
function:  
                            (      )   (      )   (      )    
3) Re-standardise the memory and global cognitive function to produce a 
mean of zero and standard deviation of one:  
  
    
 
, 
In this case z represents the standardised memory or global cognition score, X 
is the score of the test created in step two, μ is the mean of this score and σ is 
the standard deviation.   
Data on DHCR7 and CYP2R1 was available in all cohorts. When the SNPs 
rs12785878 or rs12794714 were not accessible, proxy SNPs which were in 
perfect linkage disequilibrium (i.e. SNPs that descend from single ancestral 
chromosomes and therefore are non-randomly associated) were used.   
For genetic analyses, main covariates from additional cohorts included gender, 
age, month of blood collection, education and depressive symptoms.  Table 4.7 
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describes how the main covariates for Chapter 8, education and depressive 
symptoms, were measured in each cohort. 
4.4 Comparison of 1958BC with additional cohorts 
Table 4.8 compares participant characteristics between the cohorts based on 
those eligible for analyses in Chapter 8.  While the 1958BC consists of an 
approximately equal distribution of men and women, ULSAM comprises an 
exclusively male population and WHII consists of mostly men (73.9%).  All 
participants from the 1958BC are <65 years while participants from ESTHER, 
PIVUS and ULSAM are all ≥65 years. 
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Table 4.7: Description of education and depressive variables in additional cohorts 
Cohort Education Depressive symptoms 
 Age (years, (SD))   Description Age (years, (SD))   Description 
ASPS 65.6 (8.0) 9, 10, 13 or 18 years in education 65.6 (8.0) EWL (range 0-15) 
ELSA NA NA 66.1 (9.7) 8-item CES-D:  <3, ≥3 
ESTHER 62.1 (6.6)  ≤9, 10-11 or ≥12 years in education 74.0 (2.8) 15-item GDS: <5, ≥5 
HBCS 68.1 (2.9) Folk school*/elementary/middle school, learning 
profession, elementary school or similar or lower or 
higher university degree 
68.1 (2.9) CES-D: <16, ≥16 
PIVUS 70.2 (0.2) primary school (<9 years), secondary school (9-12 
years), university level (>12 years) 
NA NA 
Tromsø 64.5 (9.9) continuous variable measuring years of education  64.5 (9.9) HSCL-10: have you felt depressed or 
sad in the past week (yes, no)  
ULSAM 71.0 (0.6) 7, 8-10 or ≥12 years in education 71.0 (0.6) ICD-10: yes, no 
WHII 55.5 (5.9) continuous variable measuring years of education 60.9 (6.0) GHQ-30: <4, ≥4 
*Folk school is a Scandinavian school model where learning-by-doing is the basic educational philosophy of the schools 
CIS-R:  Clinical Interview Schedule-Revised; EWL: Eigenschaftswörterliste.  This is a validated multidimensional tool consisting of a list of given 
adjectives describing the emotional status of a test person at the time of the interview (299). CES-D scale: Centre for Epidemiologic Studies 
Depression Scale. This is a short self-report scale design to measure depressive symptomatology based on the past week in the general population 
with higher summary scores indicating greater symptoms  (300).  A cut-off score of 3 has been shown to be clinically significant for 8-item 
questionnaire and cut-off of 16 for longer version  (301); GDS: Geriatric Depression Scale. This is specifically designed for rating depression in the 
elderly.  Cut-off score of 5 was used (302); HSCL-10: Hopkins symptom checklist-10 which is a self-reported symptom inventory consisting of 
symptoms commonly observed in the population (303); ICD-10: International classification of disease (304); GHQ: General Health Questionnaire 
(305)  
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Table 4.8: Comparison of 1958BC with additional cohorts 
 1958BC ASPS ELSA ESTHER HBCS PIVUS Tromsø ULSAM WHII 
Gender, %(N)          
Male 48.6 (3,086) 43.3 (358) 45.6 (2,525) 44.8 (4,369) 44.8 (811) 49.7 (502) 55.2 (6,804) 100 (1,194) 73.9 (3,807) 
Female 51.4 (3,260) 56.7 (468) 54.4 (3,007) 55.2 (5,380) 55.2 (1,000) 50.3 (508) 44.8 (5,532) 0 (0) 26.1 (1,343) 
Age at time of cognitive testing, mean (min-max)       
 50 
(50-50) 
65.6 
(46.8-85.7) 
66.1 
(52.0-≥99) 
74.0 
(70-81) 
68.1 
(61.2-76.8) 
70.2 
(69.8-73.7) 
64.5 
(31-88) 
71 
(69.4-74.1) 
60.9 
(50.5-73.9) 
25-hydroxyvitamin D, nmol/l, geometric mean (min-max)       
 52.9 
(9.5-187.3) 
- - 46.8 
(7.0-225.6) 
59.3 
(19.0-292.0) 
54.3 
(10.9-143.0) 
55.5 
(10.1-192.2) 
65.8 
(5.0-153.3) 
- 
missing, %(N) 7.2 (456) - - 2.5 (247) 42.9 (776) 1.0 42.0 (5,175) 0 (0) - 
Month of collection for 25(OH)D , %(N)       
January 8.1 (511) - - 12.2 (1,187) 7.8 (142) 8.4 (85) 3.2 (393) 1.0 (119) - 
February 7.1 (451) - - 9.6 (937) 3.8 (69) 8.9 (90) 4.5 (550) 9.2 (110) - 
March 6.3 (400) - - 7.2 (704) 7.2 (131) 12.2 (123) 4.4 (539) 7.0 (83) - 
April 5.2 (331) - - 6.7 (650) 7.0 (126) 9.6 (97) 2.7 (329) 8.0 (95) - 
May 5.9 (376) - - 6.9 (673) 6.6 (119) 10.5 (106) 3.7 (453) 6.4 (76) - 
June 8.9 (562) - - 7.3 (708) 3.2 (57) 8.5 (86) 3.4 (421) 4.8 (57) - 
July 7.5 (476) - - 6.6 (644) 0 (0) 0 (0) 0 (0) 0 (0) - 
August 6.6 (420) - - 10.1 (984) 4.0 (72) 6.3 (64) 3.3 (409) 4.5 (54) - 
September 12.9 (816) - - 9.6 (936) 4.7 (85) 8.8 (89) 3.8 (470) 15.2 (181) - 
October 13.6 (860) - - 7.4 (723) 4.6 (84) 10.0 (101) 3.6 (446) 14.7 (175) - 
November 13.2 (836) - - 10.2 (997) 5.1 (92) 9.4 (95) 2.5 (306) 13.5 (161) - 
December 3.9 (250) - - 6.1 (590) 3.3 (59) 7.3 (74) 2.0 (251) 7.0 (83) - 
missing 0.9 (57) - - 0.2 (16) 42.8 (775) 0 (0) 63.0 (7,769) 0 (0) - 
Depressive symptoms , %(N)        
No 92.2 (5,848) 
1.7 (0-15)* 
79.0 (4,372) 11.8 (1,148) 70.2 (1,271) - 42.0 (5,178) 99.8 (1,192) 87.5 (4,505) 
Yes 7.5 (477) 21.0 (1,160) 68.0 (6,627)
†
 14.8 (268) - 1.3 (160) 0.2 (2) 11.2 (575) 
missing 0.3 (21) 4.0 (33) 0 (0) 20.3 (1,974) 15.0 (272) - 56.7 (6,998) 0 (0) 1.4 (70) 
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 1958BC ASPS ELSA ESTHER HBCS PIVUS Tromsø ULSAM WHII 
Education
‡
 , %(N)         
Low  to high 6.1 (387) 27.1 (224) - 73.2 (7,132) 32.4 (586) 56.2 (568) 10.0 (0-48) 64.5 (770) 15.1 (0-35) 
 12.3 (779) 39.8 (329)  13.7 (1,336) 19.3 (350) 17.8 (180)  17.5 (209)  
 27.0 (1,711) 23.1 (191)  10.7 (1,044) 26.3 (477) 24.9 (251)  18.0 (215)  
 16.1 (1,023) 9.4 (78)   21.8 (394)     
 26.9 (1,707)         
missing, %(N) 11.7 (739) 0.5 (4)  2.4 (237) 0.2 (4) 1.1 (11) 51.3 (6,323) 0 (0) 7.3 (376) 
*ASPS depression N=793 mean (min-max). 
†
In ESTHER, depressive symptoms was coded as no=normal (n=1,148), yes=mild depressive (n=6,474) or severe depressive (n=153) 
‡
1958BC categories: none,  <O-level, O-level, A-level or Higher, %(N);  
ASPS categories: 9, 10 or 13 years in education, %(N); 
ESTHER categories: ≤9, 10-11 or ≥12 years in education, %(N); 
HBCS categories:  Folk school/ elementary/ middle school, learning profession, elementary school or similar or  lower/ higher university degree, %(N); 
PIVUS categories: Primary school  <9 years, Secondary school 9-12 years or university level >12 years, %(N); 
Tromsø categories:  years  of education N=6,013, mean(min-max); 
ULSAM categories:  ≤7, 8-10 or  ≥12 years in education, %(N); 
WHII categories: Total number of years in education N=4,774 mean (min-max) 
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4.5 Summary  
 Participants are primarily from the 1958 British birth cohort, with 
additional data from ASPS, ELSA, ESTHER, HBCS, PIVUS, Tromsø, 
ULSAM and WHII 
 Serum 25-hydroxyvitamin D was the main exposure variable used 
 Common mental disorders and cognitive function were the outcome 
variables used 
 Genetic data regarding APOE genotypes and vitamin D-related SNPs 
were obtained and quality control measures were applied 
 These data sources will support the aims of this thesis through the 
provision of well-defined cohorts and reliable and valid measurements of 
25(OH)D concentrations, CMDs and cognitive function.  The rich, 
detailed data obtained from these participants will facilitate both 
observational and genetic analyses so that dependable estimates and 
valid conclusions can be reached 
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 Observational study: Association between vitamin D Chapter 5
and common mental disorder 
5.1 Introduction 
Chapter 1 highlighted the public health importance of reducing the burden of 
common mental disorders (CMD) in the population and the potential role and 
biological plausibility of vitamin D in this pursuit.  CMDs can affect individuals at 
many time points throughout the life-course.  However, one US study suggested 
that the median age of onset of a Diagnostic Statistical Manual-IV (DSM-IV) 
mood disorder is 30 years and a prevalence study in the UK indicated that 
those aged 45-54 years were the most likely to have significant neurotic 
symptoms (9, 61).  Therefore, the current study focuses on the association 
between 25-hydroxyvitmain D (25(OH)D) and CMDs in mid-adulthood.    
The relationship between 25(OH)D and CMDs in adulthood has been 
investigated by many observational epidemiological studies.  In order to assess 
this epidemiological evidence, methodologies of a systematic review were 
applied, capturing data to July 22, 2013.  Studies relating to 25(OH)D and 
CMDs were identified by searching in PubMed (n=1,473).  Selected studies 
were limited to those published in the English language (n=1,227) and in human 
populations (n=977).  Search terms used are given in Appendix 3.1. 
There were 74 relevant studies identified following examination of the titles.  
From the 74, 37 were excluded following inspection of the abstracts (n=24 were 
reviews or commentary, n=6 used child or adolescent samples, n=7 were 
deemed irrelevant).  Reference lists of previous systematic reviews were 
examined for additional relevant citations (178, 306-308) (n=2), resulting in a 
total of 39 studies.  No full text was available for two of these studies; therefore 
the total number identified was 37.  Study details are given in Table 5.1.  
Further information, including study setting, groups and adjustment for 
confounders can be found in Appendix 3.2. 
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Table 5.1: Systematic review: Vitamin D and CMDs 
Author (year), country Total 
N 
Age (y) 
 
Female 
(%) 
Vitamin D, 25(OH)D, 
unless stated 
Mental 
Health test 
Results 
    Method Cut-point, 
nmol/l 
  
Cross-sectional        
Kwasky (2012)(309), 
US 
139 
 
(18-24) 100 MS  BDI  ≥20 Correlation between 25(OH)D and BDI 
Total sample: r=0.005, p=0.95  
African American: r=0.09, p=0.39  
Caucasian: r=-0.15, p=0.26 
Menkes (2012) (310), 
New Zealand 
102 (18-65) 44.1 ECL <50  
<25 
DSM-IV 
 
Depression (n=17) 
Mean 47.5 (25.7), p=0.70, t-test to estimate the 
extent to which vitamin D levels in the study differed 
from the deficiency threshold of <50nmol/l  
Zhao (2010) (311), 
US 
3,916 ≥20 51.2 RIA 
DiaSorin 
Q1:<15ng/mL 
Q2: 15-20 
Q3: 20-26 
Q4: ≥26 
PHQ-9 ≥10 OR with Q1 as reference  
Q2 (n=884) 1.24 (0.74, 2.10); Q3 0.92 (0.45, 1.88); 
Q4: 0.89 (0.45, 1.79), ptrend=0.62 
 
Nanri (2009)(312), 
Japan 
527 21-67 A 
37.1 
B  
42.4 
CBPA  CES-D ≥16 Workplace A (July )(n=159) OR with Q1 as 
reference 
Q2: .60 (0.20-1.76); Q3: 0.75 (0.27-2.08): Q4: (0.70 
(0.24-2.05) ptrend =0.62  
Workplace B  (November)(n=368) OR with Q1 as 
reference 
Q2: 0.84 (0.45-1.58); Q3: 0.83 (0.44-1.58): Q4: 
(0.59 (0.30-1.15) ptrend =0.14 
Armstrong (2007)(313) 75 (21-75)   <25 
25-50  
≥50 
HADS <25nmol/l: 13.3%; 25-50nmol/l: 56.0%; ≥50nmol/l: 
30.7 
Median (IQR) HADS 
<25nmol/l: 31.0 (23.8-36.8) versus 25-50nmol/l 22.5 
(17.0-26.2) versus ≥50nmol/l 23.5 (19.0-27.5) 
p<0.05  
Jaddou (2012)(314), 
Jordan 
4,002 ≥25 74.8 RIA Q1: >63.22 
Q2: 42.31-
DASS21 
≥14 
OR, with Q4 as referent, full adjustment 
Q1: 1.05 p=0.63; Q2 1.24, p0.03; Q3: 1.48, 
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Author (year), country Total 
N 
Age (y) 
 
Female 
(%) 
Vitamin D, 25(OH)D, 
unless stated 
Mental 
Health test 
Results 
63.22 
Q3: 27.61-
42.30 
Q4: ≤27.60 
 p<0.001. ptrend =<0.001 
Ganji (2010)(315), 
US 
7,970 27 ±0.16 
(15-39) 
  <50 
50-75 
>75 
DIS 
 
OR of current depressive episodes, with >75 as 
reference 
<500nmol/l: 1.85(0.90-3.81) 
50-75nmol/l: 0.70(0.38-1.29), p=0.021  
Knippenberg (2010)(316), 
Netherlands 
59 44.2 ± 9.2 
 
73 Unknown  HADS Pearson correlation: r=-0.326, p=0.006, Pearson 
correlation 
coefficient: -0.247, p=0.078,  
Kjærgaard (2011)(317), 
Norway 
10,086 Smokers 
Female: 52.1 
± 11.4 
Male: 
55.4 ± 11.7 
Non- 
smokers 
Female: 57.3 
± 13.0 
Male: 
57.5 ± 12.2 
50.8 ECL Smokers 
Q1: 21.7-71.4  
Q2: 44.3-83.3 
Q3: 54.9-96.8 
Q4: 67.7-201.2 
Non-smokers 
Q1: 6.7-54.5   
Q2: 37.1-65.7 
Q3: 45.9-77.9 
Q4: 56.7-182.5 
SCL-10 
≥1.85 
Smokers (n=1,966) OR, Q1 as reference 
Q2: 0.98 (0.67-1.43): Q3: 0.67 (0.44-1.00); Q4: 0.59 
(0.39-0.89), ptrend =0.003  
Non-smokers (n=8,120) OR 
Q2: 0.88 (0.70-1.11): Q3: 0.77 (0.61-0.98); Q4: 0.74 
(0.58-0.95), ptrend =0.01 
Hoang (2011)(318), 
US 
12,594 51.7±11 31.8 In-house 
 
 CES-D ≥10 OR  for each 10ng/mL increase 
Total sample: 0.92 (0.87-0.97), p=0.002 
with prior history: OR 0.90 (0.82-0.98), p=0.02 
with no prior history: OR 0.95 (0.89-1.02), p=0.17 
Pan (2009)(319), 
China 
3262 (50-70) - RIA 
DiaSorin 
Q1: 26.1 ± 5.9 
Q2: 41.1 ± 4.1 
Q3: 65.1 ± 6.0 
CES-D ≥16 Prevalence of depressive symptoms 
Q1 (n=1087): 11.1% ; Q2 (n=1088):  10.4%; Q3 
(n=1087) 7.2%  
OR with Q1 as reference 
Q2 : 1.38 (1.00-1.90); Q3 1.35 (0.94-1.96), ptrend 
=0.075 
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Author (year), country Total 
N 
Age (y) 
 
Female 
(%) 
Vitamin D, 25(OH)D, 
unless stated 
Mental 
Health test 
Results 
Motsinger (2012)(320), 
US 
15,954 79.2±4; 
79.1±4; 
79.1±4 
100 FFQ <400 IU/day 
400-799  
>800 IU/day 
Mental 
health-
related 
QOL 
 
Least squares means and standard errors, fully 
adjusted 
<400IU/day: 46.4 (0.2); 400-799IU/day 46.8(0.2); 
800IU/day 46.9 (0.3), p=0.002 
Lee (2010)(321), 
Italy, Belgium, Poland, 
Sweden, UK, Spain, 
Hungary, Estonia 
3,369 60 ±11 0 RIA ≥75 
50-74.9 
25-49.9 
<25 
BDI-II >14 
 
Mean 25(OH)D (SD) 
No depression (n=2719) 63.6 (31.6) versus 
depressed (n=432): 52.3 (25.4), p<0.001 
Percentage change in BDI score (95% CI) per 
10nmol/l decrease  
3.2 (1.1 to 5.5), p<0.05 
Percentage change in BDI score (95% CI) with 
≥75nmol/l category as reference 
50-74.9nmol/l: 10.2(-1.2, 22.9); 25-49.9 nmol/l: 22.1 
(3.7 to 43.7): <25nmol/l: 42.3 (20.5, 68.1) ptrend 
=0.01 
Stewart (2010)(322), 
UK 
2,070 ≥65 54.1 RIA 
DiaSorin 
<10ng/ML GDS ≥3 OR (95% CI), for fully adjusted 
1.46 (1.02 to 2.08), p=0.04 
Hoogendijk (2008)(323), 
Netherlands 
1282 (65-95)  CBPA Q1:≤14.7 
ng/ml 
Q2: 14.7-20.4 
Q3: 20.4-27.4 
Q4: >27.4 
CES-D, 
≥16 
DIS 
CES-D Scale score: β(95% CI) per ng/mL 
8.0 (15.2 to 0.8), p=0.03 
Compared to Q1: 
Q2: -0.01(-0.12 to 1.11), p=0.99 
Q3: -1.09 (-2.25 to 0.07), p=0.07  
Q4: -1.07(-2.28 to 0.14) 
Wilkins (2006)(324), 
US 
80 74.8±7.7 62.5 Ria 
DiaSorin 
<25 
25-50  
≥50 
Clinician - 
DSM-IC 
Mean depressive symptoms score (SD): 
<25 (n=13): 2.77 (2.62); 25-50 (n=33) 2.26 (2.29); 
≥50 (n=34): 2.24 (2.14) 
OR for Mood disorder with≥50 as reference: 
<25: 11.69 (2.04 to 66.86); 25-50: 2.56 (0.63 
to10.51), ptrend=0.21  
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Author (year), country Total 
N 
Age (y) 
 
Female 
(%) 
Vitamin D, 25(OH)D, 
unless stated 
Mental 
Health test 
Results 
Johnson (2008)(325), 
US 
158 77 81 Ria 
DiaSorin 
<25 
25-50  
≥50 
GDS, ≥11 Geriatric Depression Scale ≥11 (n=98) 
<25nmol/l: 56%; 25-<50nmol/l 12%; ≥50nmol/l 23% 
<25 versus ≥25, p= 0.02 
<50 versus ≥50, p= 0.45 
Case-control        
Cizza (2012)(326), 
Italy 
136 (21-45) Case: 100 
Control:1
00 
Unknown  MDD 
DSM-IV 
25(OH)D mean (SD) ng/mL: 
Controls: 34.20(2.27) 
MSS: 27.57(1.11) p<0.01  
Eskandari (2007)(327) 133 Case: 
35 ±6.9 
Control: 
35±6.8 
Case: 
100 
Control: 
100 
CIA  DSM-IV 25(OH)D mean (sd) ng/mL 
Control (n=41): 34 (14) 
Cases (n=75): 27 (10.1), p=0.002  
Schneider (2000)(328), 
Germany 
120 Cases: 
38.9±2.1 
48.7±2.2 
57.6±3.5 
Control: 
38.8±3.2 
Cases: 
44 
16 
56 
Control: 
39 
25(OH)D  
1,25(OH)2
D 
 ICD-10 
DSM-III-R 
25(OH)D, mean ± SD (pg/ml) 
Healthy controls (n=31): 45.9 ± 19.8 
Depression (n=25): 37.3 ± 26.1 
Schizophrenia (n=34): 35.1 ± 26.1 
Alcoholism (n=30): 45.6 ± 35.3 
1,25-dihydroxyvitamin D, mean ± SD (ng/ml) 
Healthy controls (n=31): 39.4 ± 15.7 
Depression (n=25): 29.2 ± 9.1 
Schizophrenia (n=34): 29.0 ± 11.6 
Alcoholism (n=30): 38.3 ± 16.9 
Oren (1994)(329), 
US 
15 Case: 
40±7 
Control: 
40±7 
 
Case: 
60 
Control: 
60 
Calcitriol 
CPBA 
 
 DSM-III-R 1,25-dihydroxyvitamin D pg/ml, mean (SD)  
Patients: in the dark: 35 (14); in the light: 40 (16) 
Controls: in the dark: 39 (14). In the light 43(17), 
p>0.05 
Michelson (1996) (330), 
US 
24 Case: 
41±8 
Control: 
41±7 
Case: 
100 
Control: 
100 
Calcitriol 
(column 
chromato
graphy 
25(OH)D  
 DSM-III 1,25-dihydroxyvitamin D pg/ml, mean (SD) 
Cases: 50 (20) 
Controls: 44(19), p=0.25 
25(OH)D ng/ml, mean (SD) 
Cases: 39 (18) 
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Author (year), country Total 
N 
Age (y) 
 
Female 
(%) 
Vitamin D, 25(OH)D, 
unless stated 
Mental 
Health test 
Results 
CPBA Controls: 35(16), p=0.44 
Berk (2008)(331), 
Australia 
53 Case:44.0 
(36.0-52.0) 
Control:48.0 
(33.6-71.4) 
Case: 100 
Control: 
100 
RIA 
DiaSorin 
≤50  
≤25 
Psychiatric 
inpatients 
Age and season adjusted geometric mean 
Cases: 46.4 (38.6-54.9) 
Control: 65.3 (63.2-67.4), p<0.001 
Herrán (2000)(332), 
Spain 
38 Case: 
44.7 ±12.1 
Control: 
43.5 ±8.4 
Case: 
100 
Control: 
100 
RIA 
DiaSorin 
 ICD-10 Mean (SD), ng/ml 
Patients: 27.3 (16.1)  
Controls: 23.0 (7.8), p=0.20 
Jorde (2006)(333), 
Norway 
84 
(148 
total 
cohort) 
Case: 
62.3±15.3; 
Control: 
63.5 ±13.2 
Case: 
42.8 
Control: 
38.0 
RIA 
DiaSorin 
 BDI Mean ± SD score for BDI (1-13) 
SHPT (n=21): 2.67 ±3.04  
Controls (n=63): 2.03±2.28, p<0.05 
Mean ± SD) score for BDI (14-21) 
SHPT (n=21): 2.38 ±1.56  
Controls (n=63): 2.42±2.67, p>0.05 
Mean ± SD score for BDI (total) 
SHPT (n=21): 5.05 ±3.29  
Controls (n=63): 4.45±4.46, p>0.05 
Cohort        
Bertone-Johnson 
(2011)(334), 
US 
81,189 (50-79) 100 FFQ ≥800IU/day 
≥400IU/day  
<100IU/day 
Burnam 
scale, 
≥0.06 
Prevalence OR (95% CI),  <100IU/day as reference 
≥800 IU/day: 0.79 (0.71 to 0.89), ptrend<0.001 
Prospective OR (95% CI), <100IU/day as reference 
≥800 IU/day: 0.80 (0.6 to  0.95), ptrend =0.001 
Chan (2011)(335), 
China 
939 >65 0 RIA 
DiaSorin 
Q1: ≤ 
Q2: 64-76 
Q3: 77-91 
Q4: ≥92 
GDS ≥8 Baseline with Q1 as reference 
Q2:1.39 (0.76-2.54)  Q3: 0.48 (0.23-1.01) Q4:0.46 
(0.22-0.98), ptrend =0.004 
Follow-up 
Q2:5.15 (1.17-22.70)  Q3: 1.98 (0.38-10.35) 
Q4:1.64 (0.30 -9.03), ptrend =0.82 
Milaneschi (2010)(336), 954 ≥65 55.7 RIA <50 CES-D ≥16 Increase in CES-D score: 3-year follow-up 
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Author (year), country Total 
N 
Age (y) 
 
Female 
(%) 
Vitamin D, 25(OH)D, 
unless stated 
Mental 
Health test 
Results 
Italy DiaSorin <50nmol/l versus ≥50nmol/l 
Women: 2.1 p=0.002 
Men 1.9 p=0.01 
Increase in CES-D score: 6-year follow-up 
<50nmol/l versus ≥50nmol/l 
Women 2.2, p=0.04 
Men: 1.1, p=0.20 
HR (95% CI) for <50nmol/l versus ≥50nmol/l 
Women: 2.0 (1.2 to 3.2), p=0.005 
Men: 1.6 (0.9- to.8), p=0.1 
May (2010)(337), 
US 
7,358 73.1±10.2 58.8 CIA >50ng/mL 
31-50 
16-30 
≤15 
ICD-9 HR (95% CI) with >50ng/mL l as reference, fully 
adjusted 
≤15ng/mL: (n=1325): 2.70 (1.35 to 5.40) 
16-30ng/mL: 2.15 (1.10 to 4.21) 
31-50ng/mL: 1.95 (0.99 to3.87) , ptrend =0.06 
Randomised-controlled trials       
Lansdowne (1998)(338), 
Australia 
44 (18-43) 77.2  Treatment 1 
n=150; 
400IU/day and 
9000IU vitamin 
A/day 
Treatment 2 
n=142; 
8000IU/day 
Control:  
n=149  
0IU/day  and 
10,000IU 
vitamin A/day 
PANAS Difference in PA scale between groups versus 
control: p<0.001 
Difference in NA scale between groups versus 
control: p<0.05  
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Author (year), country Total 
N 
Age (y) 
 
Female 
(%) 
Vitamin D, 25(OH)D, 
unless stated 
Mental 
Health test 
Results 
Dean (2011)(339), 
Australia 
128 Treatment 
24.45 ± 2.96 
Control:  
22.06± 2.74 
Treatment 
61.9 
Control:  
52.3 
MS Treatment 
n=63 
5000IU/day 
Control:  
n=65 
placebo/day 
BDI 
STAI 
Baseline 
BDI score (SD): Treatment: 7.24 (7.82); Placebo 
5.72 (5.56), p>0.05  
STAI score (SD): Treatment: 36.29 (10.10): 
Placebo 34.15 (8.31), p>0.05  
6-week Follow-up 
BDI score (SD): Treatment: 6.40 (0.85); Placebo 
5.38 (0.83), p=0.51 
STAI score (SD): Treatment: 36.68 (1.21): Placebo 
36.08 (1.19), p=0.23 
Harris (1993)(340), 
US 
250 (43-72) 100   POMS No correlation between 1,25-dihydroxyvitamin D or 
25(OH)D with POMS scores.  
No differences in POMS scores of those with a 
supplement versus placebo  
Jorde (2008)(341), 
Norway 
441 Treatment 1 
46 (21-70) 
Treatment 2 
48.5 (23-70 
Control:  
48 (24-69) 
Treatment 
1 
62 
Treatment 
2 
64 
 
Control:  
65.8 
 Treatment 1 
n=150; 20,000 
and 
20,000IU/week  
Treatment 2 
n=142; 
20,000IU and 
placebo/week 
Control:  
n=149 2 
placebo/week 
BDI 
 1-13 
14-21 
Baseline BDI total score  
Treatment 1: 4.5  
Treatment 2:  5.0  
Control:  4.0, no significant difference between 
three treatment groups 
12 Month BDI total score 
Treatment 1: 3.0, p<0.01 compared to baseline 
Treatment 2: 4.0,  p<0.01 compared to baseline 
Control:3.8 p>0.05 compared to baseline 
Bertone-Johnson 
(2011)(334), 
US 
36282 (50-79) 100 FFQ Treatment 
n=18,176 
400IU/day with 
1,000mg 
calcium 
Control:  
n=12,421 
Burnam 
scale, 
≥0.06 
Burnam depression scale score 
Treatment:  
<0.06: n=16,401 (90.2%); ≥0.06: n=1,708 (9.4%) 
Control:   
<0.06 n=16,244(89.7%);≥0.0 6 n=1,790 (9.9%), 
p=0.25 
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Author (year), country Total 
N 
Age (y) 
 
Female 
(%) 
Vitamin D, 25(OH)D, 
unless stated 
Mental 
Health test 
Results 
placebo/day Mean change in Buranm Scale between year 1 and 
3 
Treatment (n=1,109):0.007 
Control (n=1,143) 0 
Multivariate OR for Burnam score ≥0.06 
Treatment (n=119 cases, n=997 non-cases): 
Control (n=108 cases, 1,039 non-cases) 0; 1.16 
(0.86, 1.56) 
Kjærgaard (2012)(342), 
Norway 
344 Treatment 
52.6 (10.3) 
Control 
52.1 (9.2) 
Treatment 
51.2 
Control 
52.0 
LC-MS Treatment 
n=180 with 
25(OH)D 
<55nmol/l; 2 
x20 
000IU/week 
Control:  
n=75 with 
25(OH)D 
>70nmol/l; 2 
placebo 
000IU/week 
BDI 
HADS 
SPAQ 
MADRS 
SCID-CV 
Serum 25(OH)D at baseline 
Case: 40.1 (8.8) versus Control: 92.3 (15.8), 
p<0.05,  
BDI median at baseline 
Case: 4 (0-49) versus Control: 3 (0-23), p>0.05 
HADS median at baseline 
Case: 4 (0-25) versus Control: 3 (0-16), p<0.05 
MADRS median at baseline 
Case: 2 (0-26) versus Control: 1(0-13), p<0.05 
GSS, median at baseline 
Case: 6 (0-21) versus Control: 5 (0-15), p>0.05  
Intervention: BDI median 
Treatment (n=120): Baseline 4 (0-31); 6-months 
3(0-35), p=0.92 
Placebo (n=110):  Baseline 4 (0-49); 6-months 2 (0-
35) 
Intervention: HADS median 
Treatment: Baseline 5 (0-22); 6-months 4 (0-20), 
p=0.21 
Placebo:  Baseline 4 (0-25); 6-months 3 (0-31) 
Intervention: MADRS median 
Treatment: Baseline 2 (0-26); 6-months 2 (0-15), 
p=0.34 
Placebo:  Baseline 2 (0-25); 6-months 1 (0-28) 
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Author (year), country Total 
N 
Age (y) 
 
Female 
(%) 
Vitamin D, 25(OH)D, 
unless stated 
Mental 
Health test 
Results 
Intervention: GSS median 
Treatment: Baseline 6 (0-16); 6-months 4 (0-14), 
p=0.73 
Placebo:  Baseline 6 (0-21); 6-months 6 (0-19) 
Sanders (2011)(343), 
Australia 
2034 ≥70 100  Treatment 
n=1018 
500,000IU 
every 
autumn/winter 
Control:  
n=1016 
placebo 
GHQ (≥3) 
SF-12 
WHO Well-
being Index 
PGI-I 
 
Estimated treatment effects  
GHQ (OR, (95% CI)): 1.06 (0.81 to 1.37), p=0.69 
SF-12 (β95% CI)): -0.14(-1.00 to 0.72) p=0.75 
WHO Well-being score (OR (95% CI)) -0.04 (-0.52 
to 1.44), p=0.96 
WHO poor well-being score (OR (95% CI)): 0.85 
((0.45 to 1.61), p=0.63 
Before-after study        
Shipowick (2009)(344), 
US 
9 42.2 ±13.17 100   BDI-II 
0-13 
normal 
14-19 mild 
depression 
20-28 
moderate 
depression 
29-63 
severe 
depression 
Mean (Sd) vitamin D ng/ml 
Baseline: 21.8 (8.33) 
Follow-up: 48.2 (20.1), p=0.009 
Mean BDI-II (SD) 
Baseline: 37.8 (4.79) 
Follow-up: 21.2 (11.07), p=0.02 
 
BDI (Beck Depression Inventory); BMI (Body Mass Index);  CBPA (competitive protein-binding assay); CCLS (Cooper Centre Longitudinal Study); CES-D (Centre for Epidemiologic Studies Depression 
Scale); CIA (Chemiluminescent ImmunoAssay); CVD (Cardiovascular disease); DASS21 (Depression Anxiety Stress Scales); DIS (Diagnostic Statistical Manual); EMAS (European Male Ageing Study); FFQ 
(Food Frequency Questionnaire); GDS (Geriatric Depression Scale); CHQ (General Health Questionnaire); GOS (Geelong Osteoporosis Study); GSS (Global Seasonality Score); HADS (Hospital Anxiety and 
Depression Scale); HR (Hazard Ratio); HSE (Health Survey for England); ICD (International Classification of Disease); IWHS (Iowa Women’s’ Health Study); MADRS (The Montogmery--Åsberg Depression 
Rating Scale); MDD (Major Depressive disorder); MS (Mass spectrometry); MS (Multiple Sclerosis); NHANES (National Health and Nutrition Examination Survey); NHAPC (Nutrition and Health of Ageing  
Population in China); OAANP (Older Americans Act Nutrition Program); OR (Odds Ratio); PANAS (Positive and Negative Affect Schedule); PGI-I (Patient Global Impression Improvement)’ PHQ-9 (Patient 
Health Questionnaire-9 diagnostic algorithm); POMS (Profile of Mood States); POWER (Premenopausal, Osteoporosis, Women, Alendronate, Depression); QOL (Quality of life); SAD (Seasonal affective 
disorder); SCID-CV (Structured Clinical Interview for DSM-IV Axis I disorders-clinical Version); SCL-10 (Hopkins symptoms check list 10); SF-12 (12-item Short From Health Survey); SHPT (Secondary 
Hyperparathyroidism); SPAQ(Seasonal Pattern Assessment Scale); STAI (The State-Trait Anxiety Inventory); WHI (Women’s Health Initiative); WHO (world Health Organisation) 
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The majority of studies conducted to date were cross-sectional in design 
(n=17).  Of these, 64.7% reported a significant association between lower 
25(OH)D concentrations or intake and prevalent CMDs (mainly depressive 
symptoms) (313-315, 317, 318, 320-325).  For instance, one Norwegian study 
conducted in 8,120 middle-aged non-smokers found that the odds for having 
depression or significant mental stress in those with the highest levels of 
25(OH)D (56.7-182nmol/l) were 26% lower (95% CI 0.1% to 42%) than those 
with the lowest 25(OH)D concentrations (6.7-54.5nmol/l).  In the same study, 
smokers (n=1,966) in the highest quartile of 25(OH)D also had 41% lower odds 
(95% CI 11% to 61%) of depression than those in the lowest quartile of 
25(OH)D.  These results were adjusted for age, gender, BMI, physical activity, 
alcohol intake, education, marital status, kidney function and chronic disease 
(317).   
The review identified eight case-control studies, of which five reported 
significantly lower 25(OH)D concentrations in those with depressive disorders 
compared with controls (326-328, 331, 333).  
Three of the four prospective studies showed a significant association between 
either low vitamin D intake or low 25(OH)D concentrations and subsequent 
depressive symptoms (334, 336, 337), while the fourth study reported a cross-
sectional but not prospective association (335).  Follow-up time for these 
studies ranged from 1 to 6 years. 
Of the seven randomised controlled trials identified, two reported a significant 
improvement in depressive symptoms with vitamin D supplementation (338, 
341).  For example, in a Norwegian study of participants with a BMI of 28-47 
kg/m2, supplementation with high doses of vitamin D (i.e. either 20,000IU or 
40,000IU vitamin D per week) was found to improve scores on the Beck 
Depression Inventory (BDI) over the course of 1 year (341).  An additional study 
carried out amongst women in the US found that supplementation with 5,000IU 
vitamin D over the course of 8 weeks was associated with an average decline of 
10 points on the BDI (344).  Conversely, in an Australian study of 2,034 older 
females (aged ≥70 years), those supplemented with 500,000IU (n=1018) every 
autumn/winter did not show an improvement in CMDs symptoms as measured 
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on the General Health Questionnaire, 12-Item Short Form Health Survey, World 
Health Organisation well-being index and the Patient Global Impression 
Improvement over a period of three to five years (343). 
Findings from observational epidemiologic studies remain equivocal.  These 
heterogeneous results may be partly attributed to study design issues.  Study 
populations differed for example, some studies used only female populations 
(309, 320) where others focused exclusively on males (321, 335).  Furthermore, 
some studies focused on specific populations, for example, those with multiple 
sclerosis (316), with cardiovascular disease (337), or with fibromyalgia (313).  
Comparability between studies may also have been reduced as a result of the 
variety of diagnostic criteria and instruments used to measure depressive 
symptoms and the different assays used to assess 25(OH)D concentrations.   
A meta-analysis was conducted in 2013 to evaluate the association between 
25(OH)D and the risk of depressive symptoms (184).  The authors of this paper 
used data from cross-sectional and cohort studies consisting of more than 
50,000 study participants.  Results indicated that a 10ng/ml increase in 
25(OH)D (i.e. a 25nmol/l increase) was associated with a 4% decrease in the 
risk of depressive symptoms in cross-sectional studies and an 8% decrease in 
the incidence of depressive symptoms in cohort studies.  
This promising inverse relationship between 25(OH)D and CMDs identified from 
observational studies requires further scrutiny before a conclusion can be 
reached.  Many studies have focused on depression, while the relationships 
between 25(OH)D and other types of CMDs have been neglected.  There are 
also varieties of social and lifestyle factors that may potentially confound the 
association between 25(OH)D and CMDs, some of which were controlled for in 
previous studies.  However, there has been a lack of investigation to determine 
if lifestyle factors known to affect 25(OH)D concentrations, such as time spent 
outdoors, sun exposure habits or vitamin D supplements (26), differ between 
those with and without CMDs.  Differences in behaviour of those with CMDs 
could explain the associations observed for low 25(OH)D concentrations.  
Therefore, this chapter uses an observational study to examine if an association 
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between 25(OH)D and CMDs remains despite the potential changes in vitamin 
D-related lifestyle factors between those with and without CMDs (Chapter 2).   
5.2 Data and methods 
All data used in this chapter, including how 25(OH)D concentrations were 
collected, how CMDs were assessed and details of covariates, were described 
in Chapter 4.  Here, I will give a brief overview of the relevant data for this 
chapter.   
5.2.1 Participants 
Information was obtained from participants of the 1958 British birth cohort 
(1958BC), which is described in detail in Chapter 4.  Data came primarily from 
the 45 year biomedical survey.  Participants without measurements for vitamin 
D (n=711) and with no data on CMDs (n=30) at 45 years, as well as 1 pregnant 
woman and participants of non-European ancestry were excluded (n=159).  
Consequently, 7,401 participants were included for cross-sectional analysis.  
Participants were eligible for prospective analysis if they had information on 
vitamin D status and CMDs at 45 years and information on depressive 
symptoms at 50 years (n=5,966).  Figure 5.1 illustrates participant selection. 
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Figure 5.1: Participant selection for study on 25(OH)D and CMDs 
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5.2.2 Variables 
25(OH)D concentrations were used to assess vitamin D status.  Categorisation 
of 25(OH)D was based on previously established thresholds (Box 5.1) (42, 44). 
. 
 
 
 
 
 
 
Symptoms of CMDs were assessed when participants were 45 and 50 years 
(Chapter 4).  Briefly, at 45 years, CMDs were assessed using the Clinical 
Interview Schedule Revised (CIS-R) (240).  The presence of depressive, 
anxiety, panic and phobia symptoms in the past week were assessed and 
individually summarised on a scale of zero to four.  A score of ≥2 was used to 
indicate the presence of a clinically relevant CMD and <2 symptoms indicated 
no CMD (345). 
At 50 years, the presence of depressive symptoms in the past four weeks was 
identified using the five question Mental Health Inventory (MHI-5) (244).  
Responses were summed and standardized to a 0-100 scale with lower scores 
indicating worse mental health (244).  Although the MHI-5 was designed as a 
general mental health measure, here a cut off of ≤52 will be used to indicate the 
presence of depressive symptoms (247).   
All other covariates used in these analyses are described in Table 5.2. 
 
Box 5.1 25-Hydroxyvitamin D thresholds 
 <25nmol/l  
 ≥25 to <50nmol/l 
 ≥50 to <75nmol/l 
 ≥75 to <100nmol/l 
 ≥100nmol/l 
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Table 5.2: Covariates from 1958BC for study on 25(OH)D and CMDs 
Covariate Age (y) of measurement Description 
Season of blood collection 45 Winter (December-February), spring (March-May), summer (June-August) 
or autumn (September-November) 
Region of residence 46 Southern England and Channel Islands (South), Middle England and Wales 
(Middle), Northern England and Isle of Man (North) or Scotland. 
SEP* in childhood Father’s occupation at birth (or 
at 7 years if missing) 
Professional and managerial (Ι and ΙΙ), non-manual (ΙΙΙNM), manual (ΙΙΙM) 
and partly or unskilled (ΙV and V). 
SEP in adulthood 42 Ι and ΙΙ, ΙΙΙNM, ΙΙΙ, ΙV and V and unknown. 
Smoking 42 Never, ex-smoker, 1-19 per day or ≥20 per day 
Alcohol 45 Non-drinker, light drinker (<7 units per week), moderate (7-14 units per 
week), heavy (14-21 units per week) or very heavy (>21 units per week). 
BMI (kg/m
2
) 45 Participants weight (kg) divided by height (m
2
). Obesity=BMI ≥30kg/m
2
. 
Physical activity 42 <2-3 times/month, 1 time per week, 2-3 times per week or 4-7 times per 
week 
Frequency of consumption of oily fish (i.e. 
salmon, trout, mackerel, sardines or fresh tuna) 
45 Weekly or less than weekly 
Frequency of consumption of margarine 45 Weekly or less than weekly 
Supplements of cod liver, fish oil or others 
containing vitamin D 
45 Daily or less than daily 
Amount of time spent outside during the past 
month 
45 ≥3 or <3 hours per day 
Leisure time spent using the TV or PC 45 ≥3 or <3 hours per day 
Frequency of suncover usage 45 Most of the time or rarely 
Blistering after sunburn 45 Often, rarely, sometimes or never 
Seeking suntan 45 Often, rarely, sometimes or never 
*SEP; socioeconomic position   
121 
 
5.2.3 Statistical analysis 
Descriptive statistics 
Descriptive statistics (Chapter 3) were used to establish the distribution of 
25(OH)D concentrations and presence of CMDs in the eligible sample.  The 
distribution of 25(OH)D was found to be slightly left skewed (Appendix 3.3), 
therefore, a natural logarithmic (ln) transformation was applied to improve 
approximation of a normal distribution and geometric means are presented.  
Comorbidity between types of CMDs at 45 years was examined using the chi-
square test.  The association between demographic characteristics according to 
the presence of a CMD was described and examined using gender-adjusted 
logistic regression models with CMDs as the binary outcome. 
CMDs and vitamin D-related lifestyles 
The relationships between types of CMDs and vitamin D-related lifestyle 
behaviours (i.e. time spent outside, time spent watching TV/using a PC, use of 
suncover, blistering after sunburn, actively seeking suntan, use of vitamin D-
containing supplements, consumption of oily fish and consumption of 
margarine, table 5.2) were assessed using logistic regression models (Chapter 
3) with vitamin D-related lifestyle behaviours as the binary outcome.  These 
models were adjusted for gender and socioeconomic position (SEP) in 
adulthood. 
Cross-sectional association between 25(OH)D and CMDs 
In order to investigate the cross-sectional association between 25(OH)D and 
types of CMDs, multiple logistic regression models were used.  Here 25(OH)D 
was used as a categorical exposure (i.e. <25, 25-49, 50-74, 75-99, ≥100nmol/l) 
whereby <25nmol/l 25(OH)D was used as the reference category and types of 
CMDs were the binary outcome. 
Regression models were adjusted for: 
1) Gender and season of blood collection 
2) SEP at birth and adulthood in addition to adjustment 1 
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3) BMI in addition to adjustment 1 and 2 
4) Lifestyle factors found to be associated with CMDs; smoking, physical 
activity, PC/TV leisure time, suncover, blistering after sunburn and 
actively seeking suntan in addition to adjustment 1-3 
To examine the possibility of a more complex relationship between 25(OH)D 
and CMDs, the presence of a non-linear association was investigated (Chapter 
3).  The non-linear association was explored by including the curvature term of 
25(OH)D i.e. (25(OH)D2)  in the model.  The mean probability of having 
depressive symptoms at 45 years, over a range of 25(OH)D concentrations, 
was predicted from the multiple regression models found to be most appropriate 
for the data (i.e. linear or non-linear).  These predicted probabilities were used 
to construct the graphs displayed in Figure 5.5. 
Prospective association between 25(OH)D and depressive symptoms  
The prospective association between 25(OH)D and depressive symptoms at 50 
years was investigated using multiple logistic regression models with 
categorical 25(OH)D as the exposure and presence of depressive symptoms as 
the outcome.  Models at 50 years were adjusted for the same covariates as in 
the cross-sectional analyses, and for the presence of any CMD at 45 years. 
As with cross-sectional analyses, presence of non-linearity between 25(OH)D 
and depressive symptoms was examined by including the curvature term of 
25(OH)D.  The mean probability of having depressive symptoms at 50 years 
was predicted from the statistical model found to be most appropriate for the 
data (i.e. linear or non-linear).  These predicted probabilities were used to 
construct the graphs displayed in Figure 5.6. 
Tests for interaction between gender and 25(OH)D with symptoms of CMDs at 
45 or 50 years (Chapter 3) were conducted.  Since there was no evidence of 
interaction by gender in either cross-sectional or prospective analyses, 
combined, gender adjusted analyses are presented. 
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Additional analyses 
Additional analyses were conducted to further investigate the relationship 
between 25(OH)D and symptoms of CMDs and increase confidence in the 
results (Chapter 3).  In order to explore how reverse causality may affect the 
results of the cross-sectional association between 25(OH)D and types of CMDs, 
linear regression models with naturally log-transformed 25(OH)D as the 
outcome and CMDs as the exposure were applied.  These models were 
adjusted for the same covariates as described for cross-sectional analyses.  
Furthermore, sensitivity analysis was conducted to investigate the use of 
different thresholds (i.e. MHI-5 ≤60 and ≤75) for defining depressive symptoms 
at 50 years (Chapter 3).   
81.1% (n=5,999) of participants had complete data for all covariates.  Missing 
values ranged from 0.22% (n=16) for alcohol to 11.3% (n=836) for blistering 
after sunburn (Figure 5.2).  Multiple imputation was used to correct for missing 
data on covariates and sample inverse probability weights were used to account 
for potential selection bias (Chapter 3).  Imputed results are presented, with 
complete and weighted results in Appendices 3.7 to 3.14.  A comparison of 
results from complete-case, weighted-case and imputed datasets is given in 
Table 5.10.   
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Figure 5.2: Proportion of missing covariate observations for study on 25(OH)D and CMDs  
(N=7,401)
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5.3 Results 
5.3.1 Descriptive characteristics 
Women accounted for almost half of the study sample (49.9%).  Serum 
25(OH)D concentrations ranged from 9.5 to 230.7nmol/l.  Geometric mean 
25(OH)D concentrations were found to be slightly higher in men (53.1 nmol/l, 
95% CI 52.3 to 53.9) than women (51.2 nmol/l, 95% CI 50.4 to 52.0nmol/l).  As 
expected, average 25(OH)D concentrations were substantially higher in 
summer/autumn (60.3nmol/l, 95% CI 59.6 to 61.0nmol/l) compared with 
winter/spring (41.2nmol/l, 95% CI 40.5 to 41.9 nmol/l, p<0.001 adjusted for 
gender). 
Symptoms of depression were the most prevalent CMD at 45 years (n=595, 
8.0%), followed by anxiety (n=506, 6.8%), phobia (n=304, 4.1%) and panic 
symptoms (n=107, 1.5%).  There was evidence of comorbidity (p<0.001 
between all types of CMD) which is displayed in Figure 5.3. 
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Figure 5.3: Comorbidity of symptoms of CMDs at 45 years
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Of the participants that answered the MHI-5 at 50 years (n=5,966), 12.2% 
(n=725) had depressive symptoms (MHI-5 ≤52).  Additionally, 32.6% (n=236) of 
participants with depressive symptoms at 50 years were classified as having 
symptoms of CMDs at 45 years.  Women were significantly more likely to be 
affected by symptoms of CMDs at both 45 and 50 years than men (p<0.001).  
Figure 5.4 illustrates the geometric mean of 25(OH)D by symptoms of CMDs at 
45 years and presence of depressive symptoms at 50 years. 
As seen in Table 5.3, participant characteristics varied according to symptoms 
of CMDs.  Participants with symptoms of CMDs were less physically active and 
had poorer lifestyle habits compared with those without symptoms of CMDs.  
For example, individuals with depressive, panic and phobia symptoms were 
more likely to be obese (p≤0.04 for all, adjusted for gender) compared with 
those without symptoms of CMDs.  Participants with depressive and anxiety 
symptoms were overrepresented in groups who rarely exercised and who 
exercised the most.  Participants with symptoms of CMDs were also more likely 
than others to smoke heavily (p<0.001 for all) and be in lower SEP (p≤0.002 for 
all). 
128 
 
 
Figure 5.4: Geometric mean of 25(OH)D with standard error according to CMDs at 45 years and depressive symptoms at 50 years 
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Table 5.3: Characteristics of participants with ≥2 symptoms of CMDs at 45 years 
 Total (n=7,401) Depression (n=595) Anxiety (n=506) Panic (n=107) Phobia (n=304) 
  % (n) % (n) % (n) % (n) 
Gender      
Male 3,705 7.0 (259) 5.4 (201) 0.8 (28) 3.1 (114) 
Female 3,696 9.1 (336) 8.3 ( 305) 2.1 (79) 5.1 (190) 
Combined 7,401 8.0 (595) 6.8 (506) 1.5 (107) 4.1 (304) 
p  0.001 <0.001 <0.001 <0.001 
Season      
Winter 1,286 8.4 (108) 6.6 (85) 1.9 (24) 3.3 (42) 
Spring 1,546 7.8 (120) 5.8 (89) 0.8 (12) 4.3 (66) 
Summer 1,742 7.7 (134) 6.7 (117) 1.3 (23) 4.4 (76) 
Autumn 2,827 8.2 (233) 7.6 (215) 1.7 (48) 4.2 (120) 
p
†
  0.97 0.07 0.55 0.22 
Region      
South 2,842 7.4 (211) 6.4 (181) 1.3 (38) 3.7 (105) 
Middle 1,920 8.5 (163) 7.7 (148) 1.6 (31) 4.8 (92) 
North 1,928 8.5 (163) 6.5 (126) 1.2 (24) 3.7 (72) 
Scotland 711 8.2 (58) 7.2 (51) 2.0 (14) 4.9 (35) 
p†  0.24 0.54 0.49 0.33 
Socioeconomic Position*      
I or II 2,998 6.1 (182) 6.1 (183) 0.9 (27) 3.0 (89) 
IIINM 1,520 8.8 (133) 7.6 (115) 1.3 (20) 4.3 (66) 
IIIM 1,416 8.1 (187) 5.9 (136) 1.5 (34) 4.3 (100) 
IV or V 1,152 16.2 (93) 12.5 (72) 4.5(26) 8.5 (49) 
other/unknown 315     
p
†
  <0.001 0.002 <0.001 <0.001 
Physical Activity*      
<2-3 x per month 2,393 9.7 (233) 8.4 (200) 1.9 (45) 4.9 (118) 
1 x per  week 1,349 6.3 (85) 5.0 (67) 1.0 (13) 2.4 (32) 
2-3 x per  week 1,552 7.0 (108) 5.8 (90) 1.1 (17) 3.4 (53) 
4-7 x per  week 1,881 7.6 (142) 6.7 (126) 1.5 (28) 4.9 (92) 
Missing 226 12.0 (27) 10.2 (23) 1.8 (4) 4.0 (9) 
p
†
  0.006 0.02 0.20 0.86 
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 Total (n=7,401) Depression (n=595) Anxiety (n=506) Panic (n=107) Phobia (n=304) 
  % (n) % (n) % (n) % (n) 
Smoking status*      
Never smoked 3,409 7.0 (240) 6.2 (212) 1.2 (41) 2.8 (94) 
Ex-smoker 2,027 7.2 (146) 5.6 (113) 0.9 (19) 3.8 (77) 
Smokes 1-19 861 8.4 (72) 8.6 (74) 2.4 (21) 6.3 (54) 
Smokes ≥ 20 870 12.8 (111) 9.7 (84) 2.5 (22) 8.1 (70) 
Missing 234 11.1 (26) 9.8 (23) 1.7 (4) 3.9 (9) 
p
†
  <0.001 <0.001 <0.001 <0.001 
Alcohol  consumption      
Non-drinker 457 16.4 (75) 11.6 (53) 4.2 (19) 8.3 (38) 
Light <7 units per week 3,562 8.0 (285) 6.7 (237) 1.4 (51) 4.0 (141) 
Moderate 7-14  units per 
week 
1,852 5.7 (105) 6.0 (111) 0.7 (12) 3.0 (55) 
Heavy 14-21  units per 
week 
827 7.9 (65) 6.8 (56) 1.7 (14) 4.6 (38) 
Very heavy >21  units per 
week 
687 9.2 (63) 7.1 (49) 1.6 (11) 4.5 (31) 
Missing 16 12.5 (2) - - 6.3 (1) 
p
†
  0.08 0.81 0.51 0.83 
BMI, kg/m
2
      
<30 5,628 7.5 (424) 6.6 (370) 1.3 (71) 3.9 (217) 
≥30 1,748 9.5 (166) 7.7 (135) 2.0 (34) 4.9 (86) 
Missing 25 20.0 (5) 4.0 (1) 8.0 (2) 4.0 (1) 
p
†
  0.007 0.08 0.03 0.04 
* Socioeconomic status, physical activity and smoking status taken at 42 years. 
†
 P value from logistic regression trend test adjusted for gender 
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5.3.2 CMDs and vitamin D-related lifestyles 
Certain lifestyle characteristics have been shown to be associated with 
25(OH)D concentrations (26) (Appendix 3.6).  Analyses conducted indicate 
that symptoms of CMDs were also found to be associated with some but not all 
of the vitamin D-related lifestyle factors examined.  Compared with those 
without symptoms of CMDs, individuals with depressive, anxiety and phobia 
symptoms tended to spend more time watching TV or using a PC (p≤0.01) and 
participants with anxiety were less likely to seek a suntan (p=0.02) (Table 5.4).  
When participants did spend time in the sun, individuals with depressive and 
anxiety symptoms were less likely to use suncover compared to those without 
CMDs (p≤0.02).  Blistering after sunburn was more likely in those with 
depressive and panic symptoms compared with individuals with <2 symptoms 
(p≤0.02).  
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Table 5.4: CMDs and vitamin D-related lifestyle factors at 45 years 
  
 
 
Participants 
(n=7,401*) 
 
>3 h 
outside/d 
(n=2,944) 
 
 
>3 h 
TV/PC/d  
(n=2,376) 
 
 
Suncover most 
of the time 
(n=6,188) 
 
 
Often 
blister 
after 
sunburn 
(n=129) 
 
Often actively 
seek suntan 
(n=1,391) 
 
 
Vitamin D 
supplement 
≥ daily 
(n=1,185) 
 
 
Oily fish at 
least weekly 
(n=2,191) 
 
 
Margarine at 
least weekly  
(n=4,563) 
 
 
 N % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) 
Depressive symptoms         
< 2 symptoms 6,806 39.9 (2,715) 31.7 (2,155) 84.3 (5,740) 1.6 (110) 19.0 (1,292) 16.2 (1,100) 29.9 (2,037) 62.0 (4,216) 
≥ 2 symptoms 595 38.5  (229) 37.1 (221) 75.3 (448) 3.2 (19) 16.6 (99) 14. 2 (85) 25.9 (154) 58.3 (347) 
p
†
  0.88 0.008 <0.001 0.007 0.35 0.48 0.10 0.11 
Anxiety symptoms         
< 2 symptoms 6,895 39.9 (2,749) 31.8 (2,191) 83.4 (5,783) 1.7 (115) 19.1 (1,315) 16.0 (1,105) 29.5 (2,034) 61.9 (4,268) 
≥ 2 symptoms 506 35.5 (195) 36.6 (185) 80.0 (405) 2.8 (14) 15.0 (76) 15.8 (80) 31.0 (157) 58.3 (295) 
p†  0.89 0.01 0.02 0.09 0.02 0.84 0.56 0.19 
Panic symptoms         
< 2 symptoms 7,294 39.7 (2,897) 32.0 (2,333) 83.7 (6,105) 1.7 (123) 18.9 (1,378) 16.0 (1,170) 29.5 (2,152) 61.7 (4,503) 
≥ 2 symptoms 107 43.9  (47) 40.2 (43) 77.6 (83) 5.6 (6) 12.2 (13) 14.0 (15) 36.5(39) 56.1 (60) 
p
†
  0.19 0.07 0.45 0.02 0.07 0.73 0.09 0.57 
Phobia symptoms         
< 2 symptoms 7,097 39.7  (2,815) 31.5 (2,233) 83.7 (5,938) 1.7 (119) 18.8 (1,331) 16.1 (1,142) 29.6 (2,100) 61.8(4,383) 
≥ 2 symptoms 304 42.4 (129) 47.0 (143) 82.2 (250) 3.3 (10) 19.7 (60) 14.1 (43) 29.9 (91) 59.2 (180) 
p
†
  0.52 <0.001 0.69 0.08 0.92 0.42 0.85 0.60 
* N varies according to missing covariates, ranging from 7,243 (supplements and oily fish data missing) to 6,565 (blistering after sunburn data missing). 
†
 P value adjusted for gender and SEP position at adulthood. 
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5.3.3 Cross-sectional association 
Since some of the vitamin D-related lifestyles were found to be associated with 
symptoms of CMDs in mid-life, the next step was to examine the association 
between 25(OH)D and symptoms of CMDs while keeping these potential 
confounders constant.  Results from cross-sectional analysis are shown in 
Table 5.5.  It was observed that high 25(OH)D concentrations were associated 
with lower prevalence of depressive and panic symptoms at 45 years 
(ptrend<0.05, after full adjustment).  This association attenuated slightly after 
adjusting for covariates.  Following adjustment for SEP, BMI and lifestyle, 
participants with 25(OH)D ≥75nmol had 43% (95% CI 19% to 60%) lower odds 
of depressive symptoms and 67% (25% to 85%) lower odds of panic symptoms 
compared with those with 25(OH)D <25nmol/l.  The association between 
25(OH)D and phobia was of marginal significance and there was no significant 
relationship between 25(OH)D and anxiety symptoms after adjusting for BMI 
and vitamin D-related lifestyle factors. 
A similar pattern emerged after observing the predicted probability of having 
depressive symptoms at 45 years according to 25(OH)D concentrations (Figure 
5.5).  Here, the predicted probability of having depressive symptoms was lower 
with higher 25(OH)D concentrations.  Additionally, the probability of having 
depressive symptoms at 25(OH)D ≥75nmol/l was significantly lower compared 
with 25(OH)D <25nmol/l. 
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Table 5.5: Association between 25(OH)D and CMDs at 45 years 
 25- Hydroxyvitamin D, nmol/l (n=7,401)*   
 <25 25-49.9 50-74.9 75-99.9 ≥100 ptrend pcurvature 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)   
Depressive symptoms        
Model 1
†
 1.0 0.64 (0.48, 0.85) 0.50 (0.37, 0.67) 0.43 (0.31, 0.62) 0.32 (0.19, 0.52) <0.001 0.45 
Model 2 1.0 0.68 (0.51, 0 .90) 0.55 (0.40, 0.74) 0.47 (0.33, 0.67) 0.34 (0.21, 0.56) <0.001 0.76 
Model 3 1.0 0.68 (0.51, 0.91) 0.56 (0.41, 0.76) 0.49 (0.34, 0.70) 0.36 (0.22, 0.60) <0.001 0.78 
Model 4 1.0 0.75 (0.56, 1.00) 0.65 (0.48, 0.89) 0.59 (0.41, 0.86) 0.43 (0.26, 0.73) 0.001 0.77 
Anxiety symptoms        
Model 1
†
 1.0 0.80 (0.58, 1.12) 0.64 (0.45, 0.90) 0.67 (0.45, 0.98) 0.68 (0.42, 1.10) 0.03 0.10 
Model 2 1.0 0.82 (0.59, 1.14) 0.66 (0.47, 0.94) 0.69 (0.47, 1.02) 0.71 (0.44, 1.15) 0.05 0.14 
Model 3 1.0 0.82 (0.59, 1.15) 0.68 (0.48, 0.96) 0.71 (0.48, 1.05) 0.74 (0.45, 1.20) 0.09 0.14 
Model 4 1.0 0.94 (0.67, 1.32) 0.85 (0.59, 1.22) 0.97 (0.64, 1.46) 1.03 (0.62, 1.71) 0.98 0.49 
Panic symptoms        
Model 1
†
 1.0 0.42 (0.24, 0.75) 0.38 (0.2, 0.68) 0.19 (0.08, 0.43) 0.20 (0.07, 0.62) <0.001 0.04 
Model 2 1.0 0.46 (0.26, 0.83) 0.44 (0.24, 0.79) 0.21 (0.09, 0.49) 0.23 (0.08, 0.72) 0.001 0.12 
Model 3 1.0 0.47 (0.26, 0.84) 0.46 (0.25, 0.85) 0.23 (0.09, 0.54) 0.26 (0.08, 0.81) 0.002 0.12 
Model 4 1.0 0.53 (0.29, 0.97) 0.59 (0.31, 1.11) 0.32 (0.13, 0.79) 0.39 (0.12, 1.28) 0.048 0.22 
Phobia symptoms        
Model 1
†
 1.0 0.62 (0.42, 0.92) 0.57 (0.38, 0.86) 0.52 (0.33, 0.84) 0.17 (0.07, 0.41) <0.001 0.75 
Model 2 1.0 0.65 (0.44, 0.96) 0.62 (0.41, 0.92) 0.56 (0.34, 0.90) 0.18 (0.07, 0.44) <0.001 0.58 
Model 3 1.0 0.65 (0.44, 0.97) 0.63 (0.42, 0.94) 0.58 (0.36, 0.93) 0.19 (0.08, 0.46) <0.001 0.56 
Model 4 1.0 0.75 (0.50, 1.12) 0.81 (0.53, 1.23) 0.77 (0.47, 1.28) 0.25 (0.10, 0.62) 0.052 0.22 
* Multiple imputation used for missing information on covariates. 
†
Model 1 was adjusted for gender & season. Model 2 was adjusted for gender, season & socioeconomic position. Model 3 was adjusted for gender, season 
& socioeconomic position and Body Mass Index. Model 4 was adjusted for gender, season, socioeconomic position, Body Mass Index, smoking and 
physical activity, PC/TV leisure time, suncover, blistering after sunburn, actively seeking suntan. 
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Figure 5.5: Predicted probability of depressive symptoms according to 25(OH)D concentrations at 45 years 
N= 7,401. Values are probability (95% Prediction Interval; PI) of having depression at 45 for fully adjusted models. Purple dot line adjusted for 
gender, season and socioeconomic position (SEP). Navy dash line adjusted for gender, season, SEP and BMI. Green solid line adjusted for gender, 
season, SEP, BMI, smoking, physical activity, TV/PC time, actively seeking suntan, blistering after sunburn and use of suncover. Shaded areas show 
95% PI for fully adjusted models. 
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5.3.4 Prospective association 
Following examination of the prospective association between categorical 
25(OH)D at 45 years and depressive symptoms at 50 years (Table 5.6), it 
appeared that a non-linear relationship may be more appropriate.  Despite 
some attenuation after adjustment for BMI and vitamin D related behaviours, a 
significant non-linear association remained (pcurvature=0.02). 
Data remained supportive of a non-linear relationship following investigation of 
the predicted probability of having depressive symptoms at 50 years according 
to 25(OH)D concentrations at 45 years.  As seen in Figure 5.6, the probability 
of having depressive symptoms at 50 years was lower for participants with 
25(OH)D concentrations between 50 and 85nmol/l compared to those with 
lower or higher concentrations. 
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Table 5.6: Association between 25(OH)D and depressive symptoms at 50 years 
 25- Hydroxyvitamin D, nmol/l (n=5,966)*   
 <25 25-49.9 50-74.9 75-99.9 ≥100 Ptrend Pcurvature 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)   
Depressive symptoms (50 years)       
Model 1 1.0 0.71 (0.53, 0.94) 0.59 (0.44, 0.79) 0.58 (0.41, 0.81) 0.57 (0.37, 0.87) 0.002 <0.001 
Model 2 1.0 0.79 (0.54, 0.97) 0.91 (0.45, 0.82) 0.60 (0.43, 0.85) 0.60 (0.39, 0.91) 0.004 0.001 
Model 3 1.0 0.78 (0.58, 1.05) 0.67 (0.49, 0.91) 0.67 (0.47, 0.95) 0.17 (0.46, 1.10) 0.044 0.001 
Model 4 1.0 0.79 (0.59, 1.07) 0.70 (0.51, 0.96) 0.72 (0.50, 1.02) 0.78 (0.50, 1.21) 0.150 0.002 
Model 5 1.0 0.88 (0.65, 1.19) 0.83 (0.60, 1.14) 0.89 (0.61, 1.23) 0.96 (0.61, 1.51) 0.835 0.02 
*Multiple imputation used for missing information on covariates. N=5,966 
Model 1 was adjusted for gender & season. Model 2 was adjusted for gender, season & socioeconomic position. Model 3 was adjusted for gender, season & 
socioeconomic position and presence of CMDS at 45 years. Model 4 was adjusted for gender, season, socioeconomic position presence of CMDs at 45 
years and Body Mass Index, Model 5 was adjusted for gender, season, socioeconomic position presence of CMDS at 45 years, BMI,  smoking and physical 
activity, PC/TV leisure time, suncover, blistering after sunburn, actively seeking suntan. 
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Figure 5.6: Predicted probability of depressive symptoms at 50 years according to 25(OH)D concentrations at 45 
N=5,966. Values are probability (95% Prediction Interval; PI) of having depressive symptoms at 50 years for fully adjusted models. Purple dot line, 
adjusted for gender, season, SEP and symptoms of any CMDs at 45 years. Navy dash line adjusted for gender, season, SEP, presence of any 
CMDS at 45 years and BMI. Green solid line adjusted for gender, season, SEP, symptoms of any CMDs at 45 years, BMI, smoking, physical activity, 
TV/PC leisure time, actively seeking suntan, blistering after sunburn and use of suncover. Shaded areas show 95% PI for fully adjusted models. 
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5.3.5 Additional analysis 
To explore the possibility of reverse causality, the association between 
symptoms of CMDs (as the exposure) and naturally log-transformed 25(OH)D 
(as the outcome) was examined.  The estimates from this analysis were 
multiplied by 100 to reflect percentage change in 25(OH)D for presence of 
CMDS (346).  As seen in Table 5.8, depressive and panic symptoms were 
associated with slightly lower 25(OH)D concentrations.   
Sensitivity analysis was conducted to explore if results differed using a less 
stringent cut-off for depressive symptoms at 50 years (Table 5.7).   
Table 5.7: Distribution of different MHI-5 thresholds at 50 years in 1958BC 
MHI-5 thresholds N (%) 
≤52 725 (12.15) 
≤60 1,196 (20.05) 
≤75 2,222 (37.24) 
The overall significant prospective association between 25(OH)D and 
depressive symptoms remained despite using different thresholds of MHI-5 
(Table 5.9).  However, the protective association between 25(OH)D and 
depressive symptoms was found to be slightly stronger when using less 
restrictive thresholds for MHI-5 depressive symptoms.   
A comparison of complete-case, weighted-case and imputed datasets is given 
in Table 5.10.   
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Table 5.8: Association between CMDs and 25(OH)D at 45 years 
 N* Coefficient (95% CI), % change in 25(OH)D Ptrend 
Depressive symptoms    
Model 1
†
 7401 -10.15 (-13.74, -6.55) <0.001 
Model 2 7401 -9.28 (-12.88, -5.67) <0.001 
Model 3 7401 -8.36 (-13.10, -4.82) <0.001 
Model 4 7401 -5.47 (-8.88, -2.07) 0.002 
Anxiety symptoms    
Model 1
†
 7401 -4.78 (-8.66, -0.90) 0.02 
Model 2 7401 -4.31 (-8.19, -0.42) 0.03 
Model 3 7401 -3.78 (-7.60,  0.04) 0.05 
Model 4 7401 -0.09 (-3.77, 3.59) 0.96 
Panic symptoms    
Model 1
†
 7401 -19.71 (-27.92, -11.51) <0.001 
Model 2 7401 -18.24 (-26.46,  -10.04) <0.001 
Model 3 7401 -16.41 (-24.50,  -8.32) <0.001 
Model 4 7401 -11.01 (-18.80, -3.22) 0.01 
Phobia symptoms    
Model 1
†
 7401 -9.82 (-14.75, -4.89) <0.001 
Model 2 7401 -9.04 (-13.97, -4.11) <0.001 
Model 3 7401 -8.24 (-13.10, -3.38) 0.001 
Model 4 7401 -4.20 (-8.87, 0.47) 0.08 
* Multiple imputation used for missing information on covariates. 
†
Model 1 was adjusted for gender & season. Model 2 was adjusted for gender, season & socioeconomic position. Model 3 was adjusted for 
gender, season & socioeconomic position and Body Mass Index. Model 4 was adjusted for gender, season, socioeconomic position, Body 
Mass Index, smoking and physical activity, PC/TV leisure time, suncover, blistering after sunburn, actively seeking suntan. 
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Table 5.9: Association between 25(OH)D and depressive symptoms (MHI-5 ≤60 and ≤75)  at 50 years 
 25- Hydroxyvitamin D, nmol/l*   
 <25 25-49.9 50-74.9 75-99.9 ≥100 Ptrend Pcurvature 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)   
MHI-5  ≤60        
Model 1
†
 1.0 0.72 (0.67, 0.78) 0.55 (0.51, 0.59) 0.55 (0.50, 0.60) 0.49 (0.43, 0.54) < 0.001 < 0.001 
Model 2 1.0 0.74 (0.69, 0.80) 0.57 (0.53, 0.62) 0.57 (0.52, 0.62) 0.50 (0.45, 0.56) < 0.001 < 0.001 
Model 3 1.0 0.79 (0.73, 0.86) 0.62 (0.57, 0.67) 0.62 (0.57, 0.68) 0.59 (0.52, 0.66) < 0.001 < 0.001 
Model 4 1.0 0.80 (0.74, 0.86) 0.63 (0.58, 0.69) 0.64 (0.59, 0.71) 0.62 (0.55, 0.70) < 0.001 < 0.001 
Model 5 1.0 0.88 (0.82, 0.96) 0.74 (0.68, 0.80) 0.77 (0.70, 0.85) 0.74 (0.65, 0.83) < 0.001 < 0.001 
MHI-5 ≤75        
Model 1
†
 1.0 0.78 (0.73, 0.84) 0.66 (0.62, 0.71) 0.63 (0.58, 0.68) 0.63 (0.58, 0.70) < 0.001 < 0.001 
Model 2 1.0 0.80 (0.75, 0.86) 0.69 (0.64, 0.73) 0.65 (0.60, 0.70) 0.65 (0.59, 0.71) < 0.001 < 0.001 
Model 3 1.0 0.84 (0.79, 0.90) 0.73 (0.68, 0.78) 0.70 (0.64, 0.75) 0.73 (0.66, 0.81) < 0.001 < 0.001 
Model 4 1.0 0.85 (0.79, 0.91) 0.74 (0.69, 0.80) 0.71 (0.66, 0.77) 0.76 (0.69, 0.83) < 0.001 < 0.001 
Model 5 1.0 0.91 (0.85, 0.98) 0.84 (0.79, 0.91) 0.83 (0.76, 0.90) 0.88 (0.79, 0.97) < 0.001 < 0.001 
*Multiple imputation used for missing information on covariates. N=5,966 
†
Model 1 was adjusted for gender & season. Model 2 was adjusted for gender, season & socioeconomic position. Model 3 was adjusted for gender, season & 
socioeconomic position and presence of CMDS at 45 years. Model 4 was adjusted for gender, season, socioeconomic position presence of CMDs at 45 
years and Body Mass Index, Model 5 was adjusted for gender, season, socioeconomic position presence of CMDs at 45 years, BMI,  smoking and physical 
activity, PC/TV leisure time, suncover, blistering after sunburn, actively seeking suntan. 
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Table 5.10: Comparison of complete, weighed and imputed cross-sectional and prospective results 
 25- Hydroxyvitamin D, nmol/l   
 <25 25-49.9 50-74.9 75-99.9 ≥100 ptrend pcurvature 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)   
Cross-sectional analysis with depressive symptoms at 45 years     
Complete-case results 
(n=6,132) 
1.0 0.73 (0.52, 1.03) 0.67 (0.46, 0.96) 0.59 (0.38, 0.91) 0.40 (0.22, 0.74) 0.003 0.35 
Weighted-case results 
(n=5,935) 
1.0 0.76 (0.53, 1.08) 0.69 (0.47, 1.00) 0.59 (0.38, 0.93) 0.43 (0.23, 0.80) 0.01 0.41 
Imputed results  
(n=7,401) 
1.0 0.75 (0.56, 1.00) 0.65 (0.48, 0.89) 0.59 (0.41, 0.86) 0.43 (0.26, 0.73) 0.001 0.77 
Prospective analysis with depressive symptoms at 50 years  
Complete-case results 
(n=5095) 
1.0 0.90 (0.64, 1.26) 0.88 (0.61, 1.25) 0.92 (0.61, 1.38) 1.13 (0.68, 1.85) 0.69 0.03 
Weighted-case results 
(n=4937) 
1.0 0.90 (0.64, 1.27) 0.87 (0.61, 1.25) 0.85 (0.56, 1.28) 1.09 (0.66, 1.83) 0.99 0.02 
Imputed results 
 (n=5,966) 
1.0 0.88 (0.65, 1.19) 0.83 (0.60, 1.14) 0.89 (0.61, 1.23) 0.96 (0.61, 1.51) 0.84 0.02 
Cross-sectional results adjusted for gender, season, socioeconomic position, Body Mass Index, smoking and physical activity, PC/TV leisure time, 
suncover, blistering after sunburn, actively seeking suntan.  Prospective results additionally adjusted for presence of any CMDs at baseline 
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5.4 Discussion 
The aim of this chapter was to explore the relationship between 25(OH)D and 
CMDs using methods of observational epidemiology.  A paper related to these 
findings has been published in the peer-reviewed journal, Clinical Nutrition (347) 
and can be found in Appendix 1.1.  
The presence of a CMD can lead to changes in lifestyle that affect the health of 
the individual, such as, an increase in cigarette smoking (348), yet, little is 
known about alterations to specific vitamin D-related behaviours.  Results 
indicated that some, but not all vitamin D-related lifestyle factors differ between 
participants with and without symptoms of CMDs.  Findings suggest that those 
with symptoms of CMDs may spend more time watching TV/PC, which could 
imply a less active and indoor lifestyle resulting in reduced 25(OH)D 
concentrations.  Those with CMDs also reported harmful sun-exposure 
behaviours such as blistering after sunburn and rarely using suncover which 
have both been associated with reduced 25(OH)D concentrations.  Cross-
sectional analyses found a significant, moderate linear association between low 
25(OH)D concentrations and prevalence of depressive and panic symptoms 
remained, despite adjustment for vitamin D-related lifestyles.  Here, participants 
with 25(OH)D <25nmol/l were found to have higher odds of depressive or panic 
symptoms compared with those with ≥75nmol.  To extend these results, 
prospective analyses were conducted and a significant non-linear association 
between 25(OH)D and depressive symptoms was demonstrated.  The odds of 
having depressive symptoms were lower for participants with 25(OH)D 
concentrations between 50 and 85nmol/l compared to those with lower or 
higher concentrations. 
Comparison between findings from this study and results from previous work is 
difficult due to the variety of study designs, populations and instruments used to 
assess CMDs.  However, results are consistent with a meta-analysis (184) that 
reported a significant inverse association between 25(OH)D and CMDs using 
both cross-sectional and prospective designs.  
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There are many potential variables that can confound the relationship between 
25(OH)D and CMDs (Chapter 1).  This study had the unique inclusion of 
vitamin D-related lifestyles which have not been assessed to a great extent in 
previous work.  The discovery that these vitamin D-related lifestyles are 
different amongst those with and without symptoms of CMDs emphasise their 
potential importance on the relationship between 25(OH)D and CMDs.  In 
effect, findings imply that the association between 25(OH)D and CMDs may not 
be solely dependent on vitamin D-related behavioural traits.     
Most former cross-sectional studies examining the association between 
25(OH)D and CMDs have focused on depressive symptoms (Table 5.1). The 
potential mechanisms through which active vitamin D have been proposed to 
affect brain function (discussed Chapter 1) are relatively broad and therefore 
may not be unique in their influences on depressive symptoms.  Hence, all 
available categories of CMDs, i.e. depressive, anxiety, panic and phobia 
symptoms were examined.  The relationship found between 25(OH)D and 
depressive symptoms is in line with the literature and may be related to the 
effect of active vitamin D (i.e. 1,25(OH)2D) on certain neurotransmitters, such as 
serotonin, involved in the development of depression (349).  The association of 
25(OH)D with panic symptoms is less well documented.  The relationship 
observed in the current study may be due to specific biological mechanisms 
affected by 25(OH)D concentrations, possibly related to the overarching 
physical symptoms of the disorder.  However, a spurious relationship due to low 
numbers of individuals affected by panic in the sample (1.5%) cannot be ruled 
out.  The lack of association noted between 25(OH)D and anxiety or phobia 
may point to an aetiology that is truly independent of an influence of 25(OH)D, 
or again, may have been unduly dominated by methodological limitations.  CMD 
type-specific analyses might be used to provide insights into possible 
mechanisms, however, these would need to be interpreted with caution, given 
limitations of our mental health measures, comorbidity between different 
symptoms and the limited numbers of participants presenting with panic and 
phobia. 
The present work provides a temporal aspect to the research on 25(OH)D and 
CMDs by conducting one of few prospective studies on 25(OH)D and 
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depressive symptoms.  Other prospective investigations (334, 336) 
demonstrating a protective effect of higher 25(OH)D concentrations on 
depressive symptoms were consistent with the current reported results.  
However, Chan et al. did not replicate this finding (335).  An association was 
observed between 25(OH)D and less severe depressive symptoms was 
identified during sensitivity analyses.  This finding could imply that the 
relationship between 25(OH)D and depressive symptoms may be most 
beneficial for participants with relatively mild depressive symptoms compared 
with those with severe depressive symptoms.  Therefore the association 
between 25(OH)D and a clinical diagnosis of depression may be different 
(Table 5.1).  
Results from the small number RCTs examining the effect of vitamin D 
supplementation on CMDs have been inconsistent (341, 350), therefore the 
direction of the association remains unknown.  It is not possible to ascertain 
causality using a cross-sectional study design.  While the prospective study 
provides some temporal aspect to the relationship between 25(OH)D and 
depressive symptoms, causality remains uncertain.  Results from sensitivity 
analyses, where 25(OH)D was treated as the dependent variable, suggest that 
depressive and panic symptoms were associated with a small reduction in 
25(OH)D concentrations.  This indicates that the possibility of reverse causation 
cannot be ruled out.   
One finding that has not, to the best of my knowledge, been examined in 
previous studies, was the presence of a non-linear prospective relationship 
between 25(OH)D and depressive symptoms.  The finding of a non-linear 
association in prospective analyses has a number of potential explanations.  
The non-linear relationship between 25(OH)D and CMDs may be indicative of a 
threshold effect, whereby increasing 25(OH)D concentrations may only be 
beneficial up to levels of approximately 75nmol/l.  Any increases in 25(OH)D 
beyond this threshold could have either no effect on reducing depressive 
symptoms or may even be harmful.  Conversely, there could be an underlying 
biological explanation for the non-linear association between 25(OH)D and 
CMDs.  In a study showing associations of low and high 25(OH)D with higher 
risk of prostate cancer (351), the investigators suggested that these two levels 
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of 25(OH)D may exert their effects though different mechanisms.  They argued 
that high concentrations may affect vitamin D metabolism leading to an increase 
in 24-hydroxylation.  In the presence of very high 25(OH)D concentrations, this 
process degrades the active form of vitamin D (i.e. 1,25(OH)D2) resulting in 
reduced bioavailability of 1,25(OH)D2 in the tissue.  If this was the case, it could 
be speculated that high 25(OH)D concentrations resulted in lower 1,25(OH)D2, 
reducing stimulation of the VDR receptor in the brain.  This non-linear 
relationship could have implications for determining the most beneficial 
25(OH)D threshold to protect against depressive symptoms, however further 
replication is required.   
Results from this study should be interpreted with methodological limitations in 
mind.  Comparison between compete-case to weighted-case and imputed 
results showed no difference, thereby increasing confidence that the observed 
estimates were not affected by attrition or missing data (Chapter 3).  However, 
the use of different instruments to measure CMDs at 45 and 50 years (Chapter 
4) may have affected the ability to control for CMDs at 45 years in the 
prospective analyses by not being directly comparable.  Furthermore, 
responses to lifestyle questions may be dependent on the participant’s mood.  
This phenomenon is known as the response set effect, whereby individuals who 
have a CMD may have a tendency to answer a question in a negative way, 
which could have an effect of the validity of the questionnaire data. (352). 
The aetiology of both CMDs and vitamin D deficiency are complex and their 
association contains a multitude of confounding factors.  Although this study 
had the advantage of applying a comprehensive statistical adjustment for 
potential confounders, as with all observational epidemiology, residual 
confounding may remain.  This could be due to lack of information on some 
confounding factors as well as errors in measurement of covariates, exposures 
or outcomes.  
5.4.1 Conclusion 
The high burden of mental and behavioural disorders and concurrent high 
prevalence of vitamin D insufficiency (<75nmol/l) worldwide (17) highlight the 
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potential importance of the study findings.  Using methods from observational 
epidemiology, results from this chapter suggest that low 25(OH)D is associated 
with higher prevalence of depressive and panic symptoms and that 25(OH)D is 
modestly and non-linearly associated with subsequent depressive symptoms.   
5.5 Summary 
 There is evidence of a link between hypovitaminosis D and common 
mental disorder, but studies lack investigation of behaviours relating to 
vitamin D status, which may explain this association  
 The aim of this chapter was to assess the relationship between 25(OH)D 
and common mental disorder in mid-adulthood adjusting for vitamin D-
related lifestyles using a cross-sectional and prospective design 
 There was an association between hypovitaminosis D and prevalent 
depressive symptoms and a non-linear association between 25(OH)D 
and subsequent depressive symptoms.  However, uncertainty regarding 
the causal nature of the relationship between 25(OH)D and depressive 
symptoms remains 
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 Observational study: Association between vitamin D Chapter 6
and cognitive function 
6.1 Introduction 
Observational findings from the previous chapter were supportive of an inverse 
association between 25-hydroxyvitamin D (25(OH)D) and emotional well-being.  
As mentioned in Chapter 1, there is also some evidence of an association 
between 25(OH)D and cognitive function including work on biological 
plausibility.  It is this association between 25(OH)D and cognitive function which 
will be explored for the remainder of the thesis.  
Cognitive function changes throughout the life-course from rapid development 
in early life, to plateau in adulthood and then decline with increasing age 
(Chapter 1).  While there is consensus that cognitive decline is evident in older 
adults (aged ≥65 years), there is some suggestion that decline may begin at an 
earlier age (104).  With this earlier age in mind, work presented in this chapter 
focuses on the association between 25(OH)D and cognitive function in mid-life 
(age 50 years).  There have been a number of observational studies examining 
the association of 25(OH)D with cognitive function.  To examine the evidence to 
date, methods of a systematic review were applied on May 8, 2013.  Studies 
relating to vitamin D and cognitive function were identified by searching in 
PubMed for articles published within the past 10 years (i.e. from 2003) 
(n=2,031).  Selected studies were limited to those published in the English 
language (n=1,876) and in human populations (n=1,342).  Search terms used 
are illustrated in Appendix 4.1 There were 60 relevant studies identified 
following examination of the titles.  From the 60, 29 were excluded following 
inspection of the abstracts (n=17 were reviews or commentary, n=5 used child 
or adolescent samples, n=7 were deemed irrelevant).  Furthermore, reference 
lists of previous systematic reviews (185, 353, 354) were examined for 
additional relevant citations (n=20), resulting in a total of 51 studies.  No full text 
was available for 5 of the studies; therefore the total number identified was 46. 
Details of these studies are given in Table 6.1 which has been adapted from a 
table used in a previous systematic review (185).  Further information, including 
study setting, groups and adjustments for confounders can be found in 
Appendix 4.2.  
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Table 6.1: Systematic review: Vitamin D and cognitive function 
Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
    Method Cut-point, 
nmol/l 
  
Cross-sectional       
McGrath 
(2007)(355), 
USA 
11,
232 
(12-90) Unknown RIA DiaSorin Q1: <39.5             
Q2: 52.9                
Q3: 66.9               
Q4: 84.9                      
Q5: >84.9 
Mean reaction 
time 
Symbol-digit 
substitution              
Serial digit 
learning            
Memory and 
learning score 
Adult group:  
Mean reaction time(SD) n=4,747:     
Q1: 229(2.9); Q2:231.2(2.3): Q3:235.4(3.7): 
Q4:232.9(1.7): Q5:233.7(2.57), p=0.60 
Symbol-digit substitution mean(SD) n=4,688:      
Q1: 2.62(0.04); Q2:2.65(0.04); Q3:2.63(0.03): 
Q4:2.64(0.03); Q5:2.69(0.03),p=0.4 0 
Serial digit learning mean(SD) n=4,584:     
 Q1: 4.5(0.1); Q2:4.6(0.1); Q3:4.6(0.1); 
Q4:4.5(0.1); Q5:4.7(0.1), p=0.60   
 
Fully adjusted OR(95%CI) with Q5 as reference 
for symbol digit substitution (≥2):  
Q1: 0.75 (0.52,1.09); Q2: 0.67(0.47,0.96); Q3: 
1.00(0.72,1.40), Q4: 0.80(0.58, 1.11), p=0.11, 
  
Fully adjusted OR(95%CI) with Q5 as reference 
for serial digit learning (≥11):  
 Q1: 1.03 (0.61,1.74); Q2: 1.21(0.69,2.14); Q3: 
1.21(0.77,1.90), Q4: 0.99(0.62, 1.58), p=0.80,  
   
Elderly Group:  
memory & learning mean(SD) n=4,809:                                                                                                                                                               
Q1: 6.5(0.1); Q2:6.4(0.1); Q3:6.6(0.1); 
Q4:6.6(0.1); Q5:6.4(0.1), p=0.02 
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
El-Ghoneimy 
(2009)(356), 
Egypt 
30 (18-40) 63.3 ELISA 
Bioscientia 
<50 PASAT                                 
FST 
p-value not significant for all cognitive tests 
using Pearson correlation 
Hansen 
(2011)(357), 
Norway 
25 (20-60) 0 RIA 
In-house 
<50                    
≥50  
0-back: non- 
executive function 
2-back:excutive 
function 
2-back mean (SD) 
>50nmol/l: 36(3.84) vs. <50nmol/l 29.81(9.55) 
p<0.05, Cohen’s D=0.85 
0-back mean (SD) 
>50nmol/l: 38.57(1.02) vs. <50nmol/l 
38.27(1.49) 
p>0.10, Cohen’s D=0.23 
Tolppanen 
(2011)(358), 
USA 
493
2 
(20-90) Unknown RIA  
DiaSorin 
NA Mean reaction 
time     
Symbol-digit 
substitution              
Serial digit 
learning            
Memory and 
learning score 
Young adults mean difference (95% CI) 
Mean reaction time (n=4929):  0.00 (-0.04 to 
0.04)  
Symbol digit substitution (n=4869): 0.00(-0.03 to 
0.03)  
Serial digit learning (n=4760): 0.01(-0.05 to 0.06) 
 
Older adults mean difference (95% CI) 
Recalled items (n=4831): -0.01(-0.06 to 0.05) 
Lee (2009)(359), 
Italy, Belgium. 
Poland, 
Sweden, UK, 
Spain, Hungary, 
Estonia 
336
9 
(40-79) 0 RIA DiaSorin <25 
25-<50   
50-75 
 ≥75 
ROCF (copy)                      
ROCF (recall)                                   
CTRM                                         
DSST 
ROCF (copy)    
Beta (95%CI) per 10nmol/l: 0.06 (-0.01, 0.14)                                                                                                                                                                                                                                
Beta (95%CI) compared with ≥75: 50-74.9: -
0.33(-0.73, 0.07); 25-49.9: -0.33 (-0.73, 0.07); 
<25: -0.61 (-0.13, 0.09)    
ROCF (recall)   
Beta (95%CI) per 10nmol/l: -0.21 (-0.16, 0.12)                                                                                                                                                                                                                                
Beta (95%CI) compared with ≥75:                                                                                                  
50-74.9:-0.12(-0.57, 0.34); 25-49.9: 0.26 (-0.66, 
1.18); <25: -0.46 (-0.37, 0.45)                                                                                                                     
CTRM                                                                                                                                   
Beta (95%CI) per 10nmol/l: -0.001 (-0.15, 0.14)                                                                                                                                                                                                                                
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
Beta (95%CI) compared with ≥75:   50-74.9:-
0.14(-0.75, 0.47); 25-49.9: 0.08 (-0.87, 1.04); 
<25: -0.13 (-1.3, 1.05)               
 DSST   
Beta (95%CI) per 10nmol/l: 0.15 (0.05, 0.25), 
p<0.01                                                                                                                                                                                                                              
Beta (95%CI) compared with ≥75: 50-74.9:-
0.76(-1.31, -0.20), p<0.05; 25-49.9: -0.77 (-1.82, 
0.29); <25: -1.40 (-2.68, -0.13), p<0.05 
Seamans 
(2010)(360), 
Ireland, France, 
Rome, Italy 
387 (55-87) 49.4 ELISA 
IDS 
T1: <47.6 
T2: 47.6-85.8 
T3: >85.8 
CANTAB 
Visual memory 
working memory 
attention 
SWM between errors 
Median(IQR):  
T1 (n=127): 39.0 (21.0,52); T2(n=127): 
32.0(13,49); T3(n=126): 27.5(15.0-43.0) 
Beta(SE): 
T1 vs. T2: 3.15(2.37, p=0.19 
T1 vs. T3: 5.39(2.44), p=0.03 
Females only:  
T1 vs. T2: 2.87(3.45), p=0.41 
T1 vs. T3: 5.36(2.60), p=0.004 
 
SWM between errors (8 boxes) 
Median(IQR):  
T1: 28 (16,35); T2 25(15-31); T3: 22.0(11.0-32) 
Beta(SE): 
T1 vs. T2:1.46(1.74), p=0.40 
T1 vs. T3: 3.14(1.81), p=0.08 
Females only:  
T1 vs. T2: -1.05(2.47), p=0.67 
T1 vs. T3: 5.29(2.58), p=0.04 
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
SWM strategy 
Median(IQR):  
T1: 35 (33-38); T2 35(33-38); T3: 33.0(22-36.3) 
Beta(SE): 
T1 vs. T2: 1.41(1.00), p=0.16 
T1 vs. T3: 2.36(1.03), p=0.02 
Females only:  
T1 vs. T2: 1.81(1.38), p=0.19 
T1 vs. T3: 4.73(1.40), p=0.001 
 
SWM total errors 
Median(IQR):  
T1: 41 (22-55); T2 35(13.8-53); T3: 28.5(15.8-
45) 
Beta(SE): 
T1 vs. T2: 3.11(2.52), p=0.22 
T1 vs. T3: 5.36(2.60), p=0.04  
Females only:  
T1 vs. T2: 2.06(3.62), p=0.57 
T1 vs. T3: 10.84(3.69), p=0.004 
Benge 
(2009)(361), 
USA 
111 60.5 ± 12.3 82.9 Unknown  WAIS-III  
COWA 
Grooved Peg  
TMT 
HVLT-R 
PASAT 
CWI 
CSI (n=39) and no CSI (n=72), p-value not 
reported 
Oighara 
(1990)(362), 
Japan 
60  (63-94) 100 CPBA 
In-house 
  Dementia 
Screening Scale 
of Hasegawa 
Mean 25(OH)D (SD), ng/ml 
SDAT (n=22) 17.7 (8.5)  
VTD (n=20): 20.7 (8.2)  
No dementia (n=18): 20.7 (8.2)                                                                                                                  
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
Houston 
(2007)(363), 
Italy 
976 ≥65 55.4 RIA DiaSorin <25 
25-50     
≥50 
MMSE 
 
Men, mean MMSE (SE)    
<25nmol/l (n=59) : 23.6(0.5); 22-<50 (n=163): 
25.6(0.3): ≥50 (n=213) 25.2(0.3), ptrend =0.37 ,  
Women  , mean MMSE (SE)    
<25 (n=156): 23.9(0.3); 22-<50 (n=249): 
24.0(0.2): ≥50 (n=136) 25.0(0.3), ptrend=0.01 
Llewellyn 
(2009)(364), 
UK 
176
6 
 ≥65 59.9 RIA DiaSorin Q1: 8-30 
Q2: 34-44              
Q3: 45-65              
Q4: 66-170 
AMT                             
Cognitive 
impairment:  ≥3 
AMT 
 
OR (95%CI) with Q4 as reference fully adjusted:    
Q3: 1.09(0.64-1.86); Q2 1.43 (0.84-2.42); Q1: 
2.28 (1.36-3.83), ptrend=0.001                                                                          
Llewellyn 
(2011)(365), 
USA 
332
5 
≥65 55.2 RIA 
DiaSorin 
<25  
≥25-50 
≥50-75 
≥75 
Immediate verbal 
memory 
Delayed verbal 
memory 
orientation 
attention 
Impairment: worst 
10% of the 
distribution for 
combined scores 
Global cognitive 
function is sum of 
all, memory is 
sum of 4 memory 
tests 
Cognitive impairment OR (95%CI)  
50-75: 0.86(0.59-1.26); 25-50: 1.42 (0.96-2.09); 
<25 0.39(1.49-10.43). ptrend =0.017 
Memory impairment OR (95%CI)  
50-75: 0.59(0.43-0.83); 25-50: 1.18 (0.78-1.81); 
<25 3.18(1.20-8.44). ptrend =0.18 
Aung 
(2006)(366), 
USA 
44 ≥65 years 75 RIA DiaSorin <25 MMSE                                
CDT 
MMSE score (SD)                
<25nmol/l (n=15) 23.27 (4.43); ≥25nmol/l (n=28) 
24.82 (4.02), p=0.25      
<25nmol/l (n=15) 7(47%); ≥25nmol/l (n=28)  
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
MMSE <24, score (SD)                     
<50nmol/l (n=33) 23.91 (4.0); ≥50nmol/l (n=10) 
25.5 (4.7), p=0.29                                                                                    
CDT, n(%) 
 <25nmol/l (n=13) 4(31%); ≥25nmol/l (n=28) 
6(21), p=0.52 
CDT(abnormal), n(%)                                                                                                                                         
<50nmol/l (n=31) 9(26%); ≥50nmol/l (n=10) 
1(10%), p=0.96 
Buell 
(2009)(367), 
USA 
108
0 
(65-99) 75.9 RIA DiaSorin <25     
25-50  
≥50 
MMSE                                  
NAART                                                                        
WMS-III                                  
WMS-III LM                                                                  
TMT 
WAIS-III block 
design                               
Matrix reasoning             
COWA                                 
Beta coefficient (SE), partial correlation value: 
Executive function factor (n=931): 0.01(0.003, 
0.13; p=0.001 
Memory function factor (n=931): -0.001(0.004, -
0.002; p=0.65 
Attention/procession speed factor (n=931): 0.01 
(0.003), 0.08; p=0.03 
TMT A: <25: 92; 25-50:87; ≥50: 82.4; p<0.05 
TMT B: <25: 92; 25-50:87; ≥50: 82.4; p<0.05 
Buell 
(2010)(368), 
USA 
318 (65-99)  72.6 RIA DiaSorin  
 
AD: NINDS-
ADRDA         
VTD: NINDS-
AIREN        Other: 
DSM-IV 
 
25(OH)D, ng/ml (SD) 
AD (n=41): 16.9(6.3);  
Stroke with dementia (n=22): 17.8(8.5); 
Stroke without dementia (n=31): 19.4 (7.8);  
All dementia 16.8(6.9);  
No stroke no dementia(n=211): 20.0 (8.2)       
 
Fully adjusted all-cause dementia (n=70) 
Beta (SE): 0.79 (0.34), p=0.02  
OR (95%CI): 2.21(1.13-4.32)    
Fully adjusted Alzheimer's Disease  (n=37)  
Beta (SE): 0.98 (0.51), p=0.05      
OR (95%CI): 2.65(0.99-7.16)                                                                                                                                                                                                                  
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
Annweiler 
(2012)(369), 
France 
125 73.4±6.9 58.4 RIA 
Incstar 
Q1: 10-40 
Q2:41-59 
Q3:60-79l 
Q4:80-189 
MCI: 
neuropsychologic
al tests, physical 
examination 
&MRI scan 
CHI(n=52) vs. MCI (n=43) 
Mean 25OHD(SD): 70.6(34.2) vs. 53.5(21.8), 
p=0.006 
 
q1 n(%): 10(19.2) vs. 14(32.6) 
q2: 13(25) vs. 13(30.2) 
q3: 11(21.2) vs. 12(27.9) 
q4: 18(34.6) vs. 4(9.3), p=0.03.  
 
OR(95%CI) Fully adjusted (MCI), q4 reference 
q3: 10.24(1.22-85.94), p=0.03 
q2: 7.37(1.16-46.87), p=0.03 
q1: 49.64(4.62-533.28), p=0.001 
 
Stepwise backwards OR(95%CI) Fully adjusted 
(MCI), q4  reference 
q3: 10.29(1.38-76.75), p=0.02 
q2: 6.89(1.17-40.52), p=0.03 
q1: 25.46(3.22-201.28), p=0.002,  
 
OR(95%CI) of MCI 
0.96(0.93-0.98), p=0.002 
Wilkins 
(2006)(324), 
USA 
80 74.8±7.7 62.5 RIA DiaSorin <25                    
25-50                   
≥50                  
MMSE                                    
SBT                                     
CDR sum of 
boxes                  
Factor score 
MMSE, score (SD): 
≥50:26.12(3.46); 25-50: 26.06(4.11); <25:24.77 
(4.32), p=0.53 
SBT, score (SD): 
≥50:4.15(4.75); 25-50:7.42(4.80); <25: 
9.92(8.94), p=0.01      
Factor, score (SD): 
:≥50:-1.01(1.56); 25-50:-1.35 (1.60); <25: -
0.59(1.96), p=0.52                                               
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
CDR, score (SD): 
≥50:1.65(2.08); 25-50: 2.36 (2.56),  <25 
3.08(3.07) p=0.04                                                                                                                        
Dementia (CDR>0) Adjusted OR(95%CI):                                                                      
 <25 versus ≥50: 2.80(0.64,12.28)     
25-50 versus ≥50:1.78(0.61,5.19)                        
Wilkins 
(2009)(370), 
USA 
60 75±8.2 N/A RIA DiaSorin <50                    
≥50    
MMSE                                 
SBT 
MMSE, score (SD): 
<50 25.39(3.9); ≥50: 25.07 (4.9), p=0.78                                                                                                                         
SBT, score (SD): 
<50:10.87(7.5); ≥50: 6.31(6.7), p=0.016  
SBT: Adjusted Beta(SE),  
2.51(1.17), p=0.36 
Annweiler 
(2010)(371), 
France 
752 ≥75 
 
100 RIA DiaSorin <25 SPMSQ  
Cognitive 
impairment: 
(SPMSQ <8)  
 
SPMSQ score (SD) 
≥10ng/mL (n=623): 9.05 (1.34);<10ng/mL 
(n=129)  8.56 (1.67), p<0.001 
Adjusted Beta coefficient (95% CI) 
-0.003 (-0.012, 0.006), p=0.512   
 Adjusted OR (95%CI)       
1.99 (1.13, 3.52), p=0.017, logistic regression     
2.03 (1.17, 3.53), p=0.012, stepwise backward                                                                              
Oudshoorn 
(2008)(372), 
Netherlands 
225 77.6±7.3 65 RIA DiaSorin <50                    
≥50   
MMSE MMSE    
<50nmol/l (n=141); ≥50nmol/l (n=84)  
Fully adjusted Beta (95%CI): 0.05 p=0.01  
Perez-
Llamas(2008)(3
73), 
Spain 
86 77.4±8.1 66.3 HPLC  
CIC 
<50                 
≥50  
SPMSQ SPMSQ , score (SD)  
<50(n=50): 7.9(2.0); ≥50(n=36): 7.7 (2.0), 
p=0.70 
  
Przybelski 
(2007)(374), 
USA 
80 79.5±1.6 N/A RIA DiaSorin <25                            
25-50                           
≥50 
MMSE Pearson correlation r
2
=0.225, p=0.006 
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
Skalska 
(2012)(375) 
Poland 
140 79.67±6.99 67.10% EIA 
IDS 
T1: <23.26  
T2: 23.26-
47.75 
T3: >47.75 
AMT 
cognitive 
impairment:  
AMT <7 
AMT, mean (SD): 
T1: 704(3); t2: 6.9(3): T3: 8.4(2) 
T1 vs. t2: p=0.78 ; T2 vs. T3: 0.03 ; T1 vs. T3: 
p=0.15 
OR(95%CI) 
T2 vs. T1: 3.17(1.04-9.67) p=0.04  
Annweiler 
(2010)(376), 
France 
559
6 
80.5 ± 0.1 
 
100 
 
FFQ (dietary 
intake) 
 
<35µg/wk 
≥35µg/wk 
 
SPMSQ 
Cognitive 
impairment: 
(SPMSQ <8) 
 
SPMSQ mean (SD) 
≥35µg/wk (n=4802): 8.97 (1.24); 
<35µg/wk(n=794) 8.80 (1.31), p<0.001  
 Adjusted Beta coefficient (95%CI) 
0.001 (0.001, 0.002), p<0.024  
Adjusted OR( 95%CI) 
1.30 (1.04, 1.63), p=0.24 
Sakuma 
(2006)(377), 
Japan 
50 82.6 ±8.7 82% ELISA 
DiaSorin 
 Dementia severity 
criteria developed 
by the Japanese 
Ministry of Health, 
Labour and 
Welfare, 1993 
Serum 25(OH)D decreased as dementia 
progressed     
Cognitively normal: 53.7(17.5), p<0.05  
Annweiler 
(2011)(378), 
France 
228 
 
86±0.4 100  <25 
≥25              
 
MMSE Severe dementia % 
<10ng/ml (n=138): 42.5 >10: 25.2, p=0.1,  
Fully adjusted moderate, severe dementia 
OR(95%CI) 
2.57(1.05-6.27), p=0.04 
Step-wise backward moderate, severe dementia 
OR(95%CI) 
2.39(1.12-5.09), p=0.02                                                                                                                    
Ravaglia 
(1998)(379), 
Italy 
27 97.6 ±3.2   RIA for 
1,25OHD 
 
  
 
 
DSM-III 
 
Mean (SD), 1,25OHD concentration in pmol/L:   
Dementia (n=15): 43.2 (20.16) 
No dementia (n=12): 72.72(18.96) 
p=0.009 
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
Case-control        
Evatt 
(2008)(380), 
USA 
196 AD (47-88); 
Controls 
(39-89) 
43; 
43 
ELISA 
IDS 
NA NINCDS-ADRDA 
(AD) 
Mean ng/ml(SD) 
AD: 86.86(15.4); Control: 37(14.5), p=0.30 
Martyn 
(1989)(381), 
UK 
61 (58-90); 
(66-89) 
100 
100 
RIA  
Unknown 
NA Intellectual 
deterioration over 
a period of more 
than 6 months 
and no other 
indication of 
dementia 
Mean ug/ml 
AD (n=27): 11.5; Control(n=34):14.3 
Difference (95%CI) 
-2.8(-4.9 to -0.7), p<0.05  
Walker 
(2009)(382), 
USA 
128 61.3±1.0 
55.6±0.4 
100 
100 
RIA 
DiaSorin 
 NA Book category 
NART 
Rosen target 
detection 
RVDLT 
Serial digit 
learning 
WAIS-R digit 
symbol 
WAIS digit span 
WMS logical 
memory 
For all cognitive tests (details not presented): 
no linear associations observed between any 
baseline abnormal cognitive variable and 
25(OH)D 
no relationship between changes in cognitive 
variables and change in 25(OH)D.  
Jorde 
(2006)(333), 
Norway 
84 
(14
8 
tota
l 
coh
ort ) 
62.3±15.3; 
63.5±13.2 
42.8; 
38.0 
RIA 
DiaSorin 
NA Digit span forward 
& backward 
Seashore Rhythm  
TMT A and B 
Stroop test 
Digit symbol test 
CalCAP 
CVLT 
Beta coefficient (t value) (from total cohort 
(n=148) 
Digit span forward: 0.17 (1.39) 
Seashore Rhythm: -0.13(-0.90) 
TMT A: 0.18(1.57) 
Stroop test, 1 and 2: 0.12(1.05) 
Digit Symbol test: -0.06(-0.74) 
CalCAP: 0.04 (0.32) 
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
Verbal recall 
Visual recall 
COWA 
WAIS 
Verbal recall: 0.08(0.69) 
Visual recall: (0.13(1.21) 
Word list test: -0.03(-0.26) 
COWA: 0.13(1.08) 
Stroop test, 3: -0.07(-0.68) 
TMT B: -0.06(-0.51) 
WAIS: 0.04(0.31) 
All t values not significant 
Luckhaus 
(2009)(383), 
Germany 
47 70.4±8.2; 
67.3±10.9; 
72.4±6.1 
40; 
47; 
50 
ELISA 
IDS 
 NA NINCDS-ADRDA 
(AD) 
Mean nmol/ml (SD)  
AD (n=20): 39.5(24.5); MCI (n=19) 48(18) 
Control (n=8): 36(13), p>0.05 for all 
Ferrier 
(1990)(384), 
UK 
50 76±7 
74±5 
76.9 
75 
RIA  
in-house 
 NA DSM-III 
MTS score <30 
HII score <7 
Mean nmol/ml(SD) 
ATD(n=15): 32(9); Control(n=11): 40(25), 
p=0.30, p>0.05  
Mean pg/ml(SD)  
ATD(n=15): 22(11); Control(n=14): 20(8.4), 
p=0.30, p>0.05  
Sato 
(2005)(385), 
Japan 
200 79.7±4.5; 
79.9±5.2; 
80.6±6.8 
100; 
100; 
100 
CPBA 
Nichols 
 NA DSM-III-R 
MMSE 
Mean nmol/l(SD) 
Severe AD: 25(10); Mild AD: 40.5(10): Controls 
60.5 (11), p<0.001 
Sato 
(1998)(386), 
Japan 
186 81.3±5.4; 
80±4.7 
100 
100 
CPBA 
Nichols 
NA DSM-III-R 
NINDS-ADRDA 
Mean nmol/l(SD) 
AD: 17.7(9.7); Controls 53.9 (7.7), p<0.001 
Cohort        
Chan 
(2011)(335), 
China 
939 >65  0 RIA 
DiaSorin 
Q1: ≤63 
Q2: 64-76 
Q3: 77-91 
Q4: ≥92 
CSI-D 
Cognitive 
impairment: CSI-
D ≤28.4 
Adjusted OR (95& CI) for cognitive impairment 
with Q1 as reference: 
Q2:0.88 (0.37-2.08); Q3: 0.81(0.32-2.03); Q4: 
1.05(0.45-2.45), ptrend=0.84  
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
Slinin 
(2010)(387), 
USA 
160
6 
≥65 0 LC-MS 
In-house 
Q1: <49.8 
Q2: 62.6 
Q3: 74.4 
Q4: >74.4 
3MS 
Trials B 
 
Prevalent CI: Adjusted OR (95% CI)  adjusted 
cognitive impairment at baseline, Q4 reference 
3MS<3 (n=1,598): Q1: 0.93 (0.36,2.39); Q2: 
1.24 (0.49, 3.13);Q3: 0.98 (0.38, 2.52), ptrend 
=0.97 
Trials B<1.5SD(n=1559): Q1: 1.09 (0.61, 1.93); 
Q2: 0.81 (0.45, 1.48);Q3: 1.14 (0.65, 2.00), ptrend 
=0.96 
 
Incident CI: Adjusted OR(95%CI) at follow-up, 
Q4 reference 
3MS(n=1138): Q1: 1.41 (0.89, 2.23); Q2: 1.28 
(0.84, 1.95);Q3: 1.06 (0.70, 1.62), ptrend =0.10 
Trials B(n=1051): Q1: 1.08 (0.53, 2.19); Q2: 1.08 
(0.57, 2.04);Q3: 0.96 (0.50, 1.82); ptrend =0.75,  
Slinin 
(2012)(388), 
USA 
625
7 
≥65 100 Mass spec-  
In-house 
≤25 
50-62.4 
62.5-75 
≥75 
MMSE 
TMT B 
Baseline: OR (95%CI) with >=30 referent 
MMSE: <10ng/ml(n=425) 1.60(1.05-2.42); 10-
19(n=2037)1.09(0.82-1.44); 20-29(n=2408) 
0.79(0.60-1.03), ptrend = 0.03 
Trials B: <10ng/ml(n=425) 1.09(0.68-1.76); 10-
19(n=2037)1.23(0.90-1.68); 20-29(n=2408) 
1.12(0.82-1.52), ptrend = 0.31 
Follow-up. Decline is >1SD below with mean 
difference OR (95%CI) with >=30 referent 
MMSE: <10ng/ml(n=425) 1.58(1.12-2.22); 10-
19(n=2037)1.31(1.042-1.64); 20-29(n=2408) 
1.13(0.91-1.41), ptrend = 0.003 
TMT B: <10ng/ml(n=425) 1.00(0.64-1.56); 10-
19(n=2037)0.93(0.70-1.23); 20-29(n=2408) 
0.83(0.64-1.09), ptrend = 0.93 
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
Llewellyn 
(2010)(389), 
Italy 
858 74.0±6.8 56.8 RIA 
DiaSorin 
Q1: <25 
Q2: <50 
Q3: <75 
Q4: >75 
MMSE 
TMT A and B 
Baseline, score (SD) 
MMSE: Q1(n=175): 23.7(5.3); Q2(n=360): 
25.2(3.3); Q3(n=166):26.0(3.0); Q4(n=157): 26.3 
(2.8) 
p<0.001; 2-way interaction p=0.76 
TMT A: Q1: 151.8(94.7); Q2: 114.9(75.5); 
Q3:94.2(69.7); Q4:87.2 (62.1) 
p<0.001; 2-way interaction p=0.46 
TMT  B: Q1:239.9(78.4); Q2:219.6(80.8); 
Q3:118.5(32.4); Q4:180.5(87.0) 
p<0.001; 2-way interaction p=0.91 
Dementia n(%): Q1:16(9.1); Q2:10(2.8); 
Q3:2(1.2); Q4:1(0.6), p<0.001 
Adjusted RR (95%CI) 6-year substantial 
cognitive decline with Q4 as reference 
MMSE: Q3: 1.19 (0.84 to 1.58); Q2: 1.09(0.78 to  
1.43); Q1: 1.60 (1.19 to 2.0), ptrend =0.02 
Trials A: Q3: 0.95(0.55 to 1.51) ; Q2: 1.25(0.75 
to 1.71); Q1: 1.16(0.65 to 1.84), ptrend=0.44 
Trials B: Q3: 0.99(0.74 to 1.23) ; Q2: 1.11(0.88 
to 1.32); Q1: 1.31(1.03 to 1.51), ptrend =0.04 
Adjusted Beta(SE) year-on-year change with Q4 
as reference 
MMSE: Q3: -0.11(0.12); Q2:-0.035(0.095); Q1:-
0.32(0.109), ptrend=0.03 (all participants) 
MMSE: Q3: -0.13(0.114); Q2:-0.051(0.096); Q1:-
0.310(0.109), ptrend =0.04 (non-demented only) 
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
Breitling 
(2012)(390), 
Germany 
163
9 
74.1±2.8 
73.9±2.7 
60.2 Chemilumine
scence 
DiaSorin (for 
women) 
DIS (for men) 
Women 
Q1: 17 
Q2: 24 
Q3: 32 
Q4: 45 
Men 
Q1: 37 
Q2: 51 
Q3: 25 
Q4: 79 
COGTEL Women: fully adjusted beta-coefficient (95% CI) 
with Q5 as reference: 
Q4: -0.43(-2.33 to 1.47; Q3: -0.76(-2.69 to 1.13); 
Q2: -0.08 (-2.06 to 1.90): Q1: -1.91(-3.92,0.09), 
p=0.31 non-linearity p=0.015 
Men: fully adjusted beta-coefficient (95% CI) 
with Q5 as reference: 
Q4: -0.44(-2.52 to 1.64; Q3: 1.64(-0.71 to 3.38); 
Q2: -0.90 (-3.02 to 1.23): Q1: -1.05(-3.21 to 
1.11), p=0.15 non-linearity,  p=0.28 
Annweiler 
(2011)(391), 
France 
40 (76.4-82) 100 RIA 
Incstar 
<25 
≥25              
 
NAD: matching 
DSM-IV but not 
matching 
NINCDS-ADRDA 
criteria 
AD: matching 
NINCDS-ADRDA 
Adjusted OR (95% CI), with vitamin D deficiency 
19.57 (1.11, 343.69), p=0.04 
14.95 (1.17, 190.74), stepwise backward model 
p=0.04 
Annweiler 
(2012)(392), 
France 
498 79.8 ±3.8 100 FFQ (dietary 
intake) 
NA No dementia, AD 
and  
Other dementias: 
DSM-IV and 
NINCDS-ADRDA 
Onset of AD: Adjusted OR (95% CI) 
0.99(0.98-0.99), p=0.41 
Onset of other dementias: Adjusted OR (95% 
CI) 
1.01(1.00-1.02), p=0.07 
Randomised Controlled Trial       
Rossom 
(2012)(393), 
USA 
414
3 
Treatment  
(65-80) 
Control 
(65-80) 
Treatment  
100 
control 
100 
NA NA Probable 
dementia 
MCI 
Global cognitive 
function 
Hazard Ratio (95% CI) of Probable Dementia or 
MCI for treatment versus control: 
0.94(0.72-1.24), p=0.68 
163 
 
Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
Manders 
(2009)(394), 
Netherlands 
176 Treatment  
median 83 
(72.9-92.0 
p10-p90) 
Control 
83.0 (70.8-
91.4) 
Treatment  
69.7 
Control 
68.4 
ELISA 
DiaSorin 
  ADAS-cog(total 
score, 
memory/orientatio
n, language, and 
Praxis 
components) 
MMSE 
Verbal fluency 
test (animal and 
professions) 
Difference in cognitive tests in treatment (n=78) 
vs. controls (n=33) 
Animal test: 0.6(3.4) vs.  0.0(3.2), p=0.41 
Profession test: -0.1 (3.0) vs.  -0.3 (2.6), p=0.687 
 
ADAS-cog total: 0.0 (-5.0, 8.0) vs. 1.0 (-5.6, 6.0), 
p=0.845 
 
Memory: 0.0 (-4.8, 5.0) vs.  0.0 (-3.0, 5.0), 
p=0.79 
 
Language: 0.0 (-1.0, 2.7) vs. 0.0 (-2.6, 3.0), 
p=0.884 
 
Vitamin D concentration:  21.0 (-2.7, 57.9) vs. -
0.5 (-5.4, 24.8), p<0.001 
Chandra 
(2001)(395), 
Canada 
96 Treatment  
75 
Control 
74 
Treatment  
58.3 
control 
56.3 
CPBA 
Unknown 
NA MMSE 
Wechsler memory 
Halstead-Reitan 
categories 
Buschke 
consistent long-
term retrieval 
Digit span 
(forward) 
Salthouse 
listening span 
Long-term 
memory recall 
 
 
For all cognitive tests 
All participants combined: no significant 
correlation between levels of individual nutrients 
and cognitive function test scores, p-value not 
reported; 
No single nutrient appeared to influence 
cognition, p-value not reported 
Significant difference between treatment and 
control groups for all tests 
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Author (year), 
country 
Tot
al N 
Age (y); 
Mean ± 
SD;  
(min-max) 
Female (%) Vitamin D, 25(OH)D unless 
stated 
Cognitive tests; 
Dementia 
Criteria 
Results 
Before-after study      
Annweiler 
(2012)(396), 
France 
44 Treatment  
median 
81.06, IQR 
14.0 
 
Treatment  
54.5 
 
NA NA MMSE 
CAB 
FAB 
OR (95% CI) for improvement in cognitive tests: 
MMSE: 3.80(1.02-14.21), p=0.047 
CAB: 16.50(2.51-108.60), p=0.004 
FAB: 8.00(1.52-42.04), p=0.01 
Przybelski 
(2008)(397), 
USA 
63 Treatment  
86.2 
(2.3SE) 
 
Treatment  
68.0 
 
LC-MS 
In-house 
NA CDT 
Verbal fluency 
test 
Mean total 25(OH)D, ng/ml after 4 weeks: 
n=25: 17.3 to 63.8, p<0.001 
 
Verbal fluency mean (SEM). Baseline vs. 
treatment 
8.3 (1.2) vs. 8.3 (1.2) 
CDT: 5.1 (0.5) vs. 5.7 (0.5) 
1,25OHD (1,25 dihydroxyvitamin D);  3 MS (Modified Mini-mental State Examination);  AD (Alzheimer's Disease);  ADAS-cog (Cognition part of the Alzheimer's Disease Assessment Scale);  
AMT(Abbreviated Mental Test Score); APOE (Apolipoprotein E); ATD (Alzheimer's Type Dementia); BMI (Body Mass Index); CAB (Cognitive Assessment Battery); CalCAP (California Computerized 
Assessment Package); CANTAB (Cambridge Neuropsychological Testing Automated Battery); CDR (Clinical Dementia Rating); CDT (Clock Drawing Test (Wolf-Klein)); CHI (Cognitively Healthy 
Individuals); CIC (Chromsystems Instruments and Chemicals); COGTEL (Cognitive Telephone Screening Instrument); COWA (Controlled Oral Word Association); CPBA (Protein Binding Assay); 
CREST (Consortium for Research in Elder Self-neglect of Texas);  CRIN (Clinical Research in Neurology); CSI (Clinical Significant Impairment); CSI-D (Community Screening Instrument for 
Dementia); CTRM (Camden Topographical Recognition Memory); CVLT (California Verbal Learning Test); CWI (Colour Word Trial); DSM-III-R (Diagnostic and Statistical Manual of Mental Disorders, 
3rd Edition, Revised); DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition);  DSST (Digit-Symbol Substitution Test); EIA (Enzyme Immuno Assay); EPIDOS (Epidemiologie de 
l’Osteoporose); ELISA (Enzyme-linked Immunosorbent assay); EMAS (European Male Ageing Study);  FAB (Frontal Assessment Battery); FFQ (Food Frequency Questionnaire); FST (Faces Symbol 
Test); GAIT (Gait and Alzheimer Interaction Tracking study); HII (Hachinski Ischaemic index); HPLC (High Performance Liquid Chromatographic system);  HSE (Health Survey for England); HVLT-R 
(Hopkins Verbal Learning Test-Revised); IDS (Immunodiagnostic System Limited); IU (International Units); LC-MS (Liquid Chromatography-tandem Mass Spectrometry); MCI (Mild Cognitive 
Impairment);  MMSE (Mini-Mental State Examination); MRI (Magnetic Resonance Imaging); MrOS (Osteoporotic Fractures in Men); MS (Multiple Sclerosis); MTS (Mental Test Score); NAART (North 
American Adult Reading Test); NAD (Non-Alzheimer's Dementia); NAME (Nutrition and Memory in Elders); NART (National Adult Reading Test);  NHANES (National Health and Nutrition Examination 
Survey); NINDS-ADRDA (National Institute of Neurological Disorders and Stroke – Alzheimer’s Disease and Related Disorders Association criteria); NINDS-AIREN (National Institute of Neurological 
Disorders and Stroke –Association Internationale pour la Recherch et l’Enseignement en Neurosciences criteria); PASAT (Paced Auditory Serial Addition Task);  PHPT (Primary hyperparathyroidism); 
RIA (RadioImmunoAssay); ROCF (Rey-Osterrieth Complex Figure); RVDLT (Rey Visual Design Learning Test); SBT (Short Blessed Test); SDAT (Senile Dementia of Alzheimer Type); SPMSQ 
(Pfeiffer Short Portable Mental State Questionnaire); TMT (Trail-making test); VTD (Vascular Type Dementia); WAIS-III (Wechsler Adult Intelligence Scale-Third Edition); WMC-III LM (Wechsler 
Memory Scale-Third Edition, logical memory); WMS-III (Wechsler Memory Scale-Third Edition); ZENITH (Zinc Effects in Nutrient/Nutrient Interactions and Trends in Health and Ageing) 
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The review identified some evidence of an association between vitamin D and 
cognitive function, however results remain equivocal.  The majority of studies 
identified were cross-sectional in design (n=26).  Of these studies, 73% found a 
significant association between vitamin D and either cognitive function or 
dementia criteria, whereby participants with lower 25(OH)D concentrations were 
more likely to perform worse on cognitive tests or have dementia compared with 
those with higher concentrations (324, 355, 357, 359, 360, 363-365, 367-372, 
374-376, 378, 379).    
The second most common study design was case-control (n=8).  Although 
mean 25(OH)D concentrations were found to be significantly lower amongst 
those with dementia in some studies (381, 385, 386), results remain 
inconclusive with five case-control studies finding no significant difference in 
25(OH)D concentrations between cases and controls (333, 380, 382-384).   
There were seven cohort studies identified of which five found a significant 
association between 25(OH)D concentrations and cognitive function or 
dementia (388-392).  One study found a significant association between vitamin 
D intake and Alzheimer’s disease, but not for other dementias (392) whilst 
another identified an association between 25(OH)D concentrations and 
performance on the Mini-mental State examination (MMSE) but not for the Trail 
-making Test B (388).  Furthermore, a non-linear relationship between 25(OH)D 
concentrations and cognitive performance was observed amongst women 
(390). 
Three randomised controlled trials (RCT) examining the effect of vitamin D on 
cognitive function have been performed.  The largest one was conducted 
amongst a group of women aged ≥65 years with no dementia at baseline 
(n=4,143) (393).  There was no difference in developing dementia or mild 
cognitive impairment (MCI) between the treatment group (receiving 400IU 
vitamin D and 1,000mg calcium carbonate) compared with the placebo group 
over the follow-up time of 7.8 years.  It is difficult to determine what effect 
vitamin D supplementation alone may have had on the development of 
dementia or MCI.  Additionally, the dose of vitamin D supplementation may 
have been too low to have an effect.  The second largest RCT was completed 
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in the Netherlands amongst participants in a nursing home aged >60 years, 
who had a BMI of ≤30 kg/m2 and MMSE score of at least 10 points (n=176) 
(394).  There was no overall effect of treatment with a nutrient dense drink 
(containing vitamin D, twice a day) on the Alzheimer’s Disease Assessment 
Scale (ADAS) or a test of verbal fluency.  However, there was a beneficial effect 
of the nutrient dense drink amongst a subgroup of participants with a low BMI 
(<24.4kg/m2 at baseline).  This RCT was conducted over a period of 24 weeks 
which may be too short to see neuropsychological improvements.  The final 
RCT was carried out amongst 96 participants aged >65 years (395).  The 
treatment group received a supplement of trace elements (with 4μg vitamin D) 
over one year.  While cognitive function (i.e. immediate and long-term memory, 
abstract thinking, problem-solving ability and attention) improved, there was no 
correlation between individual nutrients and cognitive function.   
Of the two before-after studies with a comparison group design, one found a 
significant improvement in cognitive scores with vitamin D3 supplementation 
over a 16 month period (n=44) (396).  The other before-after study found no 
improvement after 4 weeks supplementation with vitamin D2 amongst 63 
nursing home residents (397).  
These heterogeneous results may be partly due to study differences.  Sample 
sizes varied from 25 (357) to 11,232  (355) as did the study populations for 
example, community, prison, hospital, clinic or institutionalised groups.  
Furthermore, some studies included only men (335, 357, 359, 387) whilst others 
focused exclusively on women (362, 371, 376, 378, 381, 382, 385, 386, 388, 
391-393).  Methods of measuring 25(OH)D also varied, with the most frequent 
one being the DiaSorin RIA method (n=18).  Additionally various vitamin D cut 
points were used for example, <25nmol/l, ≥25-50nmol/l, <50nmo/l or quartiles 
and quintiles.  There was also considerable variation in how the outcome was 
defined.  In 20 studies, the outcome included a diagnosis of dementia or 
cognitive impairment (for example, mild dementia, Alzheimer’s dementia, 
vascular type dementia).  Of the studies with a test of cognitive function, the 
most common was MMSE (n=14). Other cognitive domains measured included 
memory, attention/processing speed, executive function, verbal fluency and 
intelligence.  Another factor which may have influenced the observed estimates 
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was the control for potential confounders.  While some studies used minimal 
adjustment for example, age, gender, season and ethnicity, others included a 
range of potential confounders for example, BMI, education, chronic illness, 
smoking, alcohol, physical activity, family income, other nutrients (vitamin E, 
zinc B1, B6 and B12) amongst others see Appendix 4.2 for details.   
Interestingly, results from a random effects meta-analysis conducted in older 
adults (age ≥65 years) consisting of various study designs found significantly 
lower mean 25(OH)D concentrations amongst those with Alzheimer’s disease 
compared with controls (weighted mean difference: -6.2nmol/l 95% CI -0.6 to -
1.8).  They also observed that those with <50nmol/l 25(OH)D performed 
significantly worse on the MMSE when compared with those with ≥50nmol/l 
(average difference in MMSE score:1.2 95% CI 0.05 to 1.9) (185). 
Despite promising results from the meta-analysis, much remains unknown 
about the relationship between 25(OH)D and cognitive function.  Most of the 
evidence to date has been obtained from studies which have mainly focused on 
older adult populations (≥65 years).  Therefore, the association between 
25(OH)D and cognitive function amongst adults in mid-life remains unexplored.  
The examination of the relationship between 25(OH)D and cognitive function in 
mid-adulthood could be essential for identifying the timing of successful 
interventions to maintaining cognitive function.  
There are many potential confounders of the relationship between 25(OH)D and 
cognitive function.  While some studies have attempted to adjust for potentially 
important confounding factors such as education, others have failed to do so 
(Appendix 4.2) (355).  Research on influences on cognitive function in 
adulthood and later life is further complicated by the fact that they need to take 
account of strong influences in earlier life factors on cognitive development.  
Cognitive ability in childhood is an important predictor of cognition function in 
later life and may protect against cognitive decline in mid-life (112).  Childhood 
cognitive ability may also influence health-related behaviours and educational 
attainment in mid-life which could mediate the effects of cognitive function in 
later life. Early life factors such as childhood cognitive ability and educational 
attainment could also influence vitamin D-related behaviours in mid-life such as 
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sun-exposure behaviour and use of dietary supplements containing vitamin D, 
which may explain the association between 25(OH)D and cognitive function in 
mid-life.  Therefore, this chapter uses observational epidemiology to examine 
the prospective association between 25(OH)D and cognitive function in mid-life 
in the presence of earlier life factors (Chapter 2).  
6.2 Data and methods 
All data used in this chapter, including how 25(OH)D concentrations were 
collected, administration and standardisation of cognitive tests and the earlier 
life factors of childhood cognitive ability and educational attainment were 
described in detail in Chapter 4.  Here, I will give a brief overview of the 
relevant data for this chapter.   
6.2.1 Participants 
Information was obtained from members of the 1958 British birth cohort 
(1958BC).  For the current analyses, information was collected in childhood (7, 
11 and 16 years) and adulthood (23, 31, 42, 45, 46 and 50 years).  Eligible 
participants included those who completed at least one cognitive test at 50 
years and had 25(OH)D measurements from 45 years, were not pregnant and 
from a European ancestry (n=6,496).  Study samples varied from 6,378 for 
letter cancellation to 6,496 for animal naming and immediate word list.  Figure 
6.1 illustrates participant selection for this chapter.  
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Figure 6.1: Participant selection for study on 25(OH)D and cognitive function 
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6.2.2 Variables 
25(OH)D concentrations were used to assess vitamin D status.  Categorisation 
of 25(OH)D was based on previously established thresholds (Box 5.1) (42, 44) 
Verbal memory, verbal fluency and speed of processing were the cognitive 
domains assessed during this chapter (Chapter 4).  Pearson correlations 
between these cognitive tests ranged from 0.08 to 0.65; p<0.001, for all.  
Factors that may have influenced performance on cognitive tests were 
controlled for in the analyses (Table 4.4).   
A brief description of these earlier life factors and all other covariates used in 
these analyses are described in Table 6.2.   
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Table 6.2: Covariates from 1958BC for study on 25(OH)D and cognitive function 
Covariate Age of measurement (y) Description  
Educational attainment Highest qualification obtained by 42 
years (or by 33 years if missing) 
None or some qualifications, O-level (or equivalent), A-level (or 
equivalent) or higher degree 
Cognitive ability in childhood 7, 11 and 16 years Tests from each year were standardised for age at assessment and 
averaged to obtain a summary score for childhood cognitive ability. 
Missing data on one test were replaced by that individual’s mean 
standardised score on the other tests. 
Region of residence 46 Southern England and Channel Islands (South), Middle England and 
Wales (Middle), Northern England and Isle of Man (North) or Scotland. 
SEP* in childhood Father’s occupation at birth (or at 7 
years if missing) 
Professional and managerial (Ι and ΙΙ), non-manual (ΙΙΙNM), manual 
(ΙΙΙM) and unskilled (ΙV and V).   
SEP in adulthood 42  Ι and ΙΙ, ΙΙΙNM, ΙΙΙ,  ΙV and V and unknown.   
Smoking 42 Never or former and current 
Alcohol  45 Non-drinker, light drinker (<7 units/week), moderate (7-14 units/week), 
heavy (14-21 units/week) or very heavy (>21 units/week).  
BMI (kg/m2) 45 Participants weight (kg) divided by height (m2). Obesity=BMI ≥30kg/m2.  
Menopause 45 Post-menopausal, pre-menopausal or peri-menopausal (men coded 
separately) 
Physical activity 42 ≤1 time per week, 2-3 times per week or 4-7times per week 
Depressive symptoms 45 ≥2 symptoms in the past week measured by the Clinical-Interview 
Schedule Revised.(240) 
Frequency of consumption of oily fish (i.e. 
salmon, trout, mackerel, sardines or fresh tuna) 
45 Weekly or less than weekly 
Frequency of consumption of margarine 45 Weekly or less than weekly 
Supplements of cod liver, fish oil or others 
containing vitamin D 
45 Daily or less than daily 
Amount of time spent outside during the past 
month 
45 ≥3 or <3 hours per day 
Leisure time spent using the TV or PC 45 ≥3 or <3 hours per day 
Frequency of suncover usage 45 Most of the time or rarely 
Blistering after sunburn 45 Often, rarely, sometimes or never 
Seeking suntan 45 Often, rarely, sometimes or never 
*SEP; socioeconomic position   
172 
 
6.2.3 Statistical analysis 
Descriptive statistics 
Histograms of 25(OH)D and cognitive tests are given in Appendices 4.3 and 
4.4.  The distribution of 25(OH)D was slightly left skewed, therefore geometric 
means are reported and natural log transformation (ln) was applied when 
25(OH)D was used as an outcome (Chapter 3).  To assess the distribution of 
25(OH)D concentrations by participant demographics, gender-adjusted linear 
regression models were used with naturally log-transformed 25(OH)D as the 
outcome (Chapter 3).   
Association with earlier life factors 
Logistic regression models (Chapter 3), adjusted for gender and socioeconomic 
position (SEP) in adulthood and childhood were used to examine the 
association between earlier life factors (i.e. educational attainment and cognitive 
ability in childhood) and vitamin D-related lifestyles at 45 years.  Linear 
regression models, adjusted for gender, were then applied to establish the 
association between earlier life factors and performance on 50 year cognitive 
tests.  Here, standardised cognitive tests were used as the outcome.  
Prospective association between 25(OH)D and cognitive performance 
The prospective association between 25(OH)D and cognitive performance was 
examined using linear regression models.  Categorised 25(OH)D was the 
exposure (with <25nmol/l as the reference) and performance on standardised 
cognitive tests at 50 years was the outcome.  These regression models were 
adjusted for:  
1) Gender and measurement conditions; season of blood collection and 
factors that may have influenced cognitive testing (Table 4.4) 
2) Social conditions and cognitive factors at earlier life stages; region, 
childhood and adult SEP, childhood cognition and educational attainment 
by 42 years in addition to adjustment 1 
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3) Physical status and lifestyles; obesity, menopausal status, smoking, 
alcohol, physical activity and depressive symptoms in addition to 
adjustment 2 
The association between 25(OH)D and letter cancellation scores was found to 
vary by gender (pinteraction=0.04) therefore stratified analyses were undertaken 
(Chapter 3).  Associations for other cognitive tests did not vary by gender. 
To examine the possibility of a more complex relationship between 25(OH)D 
and cognitive function, the presence of a non-linear association was 
investigated (Chapter 3).  The non-linear association was explored by including 
the curvature term of 25(OH)D i.e. (25(OH)D2)  in the model.   
Additional analysis 
In order to examine the effect of using other, nutritional supplements in addition 
to supplements containing vitamin D, regression models were adjusted for any 
supplement use (Chapter 3). 
Of the eligible participants for this analyses, 89.1% (n=5,791) also had complete 
data for all covariates.  Missing values ranged from 0.35% (n=23) for alcohol to 
2.34% (n=152) for smoking (Figure 6.2.).  Multiple imputation was used to 
correct for missing data on covariates and sample inverse probability weights 
were used to account for potential selection bias (Chapter 3).  Imputed results 
are presented, with complete and weighted results in Appendix 4.7 to 4.8.  A 
comparison of complete-case, weighted-case and imputed datasets is given in 
Table 6.7.   
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Figure 6.2: Proportion of missing covariate observations for study on 25(OH)D and cognitive function 
 
(N=6,496). Missing menopause data relates to women only (n=3,696). 
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6.3 Results 
6.3.1 Descriptive characteristics 
Of the 6,496 participants, 49.5% were male.  25(OH)D concentrations ranged 
from 9.5 to 213.0nmol/l.  Geometric mean 25(OH)D concentrations were found 
to be higher for men (53.6, 95%CI 52.8 to 54.4nmol/l) than women (51.6, 50.7 
to 52.4nmol/l, p=0.01).   
Mean performance on immediate word recall test at 50 years was 6.6 (standard 
deviation (SD) 1.5), 5.5 (SD 1.8) for delayed word recall test, 22.5 (SD 6.3) for 
animal naming test and 334.0 (SD 88.1) for letter cancellation test.  
25(OH)D concentrations varied according to participant characteristics.  For 
example, those with 50-74.9nmol/l 25(OH)D were more likely to live in southerly 
regions, be in a higher SEP (i.e. I or II), have a non-obese BMI, be non-
smokers, light drinkers and have <2 depressive symptoms (Table 6.3).  Mean 
performance on each cognitive test according to 25(OH)D concentrations are 
displayed in Table 6.4.   
Performance on cognitive tests varied according to several characteristics 
(Appendix 4.5).  Those who performed better on cognitive tests included 
women, people living in more southerly regions with a higher SEP, non-obese 
BMI, who exercised 2-3 times per week, were non-smokers, light drinkers and 
had less than 2 symptoms of depression at 45 years.  
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Table 6.3: Distribution of 25(OH)D by participant characteristics 
 Total 25-Hydroxyvitamin D, nmol/l P-value* 
  <25 25-49.9 50-74.9 75-99.9 ≥100  
 N=6,496 n=481 n=2,177 n=2,381 n=1,047 n=410  
Season of blood collection (%)       
Winter 1,098 36.4 24.2 12.3 6.9 7.8 <0.001 
Spring 1,363 39.1 30.6 16.2 9.4 6.3  
Summer 1,525 12.5 18.6 29.5 26.7 19.3  
Autumn 2,510 12.1 26.7 42.0 57.1 66.6  
Gender (%)        
Male 3,218 40.3 49.8 49.6 52.2 52.2 0.001 
Female 3,278 59.7 50.2 50.4 47.9 47.8  
Region (%)        
South 2,503 33.5 38.5 38.9 40.3 37.8 <0.001 
Middle 1,674 22.9 25.7 26.7 26.6 22.0  
North 1,692 26.8 24.3 25.8 26.5 34.6  
Scotland 621 16.8 11.4 8.4 6.7 5.4  
Missing 6 0.0 0.1 0.1 0.00 0.2  
SEP in adulthood (%)       
I or II 2,709 39.3 41.9 41.8 41.5 43.4 0.06 
IIINM 1,373 21.2 21.4 21.8 20.3 17.8  
IIIM 1,216 15.6 17.6 18.4 22.2 22.0  
IV and V 976 18.5 15.9 15.0 12.3 13.7  
 Other/unknown 222 5.4 3.3 3.1 3.7 3.2  
SEP in childhood (%)       
I or II 1,259 14.4 20.3 20.0 19.3 17.1 0.01 
IIINM 644 9.2 8.9 10.0 11.8 11.0  
IIIM 3,122 46.6 48.6 47.3 47.5 52.9  
IV and V 1,341 26.0 20.4 21.0 19.0 17.6  
Missing 130 4.0 1.8 1.7 2.5 1.5  
Childhood cognition (mean(sd)) 
†
      
 6,428 0.12 (0.83) 0.14 (0.78) 0.18 (0.77) 0.16 (0.76) 0.08 (0.75) 0.27 
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 Total 25-Hydroxyvitamin D, nmol/l P-value* 
  <25 25-49.9 50-74.9 75-99.9 ≥100  
Educational attainment (%)       
none 504 12.5 8.2 7.2 7.0 5.1 0.13 
Some qualifications 898 14.4 13.9 14.0 12.6 15.1  
O level (or equivalent) 1,835 24.5 28.3 27.7 30.2 30.2  
A level (or equivalent) 1,077 16.4 14.8 17.0 18.1 20.2  
Degree 2,182 32.2 34.8 34.1 32.2 29.3  
BMI (kg/m2) (%)         
<30 4,920 63.6 69.4 78.3 83.3 89.5 <0.001 
≥30 1,546 35.6 30.0 21.4 16.3 10.0  
Missing 30 0.8 0.6 0.3 0.4 0.5  
Menopause (%)        
Pre-menopausal 2,099 64.5 64.2 63.4 64.7 64.8 <0.001 
Peri-menopausal 601 15.0 20.0 19.2 15.8 15.8  
Post-menopausal 123 6.3 3.7 3.3 3.6 4.1  
Other reasons 388 10.8 10.3 12.3 14.0 13.8  
Missing 67 3.5 1.9 1.9 2.0 1.5  
Physical activity (times/week) (%)       
≤1 3,323 59.5 55.5 49.6 44.8 43.4 <0.001 
2-3 1,373 16.6 19.0 21.1 26.3 25.1  
4-7 1,656 22.0 23.4 27.2 26.2 29.3  
Missing 144 1.9 2.1 2.1 2.8 2.20  
Smoking (%)        
Never/Former 4,911 59.5 74.0 78.5 78.7 78.8 <0.001 
Current 1,433 38.1 23.8 19.4 18.4 18.8  
Missing 152 2.5 2.3 2.1 2.9 2.4  
Alcohol (units/week) (%)       
Non-drinker 371 9.2 7.4 4.9 3.7 2.4 0.002 
Light (<7) 3,123 49.5 48.8 48.6 46.1 44.2  
Moderate (7-14) 1,660 19.3 23.2 27.1 28.8 28.5  
Heavy (14-21) 735 8.5 10.6 11.3 13.2 13.7  
Very heavy (>21) 584 12.5 9.7 7.6 8.2 10.7  
Missing 23 1.04 0.3 0.4 0.0 0.5  
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 Total 25-Hydroxyvitamin D, nmol/l P-value* 
  <25 25-49.9 50-74.9 75-99.9 ≥100  
Depressive symptoms (%) 
<2 symptoms 5,990 86.9 91.8 92.5 93.9 94.6 <0.001 
≥2 symptoms 481 12.3 8.0 7.1 5.8 4.9  
Missing 25 0.8 0.2 0.5 0.3 0.5  
25(OH)D, 25-hydroxyvitamin D; SEP, socioeconomic position 
* p value for trend is from linear regression adjusted for gender 
†
 Standardised summary score for childhood cognition (age 7-16 years). 
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Table 6.4: Mean performance on cognitive tests by 25(OH)D status 
  
 
 
Total* 
Verbal memory  Verbal fluency  Speed of Processing 
 Immediate word recall 
(Range 0-10) 
Delayed word recall 
( Range 0-10) 
 Animal naming 
(Range 0-65) 
 Letter cancellation 
(Range 84-780) 
 Mean SD Mean SD  Mean SD  Mean SD 
25(OH)D (nmol/l)           
<25 481 6.4 1.6 5.4 1.9  21.5 6.5  335 94 
25-49.9 2,177 6.6 1.5 5.5 1.8  22.5 6.3  329 83 
50-74.9 2,381 6.7 1.5 5.5 1.8  22.6 6.5  337 90 
75-99.9 1,047 6.6 1.4 5.5 1.8  22.5 5.7  335 86 
≥100 410 6.4 1.6 5.2 1.8  22.5 6.6  333 91 
25(OH)D, 25-hydroxyvitamin D 
* N varies according to test; 6,469 for immediate word recall and animal naming, 6,454 for delayed word recall, 6,378 for letter cancellation. 
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6.3.2 Early life factors 
Childhood cognitive ability and educational attainment were associated with 
vitamin D-related lifestyles in later life (45 years).  Participants with higher 
cognitive scores in childhood (or higher educational attainment) spent less time 
outside, less time watching TV or using PC in their leisure time, used suncover 
more often, took more supplements and ate more oily fish than those with lower 
scores from childhood (p≤0.02 for all, after adjustment for gender and SEP in 
childhood and adulthood, Figure 6.3).  While all behaviours (except time 
outside, where more time outside is associated with higher 25(OH)D 
concentrations) were associated with a higher mean 25(OH)D in mid-life 
(Appendix 3.6), also see previous work using the 1958BC (26)), there was no 
association between childhood cognition or educational attainment and 
25(OH)D concentrations at 45 years. 
Table 6.5 illustrates the association between childhood cognitive ability and 
educational attainment with cognitive performance at 50 years.  Participants 
with higher cognitive ability and educational attainment performed better on all 
50 year cognitive tests (regression coefficients ranged from 0.12 (95% CI 0.09 
to 0.15) to 0.45 (95% CI 0.43 to 0.48) and from 0.07 (95% Confidence Interval 
(CI) 0.05 to 0.09) to 0.22 (95%CI 0.20 to 0.24) respectively (p<0.001, for all, 
adjusted for gender)) (Appendix 4.6).   
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Figure 6.3: Association between childhood cognitive ability and educational attainment with cognitive performance at 50 years 
Odds ratio (95%CI) for vitamin D-related lifestyles comparing odds for lowest to highest quartile for childhood cognitive ability (or for no/some/O-
level/A-level to degree level education) 
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Table 6.5: Association between earlier life factors with cognitive performance at 50 years 
 Total* Immediate word recall 
(Range 0-10), mean 
(SD) 
Delayed word recall 
(Range 0-10), mean 
(SD) 
Animal naming 
(Range 0-65), mean 
(SD) 
Letter cancellation 
(range 84-780), mean 
(SD) 
Standardised childhood cognitive function     
<-1 SD 541 5.6 (1.4) 4.3 (1.8) 18.8 (5.6) 319.9 (89.4) 
-1 to 0 SD 2,122 6.2 (1.4) 5.1 (1.7) 20.7 (5.6) 327.2 (86.6) 
0-1 SD 2,824 6.8 (1.4) 5.8 (1.7) 23.4 (6.1) 337.9 (88.6) 
>1 SD 941 7.4 (1.4) 6.4 (1.8) 26.0 (6.6) 345.9 (86.4) 
Missing 68  
6.4 (1.6) 
5.3 (1.8) 21.3 (5.8) 335.8 (99.3) 
p 
†
  <0.001 <0.001 <0.001 <0.001 
Educational attainment     
None 504 5.8 (1.4) 4.6 (1.8) 19.2 (5.2) 313.5 (86.0) 
Some qualifications 898 6.1 (1.4) 4.9 (1.7) 20.1(5.6) 330.3 (84.3) 
O-level (or equivalent) 1,835 6.5 (1.4) 5.4 (1.7() 21.9 (5.9) 334.6 (87.63) 
A-level (or equivalent) 1,077 6.6 (1.4) 5.5 (1.8) 22.8 (6.6) 323.3 (85.2) 
Degree 2,182 7.0 (1.4) 6.0 (1.8) 24.5 (6.4) 345.0 (90.6) 
p 
‡
  <0.001 <0.001 <0.001 <0.001 
* N varies according to test: 6,469 for immediate word recall and animal naming, 6,454 for delayed word recall, 6,378 for letter cancellation. 
†
 p value from linear regression adjusted for gender. Missing values are excluded from the analyses 
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6.3.3 Vitamin D and cognitive performance 
Table 6.6 shows the relationship between 25(OH)D at 45 years and 
performance on cognitive tests at 50 years.  There was evidence of a non-linear 
association between 25(OH)D and immediate word recall (pcurvature=0.01, for the 
final model, Figure 6.4) with concentrations of both <25nmol/l and ≥75nmol/l 
25(OH)D, five years previously, associated with worse performance and levels 
of approximately 50-75nmol/l associated with better verbal memory scores. 
The non-linear relationship between 25(OH)D and cognitive function persisted 
despite adjustment for childhood cognitive ability and educational attainment 
and lifestyle factors (i.e. obesity, menopausal status, smoking, alcohol and 
physical activity and depressive symptoms) (Figure 6.4).  In fully adjusted 
models, no associations were observed for 25(OH)D and delayed word recall, 
animal naming task or letter cancellation score in men and women (Table 6.6). 
6.3.4 Additional analyses 
Weighted and complete case analyses are compared in Table 6.7 (Chapter 3)  
The additional adjustment of any (non-vitamin D) dietary supplement did not 
alter the estimates from fully adjusted, complete-case prospective analysis 
(Table 6.8). 
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Table 6.6: Association between 25(OH) D at 45 years and cognitive function at 50 years 
 25- Hydroxyvitamin D, nmol/l   
 <25 25-49.9 50-74.9 75-99.9 ≥100 ptrend pcurvature 
  Coef 95% CI Coef 95% CI Coef 95% CI Coef 95% CI   
Immediate word recall (n= 6,496) *         
Model 1
†
 1.0 0.12 (0.02 to 0.21) 0.16 (0.06 to 0.26) 0.15 (0.04 to 0.26) -0.02 (-0.16 to 0.11) 0.76 <0.001 
Model 2
‡
 1.0 0.09 (0.00 to 0.18) 0.12 (0.02 to 0.21) 0.11 (0.00 to 0.21) -0.03 (-0.15 to 0.10) 0.88 0.001 
Model 3
§
 1.0 0.07 (-0.02 to 0.16) 0.08 (-0.01 to 0.18) 0.06 (-0.04 to 0.17) -0.07 (-0.20 to 0.06) 0.31 0.01 
Delayed word recall (n= 6,454) *         
Model 1
†
 1.0 0.06 (-0.04 to 0.16) 0.09 (-0.01 to 0.19) 0.06 (-0.05 to 0.17) -0.08 (-0.21 to 0.05) 0.44 0.01 
Model 2
‡
 1.0 0.04 (-0.05 to 0.13) 0.05 (-0.04 to 0.15) 0.03 (-0.07 to 0.14) -0.07 (-0.20 to 0.05) 0.34 0.10 
Model 3
§
 1.0 0.03 (-0.06 to 0.13) 0.04 (-0.05 to 0.14) 0.02 (-0.09 to 0.12) -0.08 (-0.21 to 0.04) 0.22 0.14 
Animal naming (n=6,496) *         
Model 1
†
 1.0 0.14 (0.04 to 0.24) 0.17 (0.06 to 0.27) 0.14 (0.03 to 0.25) 0.16 (0.02 to 0.30) 0.10 0.06 
Model 2
‡
 1.0 0.11 (0.02 to 0.21) 0.11 (0.02 to 0.21) 0.08 (-0.03 to 0.19) 0.13 (-0.00 to 0.25) 0.42 0.34 
Model 3
§
 1.0 0.11 (0.01 to 0.20) 0.11 (0.01 to 0.20) 0.07 (-0.04 to 0.18) 0.12 (-0.01 to 0.25) 0.54 0.36 
Letter cancellation (men) (n=3,156) *         
Model 1
†
 1.0 -0.00 (-0.15 to 0.15) 0.07 (-0.09 to 0.22) 0.10 (-0.06 to 0.27) 0.07 (-0.13 to 0.26) 0.07 0.21 
Model 2
‡
 1.0 -0.03 (-0.17 to 0.12) 0.04 (-0.11 to 0.19) 0.08 (-0.09 to 0.25) 0.06 (-0.13 to 0.26) 0.07 0.35 
Model 3
§
 1.0 -0.04 (-0.18 to 0.11) 0.03 (-0.12 to 0.18) 0.07 (-0.09 to 0.24) 0.06 (-0.13 to 0.23) 0.07 0.49 
Letter cancellation (women) (n=3,222) *         
Model 1
†
 1.0 -0.05 (-0.18 to 0.08) 0.04 (-0.10 to 0.17) -0.05 (-0.20 to 0.10) 0.01 (-0.19 to 0.20) 0.73 0.23 
Model 2
‡
 1.0 -0.06 (-0.19 to 0.08) 0.03 (-0.10 to 0.17) -0.05 (-0.20 to 0.11) -0.00 (-0.19 to 0.19) 0.74 0.26 
Model 3
§
 1.0 -0.07 ( -0.20 to 0.07) 0.00 (-0.14 to 0.14) -0.10 (-0.25 to 0.06) -0.05 (-0.25 to 0.15) 0.67 0.36 
*N represent final model for imputed covariates. Outcomes were not imputed; 
†
adjusted for gender, season, day and time of cognitive testing, presence of others in the room, other contextual factors affecting performance (i.e. blind or poor 
eyesight, deaf or hard of hearing, too tired, illness or physical impairment that affects ability to perform, impaired concentration, very nervous or anxious, mental 
impairment, interruption or distraction, noisy environment, problems with the laptop or difficulty understanding English), word list & method of delivery (latter two 
for immediate & delayed word recall only); 
‡
additionally adjusted for region, SEP at 42 years, SEP at birth (7 years if missing), childhood cognition and educational attainment by 42 years; 
§
additionally adjusted for obese BMI, menopausal status; smoking, alcohol, physical activity; depressive symptoms at 45 years.  
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Figure 6.4: Predicted immediate word recall at 50 years according to 25(OH)D concentrations at 45 years 
Values are predicted immediate word recall (95% Prediction Interval (PI) at 50 years for fully adjusted models.  Dot line adjusted for gender, season, 
day and time of cognitive testing, presence of others in the room, other contextual factors affecting performance, word list & method of delivery.  Dash 
additionally adjusted for region, SEP at 42 years, SEP at birth (7 years if missing), childhood cognition and educational attainment by 42 years. Solid 
line additionally adjusted for obese BMI, menopausal status; smoking, alcohol, physical activity; depressive symptoms at 45 years. Shaded areas 
show 95% PI for fully adjusted models. 
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Table 6.7: Comparison of complete, weighed and imputed results for 25(OH)D association with immediate word recall 
 25- Hydroxyvitamin D, nmol/l   
 <25 25-49.9 50-74.9 75-99.9 ≥100 ptrend pcurvature 
  Coef 95% CI Coef 95% CI Coef 95% CI Coef 95% CI   
Immediate word recall (n= 6,496) *         
Complete case-results 
(n= 6,039)* 
1.0 0.08 (-0.01 to 0.18) 0.08 (-0.01 to 0.18) 0.06 (-0.05 to 0.17) -0.07 (-0.21 to 0.06) 0.19 0.004 
Weighted-case results 
(n=5935)* 
1.0 0.08 (-0.03 to 0.19) 0.08 (-0.03 to 0.19) 0.06 (-0.06 to 0.18) -0.08 (-0.23 to 0.07) 0.20 0.01 
Imputed results 
(n= 6,496)* 
1.0 0.07 (-0.02 to 0.16) 0.08 (-0.01 to 0.18) 0.06 (-0.04 to 0.17) -0.07 (-0.20 to 0.06) 0.31 0.01 
 Coef, Beta-coefficient from linear regression model 
*adjusted for gender, season, day and time of cognitive testing, presence of others in the room, other contextual factors affecting performance (i.e. blind or poor 
eyesight, deaf or hard of hearing, too tired, illness or physical impairment that affects ability to perform, impaired concentration, very nervous or anxious, mental 
impairment, interruption or distraction, noisy environment, problems with the laptop or difficulty understanding English), word list & method of delivery (latter two 
for immediate & delayed word recall only); region, SEP at 42 years, SEP at birth (7 years if missing), childhood cognition and educational attainment by 42 years, 
obese BMI, menopausal status; smoking, alcohol, physical activity; depressive symptoms at 45 years.  
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Table 6.8: Association between 25(OH) D at 45 years and cognitive function at 50 years, adjusted for dietary supplements 
 25- Hydroxyvitamin D, nmol/l   
 <25 25-49.9 50-74.9 75-99.9 ≥100 ptrend pcurvature 
  Coef 95% CI Coef 95% CI Coef 95% CI Coef 95% CI   
Immediate word recall *         
 (n=6,039)
†
 1.0 0.08 (-0.01 to 0.18) 0.08 (-0.01 to 0.18) 0.06 (-0.05 to 0.17) -0.07 (-0.21 to 0.06) 0.19 0.004 
 (n= 5,968)
‡
 1.0 0.09 (-0.01 to 0.19) 0.08 ( -0.02 to 0.18) 0.06 (-0.06 to 0.17) -0.08 (-0.21 to 0.06) 0.12 0.01 
Delayed word recall  *         
 (n=6,000)
 †
 1.0 0.05 (-0.05 to 0.14) 0.05 (-0.05 to 0.15) 0.02 (-0.09 to 0.13) -0.08 (-0.21 to 0.05) 0.16 0.08 
 (n=5,929)
 ‡
 1.0 0.05 (-0.05 to 0.15) 0.04 (-0.06 to 0.14) 0.001 (-0.11 to 0.11) -0.09 (-0.23 to 0.04) 0.07 0.14 
Animal naming *         
(n=6,039)
†
 1.0 0.10 (0.00 to 0.20) 0.10 (-0.01 to 0.20) 0.05 (-0.06 to 0.17) 0.09 (-0.04 to 0.23) 0.90 0.37 
 (n=5968)
‡
 1.0 0.10 (0.01 to 0.21) 0.10 (-0.003 to 0.21) 0.05 (-0.06 to 0.17) 0.09 (-0.05 to 0.23) 0.98 0.38 
Letter cancellation (men) *         
Model 3 (n=2,955)
†
 1.0 -0.03 (-0.19 to 0.12) 0.03 (-0.13 to 0.19) 0.06 (-0.12 to 0.24) 0.08 (-0.13 to 0.28) 0.09 0.48 
Model 2 (n=2901)
‡
 1.0 -0.04 (-0.20 to 0.12) 0.02 (-0.14 to 0.18) 0.05 (-0.13 to 0.23) 0.07 (-0.14 to 0.28) 0.12 0.52 
Letter cancellation (women)  *         
n=2,974)
†
 1.0 -0.06 (-0.20 to 0.08) -0.00 (-0.15 to 0.15) -0.13 (-0.30 to 0.03) -0.07 (-0.28 to 0.13) 0.33 0.36 
(n=3,127)
‡
 1.0 -0.06 (-0.21 to 0.08) -0.02 (-0.16 to 0.13) -0.14 (-0.31 to 0.03) -0.08 (-0.29 to 0.12) 0.27 0.43 
*Results based on complete case-analysis 
 
†
adjusted for gender, season, day and time of cognitive testing, presence of others in the room, other contextual factors affecting performance (i.e. blind or poor 
eyesight, deaf or hard of hearing, too tired, illness or physical impairment that affects ability to perform, impaired concentration, very nervous or anxious, mental 
impairment, interruption or distraction, noisy environment, problems with the laptop or difficulty understanding English), word list & method of delivery (latter two 
for immediate & delayed word recall only), region, SEP at 42 years, SEP at birth (7 years if missing), childhood cognition and educational attainment by 42 years, 
obese BMI, menopausal status; smoking, alcohol, physical activity; depressive symptoms at 45 years; 
 
‡
additionally adjusted for intake of any dietary supplement (yes/no) 
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6.4 Discussion 
A paper related to findings from this study has been published in the peer-
reviewed journal, British Journal of Nutrition (398) (Appendix 1.2).   
Results indicate that childhood cognitive performance and educational 
attainment are associated with vitamin D-related behaviours at 45 years and 
performance on cognitive tests at 50 years.  A non-linear relationship between 
25(OH)D and one measure of verbal memory (i.e. immediate word recall) was 
observed and remained significant following adjustment for earlier life factors.  
25(OH)D concentrations, in the range of 50-75nmol/l were associated with 
better performance on this verbal memory measure, compared with both lower 
25(OH)D (<25nmol/l) and higher 25(OH)D (≥75nmol/l) concentrations.  No 
significant trends were found for other cognitive tests. Only one measure of 
25(OH)D was available and it is possible that participants changed behaviour 
(and consequently their vitamin D status) during the 5 year interval. Therefore, 
inferences about the association between chronic or concurrent 
hypovitaminosis D and cognitive performance should be made with caution. 
Additionally, the influence of childhood cognitive ability on the subsequent 
association between 25(OH)D and cognitive function may have been 
underestimated due to differing measures of cognition in childhood and 
adulthood. 
Results from this study were supportive of findings from the meta-analysis cited 
in the introduction which demonstrated a 1.2 (95% CI 0.5 to 1.9) improvement in 
scores on the MMSE for participants with ≥50nmol/l compared with <50nmol/l  
25(OH)D (185).  However, compared with the meta-analysis, results for the 
1958BC differ in terms of the age group examined (i.e. 50 years versus ≥65 
years), study design (i.e. prospective design versus mixed designs) and 
cognitive assessment used (i.e. tests of three cognitive domains versus the 
MMSE, a test of global cognitive function (399)).   
Unlike this study, most investigations of the association between 25(OH)D and 
cognitive function have focused on older adult populations.  To my knowledge, 
only one previous study has investigated a younger adult population (355).  This 
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cross-sectional study examined three age groups; adolescents (12-17 years), 
younger adults (20-60 years) and older adults (60-90 years).  While no 
association between low 25(OH)D and impaired performance on psychometric 
measures assessing memory and speed of processing was observed for 
younger adults, a significant relationship between low 25(OH)D and reduced 
performance in memory tests was demonstrated amongst older adults.  The 
younger adult category encompassed a wide age range, which reduces 
comparability to the present study, in which cognitive function was assessed at 
a specific age (50 years). 
While cognitive decline is more evident in later life (105), there is some 
suggestion that decline can occur in mid-life (112).  Detecting an association 
between 25(OH)D and cognitive function in relatively young adult populations is 
further complicated by the trajectory of cognitive ageing  and neurodegenerative 
diseases.  Many cognitive disorders have a long pre-clinical phase during which 
the pathology accumulates (123).  Therefore, it is difficult to ascertain if 
associations between 25(OH)D concentrations and cognitive function in mid-life 
are reflective of pre-clinical dementia or subtle changes in cognitive ability.   
Some previous studies (Table 6.1) focused on presence of cognitive 
impairment or dementia while others, including our study, measured 
performance on individual cognitive tests.  Many studies using cognitive 
impairment or dementia as an outcome were suggestive of an association 
between higher 25(OH)D concentrations and reduced risk of impairment or 
dementia (364, 365, 368, 371, 375, 376, 379, 385, 386, 391), however this was 
not always replicated (335, 362, 377, 380).  Evidence for an association 
between 25(OH)D concentrations and individual cognitive tests were also 
inconclusive with some (324, 357, 359, 360, 367, 370, 389, 390, 394) but not all 
(333, 382, 397) producing significant findings.   
As discussed in Chapter 1, several studies investigating the impact of risk 
factors on cognitive decline and dementia over the life-course have implied that 
certain mid-life factors may be particularly relevant for later cognitive functioning 
(400).  Therefore, investigations such as this one that examine the role of 
25(OH)D in cognitive function at a time point where age-related decline is just 
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becoming apparent, are essential for informing the timing and nature of 
potential interventions (104).   
Interpreting the association between 25(OH)D and cognitive function is further 
complicated by findings of domain-specific associations.  In this study, despite 
the strong correlation (r=0.7) between the two measures of verbal memory, no 
association between 25(OH)D and delayed recall was detected.  Additionally, 
no association was found between 25(OH)D and other cognitive domains 
examined i.e. verbal fluency and speed of processing.  In contrast with our 
findings, a previous study conducted in an older adult population (65-99 years) 
in the US, found that 25(OH)D was associated with non-memory domains i.e. 
executive function (367).  Similarly in the US, a study of women aged ≥65 years 
found a significant association between 25(OH)D and MMSE scores but not for 
the Trail-Making test B (TMT B), which measures executive function.    
The finding of an association between 25(OH)D and performance on one verbal 
memory test but not the other tests of cognitive domains could be interpreted in 
two ways.  Firstly, vitamin D may have a specialised role in specific brain 
functions.  Further experimental studies are required to give insight into these 
potential processes.  Secondly, the association between 25(OH)D and the other 
cognitive domains may vary by life-stage.  Perhaps the importance of a 
person’s 25(OH)D status in terms of their cognitive function only manifests at 
later life stages.     
An interesting find from this study was the non-linear association between 
25(OH)D and cognitive function.  Two previous studies have supported this 
non-linear relationship between 25(OH)D and cognitive function.  One study of 
men aged 40-79 years suggested that reduction in cognitive function was most 
evident at <35nmo/l 25(OH)D (359).  The other study, among adults aged ≥65 
years, proposed that improvement in cognitive function plateaus with higher 
25(OH)D concentrations (390).   
There are many potential explanations for the non-linear prospective 
association between 25(OH)D and verbal memory two of which have been 
described in the discussion in Chapter 5.  Briefly, the non-linear relationship 
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may be due to a threshold effect whereby higher 25(OH)D concentrations do 
not provide any additional benefit to the improvement of cognitive function, and 
may result in a reduction in cognitive performance.  Additionally, the non-linear 
relationship may have an underlying mechanistic explanation whereby very high 
25(OH)D concentrations will ultimately lead to a reduction in the biologically 
active, 1,25(OH)2D.  Furthermore, the association between 25(OH)D and verbal 
memory may be influenced by the potential interactive effect of genetic variants 
and 25(OH)D on cognitive function, which will be examined in Chapter 7.    
In contrast to previous studies, our work aimed to incorporate a lifespan 
approach.  Childhood cognitive ability has been found to be strongly related to 
cognitive function in later life (401).  Cognitive ability in childhood has also been 
associated with reduced mortality (402) which may be mediated by healthy 
lifestyle choices (403).  The importance of educational attainment on cognitive 
function in adulthood (404) was discussed in Chapter 1.  The presented results 
replicate the finding of the importance of childhood cognitive ability and 
educational attainment on later cognitive function and interestingly, on vitamin 
D-related lifestyles in mid-life.  While this association has not been taken into 
account in previous studies, our study indicates that higher childhood cognitive 
ability and educational attainment are linked with behaviours that are associated 
with 25(OH)D concentrations in later life.  Although childhood ability and 
educational attainment did explain a proportion of the association between 
25(OH)D and cognitive function in mid-life, the non-linear relationship persisted 
despite controlling for these factors.  Therefore, it is plausible that 25(OH)D 
status may independently predict verbal memory in mid-life.   
There are a number of potential confounders that may affect the association 
between 25(OH)D and cognitive function including early-life factors such as low 
birth weight, and educational attainment (Chapter 1 for further details).  While 
this study has included some of these potential confounders in analyses, it is 
difficult to identify and accurately measure all potential confounding using an 
observational epidemiologic approach (Chapter 3).  Furthermore, the 
association between 25(OH)D and verbal memory may be influenced by the 
potential interactive effect of genetic variants and 25(OH)D on cognitive 
function.  If this gene-25(OH)D interaction is present, the effect of 25(OH)D on 
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cognitive test performance will depend on the individual’s particular genetic 
variant.  An example of a gene-25(OH)D interaction effect will be explored 
further in Chapter 7.  
6.4.1 Conclusion 
Findings from this mid-adulthood population suggest that both low and high 
25(OH)D concentrations are associated with poorer verbal memory as indicated 
by immediate word recall in mid-life, albeit with small effect sizes.  Childhood 
cognition and educational attainment appear to contribute to this association, 
but do not fully explain it. 
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6.5  Summary 
 There is evidence of a link between hypovitaminosis D and poor 
cognitive function, particularly in older adults, but studies lack a lifespan 
approach, and effects of reverse causality remain unknown  
 The aim of this chapter was to assess the relationship between 25(OH)D 
and subsequent cognitive performance in mid-adulthood and the 
influence of earlier life factors including childhood cognitive ability, on this 
association 
 Participants with both low (<25nmol/l) and high (≥75nmol/l) 25(OH)D 
concentrations at 45 years performed significantly worse on immediate 
word recall. Associations attenuated after adjustment for childhood 
cognitive ability, education, and socioeconomic position, however, for 
immediate word recall test, there was a non-linear association with 
25(OH)D even after further adjustment for obesity, menopausal status, 
smoking, alcohol, physical activity and depressive symptoms at 45 years 
(pcurvature=0.01) 
 This observational study demonstrates that 25(OH)D concentrations 
were non-linearly associated with immediate word recall in mid-life.  The 
limitations of observational approaches imply that causality and the effect 
of unmeasured confounders on the association between 25(OH)D and 
cognitive function requires further investigation  
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 Genetic Study: Gene-environment interaction Chapter 7
7.1 Introduction 
The aetiology of a particular phenotype can involve discrete actions of 
environmental and genetic causes, but also interactions between the two.  
Results from Chapter 6 identified a significant non-linear relationship between 
25-hydroxyvitamin D (25(OH)D) and a measure of memory (i.e. immediate word 
recall test) amongst 50 year old participants of the 1958 British birth cohort 
(1958BC).  Examining the effect of a gene-environment interaction (GxE) on the 
relationship between 25(OH)D concentrations and memory function may 
provide some insight into potentially distinct relationships according to the 
presence of a genetic variant.  The concept of GxE has been described in more 
detail in Chapter 3.   
Apolipoprotein E 
Apolipoprotein E (apoE) is one of a group of apolipoproteins that are present in 
the body.  The apoE protein is an important component of plasma and brain 
lipoproteins (405) and is involved in the metabolism of certain lipoproteins (for 
example, triglycerides and cholesterol).  ApoE may also contribute to the 
process of neuronal repair (406, 407) and play a role in immunoregulation and 
nerve regeneration (408).   
There are three major protein isoforms of human apoE (i.e. E-2, E-3 and E-4) 
which are determined by the alleles ε2, ε3 and ε4 (409) (Chapter 4).  There are 
six possible APOE genotypes: ε2/ε2, ε2/ε3 ε2/ε4 ε3/ε3 ε3/ε4 and ε4/ε4 (Table 
7.1). 
There is some evidence to suggest that the ε2 allele of APOE may be positively 
associated with survival amongst older adults while the ε4 allele might be 
related to reduced longevity, however the frequency of the ε2 allele is too rare in 
the population to provide a definitive conclusion (410, 411).  APOE ε4 genotype 
has been associated with many adverse health conditions including 
cardiovascular disease and neurodegenerative disorders (412) as well as an 
overall increase in morbidity and mortality in older adults (413, 414).  However, 
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APOE ε4 has been shown to have a role in protecting against some infectious 
diseases (415).  This suggests that APOE ε4 may have provided some 
evolutionary advantages in terms of pathogen resistance, but it is not 
advantageous in terms of chronic diseases.  
APOE and cognitive function 
The ε4 allele of APOE is an important genetic risk factor for late-onset 
Alzheimer’s disease (AD) (i.e. onset >65 years) (146, 147, 416) with some 
studies suggesting that APOE ε4 may account for approximately 20-50% of the 
attributable total risk for dementia (417, 418).  The presence of APOE ε4 alleles 
in the human brain has been shown to influence membrane repair, cholesterol 
transport and other cellular activities that are related to the development of AD 
(419).  Furthermore, a meta-analysis conducted in 1997 found that 
heterozygous ε4 carriers are at between three and four times higher risk and 
homozygous ε4 carriers are between ten and twelve times higher risk of 
developing AD (420). 
While APOE ε4 is a known risk factor for AD, it may also affect cognitive 
function in normal ageing .  A meta-analysis of 38 studies conducted in 2004 
found that APOE ε4 carriers performed slightly worse on cognitive tests of 
global cognitive function, episodic memory and executive functions compared 
with non-ε4 carriers (145).  The authors of this meta-analysis noted that APOE 
ε4 heterozygosity and older age were associated with smaller ε4-related 
differences in cognitive function between ε4 carriers and ε4 non-carriers (145). 
APOE and 25(OH)D 
The hypothesised association between 25(OH)D and APOE ε4 developed from 
the realisation of the non-random distribution of APOE.  In Europe, Africa and 
North America, APOE ε3 alleles are inversely correlated with ε4 (421).  In 
European populations, a strong north-south gradient was recognised whereby 
higher frequencies of APOE ε4 carriers were observed at greater latitudes  
(422, 423).  It is thought that this north-south distributional pattern is due to an 
evolutionary adaption to environmental factors (422, 423).  This adaptation may 
have provided a survival advantage to ε4 carriers in the presence of reduced 
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sunlight (422), which could indicate better protection against vitamin D 
deficiency amongst ε4 carriers (423).  Interestingly, APOE ε4 tends to be more 
prevalent in people with darker skin or those living in regions with reduced 
sunlight compared with those of moderate pigmentation but exposed to high UV 
concentrations (40). 
One study demonstrated significantly higher 25(OH)D concentrations in APOE 
ε4 targeted replacement mice compared with non-ε4 carriers (41).  The authors 
of this study also noted a positive association between APOE ε4 and 25(OH)D 
concentrations in a general human population sample (41).  During their 
commentary, Huebbe et al (41) implied that their finding of an association 
between APOE ε4 and higher 25(OH)D concentrations may be contradictory 
because both APOE ε4 and vitamin D deficiency are associated with a higher 
risk of chronic illness.  The authors hypothesised that this contradictory finding 
may imply that the relationship between 25(OH)D and adverse health conditions 
could be modified by presence of APOE ε4 genotype. 
Due to the potential associations between (1) 25(OH)D and cognitive function 
(2) APOE ε4 and lower cognitive function and (3) APOE ε4 and higher 
25(OH)D, it is plausible that the association between 25(OH)D and cognitive 
function may be modified by the presence of APOE ε4 alleles.  Therefore, this 
chapter will explore a GxE interaction between APOE genotype and 25(OH)D 
on memory function (Chapter 2). 
7.2 Data and methods 
Data for this chapter come primarily from participants of the 1958BC.  To 
explore if these results replicate in another cohort, data from participants of the 
Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) were 
also used.  
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7.2.1 Participants 
1958BC 
Details of the 1958BC were given in Chapter 4.  For the current analyses, 
eligible participants consisted of the subsample of individuals from European 
ancestry with information on APOE genotypes and for whom memory-related 
cognitive tests were conducted (n=4,848) (Figure 7.1).  Further analyses 
requiring 25(OH)D concentrations were carried out among 4,644 participants as 
204 individuals (4.2% of eligible sample) did not have information on 25(OH)D 
concentrations.  The sample with and without 25(OH)D measurements did not 
differ in relation to participant characteristics (including gender, region of 
residence, educational attainment, depressive symptoms, number of APOE ε4 
alleles and performance on memory tests) (p≥0.12).  Individuals with APOE ε2 
alleles (n=764) were not included in analyses requiring APOE ε4 due to the 
supposed counteractive effects of ε2 and ε4 (40).  Participants with APOE ε2 
alleles tended to have lower educational attainment compared with the rest of 
the sample (p=0.04), however they did not differ in relation to gender, region or 
depressive symptoms (p≥54).  
PIVUS 
Details of PIVUS were given in Chapter 4.  1,016 participants were included in 
the baseline study (70 years) during which blood samples were obtained for 
DNA extraction and 25(OH)D concentrations.  APOE genotypes were obtained 
for 941 individuals.  938 participants with information on APOE genotypes also 
had data on 25(OH)D concentrations and 739 completed memory-related 
cognitive tests at 50 years.  Eligible participants for this study consisted of the 
subsample of individuals from European ancestry with information on APOE 
genotypes and for whom memory-related cognitive tests were conducted 
(n=739).  There were 3 participants (0.41% of eligible sample) with no 
information on 25(OH)D concentrations.  Individuals with APOE ε2 alleles 
(n=108) were not included in analyses requiring APOE ε4. Participants with 
APOE ε2 alleles not differ in relation to gender, educational attainment or 
depressive symptoms (p≥13). 
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Figure 7.1 Participant selection for GxE study in 1958BC 
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7.2.2 Variables 
APOE  
A description of genotyping techniques used to obtain APOE in both cohorts is 
described in Chapter 4.  Quality checks of genetic variants for APOE were 
conducted following data exclusions.  The call rate, minor allele frequency and 
Hardy Weinberg equilibrium for the SNPs in each study is reported in Appendix 
5.1.  The minor allele frequencies were compared with HapMap data on 
populations with a European ancestry6 and were found to be similar. 
Frequencies of the six possible APOE genotypes obtained from the three main 
APOE alleles i.e. ε2 (rs7412:T and rs429358:T), ε3 (rs7412:C and rs429358:T), 
ε4 (rs7412:C and rs429358:C) are given in Table 7.1.  
Since the emphasis for this study was on the ε4 allele, further coding was 
required.  When used as a genotype count model, the number of ε4 alleles was 
coded as 0-2 depending on the presence of ε4 alleles.  This variable did not 
include any ε2 carriers since the mechanisms for APOE ε4 and ε2 on cognitive 
function may be different (section 7.1).  Therefore, the reference category was 
two ε3 alleles.  When used in a recessive model, APOE ε4 was coded as two ε3 
or one ε4 alleles versus two ε4 alleles. 
25-Hydroxyvitamin D 
Details of how 25(OH)D was measured in both cohorts can be found in Chapter 
4.  Distributions of 25(OH)D in both cohorts can be seen in Appendix 5.2.  
Since 25(OH)D was found to be skewed, geometric means are reported and 
natural log (ln) transformation was applied to approximate a normal distribution 
when 25(OH)D was used as a continuous outcome.   
                                            
6
 http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap27_B36/ 
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Table 7.1: APOE genotype frequency 
rs7412 rs429358 Allele 1 Allele 2 APOE Genotype Frequency in 1958BC (%)* Frequency in PIVUS (%)† 
TT TT ε2 ε2 ε2/ε2 0.60 0.54 
 TC - - - - - 
 CC - - - - - 
CT TT ε2 ε3 ε2/ε3 12.46 11.77 
 TC ε2 ε4 ε2/ε4 2.70 2.30 
 CC - - - - - 
CC TT ε3 ε3 ε3/ε3 57.49 58.86 
 TC ε3 ε4 ε3/ε4 23.89 24.09 
 CC ε4 ε4 ε4/ε4 2.87 2.44 
*n=4,848; 
†
 n=739 
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Memory function 
Evidence from the 1958BC indicated the relationship between 25(OH)D and 
cognitive function exists particularly in the memory domain (i.e. from a test of 
immediate word recall) (Chapter 6), therefore this study will focus on memory 
function to avoid undue multiple testing.  Details of how each of these memory-
related cognitive tests was conducted in the two cohorts are described in detail 
in Chapter 4, and are displayed in Appendix 5.3.  Each of these tests were 
standardised and combined into an overall memory function score as described 
in Chapter 4. 
Covariates 
When analyses was conducted using participants from 1958BC, the main 
covariates included gender, month of blood collection, region of residence 
(categorised as Southern England and Channel Islands (South), Middle 
England and Wales (Middle), Northern England and Isle of Man (North) or 
Scotland), education (categorised as none, <O-level or equivalent, O-level or 
equivalent, A-level or equivalent, degree) and depressive symptoms at 45 years 
(categorised as yes or no) as measured by the Clinical Revised Interview 
Schedule-Revised (239, 240).  The proportion of missing covariates ranged 
from 0.02% for region of residence to 12% for education (Table 7.2). 
Analyses conducted using data from PIVUS used the available covariates of 
gender, month of blood collection, education (categorised as primary school (<9 
years), secondary school (9-2 years), university level (>12 years).  Participants 
of PIVUS did not have information regarding region of residence or depressive 
symptoms and 1% did not have information on education (Table 7.2). 
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7.2.3 Statistical methods 
Details of statistical methods are given in Chapter 3.  Linear regression models 
were used to examine associations between 25(OH)D and APOE ε4 genotype 
with memory function.  Models were adjusted for gender, month of blood 
collection, region, education and depressive symptoms, where appropriate.  
Firstly, in a similar manner to Chapter 6, the association between 25(OH)D and 
memory function was examined.  In addition to standard adjustments, models 
were also adjusted for APOE ε4 genotype to account for the potential effect of 
APOE ε4 alleles on the relationship between 25(OH)D and memory function.  
Curvature was examined by including the quadratic term of 25(OH)D in the 
model (Chapter 3).  
Secondly, the association between APOE ε4 genotype and 25(OH)D was 
examined using a genotype count model.  In addition to standard adjustments, 
models were further adjusted for memory function. 
Thirdly, the association between APOE ε4 genotype and memory function was 
examined using a genotype count model.  Further adjustments for 25(OH)D 
concentrations were examined in the model. 
Given the presence of a non-linear association between 25(OH)D and memory 
function identified using observational data from 1958BC (Chapter 6), 
examination of effect modification by APOE ε4 genotype was started from the 
most complex model (Chapter 3).  For consistency, the interaction models used 
in the 1958BC were repeated in PIVUS.  Stratified analyses and graphical 
presentation were used to interpret the final interaction model. 
Sensitivity analyses was conducted by restricting the sample to those will full 
information on 25(OH)D and who did not have an APOE ε2 allele (1958BC 
n=3,914; PIVUS n=629). 
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7.3 Results 
7.3.1 Descriptive characteristics 
There were 4,848 and 739 eligible participants from 1958BC and PIVUS 
respectively.  Table 7.2 illustrates the main characteristics of participants from 
1958BC and PIVUS.  Gender distribution in both cohorts was approximately 
equal.  The mean age of participants of the 1958BC was 20 years younger than 
those from the Swedish cohort, PIVUS. 
Geometric means of 25(OH)D were slightly higher amongst participants of 
PIVUS.  Figure 7.2 shows the distribution of participants according to 
thresholds for 25(OH)D deficiency or insufficiency (i.e. <25 or <50nmol/l) (42, 
44).  Men were more likely to have higher mean 25(OH)D concentrations than 
women in both cohorts (p<0.01).  In the eligible sample, the proportion of 
individuals with both <25 and <50nmol/l were higher in 1958BC compared with 
PIVUS.  25(OH)D concentrations ranged from 9.5 to 169.6nmol/l amongst 
eligible participants from 1958BC and from 10.9 to 133nmol/l amongst 
participants from PIVUS.  
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Table 7.2: Characteristics of eligible participants from 1958BC and PIVUS 
  1958BC PIVUS 
Gender, %(N)   
 Male 53.9 (2,614) 49.7 (367) 
 Female 46.1 (2,234) 50.3 (372) 
Age at time of cognitive testing, mean (min-max)  
  50 (50-50) 70.2 (69.8-72.2) 
25-hydroxyvitamin D, nmol/l geometric mean (min-max)  
  52.4 (9.5-169.6) 55.0 (10.9-133) 
 missing, % (N) 4.2 (204) 0.4 (3) 
Month of 25(OH)D collection, %(N)  
 January 7.7 (377) 8.4 (61) 
 February 7.2 (350) 9.1 (64) 
 March 7.1 (343) 12.5 (84) 
 April 6.0 (293) 9.5 (67) 
 May 6.8 (327) 10.2 (76) 
 June 9.5 (459) 8.5 (64) 
 July 7.4 (357) 0 (0) 
 August 5.6 (269) 6.7 (53) 
 September 12.1 (585) 9.0 (63) 
 October 13.8 (669) 9.7 (77) 
 November 12.8 (618) 9.5 (70) 
 December 4.1 (199) 7.1 (60) 
 missing 0.1 (2) 0 (0) 
Region   
 South 38.0 (1,842) - 
 Middle 25.8 (1,251) - 
 North 26.2 (1,269) - 
 Scotland 10.0 (485) - 
 missing 0.02 (1) - 
Depressive symptoms, %(N)  
 No 92.2 (4,471) - 
 Yes 7.5 (361) - 
 missing 0.3 (16) - 
Education, % (N)*   
  5.6 (272) 53.3 (394) 
  12.3 (598) 19.5 (144) 
    26.6 (1,289) 26.3 (194) 
  16.9 (821)  
     26.6 (1,287)  
 missing 12.0 (581) 1.0 (7) 
*1958BC categories: none, <O-level, O-level, A-level or Higher;  
PIVUS categories: Primary school  <9 years, Secondary school 9-12 years or university 
level >12 years 
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Figure 7.2: Percentage of participants with <25nmol/l and <50nmol/l 25(OH)D 
1958BC: n=4,644; PIVUS: n =736 
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The distribution of APOE ε4 alleles in the two cohorts was similar, with two ε4 
alleles being the least and two ε3 alleles the most prevalent (Table 7.3).  The 
distribution of APOE ε4 alleles did not vary by gender in either cohort (p>0.67).  
Table 7.3: Distribution of APOE ε4 alleles 
 1958BC PIVUS 
APOE, % (N)   
zero ε4 alleles* 57.5 (2,787) 58.9 (435) 
one ε4 alleles 23.9 (1,158) 24.1 (178) 
two ε4 alleles 2.9 (139) 2.4 (18) 
missing 15.8 (764) 14.6 (108) 
*two ε3 alleles   
Table 7.4 displays the mean and range of each of these individual tests.  
Women performed significantly better than men in all tests except the recall with 
reminder in PIVUS (p<0.001, for all tests in both cohorts).   
Table 7.4: Mean performance on individual memory tests 
  N Mean (sd) range 
1958BC     
 immediate word recall 4,848 6.6 (1.5) 0-10 
 delayed word recall 4,848 5.4 (1.8) 0-10 
PIVUS     
 recall, no reminder 739 9.6 (2.5) 0-16 
 recall, with reminder 739 6.0 (2.3) 0-14 
7.3.2 Observational association between 25(OH)D and memory 
There was a non-linear relationship between 25(OH)D and cognitive function in 
1958BC, but this was not replicated in PIVUS (Table 7.5).  
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Table 7.5: Association between 25(OH)D and standardised memory function score 
 
   Standardised memory function score 
   Model 1* Model 2† 
 25-hydroxyvitamin D, nmol/l N(%) Coefficient (95% CI) Coefficient (95% CI) 
1958BC      
 <25 328 (7.1) Reference Reference Reference Reference 
 25-49 1,570 (33.8) 0.06 (-0.07 to 0.18) 0.04 (-0.10 to 0.17) 
 50-74 1,732 (37.3) 0.10 (-0.03 to 0.23) 0.10 (-0.04 to 0.24) 
 ≥75 1,014 (21.8) 0.001 (-0.14 to 0.14) 0.01 (-0.14 to 0.17) 
   Ptrend = 0.71 Ptrend = 0.83 
   Pcurvature = 0.01 Pcurvature = 0.02 
PIVUS      
 <25 16 (2.2) Reference Reference Reference Reference 
 25-49 253 (34.4) 0.18 (-0.35 to 0.70) 0.22 (-0.32 to 0.75) 
 50-74 328 (44.6) 0.19 (-0.34 to 0.71) 0.22 (-0.30 to 0.75) 
 ≥75 139 (18.9) 0.28 (-0.26 to 0.82) 0.32 (-0.23 to 0.86) 
   Ptrend = 0.31 Ptrend = 0.29 
   Pcurvature = 0.55 Pcurvature =0.42 
Coefficient from linear regression model; 
* adjusted for age (PIVUS) gender, month of blood collection, region (in 1958BC), education and depressive symptoms (in 1958BC): n=4,068 for 
1958BC, n=729 for PIVUS. 
† 
adjusted for age (PIVUS), gender, month, region (in 1958BC), education and depressive symptoms (in 1958BC) and number of APOE ε4 alleles: 
n=3,426 for 1958BC, n=623 for PIVUS 
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7.3.3 APOE ε4 associations 
APOE ε4 alleles and 25(OH)D 
In the 1958BC, average 25(OH)D concentrations were the highest for 
individuals with two ε4 alleles, however this association was not statistically 
significant following adjustment for gender, month of blood collection, and 
region (ptrend=0.56).  Conversely, in PIVUS, average 25(OH)D concentrations 
were slightly higher for individuals with two ε3 alleles, however, this was not 
statistically significant (ptrend=0.27 after adjusting for gender and month of blood 
collection) (Figure 7.3  and Appendix 5.4).  Further adjustment for memory did 
not affect the coefficients in the model (Appendix 5.4).  
APOE ε4 alleles and memory function 
In the 1958BC, individuals with one or two ε4 alleles had lower memory scores 
compared with those with two ε3 alleles, however this association was not 
statistically significant following adjustment for gender, region, education and 
depressive symptoms (ptrend=0.17).  In PIVUS, memory function was found to 
be significantly lower in the presence of ε4 alleles (ptrend=0.001).  The 
coefficients in these models did not change following adjustment for 25(OH)D 
concentrations, indicating that the association between APOE ε4 alleles and 
memory is independent of 25(OH)D concentrations (Table 7.6).  
   
209 
 
 
Figure 7.3: Geometric mean of 25(OH)D according to number of APOE ε4 alleles 
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Table 7.6: Association between APOE ε4 and memory score 
 Standardised memory scores 
  Model 1*  Model 2
†
 
 N(%) Coefficient (95% CI) Coefficient (95% CI) 
1958BC      
zero APOE  ε4 alleles
‡
 2,787 (68.2) Reference Reference Reference Reference 
one APOE  ε4 alleles 1,158 (28.4) -0.05 (-0.12, 0.02) -0.05 (-0.12, 0.02) 
two APOE  ε4 alleles 139  (3.4) -0.04 (-0.21, 0.13) -0.04 (-0.21, 0.13) 
  ptrend = 0.17 ptrend = 0.18 
PIVUS      
zero APOE  ε4 alleles
‡
 549 (68.5) Reference Reference Reference Reference 
one APOE  ε4 alleles 229 (28.6) -0.25 (-0.42, -0.08) -0.25 (-0.42, -0.07) 
two APOE  ε4 alleles 24 (3.0) -0.44 (-0.92, 0.03) -0.45 (-0.92, 0.03) 
  ptrend = 0.001 ptrend = 0.001 
*adjusted for age (in PIVUS), gender, region (for 1958BC), education and depressive symptoms (in 1958BC):n=3,578 for 
1958BC, n=625 for PIVUS;
  
†
adjusted for age (in PIVUS), gender, region (for 1958BC), education, depressive symptoms (in 1958BC) and 25(OH)D 
concentrations: n=3,426 for 1958BC, n=623 for PIVUS 
‡ 
refers to two ε3 alleles 
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7.3.4 GxE interaction 
1958BC 
Three-way interaction between 25(OH)D, 25(OH)D2 and number of APOE ε4 
alleles was not significant (overall pinteraction=0.75, Appendix 5.5).  However the 
curvature term (25(OH)D2) remained significant in this GxE model (p=0.02).  
Therefore, a two-way GxE model was examined, adjusting for the curvature 
term. 
The two-way GxE, adjusting for the curvature term was significant (overall 
pinteraction=0.02, Figure 7.4). 
PIVUS 
The three-way interaction was not significant (overall pinteraction=0.87, Appendix 
5.5).  Although the curvature term was not significant in this model (p=0.31), a 
two-way GxE model, adjusting for the curvature term was applied to be 
comparable with GxE models of the 1958BC.  A GxE interaction was found 
using the adjusted two-way interaction model (overall pinteraction=0.02, Figure 
7.5). 
The association between 25(OH)D and memory function, stratified by number of 
APOE ε4 alleles in both cohorts is displayed in Appendix 5.6. 
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Figure 7.4. Gene-environment interaction in 1958BC 
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Figure 7.5: Gene-environment interaction in PIVUS 
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7.3.5 Additional analyses 
Recessive models 
In the 1958BC GxE model (Figure 7.4), the greatest difference was between 
those with two APOE ε4 alleles compared with others, suggesting a recessive 
genetic model may be appropriate.  Using a recessive model, at lower 25(OH)D 
concentrations, those with two APOE ε4 alleles perform poorly on memory 
tests, however at higher 25(OH)D concentrations they score higher on memory 
tests (pinteraction=0.01 in the recessive model, Figure 7.6).  
In PIVUS, the greatest difference seemed to be between those with one or two 
APOE ε4 alleles compared with individuals with two ε3 alleles.  The recessive 
GxE model was not significant in PIVUS (pinteraction=0.24 in the recessive model, 
Figure 7.7).   
Stratified analyses using these recessive models in both cohorts are given in 
Appendix 5.7. 
Sensitivity analyses 
There was no difference in results when restricting analyses to those with 
information on 25(OH)D and memory function with no APOE ε2 alleles 
(Appendices 5.8 to 5.11). 
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Figure 7.6: Gene-environment interaction in 1958BC, using recessive model 
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Figure 7.7: Gene-environment interaction in PIVUS, using recessive model
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7.4 Discussion 
The purpose of this study was to examine if the non-linear relationship between 
25(OH)D and memory function (Chapter 6), and in particular the suggested 
poor memory function in individuals with the highest concentrations, is affected 
by APOE genotype.  A paper related to findings in this study can be found in 
Appendix 1.3. 
The non-linear association between 25(OH)D and memory in 1958BC (here and 
in Chapter 6) did not replicate in PIVUS.  Inconsistent findings between 
1958BC and PIVUS could be due to differences in the distribution of 25(OH)D 
concentrations between the cohorts.  Mean 25(OH)D concentrations in PIVUS 
were higher compared with 1958BC and there were fewer individuals at the 
extremes of the distribution (i.e. 2.4% had <25nmol/l while 3.1% had 
≥100nmol/l), possibly reducing the ability to detect associations between 
25(OH)D and memory amongst participants with high and low 25(OH)D 
concentrations. 
Associations between APOE ε4 alleles and 25(OH)D were not significant in 
either 1958BC or PIVUS and they were in opposing directions.  While the 
direction of the relationship between APOE ε4 alleles and higher 25(OH)D 
concentrations in 1958BC is consistent with previous studies, the association 
between APOE ε4 and lower 25(OH)D in PIVUS is not (40).  The opposing 
trends between APOE ε4 alleles and 25(OH)D in the two cohorts may be 
affected by cohort differences and/or methodological issues.  For example, 
participants of 1958BC are aged 50 years while individuals from PIVUS are 
aged 70 years, which could indicate that the relationship between APOE ε4 
alleles and 25(OH)D may be age-dependent.  Furthermore, despite the similar 
distribution of APOE ε4 alleles across the two cohorts, there is a limited number 
of participants with two APOE ε4 alleles in PIVUS (n=24) which may have 
resulted in a reduction in power. 
The association between APOE ε4 alleles and reduced memory function was 
weaker and not significant in 1958BC compared with PIVUS.  This observation 
suggests that the association between APOE ε4 alleles and reduced memory 
218 
 
function may be stronger amongst older people.  Findings were consistent with 
a previous study indicating that the APOE ε4 allele is not associated with 
reduced intelligence in females aged 19-21 years (424).  Similarly, results were 
supportive of studies showing no significant association between the APOE ε4 
allele and lower performance on cognitive tests amongst middle aged adults 
(425, 426).  However, in contrast to our findings, another study found that the 
APOE ε4 allele is associated with lower measures of learning and memory 
tasks amongst middle-aged adults (24-60 years) (427).  One potential difficulty 
in assessing memory function is the inability to ascertain if the effects of APOE 
ε4 genotype on memory function in mid-adulthood are independent of any pre-
clinical signs of dementia. 
Evidence for the discrete association of APOE ε4 alleles with 25(OH)D and 
memory in 1958BC and PIVUS remains uncertain.  However, the presence of a 
GxE interaction may mask direct effects and could notably alter the observed 
associations (194).  Findings from GxE analyses suggest that increasing 
25(OH)D concentrations would be particularly beneficial for homozygous APOE 
ε4 carriers in 1958BC, while both heterozygous and homozygous APOE ε4 
carriers in PIVUS may benefit from increasing 25(OH)D concentrations.  The 
presence of an age-dependent interaction could explain the slightly different 
interaction results between the two cohorts.  For example, in mid-adulthood, the 
discerning effect of APOE ε4 alleles on the relationship between 25(OH)D and 
memory may be particularly noticeable amongst those with two alleles of APOE 
ε4.  The influence of APOE ε4 on the relationship between 25(OH)D and 
memory may increase with age causing the presence of any APOE ε4 to affect 
the association. 
There are relatively few robust and replicable examples of GxE interactions in 
the literature and even fewer examining APOE and 25(OH)D.  To the best of my 
knowledge, this study displays novel findings of effect modification by APOE ε4 
alleles on the association between 25(OH)D and memory.  In line with this 
study, there is some evidence of effect modification by APOE genotype on the 
association of certain lifestyle and health factors with cognitive function.  Kang 
et al. examined 70-80 year old participants of the Nurse’s Health Study and 
found the risk of cognitive decline was particularly high amongst APOE ε4 
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carriers who have untreated hypertension (198).  However, Brown et al found 
no evidence of interaction between APOE ε4 and homocysteine, folate, B6 or 
B12 in predicting cognitive function amongst older adults (70-79 years) (428).  
Kang et al took a similar approach to coding APOE ε4 as the presented study 
i.e. excluding ε2 carriers from analyses.  However, Brown et al coded APOE ε4 
as either carriers or non-carriers with no reference to treatment of ε2 carriers.  
Since there is some suggestion that those with an APOE ε2 allele may perform 
better on memory tests (429, 430), the exclusion of ε2 carriers may be 
beneficial in examining the independent actions of ε4.   
Interestingly, a study using participants who were in a similar age group to the 
1958BC (<64 years), found no association between APOE ε4 and any 
measured cognitive domain nor did it display any interaction effects with certain 
risk factors (i.e. head trauma and alcohol abuse) (426).  However, in a 4-year 
follow-up to this study, APOE ε4 was associated with lower cognitive function, 
as measured by the Mini-Mental State Examination, and there was evidence for 
interaction effects with low education and previous head trauma (431).  This 
suggests that the modifying effect of APOE genotype may become more 
pronounced when participants are older.  
Interpretation of the results may be limited as there were differences in how the 
memory tests in 1958BC and PIVUS were measured and mean concentrations 
on 25(OH)D were higher and deficiency and insufficiency prevalence was lower 
in in PIVUS compared with 1958BC.  Additionally, there are relatively small 
numbers of participants with two APOE ε4 which may have reduced the ability 
to detect differences in this group.  Precision could have been affected by 
missing information on 25(OH)D concentrations, although it is unlikely that 
missing data introduced bias since those with missing 25(OH)D measurements 
were similar to the remaining sample.  Furthermore, there was no difference in 
results when restricting analyses to participants with complete data on 
25(OH)D.  Causality cannot be determined as we cannot rule out the possibility 
of unmeasured confounding despite adjustment for gender, month of blood 
collection, region of residence, education and depressive symptoms.   
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7.4.1 Conclusion 
Results from this chapter suggest that, for memory, increasing 25(OH)D 
concentrations would be particularly beneficial for those with APOE ε4 alleles.  
The possibility to improve cognitive outcomes in genetically susceptible 
individuals who carry two APOE e4 alleles is intriguing; however, these novel 
findings clearly require independent replication to consolidate the evidence 
before randomised controlled trials to examine these effects are warranted. 
7.5 Summary 
 The aim of this chapter was examine if APOE ε4 genotype contributes to 
the association between 25(OH)D and memory function 
 There was evidence of interaction between APOE ε4 and 25(OH)D in 
1958BC and PIVUS suggesting the non-linear relationship between 
25(OH)D and memory function is most pronounced in those with APOE 
ε4 alleles compared with two ε3 alleles 
 This GxE interaction study suggests that the relationship between 
25(OH)D and memory function may be modified by the presence of 
APOE ε4 alleles.  However, this interaction may be age dependent and 
requires replication in larger, independent studies across many age 
groups  
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  Genetic study: Mendelian randomisation to assess Chapter 8
vitamin D and cognitive function 
8.1 Introduction 
Findings from observational study of the 1958 British birth cohort (1958BC) 
suggest there is a non-linear association between 25(OH)D and memory 
function (Chapter 6) which could be subject to effect modification by APOE ε4 
alleles (Chapter 7).  
Well-conducted observational studies may allude to an association between an 
exposure and outcome, however their inherent limitations can obscure the 
nature of the relationship between 25(OH)D and cognitive function through 
unmeasured confounding and the possibility of reverse causality (Chapter 3).  
Mendelian Randomisation (MR) is an approach that uses a genetic variant 
(associated with the exposure of interest) to estimate the causal relationship 
between an exposure and outcome (Figures 3.4 and 3.5).  As described in 
Chapter 3, this method can help to overcome some limitations of observational 
studies as it relies on the random assignment of genetic variants from parents 
to offspring to reduce the possibility of confounding (432).  Furthermore, since 
the genetic variant is established at birth, the possibility of reverse causality is 
minimised (432).   
The causal relationship between 25(OH)D and cognitive function will be 
evaluated using MR analyses, whereby genetic variants (in this case, single 
nucleotide polymorphisms, SNPs) are used as a proxy for lifelong 25(OH)D 
status (Chapter 2). 
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8.2 Data and methods  
8.2.1 Participants 
MR studies generally require large sample sizes to capture the small variation in 
the exposure that can be attributed to the genetic variant (Chapters 3 and 4).  If 
the sample size is too small, a real effect may not be detected.  To increase the 
sample size, data were obtained from nine European cohorts (Chapter 4): 
1) 1958 British birth cohort (1958BC) 
2) Austria Stroke Prevention Survey (ASPS) 
3) English Longitudinal Study of Ageing (ELSA) 
4) Epidemiologische Studie zu Chancen der Verhütung, Früherkennung 
und optimierten Therapie chronischer Erkrankungen in der älteren 
Bevölkerung (ESTHER) 
5) Helsinki Birth Cohort Study (HBCS) 
6) The Prospective Investigation of the Vasculature in Uppsala Seniors 
(PIVUS)  
7) The Tromsø Study (Tromsø) 
8) Uppsala Longitudinal Study of Adult Men (ULSAM) 
9) Whitehall II (WHII) 
Data was restricted to participants with information on at least one genetic 
variant, at least one cognitive outcome and who had data relating to 25(OH)D 
concentrations (Chapter 4 for further details).  Three cohorts (ASPS, ELSA and 
WHII) that did not have information on 25(OH)D concentrations were restricted 
to participants with data on genetic variants and cognitive outcomes.  In order to 
minimise the possibility of population stratification (see Chapter 3 for definition), 
participants from non-European ancestry were excluded.  Further exclusions for 
HBCS included those with a history of stroke (n=107) and those with a 
discrepancy between reported gender and gender determined by their genotype 
(n=8).       
Table 8.1 outlines the sample size, number of participants with available data 
on the genetic variants, 25(OH)D, cognitive outcomes and mean age at the time 
of cognitive testing. 
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Table 8.1: Eligible participants for MR study 
 Participants Year of 
cognitive test 
Mean age (SD) at 
cognitive test 
DHCR7 CYP2R1 25-hydroxyvitamin D Memory Global cognition 
1958BC 6,346 2008 50 (0) 6,212 5,752 5,890 6,260 6,151 
ASPS 826 1994-2003 65.6 (8.0) 826 826 0 780 740 
ELSA 5,532 2002 66.1 (9.7) 5,476 5,483 0 5,477 5,361 
ESTHER 9,749 2005-2008 74.0 (2.8) 8,312 8,296 9,502 1,694 1,694 
HBCS 1,811 2001-2003 68.1 (2.9) 1,629 1,630 1,035 1,017 1,017 
PIVUS 1,010 2006-2011 70.2 (0.2) 986 901 999 794 768 
Tromsø 12,336 2001 64.5 (9.9) 11,806 9,404 7,161 4,898 4,605 
ULSAM 1,194 1991-1995 71.0 (0.6) 1,123 1,124 1,194 0 858 
WHII 5,150 2002-2004 60.9 (6.0) 4,510 4,501 0 5,073 5,043 
Total 43,954   40,743 37,694 25,781 25,997 26,281 
 
 
224 
 
8.2.2 Variables 
Genetic variants 
The genetic variants used in this chapter are detailed in Chapter 4.  Briefly, 
DHCR7 and CYP2R1 were found to be effective instruments for MR studies on 
vitamin D, particularly when they are combined into a synthesis score.  The 
synthesis score has been found to explain more variation in 25(OH)D 
concentrations and was more robust to the MR assumptions compared with 
individual genetic variants (207).   
A description of the genotyping techniques used in each cohort to obtain these 
genetic variants is described in Chapter 4.  Quality checks of each genetic 
variant were conducted following data exclusions.  The call rate, minor allele 
frequency and Hardy Weinberg equilibrium for the genetic variants in each 
study are reported in Appendix 6.1.  The minor allele frequencies were 
compared with HapMap data on populations with a European ancestry7 and 
were found to be approximately similar. 
For analysis purposes, both DHCR7 and CYP2R1 genotypes were coded as 0-
2 depending on the presence of alleles associated with increasing 25(OH)D 
concentrations.  In this case, the homozygous genotypes with two vitamin D-
increasing alleles were coded as 2.  The synthesis score was created using 
DHCR7 and CYP2R1 genotypes by summing them on the basis of their alleles 
(207).  The few participants with 0 and 1 alleles associated with increasing 
25(OH)D concentrations (ranging from 9.6% in 1958BC to 17.4% in Tromsø) 
were grouped together. 
Exposure: 25-hydroxyvitamin D 
Information on 25(OH)D was available in six cohorts (Table 8.1).  Details of how 
25(OH)D concentrations were measured in each cohort can be found in 
Chapter 4.  In Tromsø, 25(OH)D concentrations had been shown to be 
overestimated in smokers, therefore models with 25(OH)D analysed in Tromsø 
were controlled for smoking status (433).  In ESTHER, 25(OH)D concentrations 
                                            
7
 http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap27_B36/#search 
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of 780 women with 0 to 29.5nmol/l were recorded as 29.54nmol/l due to the 
lower detection limit of the Diasorin assay employed to measure the serum 
sample in 2001.  The assay used for men did not have this detection limit.  
Additionally, in ESTHER, those with >250nmol/l (n=6) were excluded from 
analyses.  No 25(OH)D measurements were available for participants of ASPS, 
ELSA or WHII.  
Distributions of 25(OH)D in each cohort can be seen in Appendix 6.2.  Since 
25(OH)D was found to be skewed, natural log (ln) transformation was applied to 
approximate a normal distribution.  In order to examine the analyses stratified 
by 25(OH)D concentrations, gender and study specific 25(OH)D tertiles were 
created, where each tertile contains a third of the cohort’s eligible participants 
(Table 8.2). 
Outcomes: Global and memory cognitive function 
Cognitive tests in each cohort were segregated into a standardised memory or 
global cognitive domain (Chapter 4).  Table 8.3 illustrates how cognitive tests 
were grouped and Appendix 6.3 presents the distribution of tests in each 
cohort.  
Covariates 
MR analyses are based on the assumption that potential confounders are 
distributed equally between individuals with and without the effect allele, similar 
to the randomisation process in a randomised controlled trial (Chapter 3).  
Therefore, the number of covariates included are limited to those that have 
been shown to be strongly associated with cognitive function and/or 25(OH)D 
concentrations.  The main covariates include; gender, age (in years) (434), 
month of blood collection for 25(OH)D, education (434-436) and depressive 
symptoms (437-439).  A description of how education and depressive 
symptoms were measured in each cohort is given in Table 4.7. 
 
 
226 
 
Table 8.2: Gender and study specific 25(OH)D tertiles in each cohort 
 Gender-specific 25(OH)D tertile 1, nmol/l Gender-specific 25(OH)D tertile 2, nmol/l Gender-specific 25(OH)D tertile 2, nmol/l 
Study N mean SD min max N mean SD min max N mean SD min max 
1958BC 1,881 31.8 8.1 9.5 44.8 1,996 55.3 6.5 43.4 66.5 2,013 86.5 17.3 66.5 187.3 
ESTHER 3,117 31.0 5.1 7.0 41.7 3,178 46.5 7.1 35.9 63.6 3,207 74.8 21.9 49.3 225.6 
HBCS 340 42.7 7.1 19.0 53.0 345 60.1 4.7 51.0 69.0 350 83.3 18.6 67.0 292.0 
PIVUS 332 37.4 7.3 10.9 49.7 326 55.9 5.2 45.0 66.0 341 79.1 14.4 61.0 143.0 
Tromsø 2,374 38.5 7.8 10.1 50.0 2,390 56.9 4.7 48.2 65.2 2,397 81.1 14.7 65.3 192.2 
ULSAM 398 48.6 9.4 5.0 59.9 398 68.1 4.8 60.0 76.4 398 89.4 12.4 76.4 153.3 
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Table 8.3: Categorisation of cognitive tests in each cohort 
Cohort Memory Domain Global Cognition 
1958BC  Immediate word recall 
Delayed word recall 
 
Immediate word recall 
Delayed word recall 
Verbal fluency  
Speed of processing  
ASPS  Word association 
Digit association 
Story recall 
Trail recall 
Design recall 
Wisconsin card sorting test  
Alters-Konzentrations-Test  
TMT-B  
Digit-span backward 
Digit-span forward 
Complex reaction time task 
Word association 
Digit association 
Story recall 
Trail recall 
Design recall 
 
ELSA  Immediate word recall 
Delayed word recall 
 
Immediate word recall 
Delayed word recall 
Verbal fluency  
Speed of processing  
Orientation in time 
ESTHER  Verbal short-term memory 
Working memory 
Verbal long-term memory 
 
Verbal short-term memory 
Working memory 
Verbal long-term memory 
Verbal fluency 
Inductive reasoning 
HBCS  Immediate verbal recall 
Delayed verbal recall 
Verbal learning 
Immediate verbal recall 
Delayed verbal recall 
Verbal learning 
Verbal fluency 
PIVUS  7MS: word recall with reminder 
7MS: word recall without reminder 
 
7MS: word recall with 
reminder 
7MS: word recall without 
reminder 
7MS: clock drawing 
7MS: verbal fluency 
7MS: orientation in time 
TMT-A 
TMT-B 
MMSE 
Tromsø  
 
12-word memory test 
 
12-word memory test 
Finger tapping test 
Digit symbol coding test 
ULSAM  NA MMSE 
TMT-A 
TMT-B 
WHII  Memory test score Memory test score 
Alice-Heim 4 
Mill Hill Score 
Verbal fluency (phonemic) 
Verbal fluency (semantic) 
Global cognition: Derived variable to capture the full range of cognitive measures captured 
in the cohorts. MMSE: Mini-mental state examination; 7MS: 7-minute screen test; TMT: 
Trail making test 
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In 1958BC, MR models using 25(OH)D were additionally controlled for region of 
residence at 46 years (categorised as Southern England and Channel Islands 
(South), Middle England and Wales (Middle), Northern England and Isle of Man 
(North) or Scotland).  Models involving 25(OH)D analysed in Tromsø were also 
adjusted for smoking status (categorised as do not smoke or smoke daily).   
Additional covariates from the 1958BC were used to investigate the suitability of 
the chosen genetic variants as instruments for MR analyses.  These covariates 
included; region of residence (south or north), socioeconomic position (SEP) 
(I/II/IIINM or IIIM/IV/V), educational attainment (none/some/O-level/A-level or 
degree), depressive symptoms (yes/no), BMI (<30kg/m2 or ≥30kg/m2), alcohol 
consumption (non-/light/moderate drinker or heavy/very heavy drinker), smoking 
(yes or no), time spent outside (<3 hours/day or ≥3hours/day), time spent 
watching TV/using a PC (<3 hours/day or ≥3 hours/day), use of suncover (rarely 
or most of the time), vitamin D supplement (<one a day or  ≥one a day) and oily 
fish consumption (<weekly or ≥weekly).  A description of these variables can be 
found in Chapter 4. 
8.2.3 Statistical methods 
Chapter 3 provides detail on the MR approach and analyses.  This section 
outlines additional information regarding the statistical methods used.  
Analyses of observational data 
Linear regression models were used to examine the association between 
25(OH)D and the two measures of cognitive function in 1958BC, ESTHER, 
HBCS, PIVUS, Tromsø and one measure of cognitive function in ULSAM.  In 
these analyses, naturally log-transformed 25(OH)D was included in the model 
as a continuous exposure and global and memory cognitive scores were the 
standardised outcomes.  Estimates from these models were divided by 100 to 
reflect change in cognitive function for a 1% increase in 25(OH)D 
concentrations (346).  These models were adjusted for age, gender, month of 
25(OH)D blood collection, educational attainment and depressive symptoms.  
Analyses in 1958BC and Tromsø additionally controlled for region of residence 
and smoking status respectively. 
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Since findings from Chapter 6 implied there was a non-linear association 
between 25(OH)D and cognitive function, presence of a significant curvature 
was investigated (Chapter 3).  Effect modification was examined from the most 
complex models, which tests for interaction between gender or age, 25(OH)D 
and the curvature term of 25(OH)D (Chapter 3).  Effect modification by age 
(grouped as <65 year and ≥65 years) was assessed in individual cohorts where 
possible.  Observational analyses were stratified based on findings from the 
interaction analyses.   
All analyses were conducted in individual cohorts with available data and 
combined into a meta-analysis.  As specified in Chapter 3, random effects 
meta-analysis were run if the Q statistic indicated significant heterogeneity at 
the alpha level of 0.05.  Further sensitivity analysis was conducted to account 
for potential heterogeneity not captured by the alpha level.  There was no 
difference between fixed and random effects meta-analysis in any of the models 
examined.  
MR instrument validation  
A number of steps were taken to ensure the chosen genetic variants are 
suitable instruments for MR analyses.  
a) The genetic variant’s association with naturally log-transformed 25(OH)D 
was assessed in terms of both average increase in vitamin D-increasing 
allele and the influence of each additional allele compared with zero 
vitamin D-increasing alleles.  The strength of the relationship between 
genetic variants with 25(OH)D was examined by calculating the F-
statistic (Chapter 3).  This investigation used coefficients obtained from 
meta-analyses which were weighted by study sample size. 
b) The assumption of an independent association between the genetic 
variants and 25(OH)D was examined using data from the 1958BC 
(Chapter 3 for more details).  Covariates included; region of residence, 
SEP in adulthood, educational attainment, depressive symptoms, BMI, 
alcohol consumption, smoking status, time spent outside during the last 
month, time spent using PC or TV, use of suncover, use of vitamin D 
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supplements and consumption of oily fish.  The association between 
genetic variants and 25(OH)D were adjusted for these covariates to 
examine independency.  
c) The direct association between the genetic variants and covariates, 
adjusted for 25(OH)D were also examined. Bonferroni correction was 
applied to account for multiple testing (440).  As there were 12 
confounders, the p-value applied was <0.004 (i.e. 0.05/12).  
d) Interaction between the potential confounders and genetic variants with 
naturally log-transformed 25(OH)D were investigated.  Bonferroni 
correction was applied to account for multiple testing (i.e. 0.05/12). 
e) To assess if the relationship between the genetic variants and 25(OH)D 
is non-linear, squared terms for DHCR7 and CYP2R1 on naturally log-
transformed 25(OH)D were assessed in 1958BC. 
MR analyses 
The main steps for MR analyses are outlined in detail in Chapter 3.  Firstly, the 
association of the genetic variants with naturally log-transformed 25(OH)D was 
assessed using linear regression models adjusted for age, gender, month of 
25(OH)D assessment and additional adjustments were made for 1958BC 
(region of residence), Tromsø (smoking status) and HBCS (principal 
components to control for potential population stratification).  The estimates 
from this analysis were multiplied by 100 to reflect percentage change in 
25(OH)D per vitamin D-increasing allele (346).  For consistency, the genetic 
variant association with 25(OH)D was stratified according to results from the 
observational interaction analyses.    
Secondly, the association of genetic variants with cognitive function was 
assessed using linear regression models.  ULSAM had information on global 
cognitive function only.  These estimates reflect the change in cognitive function 
per vitamin D-increasing allele.  These analyses were adjusted for age, gender, 
education and depressive symptoms in addition to principal components in 
HBCS.  Analyses were stratified according to results from the observational 
interaction analyses.  
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As with observational analyses, MR analyses were conducted in individual 
cohorts with available data and combined into meta-analyses.  There was no 
difference between fixed and random effects meta-analysis in the MR analyses. 
Finally, the IV ratio was calculated using the meta-analysed coefficients 
examining 1) the association of genetic variants with 25(OH)D and 2) the 
association of genetic variants with cognitive function (Chapter 3).  
Meta-regression 
Meta-regression was used to examine heterogeneity amongst the cohorts using 
results from the meta-analysed observational analyses (441) (Chapter 3).  
Study characteristics that were hypothesised a priori to affect the association 
included gender, age group (<65 versus ≥65 years) and country region 
(categorised as UK (1958BC, ELSA and WHII), Europe (ASPS and ESTHER) 
and Nordic (HBCS, PIVUS, Tromsø and ULSAM). 
8.3  Results 
8.3.1 Descriptive results 
The distribution of 25(OH)D and the main covariates can be seen in Table 4.7.  
Most cohorts have an equal distribution of men and women.  However, ULSAM 
consists of an exclusively male population and WHII consists of mostly men 
(73.9%).  All participants from the 1958BC are <65 years while participants from 
ESTHER, PIVUS and ULSAM are all ≥65 years.  ASPS, ELSA, HBCS, Tromsø 
and WHII consist of participants in both age groups.  The lowest mean 25(OH)D 
concentrations were found in ESTHER (46.8nmol/l) with the highest seen in 
ULSAM (65.8nmol/l).  
The distribution of genetic variants in each cohort can be seen in Appendix 6.4.  
As expected, the percentage of participants was lowest for those with two 
copies of the 25(OH)D lowering allele in each cohort.  
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8.3.2 Observational association 
The 1958BC, ESTHER, HBCS, PIVUS, Tromsø and ULSAM were eligible for 
inclusion in observational analyses as participants had data on both 25(OH)D 
and cognitive function.   
Individual observational results between cohorts were heterogeneous (Table 
8.4).  In ESTHER, there was evidence for higher global and memory cognitive 
function per 10% increase in 25(OH)D concentrations (p<0.01 for both 
outcomes).  In Tromsø, global cognitive function was found to be higher with 
increasing 25(OH)D concentrations (p=0.002), however the association with 
memory function was not significant (p=0.80).  There was no linear association 
between 25(OH)D and either global or memory function in the remaining 
cohorts although the coefficients for HBCS and USLAM indicated lower 
cognitive function with higher 25(OH)D concentrations.  The coefficients for 
global and memory cognitive function in 1958BC and PIVUS were in opposing 
directions.  
There was a non-linear association between 25(OH)D and both global and 
memory cognitive function in 1958BC (p<0.04), however no significant  
curvature was found in the other cohorts (Table 8.4).   There was no effect 
modification by gender or age-group (i.e. <65 versus ≥65 years) on the 
association between 25(OH)D and cognitive function in any cohort (Table 8.4).   
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Table 8.4: Association between and 25(OH)D and cognitive function 
Cohort Cognitive outcome N Coefficient, per 10% 
increase in 25(OH)D 
(se) p-value pcurvature pgender 
interaction 
page 
interaction
† 
1958BC Global cognition 5,028 0.002 (0.003) 0.57 0.04 0.41* - 
 Memory Cognition 5,125 -0.001 (0.003) 0.67 0.02 0.19* - 
ESTHER Global cognition 1,553 0.02 (0.01) 0.00 0.89 0.35 - 
 Memory Cognition 1,553 0.02 (0.01) 0.01 0.78 0.92 - 
HBCS Global cognition 725 -0.01 (0.01) 0.66 0.94 0.71 0.76 
 Memory Cognition 725 -0.01 (0.01) 0.40 0.89 0.74 0.91 
PIVUS Global cognition 752 -0.004 (0.01) 0.73 0.26 0.30 - 
 Memory Cognition 777 0.01 (0.01) 0.44 0.98 0.67 - 
Tromsø Global cognition 2,072 0.02 (0.01) 0.002 0.40 0.07 0.66 
 Memory Cognition 2,193 0.002 (0.01) 0.80 0.13 0.42 0.27 
ULSAM Global cognition 858 -0.02 (0.01) 0.18 0.17 N/A - 
*p from 2-way interaction, adjusted for 25(OH)D2 
†1958BC are all <65 years. ESTHER, PIVUS and ULSAM are all ≥65 years 
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The individual observational results examining the association of 25(OH)D with 
global and memory cognitive function were combined into meta-analyses in 
order to obtain pooled estimates.  There was heterogeneity between the studies 
for global cognitive function (I2=67.4%, pheterogeneity=0.01), therefore a random-
effects model was used.  There was no significant heterogeneity between the 
studies for memory cognitive function (I2= 46.2%, pheterogeneity=0.12 for memory 
cognition) therefore, a fixed effects model was used in this case.  There was no 
linear association between 25(OH)D and either global or memory cognitive 
function using these models (p>0.32 for both, Figures 8.1 and 8.2).  However 
using a fixed effects meta-analyses (I2=0.0%, pheterogeneity≥0.48 for both 
outcomes), there was a non-linear association between 25(OH)D and both 
global and memory cognitive function (pcurvature<0.01 for both, Figure 8.3).   
There was no effect modification by gender or age group on the association 
between 25(OH)D and either global or memory cognitive function  (p≥0.49 for 
gender interaction and p≥0.29 for age-group interaction for both outcomes 
(Appendices 6.5 and 6.6).   
Since there was a non-linear relationship between 25(OH)D and cognitive 
function, meta-analysed observational results were stratified by study-specific 
25(OH)D tertiles (Table 8.2).  When stratified by 25(OH)D tertiles, coefficients 
for global cognitive function per 10% increase in 25(OH)D were 0.01 (95% CI -
0.001 to 0.03) in the lowest third (tertile 1 (T1)), 0.03 (95% CI 0.01 to 0.06) for 
T2 and -0.02 (95% CI -0.04, -0.004) for the highest third (T3).  The coefficients 
for memory cognition per 10% increase in 25(OH)D were 0.003 (95% CI -0.01 
to 0.02) for T1, 0.02 (95% CI -0.2 to 0.01) for T2 and -0.002 (95% CI -0.04 to -
0.01) for T3 (Figures 8.4 and 8.5).  
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Figure 8.1: Association between 25(OH)D and global cognitive function 
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Figure 8.2: Association between 25(OH)D and memory function 
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Figure 8.3: Non-linear association between 25(OH)D and cognitive function 
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Figure 8.4: Association of 25(OH)D with global cognition: Stratified by 25(OH)D tertiles 
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Figure 8.5: Association of 25(OH)D with memory function: Stratified by 25(OH)D tertiles 
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8.3.3 IV validation 
To determine the suitability of the genetic variants for use in MR analysis, firstly, 
the strength of the genetic variant’s association with 25(OH)D was assessed.  
Figure 8.6 used fixed-effects meta-analyses to illustrate that the addition of 
each vitamin D-increasing allele is associated with greater increases in 
25(OH)D concentrations.  The weighted F-statistic was 31.42 for DHCR7, 49.19 
for CYP2R1 and 62.34 for the synthesis score.  Since these F-statistics are 
>10, all genetic variants can be considered strong enough to use as a proxy for 
25(OH)D in MR analyses (Staiger & Stock 1997).   
The assumption of an independent association between genetic variants and 
25(OH)D was examined using data from the 1958BC.  The association between 
CYP2R1 and synthesis score with 25(OH)D was not found to be sensitive to 
adjustment by lifestyle and dietary factors (Figure 8.7).  However, the 
relationship between DHCR7 and 25(OH)D was affected by dietary and lifestyle 
factors.  This finding suggests that the association between DHCR7 and 
25(OH)D may not be independent of potential confounding factors.  
Figure 8.8 shows the direct associations between genetic variants with these 
lifestyle and dietary factors.  There was an association between DHCR7 with 
region of residence and use of suncover following application of Bonferroni 
correction (correcting for 12 tests) and adjusting for 25(OH)D concentrations.  
DHCR7 was associated with reduced odds of living in southerly regions and 
increased odds of using suncover most of the time.  
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Figure 8.6: Association of effect alleles with 25(OH)D 
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Figure 8.7: Association between genetic variants and 25(OH)D, adjusted for lifestyle factors 
Cofounders include region of residence, socioeconomic position (SEP) in adulthood, educational attainment, depressive symptoms, BMI, alcohol 
consumption, smoking status, time spent outside during the last month, time spent using personal computer (PC) or television (TV), use of suncover, 
use of vitamin D supplements and consumption of oily fish 
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Figure 8.8: Association between genetic variants and potential confounders 
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There was no effect modification by these lifestyle and dietary factors on the 
association of genetic variants with 25(OH)D (Bonferroni corrected 
pinteraction≥0.36).  There was no non-linear association between genetic variants 
with 25(OH)D (Bonferroni corrected pcurvature ≥0.60).  
8.3.4 Mendelian randomisation analyses 
Genetic variant association with 25(OH)D 
1958BC, ESTHER, HBCS, PIVUS, Tromsø and ULSAM were included when 
examining the association of genetic variants with 25(OH)D.   
As expected, the 25(OH)D concentrations were higher per vitamin D-increasing 
allele across all cohorts except HBCS (Table 8.5)  
These individual results were combined into meta-analyses, with a random 
effects model for DHCR7 (I2=73.7%, pheterogeneity=0.002) and fixed effects models 
for CYP2R1 and the synthesis score (I2≤53.3%, pheterogeneity≥0.06).  25(OH)D 
concentrations were higher per vitamin D-increasing allele of both genetic 
variants and the synthesis score  (Figures 8.9 to 8.11).  DHCR7 showed 2.3% 
(95% CI 0.4% to 4.2%) higher 25(OH)D concentrations and CYP2R1 showed 
3.1% (95% CI 2.8% to 4.0%) higher 25(OH)D concentrations per vitamin D-
increasing allele.  The synthesis score indicated 2.9% (95% CI 2.2 to 3.5%) 
higher 25(OH)D concentrations per vitamin D-increasing allele.  
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Table 8.5: Association between genetic variants and 25-hydroxyvitamin D 
Cohort Genetic variant N Coefficient, % change in 25(OH)D 
per vitamin D-increasing allele 
(se) p-value 
1958BC DHCR7 5,773 5.34 (0.92) <0.001 
 CYP2R1 5,335 3.15 (0.79) <0.001 
  Synthesis score 5,238 4.08 (0.62) <0.001 
ESTHER DHCR7 1,369 4.37 (1.55) 0.005 
 CYP2R1 1,370 1.13 (1.38) 0.41 
 Synthesis score 1,362 2.35 (1.04) 0.02 
HBCS DHCR7 707 -0.47 (1.70) 0.78 
 CYP2R1 708 7.20 (1.61) <0.001 
 Synthesis score 707 3.70 (1.24) 0.003 
PIVUS DHCR7 981 1.03 (1.61) 0.52 
 CYP2R1 896 4.93 (1.61) 0.002 
 Synthesis score 887 3.30 (1.23) 0.012 
Tromsø DHCR7 3,336 1.13 (0.73) 0.12 
 CYP2R1 3,351 2.42 (0.73) 0.001 
 Synthesis score 3,320 2.01 (0.55) <0.001 
ULSAM DHCR7 1,123 1.60 (1.32) 0.23 
 CYP2R1 1,124 3.20 (1.30) 0.01 
 Synthesis score 1,118 2.21 (0.97) 0.02 
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Figure 8.9: Association between DHCR7 and 25(OH)D 
Beta reflects % change in 25(OH)D per vitamin D-increasing allele
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Figure 8.10: Association between CYP2R1 and 25(OH)D 
Beta reflects % change in 25(OH)D per vitamin D-increasing allele
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Figure 8.11: Association between synthesis score and 25(OH)D 
Beta reflects % change in 25(OH)D per vitamin D-increasing allele 
249 
 
To be consistent with observational analyses, the association of the meta-
analysed genetic variants with 25(OH)D were stratified by study-specific 
25(OH)D tertiles (Appendices 6.7 to 6.9). 
DHCR7 was associated with 1.5% higher (95% CI 0.4% to 2.5%) 25(OH)D 
concentrations per vitamin D-increasing allele in T1, 0.1% lower (95% CI 0.5% 
lower to 0.4% higher) 25(OH)D concentrations in T2 and 1.5% higher (95% CI 
0.8% to 2.3%) concentrations in T3.    
CYP2R1 showed 0.5% lower (95% CI 1.4% lower to 0.52% higher) 25(OH)D 
concentrations per vitamin D-increasing allele in T1, 0.1% lower (95% CI 0.3% 
lower to 0.5% higher) in T2 and 2.8% higher (95% CI 2.0% to 3.5%) in 25(OH)D 
concentrations in T3.   
The synthesis score demonstrated 0.4% higher (95% CI 0.3% lower to 1.2% 
higher) 25(OH)D concentrations per vitamin D-increasing allele in T1, 0.01% 
higher (95% CI 0.3% lower to 0.3% higher) in T2 and 2.3% higher (95% CI 
1.7% to 2.8%) in 25(OH)D concentrations per vitamin D-increasing allele in T3.  
Genetic variant association with cognitive function 
All cohorts were included when investigating the association of genetic variants 
with global and memory cognitive function.  The results for each individual 
cohort can be found in Appendix 6.10. 
There were no significant associations between the genetic variants or 
synthesis score with global or memory function in any of the cohorts.  
Furthermore, the direction of the relationship varied according to cohort.  For 
example, the coefficient for 1958BC suggested higher global and memory 
cognitive function while WHII suggested lower cognitive function per vitamin D-
increasing allele of the synthesis score.  
These individual results were combined into fixed effects meta-analyses 
(I2≤35.9%, pheterogeneity≥0.23 for global cognitive function and I
2≤34.8%, 
pheterogeneity≥0.15 for memory cognitive function).  There was no association 
between either genetic variants or synthesis score with global cognitive function 
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(p≥0.08, Figures 8.12 to 8.14).  DHCR7 indicated a slightly higher memory 
cognitive function per vitamin D-increasing allele (p=0.04) however, there was 
no relationship between CYP2R1 or the synthesis score with memory cognitive 
function (p≥0.29, Figures 8.12 and 8.14).  Furthermore, the coefficients for both 
global and memory cognitive function were in the opposing direction for DHCR7 
and CYP2R1. 
Table 8.6 displays results stratified by 25(OH)D tertiles. There was a trend for 
lower global cognitive function per vitamin D-increasing allele of CYP2R1 in T2, 
however this was not significant in T1 or T3.  The coefficients for DHCR7 and 
synthesis score with global cognitive function across all 25(OH)D tertiles were in 
opposing directions and were not significant. 
There was no association between either genetic variant or synthesis score with 
memory cognitive function across any of the 25(OH)D tertiles. 
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Figure 8.12: Association between DHCR7 and cognitive function 
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Figure 8.13: Association between CYP2R1 and cognitive function 
253 
 
 
Figure 8.14: Association between synthesis score and cognitive function
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Table 8.6: Meta-analysed association between genetic variants and cognitive function: Stratified by 25(OH)D tertiles 
  Global Cognition Memory cognition 
 25(OH)D tertiles Coef 95% CI Pvalue pheterogeneity Coef 95% CI Pvalue pheterogeneity 
DHCR7 T1 0.002 (-0.04 to 0.05) 0.94 0.90 0.02 (-0.03 to  0.06) 0.49 0.74 
 T2 0.02 (-0.02 to 0.06) 0.40 0.66 0.03 (-0.02 to 0.08) 0.18 0.60 
 T3 0.01 (-0.03 to 0.05) 0.68 0.64 0.01 (-0.03 to 0.06) 0.63 0.58 
CYP2R1 T1 -0.01 (-0.05 to 0.04) 0.83 0.18 0.02 (-0.03 to 0.07) 0.37 0.21 
 T2 -0.05 (-0.09 to -0.01) 0.02 0.26 -0.03 (-0.09 to 0.02) 0.18 0.43 
 T3 -0.02 (-0.06 to 0.03) 0.44 0.16 0.003 (-0.04 to 0.05) 0.91 0.21 
Synthesis score T1 -0.01 (-0.05 to 0.02 ) 0.46 0.57 0.01 (-0.03 to 0.05) 0.59 0.73 
 T2 -0.01 (-0.05 to 0.02 ) 0.41 0.15 -0.002 (-0.04 to 0.03) 0.94 0.47 
 T3 -0.01 (-0.05 to 0.05) 0.39 0.39 -0.01 (-0.04 to 0.03) 0.78 0.62 
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IV ratio 
Calculation of the IV ratio is the final step in the MR analysis to estimate the 
causal effect of 25(OH)D on cognitive function (Table 8.7).  There was no 
causal association between 25(OH)D and cognitive function using DHCR7, 
CYP2R1 or the combined synthesis score.   
In keeping with previous analyses, Table 8.8 illustrates the IV ratio stratified by 
25(OH)D tertiles.  There was no causal association between 25(OH)D and 
cognitive function across any 25(OH)D tertiles and the estimates were 
inconsistent across the different genetic variants.  
Meta-regression 
In observational analyses, the association of 25(OH)D with global or memory 
cognitive function did not vary by the examined the study level factors of age 
group (pmeta-regression=0.97) and country (pmeta-regression=0.48).  
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Table 8.7: Instrumental variable ratio 
 
  Genetic variant with 25(OH)D, per 
allele 
Genetic variant with outcome, per 
allele 
IV estimate for causal effect, per 
10% increase in 25(OH)D 
  Coefficient, % (se) Pvalue Coefficient* (se) P-value Coefficient
† (se) Pvalue 
Global cognition          
 DHCR7 2.28 (0.96) 0.02 0.01 (0.01) 0.19 0.05 (0.05) 0.25 
 CYP2R1 3.12 (0.43) <0.001 -0.02 (0.01) 0.08 -0.05 (0.03) 0.09 
Synthesis score 2.87 (0.33) <0.001 -0.005 (0.01) 0.47 -0.02 (0.02) 0.47 
Memory cognition          
 DHCR7 2.28 (0.96) 0.02 0.02 (0.01) 0.04 0.09 (0.06) 0.12 
 CYP2R1 3.12 (0.43) <0.001 -0.01 (0.01) 0.29 -0.03 (0.03) 0.30 
Synthesis score 2.87 (0.33) <0.001 0.0002 (0.01) 0.97 0.001 (0.03) 0.97 
*Coefficient represents the difference in cognitive function (standard deviation(sd)) per vitamin D-increasing allele 
† Calculated as the ratio between the genetic variant association with the outcome and 25(OH)D.  Coefficients can be interpreted 
as change in cognitive function (sd) per 10% increase in 25(OH)D concentrations 
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Table 8.8: Instrumental variable ratio: Stratified by 25(OH)D tertiles 
 
  Study-
specific 
25(OH)D 
tertiles 
Genetic variant with 25(OH)D, 
per allele 
Genetic variant with outcome, 
per allele 
IV estimate for causal effect, 
per 10% increase in 25(OH)D 
  Coefficient (se) Pvalue Coefficient (se) P-value Coefficient (se) Pvalue 
Global cognition           
 DHCR7 T1 1.47 (0.54) 0.01 0.002 (0.02) 0.94 0.01 (0.15) 0.94 
  T2 -0.17 (0.44) 0.70 0.02 (0.02) 0.40 -1.03 (2.96) 0.73 
  T3 1.54 (0.39) <0.001 0.009 (0.02) 0.02 0.06 (0.14) 0.68 
 CYP2R1 T1 -0.46 (0.50) 0.36 -0.006 (0.02) 0.80 0.13 (0.52) 0.81 
  T2 0.07 (0.20) 0.71 -0.05 (0.02) 0.02 -6.54 (17.82) 0.71 
  T3 2.96 (0.68) <0.001 -0.02 (0.02) 0.44 -0.06 (0.08) 0.44 
Synthesis score T1 0.41 (0.38) 0.28 -0.01 (0.02) 0.46 -0.32 (0.52) 0.54 
 T2 0.01 (0.16) 0.95 -0.01 (0.02) 0.41 -14.79 (247.8) 0.95 
 T3 2.28 (0.28) <0.001 -0.01 (0.02) 0.39 -0.06 (0.07) 0.39 
Memory cognition           
 DHCR7 T1 1.47 (0.54) 0.006 0.02 (0.02) 0.49 0.11 (0.17) 0.67 
  T2 -0.17 (0.44) 0.70 0.03 (0.02) 0.18 -1.89 (5.12) 0.37 
  T3 1.54 (0.39) <0.001 0.01 (0.02) 0.63 0.07 (0.15) 0.48 
 CYP2R1 T1 -0.46 (0.50) 0.36 0.02 (0.02) 0.37 -0.47 (0.74) 0.52 
  T2 0.07 (0.20) 0.71 -0.03 (0.02) 0.18 -4.21 (11.76) 0.72 
  T3 2.96 (0.68) <0.001 0.003 (0.02) 0.91 0.01 (0.08) 0.91 
Synthesis score T1 0.01 (0.02) 0.59 0.41 (0.38) 0.28 0.24 (0.51) 0.63 
  T2 -0.002 (0.02) 0.94 0.01 (0.16) 0.95 -1.58 (33.11) 0.96 
  T3 -0.002 (0.02) 0.78 2.28 (0.28) <0.001 -0.02 (0.08) 0.78 
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8.4 Discussion 
Results using data from nine European cohorts found that the non-linear 
observational association of 25(OH)D with both global and memory cognitive 
function replicates results from previous chapters.  Both global and memory 
cognitive scores tended to be higher with increasing 25(OH)D concentrations 
amongst participants in the lower and mid-25(OH)D tertiles, while in the highest 
tertile, cognitive scores were lower with increasing 25(OH)D concentrations. 
The genetic variants, DHCR7, CYP2R1 and their combined synthesis score 
were associated with higher 25(OH)D concentrations.  Therefore, it is expected 
that the genetic variants should be associated with higher global and cognitive 
function scores if there is a causal association between 25(OH)D and cognitive 
function.  However, results indicate that the association with global or memory 
cognition was in the opposing direction for DHCR7 and CYP2R1, and no overall 
association was observed for the synthesis score.  Furthermore, when stratified 
by 25(OH)D tertiles, the relationships between the genetic variants and 
cognitive function did not mimic those evident in the observational analyses.  
The IV ratio, which was calculated overall and per tertile, reflected these 
inconsistent findings, implying that there is no evidence for 25(OH)D 
concentrations acting as a causal factor for cognitive function, when using 
DHCR7 and CYP2R1 as IVs.  
Although MR analyses can contribute evidence when establishing a causal 
association between 25(OH)D and cognitive function, the gold standard method 
is an RCT.  A limited number of RCTs have been conducted to assess the 
causal relationship between 25(OH)D and cognitive function (Table 6.1).  In 
contrast to the MR findings, one RCT conducted amongst older adults 
(≥65years) based in the community found a significant difference in the 
treatment versus placebo groups over a period of one year (395).  However, the 
treatment consisted of 4.0μg of vitamin D in combination with vitamin A, β-
carotene, thiamine, riboflavin, niacin, vitamin B6, vitamin E, iron, zinc, copper, 
selenium, iodine, calcium and magnesium.  Another RCT was consistent with 
MR results as there was no difference in cognitive tests amongst 
institutionalised older adults (≥65years who had evidence of mild-to moderate 
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cognitive impairment (Mini-mental State Examination score ≥10)) over 24 weeks 
(394).  The treatment in this case involved a nutrient dense drink consisting of 
macronutrients, B-vitamin D, vitamin A, Vitamin D, vitamin E, vitamin K and 
vitamin C, minerals and trace elements.  MR findings were supportive of results 
from the biggest RCT to date which was carried out amongst older women (≥65 
years) who participated in the Women’s Health Initiative (393).  In this RCT, 
supplementation with 400 International Units (IU) of vitamin D and calcium over 
a mean follow-up of 7.8 years did not protect against cognitive impairment.  
Comparison between the MR study and these RCTs can be difficult as RCTs 
have mainly focused on older populations and vitamin D has been used in 
varying amounts and in combination with other nutrients. 
Results from the meta-analysis indicate a strong non-linear relationship, 
suggesting that both lower and higher 25(OH)D concentrations may reduce 
cognitive function.  Therefore, the association between the genetic variants and 
cognitive function was stratified into tertiles.  There was no consistent evidence 
of an association between genetic variants across tertiles.  However, the range 
of 25(OH)D concentrations in the highest tertile was 89.8nmol/l compared with 
13.7nmol/l in T2 and 26.4nmol/l in T1.  These large ranges may have led to 
spurious findings.  Stratification by 25(OH)D tertiles could have led to collider 
bias if the association of two variables (i.e. genetic variants and cognitive 
function), changes upon conditioning on a third variable (i.e. 25(OH)D), when 
this third variable is affected by the other two (442).  Although analyses has 
included 43,954 participants across 9 European cohorts, the genetic analyses is 
likely to be underpowered to detect small causal effects operating at the 
extremes of the 25(OH)D distribution.  Power is an issue in MR studies due to 
the large sample size required to detect the small effect of a genetic variant on 
an exposure.  Although a power calculation was beyond the scope of this 
thesis, an illustrative power calculation was conducted on a hypothetical MR 
study of the association between 25(OH)D and blood pressure which indicated 
that 80,000 participants would be required (207).   
Results from meta-regression found no evidence that the association of 
25(OH)D with global or memory cognitive function varied by age group (i.e. <65 
versus ≥65 years), however, this could be due to lack of studies examining the 
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effect amongst older age groups.  There was also no evidence of country level 
difference, which could be explained by the use of a genetically homogenous 
Caucasian population. 
The success of an MR study relies upon the ability of the genetic variant to 
accurately proxy the exposure of interest (3).  The choice of suitable genetic 
variants for MR analyses on 25(OH)D is thwarted by the complex metabolic 
pathway of vitamin D.  There are numerous genes involved in the enzymatic 
conversions before vitamin D becomes a biologically active substance, making 
the choice of a reliable genetic variant more difficult.  However, one study 
conducted in 2012, which evaluated genetic makers identified from genome 
wide association studies as instruments for MR studies on vitamin D found that 
DHCR7 and CYP2R1 were suitable instruments (207).   Furthermore, the F-
statistic, which takes into account the amount of variation in 25(OH)D due to the 
genetic variant, suggested that DHCR7 and CYP2R1 were considered strong 
instruments to proxy 25(OH)D (3).     
The assumption of an independent association between the genetic variants 
and 25(OH)D (Chapter 3) was examined in the 1958BC. While the relationship 
between CYP2R1 and 25(OH)D was not affected by adjustment for potentially 
important covariates, DHCR7 was.  Investigation of a direct association 
between DHCR7 and these covariates revealed a significant association with 
region and use of suncover.  This could imply that population stratification 
(Chapter 3) and, to some extent, behavioural factors may confound the 
relationship between DHCR7 and 25(OH)D.  These findings reduce the 
reliability of the role of DHCR7 as an appropriate instrument to estimate the 
causal effect of 25(OH)D on cognitive function.  
In addition to the independent association between genetic variants and 
25(OH)D, the association should also be linear and unaffected by statistical 
interactions (3).  The was no evidence of effect modification by covariates on 
the association between the genetic variants and 25(OH)D.   While the 
association between DHCR7 and 25(OH)D was linear, there was suggestion of 
a non-linear relationship between CYP2R1 and 25(OH)D.  When stratified by 
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tertiles, results implied the effect of CYP2R1 on increasing 25(OH)D may be 
more prominent amongst participants with higher 25(OH)D concentrations.  
Pleiotropy can also reduce reliability of the genetic variants to estimate 
25(OH)D concentrations.  Pleiotropy occurs when the genetic variant influence 
more than one phenotypic trait.  It is not possible to formally test for the 
presence of pleiotropy (see Chapter 3 for details) (443).  An earlier study in 
1958BC did not find evidence of pleiotropy following investigations of markers 
for cardiovascular health (207).  However, the extent of potential effects of 
these genetic variants remains unknown at this stage.  For example, DHCR7 
could influence cognitive function via its effect on cholesterol metabolism.  
Conclusion 
There was no evidence for 25(OH)D concentrations acting as a causal factor for 
cognitive performance in mid- to later-life.  However, the observational 
association between 25(OH)D and cognitive function was strongly non-linear, 
and our genetic analyses may have been underpowered to detect small causal 
effects operating at the extremes of 25(OH)D distribution. 
 
8.5 Summary 
 Previous chapters have suggested a non-linear observational association 
between 25(OH)D and cognitive function 
 The aim of this chapter was to assess the causal association between 
25(OH)D and cognitive function using a Mendelian randomisation 
approach 
 Data from nine European cohorts demonstrated a significant non-linear 
observational association between 25(OH)D and cognitive function, but 
there was no evidence of a genetic association 
 Overall, there is uncertainty regarding a true causal non-linear 
association between 25(OH)D and cognitive function  
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 Discussion Chapter 9
Concern regarding the widespread global prevalence of low vitamin D status is 
amplified by the potential role of vitamin D in a variety of non-skeletal health 
outcomes, including brain function (56).  Correspondingly, evidence for the role 
of vitamin D in both mental health and cognitive function has been 
accumulating.  Since both mental health and cognitive function are of significant 
public health importance (Chapter 1), this thesis examined the two outcomes, 
with an emphasis on cognitive function.  
The overall aim was to expand previous research by using a variety of study 
designs, including observational and genetic studies, to investigate whether 
vitamin D status (as measured by 25-hydroxyvitamin D, 25(OH)D) affects 
common mental disorders (CMD) and cognitive function.  Observational findings 
were supportive of a non-linear association of 25(OH)D with CMDs and memory 
function.  There was some suggestion that presence of apolipoprotein (APOE) 
ε4 alleles can modify the association between 25(OH)D and memory function.  
However, there was no evidence for a casual association between 25(OH)D 
and cognitive function using a Mendelian randomisation (MR) approach. 
Mental health and cognitive function are complex entities, each influenced by an 
array of social, environmental, biological, psychological and genetic risk factors 
(Chapter 1) that can interact and accumulate over the life-course.  Their 
complexity makes identification of explicit risk factors challenging.  Moreover, 
there may be a certain period over the life-course during which specific risk 
factors manifest their importance.  It is plausible that vitamin D can affect mental 
health and cognitive function throughout the life-course (Chapter 1).  However, 
given the multitude of factors that can influence an individual’s cognitive 
function and mental health,  it is not surprising that the magnitude of the effect 
of 25(OH)D on both CMDs and cognitive function from observational study was 
small in comparison to, for example, the effects of age on cognitive function 
(101) or early life psychological health on CMDs (69).  
This work focused on CMDs and cognitive function in adulthood, with an 
emphasis on mid-life (~45-50 years).  CMDs, which are a leading cause of 
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Disability Adjusted Life Years (60), have been found to be particularly prevalent 
amongst adults in mid-life (9, 61).  Furthermore, by examining cognitive function 
in mid-adulthood, there is potential to identify associations at a life stage when 
cognitive decline is only beginning to emerge.  
9.1 Methodological considerations 
Participants 
Participants came primarily from the 1958 British birth cohort (1958BC).  A 
major strength of this cohort is its large sample with extensive information on 
lifestyle, health and economic factors which have been gathered throughout the 
follow-up studies.  The variables measured in each sweep of the 1958BC can 
be taken into account during analyses, which facilitates unravelling complex 
associations of vitamin D with CMDs and cognitive function.  However, for some 
variables, such as vitamin D-related lifestyles, there was a reliance on self-
reported data, which may have introduced some social desirability bias or 
random error.  Furthermore there was no substantial information on dietary 
intake which limited the scope of the analyses.   
Overall, cohort members of 1958BC are predominantly white, which although 
reflective of society at the time, is not representative of the demographic today 
(444).  The 1958BC has been shown to represent the national population in 
terms of socioeconomic characteristics (233), marriage status and employment 
(216), however, it under-represents ethnic minorities (216).  Additionally, like all 
longitudinal cohort studies, some sample attrition occurred in 1958BC where 
those with externalising or internalising behaviours and poor reading or maths 
scores were moderately under-represented (216).  Despite this, participants 
remaining in the study at 45 years were representative of those in the original 
cohort (216) and results using inverse probability weights applied in Chapters 5 
and 6 did not differ from analyses without these weights.  
Data from the eight additional European cohorts in Chapter 8 enabled 
comparison to identify potential cohort effects.  However, all data from these 
cohorts were from individuals with European ancestry, again reducing 
generalisability of findings to ethnic minorities.  
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Exposure: 25(OH)D 
Vitamin D status was assessed using 25(OH)D concentrations.  While this is not 
the biologically active form of vitamin D (Figure 1.1), it provides a useful marker 
of vitamin D exposure as it incorporates both endogenous synthesis and dietary 
intake (44).  There have been some concerns about inaccurate measurements 
of serum 25(OH)D concentrations due to assay imprecision, however this has 
been partly overcome by calibration tools.  25(OH)D concentrations in the 
1958BC were standardised to the mean of the Vitamin D External Quality 
Assessment Scheme (DEQAS) to enable comparison with other studies (235).  
Although DEQAS can provide standardised measures for 25(OH)D, there is still 
no guarantee that the 25(OH)D measurements are valid.  Unfortunately, there 
was only one measure of 25(OH)D concentrations available from the 1958BC 
(at 45 years).  While there is some evidence to suggest that 25(OH)D 
concentrations at a single time point are reflective of long-term status (445), it is 
possible that participants changed their behaviour, and consequently their 
vitamin D status, during the follow-up period in Chapters 5 and 6.  Therefore, 
any inferences about the association between chronic or concurrent 
hypovitaminosis D and CMDs or cognitive function in observational study 
should be made with caution.   
The cohort studies ESTHER, HBCS, PIVUS Tromsø and ULSAM used in 
Chapter 8, (with PIVUS also used in Chapter 7) applied different methods to 
measure 25(OH)D concentrations, which could add to the source of  
heterogeneity between studies.   
Outcome: Mental Health 
The 1958BC used standardised methods, which aim to minimise interviewer 
bias (239), to measure symptoms of CMDs.  The Clinical-Interval Schedule 
Revised (CIS-R) and Mental Health-Inventory 5 (MHI-5) have been used in 
previous studies (Chapter 4).  One advantage of the CIS-R is its ability to 
capture a variety of CMDs, such as depressive, anxiety, panic and phobia 
symptoms.  This enabled investigation of the association between 25(OH)D with 
symptoms of different types of CMDs, which may have distinct biological 
mechanisms.  
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While these instruments can capture symptoms and signs of CMDs, they were 
not used as a clinical diagnostic assessment.  Furthermore, the CIS-R and MHI-
5 only capture symptoms over a short period of time (one week for CIS-R 
versus one month for MHI-5).  This could introduce some bias since individuals 
with long-duration of symptoms may be over-represented and those with 
symptoms lasting only short periods may not be captured.  The nuances 
between CIS-R and MHI-5 may have affected the ability to control for baseline 
CMDs in the prospective analyses of Chapter 5.  Bias may have been 
introduced due to the potential reluctance of some individuals to respond to 
questions regarding mental health.  Moreover, personality differences in 
people’s perception of well-being may have influenced the reporting of 
symptoms.  For example, it has been found that women who were more socially 
outgoing reported higher well-being on all dimensions (446). 
Outcome: Cognitive function 
Cognitive tests from the 1958BC and additional cohorts used in Chapters 7 and 
8 have been validated in previous studies (Chapter 4).  In 1958BC, the 
influence of childhood cognitive ability on the subsequent association between 
25(OH)D concentrations and cognitive function (Chapter 6) may have been 
underestimated due to different measures of cognitive function in childhood and 
adulthood.   
A composite measure of global cognitive function was used in Chapter 8 to 
obtain a more stable representation of cognitive function in the cohorts.  Since 
previous studies have emphasised the role of vitamin D in Alzheimer’s disease, 
a separate memory function score was created.  Summed standardised scores 
from individual testes were used to create these scores.  While factor analysis 
and principal components would be more complex alternatives to create a 
combined cognitive score, they were beyond the scope of this thesis.   
Genetic data 
Genotyping was subjected to specific quality control procedures as outlined in 
Chapter 4.  
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As discussed in Chapters 3 and 8, the success of a MR study is dependent on 
the ability of genetic variants to proxy 25(OH)D concentrations, be independent 
of confounding, and have no pleiotropic effects that may influence the outcome.  
The genetic variants all had an F-statistic >10, indicating their strength for use 
in MR study (221).  There was some doubt on the role of DHCR7 as it was 
found to be associated with region and use of suncover.  However DHCR7, was 
robust to these assumptions when combined into a synthesis score along with 
CYP2R1.  Nevertheless, the possibility of pleiotropic effects of either the 
individual genetic variants or synthesis score cannot be ruled out.  
Statistical methods  
Strengths and limitations of observational and genetic studies were described in 
detail in Chapter 3.  While every effort was made to control for potential 
confounders in observational studies, the presence of unknown confounding 
cannot be ruled out.  Furthermore, the presence of interaction, for example, by 
vascular pathologies on cognitive function, could be an important effect modifier 
in the relationship between 25(OH)D and outcomes.  However, the exploration 
of all these possibilities was beyond the scope of this work. 
A main limitation of the thesis was the lack of genetic study on CMDs.  It was 
decided to use cognitive function as an example of genetic epidemiology to 
explore causal associations with 25(OH)D.  This decision was partly due to a 
lack of validated statistical methods for binary outcomes for use in MR study 
(206).      
There was a consistent non-linear association of 25(OH)D with CMDs and 
cognitive function.  However, the studies, in particular genetic studies, may 
have been underpowered to detect small effects operating at the extremes of 
the 25(OH)D distribution.  Furthermore, the potential of a non-linear association 
between 25(OH)D and cognitive function may affect the linearity assumption in 
MR analyses and its ability to estimate the causal effect (206, 443). 
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To determine the sample size required for MR analyses illustrative power 
calculations would have been required (207), but was beyond the scope of this 
thesis.  
9.2 Main findings 
1) Association of 25(OH)D with CMDs 
There was evidence to support an association of low 25(OH)D concentrations 
with current and subsequent risk of depressive symptoms in mid-adulthood.  
There was some suggestion of a non-linear prospective relationship between 
25(OH)D and depressive symptoms.  Additionally, differences in vitamin D-
related behaviours amongst those with symptoms of CMDs compared with 
those without CMDs, did not explain associations observed for low 25(OH)D 
concentrations.  While a seasonal trend for CMDS was not observed, the extent 
to which season, rather than 25(OH)D status alone, affects CMDs remains 
uncertain. Interestingly, there was evidence of a cross-sectional association of 
25(OH)D with depressive and panic symptoms but not with anxiety or phobia 
symptoms.  These distinct relationships may reflect a true aetiological difference 
between CMDs, or may be an artefact of methodological limitations.  One 
limitation of this study was lack of exploration of early life factors, such as 
emotional problems in the analyses, which reduced the ability to integrate a life-
course perspective in the study.   
Overall, this study strengthened the hypothesis of an association between 
25(OH)D and CMDs in mid-life by providing insight into behavioural changes 
and examining a prospective approach.   
2) Association of 25(OH)D with cognitive function 
There was observational evidence of a non-linear association between 
25(OH)D and a measure of memory function in mid-life.  The novel approach in 
this study was the examination of cognitive function in a mid-adulthood (i.e. 50 
years) sample.  This study was supportive of previous work (table 6.1), and 
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went one step further to incorporate early life variables (i.e. educational 
attainment and childhood cognitive ability).  Some of these early life variables 
may influence cognitive reserve, where the brain buffers the effects of 
neuropathology (447).  Although these early life variable did attenuate the non-
linear association between 25(OH)D and memory function, they did not fully 
explain it. 
Further exploration identified that increasing 25(OH)D may be particularly 
beneficial for those with APOE ε4 alleles.  The study was strengthened by the 
examination of a younger (50 years) and older (70 years) cohort.  This adds to 
the complexity of the relationship between 25(OH)D and memory, implying that 
there are genetic factors which can mediate an individual’s memory function. 
However, there was no evidence for 25(OH)D concentrations acting as a causal 
factor for cognitive performance in mid- to later-life using methods of genetic 
epidemiology.  This finding is in stark contrast with observational results.  The 
interpretation of the study is complicated by the potential of a non-linear effect, 
therefore the lack of casualty identified could be due to methodological 
limitations.  However, it is plausible that the low 25(OH)D concentrations 
observed are a consequence of having lower memory function.    
9.3 Implications of findings 
Findings support the hypothesis for an association between 25(OH)D and the 
brain.  However, whether vitamin D can cause neurological changes, affecting 
CMDs and cognitive function remains uncertain.  Evidence for a non-linear 
association was ubiquitous.  There has been debate about whether a threshold 
for 25(OH)D concentrations exists for diseases (448-451), with further studies 
required to reach consensus.  The threshold debate is important and it may be 
the basis for estimating vitamin D intake recommendations, and inform 
decisions of dosing amounts for RCTs.  Findings from observational analyses 
demonstrate the threshold effect between 25(OH)D and depressive symptoms 
as well as 25(OH)D and memory cognitive function.  Although, genetic studies 
indicate a deviation from a linear trend between 25(OH)D and cognitive 
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function, demonstrating a threshold effect was difficult due to the lack of 
participants in the extremes of the 25(OH)D distribution. 
An interesting finding from this work was the non-linear association for 25(OH)D 
concentrations with both CMDs and cognitive function.  It is possible that CMDs 
and cognitive function co-occur (Chapter 1).  Interestingly, the association 
between 25(OH)D and cognitive function remained following adjustment for 
depressive symptoms.   
Studies focused on mid-adulthood associations, and it is likely that the 
relationship of 25(OH)D with CMDs and in particular, with cognitive function will 
change with age.    Previous studies have found that healthy dietary choice and 
physical activity in early mid-life may be beneficial in reducing the rate of 
cognitive decline and, ultimately, the risk of dementia (452).  Therefore, findings 
presented in the thesis may provide some insight into potential interventions at 
a time point before the effects of neuropathology become apparent.  
Evidence for effect modification by APOE ε4 may not have a clinical role due to 
ethical issues surrounding the disclosure of APOE genotyping results (453).  
However the gene-environment results presented raised potentially interesting 
mechanisms through which 25(OH)D may affect cognitive function that should 
be examined in future studies.   
Overall, this work aspired to investigate potential mechanisms through which 
quality of life could be improved.  The identification of an association between 
25(OH)D and symptoms of CMDs, could support the development of cheap 
effective public health policies to prevent or improve symptoms of CMDs which 
are often left undiagnosed and untreated throughout an individual’s life.  
Similarly, avoiding low  25(OH)D concentrations could delay the onset of 
cognitive decline in later life, and improve the quality of life of individuals (154).  
Vitamin D status tends to decrease with increasing age (Chapter 1).  Adults 
who are deficient in vitamin D have a higher risk of osteoporosis, muscle 
weakness, fractures and falls which could affect their physical function and their 
ability to partake in social interactions, thereby increasing their risk of CMDs 
and cognitive decline.  Therefore, although evidence for a causal relationship of 
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25(OH)D with CMDs and cognitive function was lacking, ensuring public health 
messages to avoid vitamin D deficiency amongst adults is justified.   
9.4 Potential areas for future research 
In order to validate findings, analyses conducted during this thesis would 
require replication, preferably in larger cohorts.  Examining the association 
between 25(OH)D and cognitive function in mid-life provides a bases for future 
studies.  It would be interesting to see how the associations will change as the 
1958BC ages and cognitive decline and dementia become evident.  
Furthermore, larger meta-analyses that incorporate a variety of ages could 
provide some insight into the age differences in the associations.  
It would be beneficial to examine the associations of 25(OH)D with CMDs and 
cognitive function amongst ethnic minorities to get a broader view of the 
situation amongst the general population, and amongst specific population sub-
groups.  Ideally in future studies, 25(OH)D would be measured at various points 
over the life-course and both CMDs and cognitive function would consist of 
comparable, repeated measures.  These methods would allow investigation of a 
life-course association, which would be beneficial to the design of future public 
health interventions.  
As statistical methods for MR studies are developed, it would be interesting to 
investigate the causal role of 25(OH)D in CMDs.  The gold standard approach 
would be large, long-term RCT which could use various doses of 25(OH)D with 
participants with varying baseline 25(OH)D concentrations to determine the if 
there is a causal role of 25(OH)D in CMDs and cognitive function.  This method 
would allow for exploration of the most effective dose and time point to target an 
intervention for prevention of mental illness and reduced cognitive function.  
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Appendix 2 Additional information for Chapter 3 
Appendix 2.1:  Glossary of genetic terms (3, 187): 
 Alleles are variant forms of a single-nucleotide polymorphism (SNP), a 
specific polymorphic site or a whole gene detectable at a locus 
 A Chromosome carries a collection of genes located on a string of DNA. 
A homologous chromosome carries the same collection of genes, but 
each gene can be represented by a different allele on the two 
homologues. Offspring will receive one of those homologues, but not 
both 
 Calculating the call rate will give the amount of missing genotypes of 
each SNP or individual. Low call rates indicate poor genotyping quality.  
 Discordance refers to the presence of a specific trait in only one member 
of a pair of for example, identical twins 
 DNA (deoxyribonucleic acid) is a molecule containing genetic instructions 
used in development and function of organisms. DNA consists of 
sequence containing four nucleotide bases, Adenine (A), Tyrosine (T), 
Guanine (G) and Cytosine (C). Two strands of DNA form a double-helix 
in which A on one strand bind with T on the other as G binds with C  
 A gene is a unit of inheritance consisting of a DNA sequence, including 
introns, exons and regulatory regions 
 Genotype is the genetic makeup of an individual. It refers to the two 
alleles inherited at a specific locus. If they are the same, the genotype is 
homozygous, if they are different, heterozygous 
 Genotyping is the process of determining which genetic variants an 
individual possesses 
 Haplotype is the set of alleles present at a series of linked loci on a 
chromosome; a person has two haplotypes for any such series of loci, 
one inherited from the mother and the other from the father 
 Under Hardy-Weinberg equilibrium (HWE), alleles segregate randomly in 
the population, allowing expected genotype frequencies to be calculated 
from allele frequencies. For example, if the allele G is p and T is (1- p), 
the expected frequencies of genotypes GG, GT and TT are: 
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p2+ 2pq+q2 =1.  Comparison of expected versus observed genotype 
frequencies provides a test of HWE using a chi-square statistic    
 Heterozygosity refers to having different alleles at one or more 
corresponding chromosomal loci 
 A locus is the position in a DNA sequence and can be used to refer to a 
SNP or to a larger region of DNA sequence 
 Minor allele frequency (MAF) is the frequency at which the least common 
allele occurs in a given population 
 Meiosis is a type of cell division necessary for reproduction 
 Nucleotides are molecules that serve as subunits of nucleic acids like 
DNA 
 Polymorphism is the existence of two or more variants at a locus. It is 
usually restricted to common genetic variants i.e. above 1% prevalence 
in the population. Below this, variants are referred to as mutations 
 Single nucleotide polymorphisms (SNPs) are positions along a 
chromosome where the genetic code varies between individuals by a 
single base pair 
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Appendix 3 Additional information for Chapter 5 
Appendix 3.1: PubMed search terms 
((Depression OR Major Depressive Disorder OR Affective Mood disorders OR 
Mood disorder OR Dysthymia OR Dysthymic disorder OR Anxiety OR 
generalized anxiety disorder OR Panic OR Phobia OR Common mental 
disorders OR Psychiatric disorders)) AND ("Vitamin D"[MeSH Terms] OR 
cholecalciferol OR ergocalciferol OR "vitamin D" OR "vitamin D3" OR "vitamin 
D2" OR "Vitamin D"[Substance] OR "vitamin D deficiency"[mesh] OR Calcifediol 
[mesh] OR "25-hydroxyvitamin D"[text word] OR "25(OH)D"[text word]). 
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Appendix 3.2: Results from systematic review 
Author (year), country Setting (Study Name) Groups Adjustment 
Cross-sectional    
Kwasky (2012)(309), 
US 
University campus African American 
Caucasian 
none 
Menkes (2012) (310), 
New Zealand 
Psychiatric inpatients Schizophrenia (n=38); Schizoaffective 
(n=11); 
Bipolar disorder (n=19); 
Depression (n=17);  
Miscellaneous (n=17) 
none 
Zhao (2010) (311), 
US 
NHANES  age, gender, race/ethnicity, 
education, marital status, BMI, 
cotinine(smoking), physical activity, 
alcohol, creatinine, chronic 
conditions 
Nanri (2009) (312), 
Japan 
Municipal office 
employees 
 workplace, age, gender, BMI, marital 
status, job position, occupation, non-
job physical activity, smoking, 
alcohol consumption and folate 
Armstrong (2007)(313)  Fibromyalgia none 
Jaddou (2012)(314), 
Jordan 
Community  age, gender, marital status, 
education, BMI, serum creatinine, 
number of chronic diseases, 
smoking, exercise and altitude 
Ganji (2010)(315), 
US 
NHANES  age, gender, race/ethnicity, 
education, smoking, physical 
activity, alcohol drinking, BMI, 
abdominal obesity and serum 
calcium concentrations 
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Knippenberg (2010)(316), 
Netherlands 
MS outpatients and 
patients 
 age expanded Disability Status 
Scale, fatigue 
Kjærgaard (2011)(317), 
Norway 
Tromsø Community age, gender, BMI, physical exercise, 
alcohol, education, marital status, 
kidney function and chronic disease 
Hoang (2011)(318), 
US 
CCLS   
Pan (2009)(319), 
China 
NHAPC  age, gender, urban/rural, BMI, 
physical activity, smoking , social 
activity level, marital status, 
household income and number of 
chronic diseases, geographic 
location 
Motsinger (2012)(320), 
US 
IWHS postmenopausal women age, energy intake, BMI, education, 
smoking, living arrangement, 
antidepressant usage, comorbidity 
history and physical activity 
Lee (2010)(321), 
Italy, Belgium, Poland, 
Sweden, UK, Spain, 
Hungary, Estonia 
EMAS  age, physical activity, BMI, physical 
function, serum creatinine, number 
of morbidities, number of adverse 
life events 
Stewart (2010)(322), 
UK 
HSE  age, gender, social class, season of 
examination, physical health status 
Hoogendijk (2008)(323), 
Netherlands 
Longitudinal Ageing  
Study Amsterdam 
Cases: Female subgroup (n=33) from 
psychiatric inpatients 
Controls: (n=691) no psychiatric illness 
from GOS 
age, gender, smoking, BMI, chronic 
conditions, serum creatinine, 
season, urbanization and physical 
activity 
Wilkins (2006)(324), 
US 
Community 40 Mild dementia 
40 non-demented 
age, season, race, gender 
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Johnson (2008)(325), 
US 
OAANP  age, gender, race 
Case-control    
Cizza (2012)(326), 
Italy 
POWER premenopausal with MDD (n=92); 
premenopausal controls (n=44) 
 
Eskandari (2007)(327) 89 MDD 
44 control 
 none 
Schneider (2000)(328), 
Germany 
out-patient clinic 34 schizophrenia 
30 alcohol addiction 
25 major depression 
31 healthy controls 
none 
Oren (1994)(329), 
US 
15 SAD 
15 age and gender-
matched controls 
 none 
Michelson (1996) (330), 
US 
24 past or current major 
depression 
24 controls, age and BMI-
matched 
 none 
Berk (2008)(331), 
Australia 
Psychiatric inpatients, 
with predominately mood, 
adjustment, personality 
and substance use 
disorders 
Bipolar (n=18) 
Depression (n=14) 
Personality disorder (n=5) 
Alcohol/substance (n=4) 
Post-traumatic stress 
(n=2) 
Anxiety (n=1 
Schizoaffective (n=1) 
Cases: Female subgroup (n=33) from 
psychiatric inpatients 
Controls: (n=691) no psychiatric illness 
from GOS 
Age, season 
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Unknown (n=9) 
Herrán (2000)(332), 
Spain 
Patients in mental health 
unit 
19 Depressive 
19 Controls, age matched 
none 
Jorde (2006)(333), 
Norway 
Community (Tromsø) 21 SHPT 
63 Controls 
none 
Cohort    
Bertone-Johnson 
(2011)(334), 
US 
WHI, 3 years postmenopausal women age, race/ethnicity, BMI, waist-to-hip 
ratio, education, smoking, alcohol, 
past hormone therapy use, totally 
energy intake, marine omege-3 fatty 
acid intake, marital status, physical 
activity, physical function score, 
history of cardiovascular disease 
and solar irradiance 
Chan (2011)(335), 
China 
Community, 4 year follow-
up 
 age, number of diseases, smoking, 
alcohol BMI, physical activity, 
mobility limitations, dietary intake, 
season of blood measurement and 
PTH 
Milaneschi (2010)(336), 
Italy 
InCHIANTI, 6 year follow-
up 
 Age, gender, education, smoking, 
alcohol,. MMSE score, BMI, season, 
number of drugs, vitamin D 
supplements, physical activity, 
chronic diseases 
May (2010)(337), 
US 
CVD patients, follow-up 
1.07 ±1.13 years 
 PTH, season 
Randomised-controlled trial   
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Lansdowne (1998)(338), 
Australia 
University campus, 5 days Treatment 1 
n=150; 400IU/day and 9000IU vitamin 
A/day 
Treatment 2 
n=142; 8000IU/day 
Control:  
n=149  0IU/day  and 10,000IU vitamin 
A/day 
 none 
Dean (2011)(339), 
Australia 
Community, 6 weeks Treatment 
n=63 5000IU/day Control:  
n=65 placebo/day 
NA 
Harris (1993)(340), 
US 
community, 1 year Treatment (n=125): 400 IU/day and 
337mg calcium/day 
Control: (n=125): 
0IU/day and 337mg calcium/day 
none 
 
Jorde (2008)(341), 
Norway 
BMI 28-47kb/m2, 1 year Treatment 1 
n=150; 20,000 and 20,000IU/week  
Treatment 2 
n=142; 20,000IU and placebo/week 
Control:  
n=149 2 placebo/week 
Na 
Bertone-Johnson 
(2011)(334), 
US 
WHI, 2 year intervention Treatment 
n=18,176 400IU/day with 1,000mg 
calcium 
Control:  
n=12,421 placebo/day 
age, race, WHI hormone Trial 
intervention, WHI dietary 
Modification Trial intervention and 
depressive symptoms above the 
threshold level at year 1 
Kjærgaard (2012)(342), 
Norway 
Tromsø, 6-month Treatment 
n=180 with 25(OH)D <55nmol/l; 2 x20 
000IU/week 
Control:  
n=75 with 25(OH)D >70nmol/l; 2 
placebo 000IU/week 
NA 
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Sanders (2011)(343), 
Australia 
Vital D study , 3-5 years Treatment 
n=1018 500,000IU every 
autumn/winter Control:  
n=1016 placebo 
 
Before-after  study    
Sanders (2011)(344), 
US 
Patients being treated for 
vitamin D deficiency 
<40ng/mL, 8 week follow-
up 
 na 
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Appendix 3.3: Distribution of 25(OH)D in the sample 
 
323 
 
Appendix 3.4: Distribution of CMDS in the sample, before categorisation 
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Appendix 3.5: Distribution of MHI-5, before categorisation 
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Appendix 3.6: Geometric mean of 25(OH)D according to vitamin D-related lifestyles at 
45 years 
 Total* Geometric mean 25(OH), nmol/l (95% CI)† 
Time spent outside per day  
<3 hours 3,886 48.33 (47.64,  49.04) 
≥3 hours 2,944 58.18 (57.24, 59.14) 
Missing 571 49.50 (47.50, 51.57) 
p
‡
  <0.001 
TV/PC time per day   
<3 hours 4,695 54.66 (53.96, 55.37) 
≥3 hours 2,376 48.09 (47.16, 49.03) 
Missing 330 47.45 (44.87, 50.18) 
p
‡
  <0.001 
Use of sun cover   
most times 6,188 52.76 (52.16, 53.37) 
rarely 666 48.08 (46.26, 49.98) 
Missing 547 50.19 (48.13, 52.35) 
p‡  <0.001 
Blistering after sunburn   
rarely/never/sometimes 6,436 52.59 (51.99, 53.19) 
often 129 41.99 (38.91, 45.32) 
Missing 836 50.39 (48.72, 52.12) 
p
‡
  <0.001 
Seeking sun tan   
rarely/never/sometimes 5,254 49.76 (49.14, 50.39) 
often 1391 63.96 (62.56, 65.40) 
Missing 756 49.41 (47.70, 51.19) 
p
‡
  <0.001 
Vitamin D-containing supplements   
< daily 6,058 50.72 (50.11, 51.32) 
≥ daily 1,185 60.80 (59.43, 62.20) 
Missing 158 47.18 (43.54, 51.14) 
p
‡
  <0.001 
Oily fish consumption   
≥ weekly 2,191 54.49 (53.45, 55.55) 
< weekly 5,052 51.32 (50.66, 51.99) 
Missing 158 46.50 (42.84, 50.48) 
p
‡
  <0.001 
Margarine consumption   
≥ weekly 4,563 52.83 (52.14, 53.53) 
< weekly 2,601 51.18 (50.23, 52.15) 
Missing 237 49.27 (46.15, 52.61) 
p
‡
 0.01  
*Based on eligible sample for Chapter 5 (N=7,401) 
‡
 Data obtained when participants were aged 45 years.  25(OH)D range: 9.5-230.7nmol/l 
‡
 P value from linear regression with naturally log-transformed 25(OH)D adjusted for gender 
and SEP in adulthood 
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Appendix 3.7: Association between 25(OH)D and CMDs: complete case results 
 25- Hydroxyvitamin D, nmol/l  
 <25 25-49.9 50-74.9 75-99.9 ≥100 Ptrend 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)  
Depressive symptoms       
Model 1* (n=7401) 1.0 0.64 (0.48, 0.85) 0.50 (0.37, 0.67) 0.43 (0.31, 0.62) 0.32 (0.19, 0.52) < 0.001 
Model 2 (n=7401) 1.0 0.68 (0.52, 0.91) 0.55 (0.41, 0.74) 0.47 (0.33, 0.67) 0.34 (0.21, 0.57) < 0.001 
Model 3 (n=7376) 1.0 0.71 (0.53, 0.94) 0.58 (0.43, 0.79) 0.51 (0.35, 0.73) 0.37 (0.22, 0.62) < 0.001 
Model 4 (n=6132) 1.0 0.73 (0.52, 1.03) 0.67 (0.46, 0.96) 0.59 (0.38, 0.91) 0.40 (0.22, 0.74) 0.003 
Anxiety symptoms        
Model 1* (n=7401) 1.0 0.80 (0.58, 1.12) 0.64 (0.45, 0.90) 0.67 (0.45, 0.98) 0.68 (0.42, 0.98) 0.03 
Model 2 (n=7401) 1.0 0.83 (0.59, 1.16) 0.68 (0.48, 0.96) 0.70 (0.48, 1.04) 0.73 (0.45, 1.18) 0.07 
Model 3 (n=7376) 1.0 0.82 (0.59, 1.15) 0.68 (0.48, 0.97) 0.72 (0.48, 1.07) 0.75 (0.46, 1.22) 0.12 
Model 4 (n=6132) 1.0 0.97 (0.66, 1.43) 0.90 (0.60, 1.35) 1.00 (0.63, 1.59) 1.09 (0.62, 1.93) 0.83 
Panic symptoms       
Model *1 (n=7401) 1.0 0.42 (0.24, 0.75) 0.38 (0.21, 0.68) 0.19 (0.08, 0.43) 0.20 (0.07, 0.62) < 0.001 
Model 2 (n=7401) 1.0 0.46 (0.26, 0.83) 0.44 (0.24, 0.81) 0.22 (0.09, 0.50) 0.24 (0.08, 0.73) 0.001 
Model 3 (n=7376 1.0 0.48 (0.26, 0.87) 0.49 (0.26, 0.91) 0.25 (0.10, 0.58) 0.28 (0.09, 0.87) 0.004 
Model 4 (n=6010) 1.0 0.41 (0.20, 0.83) 0.64 (0.31, 1.33) 0.27 (0.10, 0.79) 0.47 (0.13, 1.62) 0.20 
Phobia symptoms        
Model 1* (n=7401) 1.0 0.62 (0.42, 0.92) 0.57 (0.38, 0.86) 0.52 (0.33, 0.84) 0.17 (0.07, 0.41) < 0.001 
Model 2 (n=7401) 1.0 0.66 (0.44, 0.98) 0.63 (0.41, 0.94) 0.56 (0.35, 0.90) 0.18 (0.07, 0.44) < 0.001 
Model 3 (n=7376 1.0 0.65 (0.44, 0.97) 0.63 (0.42, 0.96) 0.58 (0.36, 0.94) 0.19 (0.08, 0.46) 0.001 
Model 4 (n=6132) 1.0 0.73 (0.46, 1.16) 0.80 (0.50, 1.30) 0.76 (0.44, 1.34) 0.28 (0.11, 0.71) 0.09 
*Model 1 was adjusted for gender & season. Model 2 was adjusted for gender, season & socioeconomic position. Model 3 was adjusted for gender, season & 
socioeconomic position and Body Mass Index. Model 4 was adjusted for gender, season, socioeconomic position, Body Mass Index, smoking and physical 
activity, PC/TV leisure time, suncover, blistering after sunburn, actively seeking suntan.  
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Appendix 3.8: Association between 25(OH)D and CMDs: weighted-case results 
 25- Hydroxyvitamin D, nmol/l  
 <25 25-49.9 50-74.9 75-99.9 ≥100 Ptrend 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)  
Depressive symptoms       
Model 1*  (n=7154) 1.0 0.66 (0.49, 0.88) 0.50 (0.36, 0.68) 0.44 (0.30, 0.64) 0.33 (0.20, 0.56) < 0.001 
Model 2 (n=7154) 1.0 0.70 (0.52, 0.94) 0.55 (0.40, 0.75) 0.48 (0.33, 0.70) 0.36 (0.22, 0.61) < 0.001 
Model 3 (n=7132) 1.0 0.73 (0.54, 0.98) 0.59 (0.42, 0.81) 0.53 (0.36, 0.77) 0.40 (0.24, 0.68) < 0.001 
Model 4 (n=5935) 1.0 0.76 (0.53, 1.08) 0.69 (0.47, 1.00) 0.59 (0.38, 0.93) 0.43 (0.23, 0.80) 0.01 
Anxiety symptoms       
Model 1*  (n=7154) 1.0 0.79 (0.56, 1.11) 0.62 (0.43, 0.90) 0.64 (0.42, 0.96) 0.66 (0.40, 1.08) 0.03 
Model 2 (n=7154) 1.0 0.82 (0.58, 1.16) 0.66 (0.46, 0.95) 0.68 (0.45, 1.03) 0.70 (0.43, 1.16) 0.06 
Model 3 (n=7132) 1.0 0.81 (0.57, 1.14) 0.67 (0.46, 0.96) 0.69 (0.46, 1.05) 0.72 (0.43, 1.19) 0.10 
Model 4 (n=5936) 1.0 0.97 (0.65, 1.44) 0.87 (0.57, 1.33) 0.94 (0.56, 1.54) 1.03 (0.58, 1.80) 0.90 
Panic symptoms       
Model 1*  (n=7154) 1.0 0.42 (0.23, 0.75) 0.36 (0.20, 0.66) 0.20 (0.08, 0.47) 0.19 (0.06, 0.59) < 0.001 
Model 2 (n=7154) 1.0 0.45 (0.25, 0.82) 0.41 (0.23, 0.75) 0.23 (0.10, 0.55) 0.22 (0.07, 0.68) 0.001 
Model 3 (n=7132) 1.0 0.47 (0.25, 0.88) 0.46 (0.24, 0.88) 0.27 (0.10 0.67) 0.27 (0.08, 0.85) 0.01 
Model 4 (n=5858) 1.0 0.39 (0.19, 0.83) 0.62 (0.30, 1.30) 0.26 (0.09, 0.76) 0.44 (0.13, 1.15) 0.16 
Phobia symptoms       
Model 1*  (n=7154) 1.0 0.67 (0.45, 1.01) 0.61 (0.40, 0.92) 0.53 (0.33. 0.86) 0.19 (0.08, 0.46) < 0.001 
Model 2 (n=7154) 1.0 0.71 (0.46, 1.07) 0.66 (0.43, 1.01) 0.57 (0.65, 0.92) 0.20 (0.08, 0.50) < 0.001 
Model 3 (n=7132) 1.0 0.70 (0.46, 1.06) 0.66 (0.43, 1.02) 0.56 (0.35, 0.95) 0.21 (0.08, 0.51) 0.001 
Model 4 (n= 5817) 1.0 0.39 (0.19, 0.83) 0.62 (0.30, 1.30) 0.26 (0.09, 0.76) 0.44 (0.14, 1.46) 0.17 
* Model 1 was adjusted for gender & season. Model 2 was adjusted for gender, season & socioeconomic position. Model 3 was adjusted for gender, season & 
socioeconomic position and Body Mass Index. Model 4 was adjusted for gender, season, socioeconomic position, Body Mass Index, smoking and physical 
activity, PC/TV leisure time, suncover, blistering after sunburn, actively seeking suntan.  
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Appendix 3.9: Association between 25(OH)D and depressive symptoms at 50 years: complete case results 
 25- Hydroxyvitamin D, nmol/l   
 <25 25-49.9 50-74.9 75-99.9 ≥100 Ptrend Pcurvature 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)   
Depressive symptoms (50 years)       
Model 1* (n=5966) 1.0 0.71 (0.53, 0.94) 0.59 (0.43, 0.79) 0.58 (0.41, 0.81) 0.57 (0.37, 0.87) 0.002 < 0.001 
Model 2 (n= 5966) 1.0 0.73 (0.54, 0.97) 0.61 (0.45, 0.82) 0.61 (0.43, 0.85) 0.60 (0.39, 0.92) 0.006 0.001 
Model 3  (n= 5966) 1.0 0.78 (0.58, 1.05) 0.67 (0.49, 0.91) 0.68 (0.47, 0.96) 0.71 (0.46, 1.10) 0.049 0.001 
Model 4 (n= 5947) 1.0 0.79 (0.58, 1.06) 0.70 (0.51, 0.95) 0.72 (0.51, 1.03) 0.78 (0.50, 1.21) 0.164 0.001 
Model 5 (n=5095) 1.0 0.90 (0.64, 1.26) 0.88 (0.61, 1.25) 0.92 (0.61, 1.38) 1.13 (0.68, 1.85) 0.690 0.03 
* Model 1 was adjusted for gender & season. Model 2 was adjusted for gender, season & socioeconomic position. Model 3 was adjusted for gender, season 
& socioeconomic position and presence of CMDS at 45 years. Model 4 was adjusted for gender, season, socioeconomic position presence of CMDS at 45 
years and Body Mass Index, Model 5 was adjusted for gender, season, socioeconomic position presence of CMD at 45 years, BMI,  smoking and physical 
activity, PC/TV leisure time, suncover, blistering after sunburn, actively seeking suntan.  
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Appendix 3.10: Association between 25(OH)D and depressive symptoms at 50 years: weighted-case results 
 25- Hydroxyvitamin D, nmol/l   
 <25 25-49.9 50-74.9 75-99.9 ≥100 Ptrend Pcurvature 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)   
Depressive symptoms (50 years)       
Model 1* (n=5772) 1.0 0.74 (0.55, 0.99) 0.60 (0.44, 0.81) 0.55 (0.39, 0.78) 0.56 (0.36, 0.87) 0.001 0.001 
Model 2 (n=5772) 1.0 0.76 (0.56, 1.02) 0.62 (0.46, 0.85) 0.58 (0.41, 0.83) 0.60 (0.38, 0.93) 0.003 0.001 
Model 3 (n=5772) 1.0 0.81 (0.60, 1.09) 0.68 (0.50, 0.92) 0.64 (0.45, 0.91) 0.70 (0.45, 1.10) 0.020 0.001 
Model 4 (n=5756) 1.0 0.81 (0.60, 1.10) 0.70 (0.52, 0.96) 0.68 (0.47, 1.00) 0.76 (0.48, 1.19) 0.072 0.001 
Model 5 (n=4937) 1.0 0.90 (0.64, 1.27) 0.87 (0.61, 1.25) 0.85 (0.56, 1.28) 1.09 (0.66, 1.83) 0.994 0.02 
N=5966b Model 1 was adjusted for gender & season. Model 2 was adjusted for gender, season & socioeconomic position. Model 3 was adjusted for gender, 
season & socioeconomic position and presence of CMDS at 45 years. Model 4 was adjusted for gender, season, socioeconomic position presence of CMD at 
45 years and Body Mass Index, Model 5 was adjusted for gender, season, socioeconomic position presence of CMDS at 45 years, BMI,  smoking and 
physical activity, PC/TV leisure time, suncover, blistering after sunburn, actively seeking suntan.  
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Appendix 3.11: Association between CMD and 25(OH)D where 25(OH)D is the outcome: complete case results 
 N Coefficient (95% CI), % change in 25(OH)D Ptrend 
Depressive symptoms    
Model 1* 7,401 -10.15 (13.74, -6.56) <0.0001 
Model 2 7,194 -8.42 (-12.09, -4.75) <0.0001 
Model 3 7,171 -7.06 (-10.68, -3.44) <0.0001 
Model 4 5,966 -4.68 (-8.53, -0.83) 0.02 
Anxiety symptoms    
Model 1* 7,401 -4.78 (-0.09, -8.66) 0.02 
Model 2 7,194 -3.192 (-7.13,  0.74) 0.11 
Model 3 7,171 -2.48 (-6.35,  1.39) 0.21 
Model 4 5,966 0.77 (-3.25, 4.79) 0.71 
Panic symptoms    
Model 1* 7,401 -19.71 (-27.91, -11.52) <0.0001 
Model 2 7,194 -17.72 (-26.17, -9.28) <0.0001 
Model 3 7,171 -15.27 (-23.62, -6.92) <0.0001 
Model 4 5,966 -8.25  (-16.99, 0.50) 0.07 
Phobia symptoms    
Model 1* 7,401 -9.82 (-14.75, -4.89) <0.0001 
Model 2 7,194 -8.47  (-13.48, -3.46) 0.001 
Model 3 7,171 -7.51 (-12.44, -2.58) 0.003 
Model 4 5,966 -4.15 (-9.25,  0.94) 0.11 
* Model 1 was adjusted for gender & season. Model 2 was adjusted for gender, season & socioeconomic position. Model 3 was 
adjusted for gender, season & socioeconomic position and Body Mass Index. Model 4 was adjusted for gender, season, 
socioeconomic position, Body Mass Index, smoking and physical activity, PC/TV leisure time, suncover, blistering after sunburn, 
actively seeking suntan. 
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Appendix 3.12: Association between CMDs and 25(OH)D where 25(OH)D is the outcome: weighted-case results 
 N Coefficient (95% CI), % change in 25(OH)D Ptrend 
Depressive symptoms    
Model 1* 7,154 -10.03 (-13.98, -6.07) <0.0001 
Model 2 7,004 -8.17 (-12.14, -4.20) <0.0001 
Model 3 6,983 -6.75 (-10.63,  -2.86) 0.001 
Model 4 5,817 -4.59 (-8.540, -0.63) 0.02 
Anxiety symptoms    
Model 1* 7,154 -5.03 (-9.24,  -0.81) 0.02 
Model 2 7,004 -3.25 (-7.45, 0.95) 0.13 
Model 3 6,983 -2.53 (-6.65, 1.60) 0.23 
Model 4 5,817 0.34 (-3.76, 4.44) 0.87 
Panic symptoms    
Model 1* 7,154 -19.77 (-29.05, -10.49) <0.0001 
Model 2 7,004 -17.78 (-27.42, -8.14) <0.0001 
Model 3 6,983 -15.20 (-24.89, -5.50) 0.002 
Model 4 5,817 -9.02 (-18.74, 0.71) 0.07 
Phobia symptoms    
Model 1* 7,154 -9.82 (-14.86, -4.79) <0.0001 
Model 2 7,004 -8.27 (-13.31, -3.22) 0.001 
Model 3 6,983 -7.53 (-12.60,  -2.46) 0.004 
Model 4 5,817 -4.03 (-9.23,  1.17) 0.13 
* Model 1 was adjusted for gender & season. Model 2 was adjusted for gender, season & socioeconomic position. Model 3 was 
adjusted for gender, season & socioeconomic position and Body Mass Index. Model 4 was adjusted for gender, season, 
socioeconomic position, Body Mass Index, smoking and physical activity, PC/TV leisure time, suncover, blistering after sunburn, 
actively seeking suntan. 
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Appendix 3.13: Examination of MHI-5 cut point ≤60 and ≤75: complete case results 
 25- Hydroxyvitamin D, nmol/l   
 <25 25-49.9 50-74.9 75-99.9 ≥100 Ptrend Pcurvature 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)   
MHI-5  ≤60        
Model 1* (n=5966) 1.0 0.72 (0.57, 0.92) 0.55 (0.43, 0.70) 0.55 (0.41, 0.73) 0.49 (0.34, 0.69) <0.001 0.001 
Model 2 (n=5810) 1.0 0.76 (0.60, 0.98) 0.58 (0.45, 0.75) 0.58 (0.44, 0.78) 0.53 (0.37, 0.76) <0.001 0.002 
Model 3 (n=5810) 1.0 0.80 (0.62, 1.04) 0.62 (0.48, 0.81) 0.62 (0.46, 0.84) 0.60 (0.42, 0.88) <0.001 
0.002 
Model 4 (n= 5793) 1.0 0.81 (0.63, 1.04) 0.64 (0.49, 0.83) 0.65 (0.48, 0.88) 0.63 (0.44, 0.92) 0.001 0.003 
Model 5 (n=4964) 1.0 0.90 (0.68, 1.20) 0.71 (0.53, 0.97) 0.76 (0.54, 1.07) 0.80 (0.52, 1.22) 0.07 0.03 
MHI-5  ≤75        
Model 1* (n=5966 1.0 0.78 (0.63, 0.97) 0.66 (0.53, 0.82) 0.63 (0.49, 0.80) 0.63 (0.47, 0.85) <0.001 0.001 
Model 2 (n=5810) 1.0 0.85 (0.66, 1.02) 0.70 (0.56, 0.88) 0.67 (0.52, 0.86) 0.68 (0.50, 0.82) 0.001 0.003 
Model 3 n=5810) 1.0 0.86 (0.68, 1.07) 0.74 (0.59, 0.93) 0.71 (0.55, 0.91) 0.76 (0.56, 1.03) 0.01 0.004 
Model 4 (n= 5793) 1.0 0.86 (0.69, 1.08) 0.78 (0.60, 0.95) 0.73 (0.57, 0.94) 0.79 (0.58, 1.07) 0.02 0.004 
Model 5 (n=4964) 1.0 0.97(0.76, 1.25) 0.84(0.65, 1.10) 0.87 (0.65, 1.16) 0.91 (0.64, 1.30) 0.25 0.02 
*Model 1 was adjusted for gender & season. Model 2 was adjusted for gender, season & socioeconomic position. Model 3 was adjusted for gender, season & 
socioeconomic position and presence of CMDS at 45 years. Model 4 was adjusted for gender, season, socioeconomic position presence of CMDS at 45 
years and Body Mass Index, Model 5 was adjusted for gender, season, socioeconomic position presence of CMD at 45 years, BMI,  smoking and physical 
activity, PC/TV leisure time, suncover, blistering after sunburn, actively seeking suntan. 
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Appendix 3.14: Examination of MHI-5 cut point ≤60 and ≤75:  weighted-case results 
 25- Hydroxyvitamin D, nmol/l   
 <25 25-49.9 50-74.9 75-99.9 ≥100 Ptrend Pcurvature 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)   
MHI-5  ≤60        
Model 1* (n=5772) 1.0 0.74(0.58, 0.95) 0.56 (0.43, 0.72) 0.53 (0.40, 0.71) 0.48 (0.33, 0.69) <0.001 0.001 
Model 2 (n=5657) 1.0 0.79 (0.62, 1.02) 0.60 (0.46, 0.78) 0.58 (0.43, 0.78) 0.53 (0.36, 0.77) <0.001 0.002 
Model 3 (n=5657) 1.0 0.83 (0.64, 1.08) 0.64 (0.49, 0.83) 0.61(0.45, 0.83) 0.60 (0.41, 0.88) <0.001 0.002 
Model 4 (n=5642) 1.0 0.83 (0.64, 1.08) 0.65 (0.50, 0.85) 0.64 (0.47, 0.87) 0.63 (0.43, 0.92) 0.001 0.003 
Model 5 (n=4841) 1.0 0.90 (0.67, 1.21) 0.72 (0.53, 0.98) 0.73 (0.51, 1.03) 0.79 (0.51, 1.22) 0.05 0.02 
MHI-5  ≤75        
Model 1* (n=5772) 1.0 0.80 (0.64, 0.99) 0.67 (0.54, 0.84) 0.62 (0.48, 0.80) 0.65 (0.48, 0.88) <0.001 0.001 
Model 2 (n= 5657) 1.0 0.84 (0.67, 1.05) 0.71 (0.57, 0.90) 0.67 (0.52, 0.86) 0.70 (0.51, 0.95) 0.001 0.003 
Model 3 (n=5657) 1.0 0.87 (0.69, 1.09) 0.75 (0.59, 0.94) 0.70 (0.54, 0.91) 0.77(0.57, 1.06) 0.01 0.002 
Model 4 (n=5642) 1.0 0.88 (0.70, 1.10) 0.76 (0.60, 0.96) 0.72 (0.56, 0.94) 0.80 (0.59, 1.10) 0.02 0.003 
Model 5 (n=4841) 1.0 0.97 (0.75, 1.26) 0.85 (0.65, 1.12) 0.86 (0.63, 1.16) 0.92 (0.64, 1.32) 0.24 0.02 
*Model 1 was adjusted for gender & season. Model 2 was adjusted for gender, season & socioeconomic position. Model 3 was adjusted for gender, season & 
socioeconomic position and presence of CMDS at 45 years. Model 4 was adjusted for gender, season, socioeconomic position presence of CMDS at 45 
years and Body Mass Index, Model 5 was adjusted for gender, season, socioeconomic position presence of CMD at 45 years, BMI,  smoking and physical 
activity, PC/TV leisure time, suncover, blistering after sunburn, actively seeking suntan. 
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Appendix 4 Additional information for Chapter 6 
Appendix 4.1: PubMed search terms 
(("Vitamin D"[MeSH Terms] OR cholecalciferol OR ergocalciferol OR "vitamin 
D" OR "vitamin D3" OR "vitamin D2" OR "Vitamin D"[Substance] OR "vitamin D 
deficiency"[mesh] OR Calcifediol[mesh] OR "25-hydroxyvitamin D"[text word] 
OR "25(OH)D"[text word])) AND (((((((((((((((Cognition) OR cognitive*) OR 
intelligence) OR learning) OR mental process) OR memory) OR recall) OR 
information processing) OR global impairment) OR attention) OR 
neuropsychological test*) OR problem solving) OR perception) OR spatial 
recognition) OR recognition).  
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Appendix 4.2: Additional results from vitamin D and cognition systematic review 
Author (year), 
country 
Total N Setting  
(Study Name) 
Groups Adjustment 
Cross-sectional    
McGrath 
(2007)(355), 
USA 
11,232 Community 
(NHANES III) 
1,676 adolescent 12-17years;  
4,747 adult 20-60 years; 
4809 elderly 60-90 years 
Age, gender, activity, ethnicity 
El-Ghoneimy 
(2009)(356), 
Egypt 
30 Unknown Patients with MS.  none 
Hansen 
(2011)(357), 
Norway 
25 Prison NA none 
Tolppanen 
(2011)(358), 
USA 
4932 Community 
(NHANES III) 
Younger adults (20-59 years);   
Older adults (60-90 years) 
Age, gender, race, health status, poverty-income ratio of 
household, education, outdoor physical activity, smoking 
alcohol 
Lee (2009)(359), 
Italy, Belgium. 
Poland, Sweden, 
UK, Spain, 
Hungary, Estonia 
3369 Community (EMAS) NA Age, education, BMI, physical activity, functional 
performance, mood/depression, season, smoking alcohol, 
centre 
Seamans 
(2010)(360), 
Ireland, France, 
Rome, Italy 
387 Community 
(ZENITH) 
NA Gender, age, BMI, zinc status, season 
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Author (year), 
country 
Total N Setting  
(Study Name) 
Groups Adjustment 
Benge 
(2009)(361), 
USA 
111 Hospital 39 PHPT with CSI; 
72 PHPT without CSI 
 none 
Oighara 
(1990)(362), 
Japan 
60 Hospital 18 non-demented; 
22 SDAT;  
20 VTD 
none 
Houston 
(2007)(363), 
Italy 
976 Community 
(InCHIANTI) 
435 men; 
541 women 
Age 
Llewellyn 
(2009)(364), 
UK 
1766 Community and 
institutionalised 
(HSE) 
 212 cognitively impaired; 
1554 cognitively normal 
Age, education, ethnicity, season, smoking, alcohol, 
psychiatric morbidity, hypoalbuminemia, self-report 
medical history, impaired mobility 
Llewellyn 
(2011)(365), 
USA 
3325 Community 
(NHANES) 
NA Age, gender, ethnicity, education, season, smoking, BMI, 
alcohol, vitamin E, family income, impaired mobility, 
limited physical activity, 
Aung (2006)(366), 
USA 
44 Community (CREST) Self-neglecting elders none 
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Author (year), 
country 
Total N Setting  
(Study Name) 
Groups Adjustment 
Buell (2009)(367), 
USA 
1080 Community (NAME) NA Age, gender, race, education, BMI, kidney function, 
centre, season, physical activity, alcohol use, 
homocysteine, ApoE allele status, plasma B vitamins, 
multi-vitamin use 
Buell (2010)(368), 
USA 
318 Community (NAME) Recipient of home care Age, race, gender, BMI, education 
Annweiler 
(2012)(369), 
France 
125 Community 
(GAIT) 
43 MCI; 
52 CHI 
Age, gender, BMI, number of comorbidities, education, 
MMSE score, Frontal Assessment Battery score, Geriatric 
Depression Scale, creatine clearance, season 
Wilkins 
(2006)(324), 
USA 
80 Community 40 mild dementia  
40 non-demented 
Age, race, gender 
Wilkins 
(2009)(370), 
USA 
60 Community 30 African Americans; 
30 European Americans 
Weight, gender, race, education, age 
Annweiler 
(2010)(371), 
France 
752 Community 
(EPIDOS) 
 
NA Age, BMI, number of chronic diseases, hypertension, 
depression, use of psychoactive drugs, education, 
physical activity, PTH, calcium 
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Author (year), 
country 
Total N Setting  
(Study Name) 
Groups Adjustment 
Oudshoorn 
(2008)(372), 
Netherlands 
225 Clinic Outpatients with probable AD Age, gender, mobility, action radius, education, vitamins 
b1, b6, b12 
Perez-
Llamas(2008)(373
), 
Spain 
86 Institutionalised Nursing home none 
Przybelski 
(2007)(374), 
USA 
80 Clinic With cognitive symptoms from 
outpatient clinic 
none 
Skalska 
(2012)(375) 
Poland 
140 Community, Hospital 
and Institution 
62 Geriatric outpatient; 
31 geriatric ward; 
47 Institutionalised  
  
Annweiler 
(2010)(376), 
France 
5596 Community 
(EPIDOS) 
 
NA BMI, sun exposure at midday, season, disability, number 
of chronic diseases, hypertension, depression, use of 
psychoactive drugs, education 
Sakuma 
(2006)(377), 
Japan 
50 Hospital Acute hip fracture cases  
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Author (year), 
country 
Total N Setting  
(Study Name) 
Groups Adjustment 
Annweiler 
(2011)(378), 
France 
228 
 
Hospital Geriatric inpatients Age, gender, supine pulse pressure, number of acute and 
chronic diseases, psychoactive drugs, morphine, 
corticoids, PTH, albumin, creatine 
Ravaglia 
(1998)(379), 
Italy 
27 Community 15 dementia; 
12 non-demented 
Age, education 
Case-control    
Evatt (2008)(380), 
USA 
196 CRIN registry 
database 
97 AD; 
99 controls, matched on age, 
gender, race, APOE, residence 
none 
Martyn 
(1989)(381), 
UK 
61 Hospital  27 AD; 
34 controls 
none 
Walker 
(2009)(382), 
USA 
128 Hospital 
Community 
39 patients with PHPT 
underwent surgery 
89 controls 
Age. IQ, education, anxiety and depression 
Jorde (2006)(333), 
Norway 
84 
(148 
total 
cohort ) 
Community (Tromsø) 
 
21 SHPT: 
63 controls 
none 
Luckhaus 
(2009)(383), 
Germany 
47 Outpatient clinic 20 AD; 
19 MCI; 
8 controls, matched on age 
Gender 
Ferrier 
(1990)(384), 
UK 
50 Hospital & 
community 
26 ATD cases 
24 controls matched on age, 
gender  
none 
Sato (2005)(385), 
Japan 
200 Clinic 
Community 
58 severe AD; 
48 mild AD; 
100 matched controls 
no  
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Author (year), 
country 
Total N Setting  
(Study Name) 
Groups Adjustment 
Sato (1998)(386), 
Japan 
186 Institutionalized 
Community 
46 AD; 
140 controls, matched on age 
no  
Cohort     
Chan (2011)(335), 
China 
939 Community 939 baseline 
629 follow-up, 4 years 
Number of diseases, smoking, alcohol, BMI, physical 
activity, mobility limitations, dietary intake, season of blood 
measurement, serum PTH 
Slinin (2010)(387), 
USA 
1606 Community (MrOS) Mean follow-up 4.6 years Alcohol, Age, BMI, education, health,(self-reported), IADL, 
physical activity, race, season, site, smoking 
Slinin (2012)(388), 
USA 
6257 Community (Study of 
Osteoporotic 
Fractures) 
Mean follow-up, 4 years Clinic site, season, age at baseline, education, self-
reported health, daily living impairments, smoking, BMI, 
hypertension, diabetes, depression, baseline cognitive 
function 
Llewellyn 
(2010)(389), 
Italy 
858 Community 
(InCHIANTI) 
Mean follow-up 2 years Alcohol, age, BMI, cognitive score(baseline), depressive 
symptoms, education, energy intake(total), impaired 
mobility, season, gender, smoking, vitamin E 
Breitling 
(2012)(390), 
Germany 
1639 Community 
(ESTHER) 
987 women 
652 men 
Follow-up 5 years 
Age, education, BMI, season, smoking, alcohol, chronic 
disease (Cerebrovascular disease, depression, cancer 
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Author (year), 
country 
Total N Setting  
(Study Name) 
Groups Adjustment 
Annweiler 
(2011)(391), 
France 
40 Hospital 
Community 
39 patients with PHPT 
underwent surgery 
89 controls 
Subtle cognitive impairments at baseline, presence of 
cardiovascular risk factors at baseline, and diagnosis of 
Parkinson's disease at baseline 
Annweiler 
(2012)(392), 
France 
498 Community 
(EPIDOS) 
Follow-up 7 years Age, AMI, baseline cognition, education, physical activity, 
sun exposure at mid-day, chronic diseases, hypertension, 
depression, psychoactive drugs 
RCT     
Rossom 
(2012)(393), 
USA 
4143 Women’s Health 
Initiative mean 7.8 
years 
Treatment 
n=2034;1,000mg calcium 
carbonate & 400 IU vitamin D3 
Control 
N=2109; Placebo 
NA 
Manders 
(2009)(394), 
Netherlands 
176 Institution, 24 weeks Treatment  
n=119; nutrient dense drink with 
520IU vitamin D daily 
Control 
n=57; placebo drink no vitamins 
or minerals daily 
NA 
Chandra 
(2001)(395), 
Canada 
96 Community, 12 
months 
Treatment  
n=48; 160IU vitamin D2 daily 
Control 
n=48; placebo tablets containing 
calcium and magnesium daily 
NA 
Before-after     
Annweiler 
(2012)(396), 
France 
44 outpatients, 16 
months 
Treatment  
n=20; 800IU/d or 100,000 
IU/month 
Control 
Age, gender, cognitive score and baseline and between-
visit time 
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Author (year), 
country 
Total N Setting  
(Study Name) 
Groups Adjustment 
n=24; unknown 
Przybelski 
(2008)(397), 
USA 
63 Institution, 4 weeks Treatment  
n=25; 50000IU oral D2 received 
3 times per week 
Control 
n=38; placebo or increase of 
vitamin D supplementation over 
what receiving at baseline 
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Appendix 4.3: Distribution of 25-Hydroxyvitamin D in the sample 
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Appendix 4.4: Distributions of cognitive outcomes used in this chapter, before standardisation 
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Appendix 4.5: Performance on cognitive tests according to participant characteristics 
  
 
 
Total* 
Verbal memory  Verbal fluency  Speed of processing 
 Immediate word recall 
(Range 0-10) 
Delayed word recall 
( Range 0-10) 
 Animal naming 
(Range 0-65) 
 Letter cancellation 
(Range 84-780) 
 Mean SD Mean SD  Mean SD  Mean SD 
Gender          
Male 3,218 6.4 1.5 5.2 1.8  22.5 .5  321.3 55.1 
Female 3,278 6.7 1.5 5.7 1.8  22.4 6.2  346.5 89.2 
Combined  6.6 1.5 5.5 1.8  22.5 6.3  334.0 88.1 
p  <0.001 <0.001  0.44  <0.001 
Region          
South 2,503 6.7 1.5 5.6 1.8  23.1 6.3  333.8 84.9 
Middle 1,674 6.6 1.5 5.5 1.8  22.1 6.6  336.8 94.7 
North 1,692 6.5 1.5 5.3 1.8  22.4 6.2  333.3 87.1 
Scotland 621 6.4 1.6 5.5 1.9  21.1 6.0  329.3 85.2 
Missing 6 6.8 1.2 5.5 1.7  26.8 4.9  339.8 78.6 
p 
§
  <0.001 <0.001  <0.001  0.3 
Socioeconomic position in adulthood†         
I or II 2,709 6.9 1.4 5.9 1.8  23.9 6.5  342.4 88.9 
IIINM 1,373 6.7 1.4 5.6 1.8  22.0 6.1  340.0 89.9 
IIIM 1,216 6.2 1.4 4.9 1.7  21.6 6.1  317.8 84.3 
IV and V 976 6.2 1.5 5.0 1.8  20.7 .8  324.9 84.6 
Other/unknown 222 6.2 1.6 4.9 2.0  21 6.  323.0 86.8 
p 
§
  <0.001 <0.001  0.001  <0.001 
BMI( kg/m2)‡          
<30 4,920 6.6 1.5 5.5 1.8  22.6 6.4  335.7 89.1 
≥30 1,546 6.5 1.4 5.4 1.8  21.9 6.2  328.9 84.7 
Missing 30 6.6 1.6 4.9 1.9  21.9 6.7  318.4 80.6 
p
§
  0.002 0.01  <0.001  0.0 
Menopause‡          
Pre-menopausal 2,099 6.6 1.4 5.7 1.8  22.5 6.2  345.5 88.5 
Peri-menopausal 601 6.8 1.4 5.9 1.7  22.7 6.2  344.9 84.4 
Post-menopausal 123 6.6 1.5 5.5 1.8  21.7 6.9  337.7 89.3 
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Total* 
Verbal memory  Verbal fluency  Speed of processing 
Other reasons 388 6.6 1.6 5.6 1.9  21.8 5.8  354.4 97.1 
Missing 66 6.2 1.9 5.4 2.0  20.7 5.4  359.4 101.5 
p  <0.001 <0.001  0.74  <0.001 
Physical activity (times/week) 
†
         
≤1 3,323 6.5 1.5 5.4 1.8  22.4 6.4  330.5 86.4 
2-3  1,373 6.7 1.4 5.6 1.8  23.0 6.4  336.3 88.9 
4-7  1,656 6.6 1.5 5.5 1.8  22.7 6.1  338.9 89.6 
Missing 144 6.3 1.6 5.2 1.8  22.5 5.9  336.7 98.8 
p §  <0.001 <0.001  <0.001  <0.00 
Smoking
†
          
Never/Former 4,911 6.7 1.5 5.6 1.8  22.8 6.3  335.5 87.7 
Current 1,433 6.3 1.5 5.2 1.8  21.4 6.2  328.9 88.3 
Missing 152 6.3 1.7 5.2 2.0  22.5 6.0  334.3 95.7 
p 
§
  <0.001 <0.001  <0.001  0.01 
Alcohol (units/week)l
‡
          
Non-drinker 5,154 6.2 1.5 4.9 1.8  21.5 6.4  336.4 93.0 
Light (<7) 1,319 6.6 1.5 5.5 1.8  22.1 6.3  332.9 86.2 
Moderate (7-14) 1,660 6.7 1.5 5.7 1.8  22.9 6.3  338.5 90.7 
Heavy (14-21)  735 6.7 1.4 5.5 1.8  23.3 6.3  334.9 88.0 
Very heavy (>21)  584 6.4 1.6 5.4 1.8  23.0 6.4  324.4 85.6 
Missing 23 6.3 1.8 4.9 2.2  21.7 6.0  336.5 121. 
p 
§
  <0.001 <0.001  <0.001  0.01 
Depressive symptoms
‡
          
<2 symptoms 5,990 6.6 1.5 5.5 1.8  22.5 6.3  334.2 87.7 
≥2 symptoms 481 6.4 (1.5 5.2 1.9  21.5 6.1  331.1 90.5 
Missing 25 6.6 1.3 5.6 2.0  23.6 4.6  342.7 130.1 
p
§
  <0.001 <0.001  <0.001  0.23 
* N varies according to test; 6,469 for immediate word recall and animal naming, 6,454 for delayed word recall, 6378 for letter cancellation. 
†
 Data obtained when participants were aged 42 years 
‡
 Data obtained when participants were aged 45 years 
§
p value from linear regression with standardised cognitive outcomes, adjusted for gender 
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Appendix 4.6: Association between early life factors and standardised cognitive tests at 50 years 
 Immediate word recall Delayed word recall Animal naming Letter cancellation 
 Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) 
Educational attainment* 0.21 (0.19, 0.23) 0.20 (0.18, 0.22) 0.22 (0.20, 0.24) 0.07 (0.05, 0.09) 
p 
‡
 <0.001   <0.001 <0.001 
Childhood cognition
†
 0.45 (0.43, 0.48) 0.43 (0.40, 0.46) 0.44 (0.41, 0.47) 0.12 (0.09, 0.15) 
p 
‡
 <0.001 <0.001 <0.001 <0.001 
*N varies according to test; 6,496 for immediate word recall and animal naming, 6,454 for delayed word recall, 6,378 for letter cancellation 
† 
N varies according to test; 6,428 for immediate word recall and animal naming, 6,386 for delayed word recall, 6,312 for letter cancellation  
‡
 p value from linear regression adjusted for gender 
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Appendix 4.7: Association between 25(OH)D at 45 years and standardised cognitive function 50 years: complete-case results 
 25- Hydroxyvitamin D, nmol/l   
 <25 25-49.9 50-74.9 75-99.9 ≥100 ptrend pcurvature 
  Coef 95% CI Coef 95% CI Coef 95% CI Coef 95% CI   
Immediate word recall *         
Model 1
†
 (n=6,496) 1.0 0.12 (0.02 to 0.21) 0.16 (0.06 to 0.26) 0.15 (0.04 to 0.26) -0.02 (-0.16 to 0.11) 0.76 <0.001 
Model 2
‡
 (n=6,303) 1.0 0.09 (0.00 to 0.19) 0.12 (0.02 to 0.21) 0.10 (-0.00 to 0.21) -0.05 (-0.12 to 0.09) 0.68 0.001 
Model 3
§
 (n=6,039) 1.0 0.08 (-0.01 to 0.18) 0.08 (-0.01 to 0.18) 0.06 (-0.05 to 0.17) -0.07 (-0.21 to 0.06) 0.19 0.004 
Delayed word recall  *         
Model 1† (n=6,454) 1.0 0.06 (-0.04 to 0.15) 0.09 (-0.01 to 0.19) 0.06 (-0.05 to 0.17) -0.08 (-0.21 to 0.05) 0.44 0.01 
Model 2
‡
 (n=6,264) 1.0 0.04 (-0.05 to 0.13) 0.06 (-0.03 to 0.16) 0.03 (-0.07 to 0.14) -0.07 (-0.20 to 0.06) 0.35 0.06 
Model 3
§
 (n=6,000) 1.0 0.05 (-0.05 to 0.14) 0.05 (-0.05 to 0.15) 0.02 (-0.09 to 0.13) -0.08 (-0.21 to 0.05) 0.16 0.08 
Animal naming *         
Model 1† (n=6,496) 1.0 0.14 (0.04 to 0.24) 0.17 (0.06 to 0.27) 0.14 (0.03 to 0.25) 0.16 (0.02 to 0.30) 0.10 0.06 
Model 2
‡
 (n=6,303) 1.0 0.11 (0.02 to 0.21) 0.11 (0.02 to 0.21) 0.08 (-0.03 to 0.19) 0.12 (-0.01 to 0.25) 0.46 0.31 
Model 3
§
 (n=6,039) 1.0 0.10 (0.00 to 0.20) 0.10 (-0.01 to 0.20) 0.05 (-0.06 to 0.17) 0.09 (-0.04 to 0.23) 0.90 0.37 
Letter cancellation (men) *         
Model 1
†
 (n=3,156) 1.0 -0.01 (-0.15 to 0.15) 0.07 (-0.09 to 0.22) 0.10 (-0.06 to 0.27) 0.07 (-0.13 to 0.26) 0.07 0.21 
Model 2
‡
 (n=3,060) 1.0 -0.02 (-0.17 to 0.13) 0.05 (-0.11 to 0.20) 0.08 (-0.09 to 0.25) 0.07 (-0.12 to 0.27) 0.06 0.26 
Model 3 (n=2,955) 1.0 -0.03 (-0.19 to 0.12) 0.03 (-0.13 to 0.19) 0.06 (-0.12 to 0.24) 0.08 (-0.13 to 0.28) 0.09 0.48 
Letter cancellation (women)  *         
Model 1
†
 (n=3,222) 1.0 -0.05 (-0.18 to 0.08) 0.04 (-0.10 to 0.17) -0.05 (-0.20 to 0.10) 0.01 (-0.19 to 0.20) 0.73 0.23 
Model 2
‡
 (n=3,127) 1.0 -0.06 (-0.19 to 0.08) 0.04 (-0.10 to 0.18) -0.06 (-0.21 to 0.10) -0.02 (-0.22 to 0.17) 0.86 0.17 
Model 3
§
 (n=2,974) 1.0 -0.06 (-0.20 to 0.08) -0.00 (-0.15 to 0.15) -0.13 (-0.30 to 0.03) -0.07 (-0.28 to 0.13) 0.33 0.36 
 Coef, Beta-coefficient from linear regression model 
*N for immediate word recall varied from 6,496 to 6,039 for final model.  N for delayed word recall varied from 6,454 to 6,000 for final model). N for animal varied 
from 6,496 to 6,039. N for letter cancellation (men) varied from 3,156 to 2,955 for final model. N for letter cancellation (women) varied from 3,222 to 2,974. 
†
adjusted for gender, season, day and time of cognitive testing, presence of others in the room, other contextual factors affecting performance (i.e. blind or poor 
eyesight, deaf or hard of hearing, too tired, illness or physical impairment that affects ability to perform, impaired concentration, very nervous or anxious, mental 
impairment, interruption or distraction, noisy environment, problems with the laptop or difficulty understanding English), word list & method of delivery (latter two 
for immediate & delayed word recall only); 
‡
additionally adjusted for region, SEP at 42 years, SEP at birth (7 years if missing), childhood cognition and educational attainment by 42 years; 
§
additionally adjusted for obese BMI, menopausal status; smoking, alcohol, physical activity; depressive symptoms at 45 years.  
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Appendix 4.8: Association between 25(OH)D at 45 years and standardised cognitive function 50 years:  weighed-case results 
 25- Hydroxyvitamin D, nmol/l   
 
<25 
25-49.9 50-74.9 75-99.9 ≥100 ptren
d 
pcurvatu
re 
  Coef 95% CI Coef 95% CI Coef 95% CI Coef 95% CI   
Immediate word recall *         
Model 1† (n=6,286) 1.0 0.12 (0.01 to 0.23) 0.17 (0.05 to 0.28) 0.16 (0.04 to 0.28) -0.02 (-0.17 to 0.12) 0.79 <0.001 
Model 2 (n=6,303)‡ 1.0 0.09 (-0.01 to 0.20) 0.11 (0.01 to 0.22) 0.10 (-0.01 to 0.22) -0.04 (-0.19 to 0.10) 0.71 0.01 
Model 3 (n=6,039)§ 1.0 0.08 (-0.03 to 0.19) 0.08 (-0.03 to 0.19) 0.06 (-0.06 to 0.18) -0.08 (-0.23 to 0.07) 0.20 0.01 
Delayed word recall  *         
Model 1† (n=6,244) 1.0 0.06 (-0.04 to 0.17) 0.09 (-0.02 to 0.19) 0.07 (-0.05 to 0.18) -0.09 (-0.23 to 0.05) 0.38 0.01 
Model 2 (n=6,157)‡ 1.0 0.04 (-0.06 to 0.14) 0.05 (-0.05 to 0.16) 0.03 (-0.08 to 0.15) -0.08 (-0.22 to 0.05) 0.30 0.05 
Model 3 (n=5,899)§ 1.0 0.05 (-0.06 to 0.15) 0.05 (-0.06 to 0.15) 0.02 (-0.10 to 0.14) -0.09 (-0.23 to 0.05) 0.13 0.07 
Animal naming *         
Model 1† (n=6,286) 1.0 0.14 (0.04 to 0.25) 0.17 (0.06 to 0.27) 0.14 (0.03 to 0.26) 0.14 (0.00 to 0.28) 0.14 0.08 
Model 2 (n=6,196)‡ 1.0 0.11 (0.01 to 0.21) 0.11 (0.01 to 0.21) 0.08 (-0.03 to 0.19) 0.11 (-0.02 to 0.25) 0.52 0.34 
Model 3 (n=5,938)§ 1.0 0.10 (-0.01 to 0.20) 0.09 (-0.01 to 0.20) 0.06 (-0.06 to 0.18) 0.09 (-0.01 to 0.15) 0.90 0.40 
Letter cancellation (men) *         
Model 1† (n=3,053) 1.0 0.01 (-0.15 to 0.17) 0.08 (-0.08 to 0.24) 0.13 (-0.05 to 0.30) 0.09 (-0.12 to 0.30) 0.04 0.28 
Model 2 (n=3,003)‡ 1.0 0.01 (-0.16 to 0.16) 0.07 (-0.09 to 0.23) 0.11 (-0.06 to 0.29) 0.11 (-0.10 to 0.32) 0.04 0.35 
Model 3 (n=2,901)§ 1.0 -0.01 (-0.18 to 0.16) 0.05 (-0.12 to 0.22) 0.10 (-0.09 to 0.28) 0.11 (-0.11 to 0.33) 0.05 0.55 
Letter cancellation (women)  *         
Model 1† (n=3,120) 1.0 -0.07 (-0.21 to 0.08) 0.03 (-0.12 to 0.17) -0.06 (-0.23 to 0.10) -0.04 (-0.23 to 0.15) 0.94 0.12 
Model 2 (n=3,080)‡ 1.0 -0.06 (-0.21 to 0.08) 0.03 (-0.12 to 0.18) -0.05 (-0.22 to 0.12) -0.05 (-0.24 to 0.15) 0.93 0.10 
Model 3 (n=2,929)§ 1.0 -0.07 (-0.22 to 0.08) -0.01 (-0.16 to 0.15) -0.14 (-0.31 to 0.03) -0.10 (-0.31 to 0.10) 0.26 0.26 
 Coef, Beta-coefficient from linear regression model 
*N for immediate word recall varied from 6,286 to 5,938 for final model.  N for delayed word recall varied from 6,244 to 5,899 for final model. N for animal naming 
varied from 6,286 to 5,938 for final model. N for letter cancellation (men) varied from 3,053 to 2,901 for final model. N for letter cancellation (women) cared from 
3,120 to 2,929 for final model.  
†adjusted for gender, season, day and time of cognitive testing, presence of others in the room, other contextual factors affecting performance (i.e. blind or poor 
eyesight, deaf or hard of hearing, too tired, illness or physical impairment that affects ability to perform, impaired concentration, very nervous or anxious, mental 
impairment, interruption or distraction, noisy environment, problems with the laptop or difficulty understanding English), word list & method of delivery (latter two 
for immediate & delayed word recall only); 
‡additionally adjusted for region, SEP at 42 years, SEP at birth (7 years if missing), childhood cognition and educational attainment by 42 years; 
§additionally adjusted for obese BMI, menopausal status; smoking, alcohol, physical activity; depressive symptoms at 45 years.  
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Appendix 5: Additional information for Chapter 7 
 
Appendix 5.1: SNP quality control 
Study SNP Alleles Measured Call Rate MAF HWE Imputed or genotyped? 
1958BC rs7412 C/T 99.98 0.08 0.64 Imputed  
  rs429358 T/C 99.86 0.16 0.19 Genotyped 
PIVUS rs7412 C/T 100.00 0.08   0.82 Genotyped 
  rs429358 T/C 99.47 0.16 1.00 Genotyped 
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Appendix 5.2: Distribution of 25(OH)D in each cohort 
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Appendix 5.3: Distribution of memory function in each cohort
353 
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Appendix 5.4: Association between APOE ε4 and naturally log-transformed 25(OH)D 
 25-Hydroxyvitamin D (nmol/l) 
  Model 1  Model 2  
 N(%) Coefficient (95% CI) Coefficient (95% CI) 
1958BC      
zero APOE  ε4 alleles 2,787 (68.2) Reference Reference Reference Reference 
one APOE  ε4 alleles 1,158 (28.4) -0.01 (-0.04 to 0.02) -0.01 (-0.04 to 0.02) 
two APOE  ε4 alleles 139 (3.4) 0.06 (-0.01 to 0.13) 0.06 (-0.01 to 0.13) 
 
 ptrend  = 0.56 ptrend  =0.55 
PIVUS      
zero APOE  ε4 alleles 549 (68.5) Reference Reference Reference Reference 
one APOE  ε4 alleles 229 (28.6) -0.03 (-0.09 to 0.03) -0.02 ( -0.09 to 0.04) 
two APOE  ε4 alleles 24 (3.0) -0.06 (-0.23 to 0.10) -0.06 (-0.22 to 0.11) 
 
 ptrend  =0.27 ptrend  =0.32 
Model 1 adjusted for age (in PIVUS), gender, month, region (for 1958BC):n=3,913 for 1958BC, n=629 for PIVUS; 
Model 2 adjusted for age (in PIVUS), gender, month, region (for 1958BC), standardised memory score: n=3,913 for 
1958BC, n=629 for PIVUS 
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Appendix 5.5: 3-way interaction between 25(OH)D, 25(OH)D2 and number of APOE ε4 alleles
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Appendix 5.6: Association between 25(OH)D and memory, stratified by number of APOE ε4 alleles 
   Standardised memory score 
   zero APOE ε4 alleles* one APOE ε4 alleles† two APOE ε4 alleles‡ 
25(OH)D, nmol/l  Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) 
1958BC        
 <25 328 (7.1) Reference Reference Reference Reference Reference Reference 
 25-49 1,570 (33.8)   0.09 (-0.08, 0.26) -0.14 (-0.39, 0.10) 0.41  (-0.48, 1.30) 
 50-74 1,732 (37.2) 0.13 (-0.04, 0.30) -0.03   (-0.28, 0.23) 0.70 (-0.22, 1.62) 
 ≥75 1,014 (21.9) 0.05 (-0.14, 0.24) -0.17 (-0.44, 0.11) 0.77 (-0.23, 1.77) 
   ptrend  =0.86 ptrend  =0.65 ptrend  =0.10 
   Pcurvature = 0.03 Pcurvature = 0.24 Pcurvature = 0.18   
PIVUS        
 <25 16 (2.2) Reference Reference Reference Reference Reference Reference 
 25-49 253 (34.4) 0.02 (-0.39, 0.44) 0.60 (-0.76, 1.95) -8.88 (-18.51, 0.75) 
 50-74 328 (44.6) -0.03 (-0.44, 0.38) 0.99 (-0.38,  2.35) -5.07 (-12.37, 2.24) 
 ≥75 139 (18.9) -0.04 (-0.47, 0.39) 1.13 (-0.26, 2.53) omitted omitted 
 Ptrend  ptrend  =0.47 ptrend  =0.02 ptrend  =0.04 
   Pcurvature = 0.20 Pcurvature = 0.58 Pcurvature = 0.09 
Coefficient from linear regression model; 
adjusted for age (PIVUS) gender, month of blood collection, region (in 1958BC), education and depressive symptoms (in 1958BC):  
* n= 2,328 for 1958BC, n= 430 for PIVUS. 
†
 n= 972 for 1958BC, n= 176 for PIVUS. 
‡
 n=126 for 1958BC, n=17 for PIVUS. 
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Appendix 5.7: Association between 25(OH)D and memory, stratified by recessive model of APOE ε4 alleles 
   Standardised memory score 
   zero or one APOE ε4 alleles* two APOE ε4 alleles† 
25(OH)D, nmol/l  Coefficient (95% CI) Coefficient (95% CI) 
1958BC      
 <25 328 (7.1) Reference Reference Reference Reference 
 25-49 1,570 (33.8) 0.03 (-0.11, 0.18) 0.41 (-0.48, 1.30) 
 50-74 1,732 (37.2) 0.09 (-0.05, 0.23) 0.70 (-0.22, 1.62) 
 ≥75 1,014 (21.9) -0.01 (-0.16, 0.15) 0.77 (-0.23, 1.77) 
   Ptrend  = 0.96 Ptrend  = 0.10    
   Pcurvature = 0.02 Pcurvature = 0.08 
PIVUS      
 <25 16 (2.2) Reference Reference Reference Reference 
 25-49 253 (34.4) 0.17 (-0.31, 0.66) -8.88 (-18.51, 0.75) 
 50-74 328 (44.6) 0.22 (-0.26, 0.71) -5.07 (-12.37, 2.24) 
 ≥75 139 (18.9) 0.29 (-0.21, 0.79) omitted  omitted 
   Ptrend  = 0.19 Ptrend  = 0.04 
   Pcurvature = 0.29 Pcurvature = 0.09 
Coefficient from linear regression model; 
adjusted for age (PIVUS) gender, month of blood collection, region (in 1958BC), education and depressive symptoms (in 1958BC): 
* n=3,300 for 1958BC, n=606 for PIVUS. 
†
 n=126 for 1958BC, n=17 for PIVUS. 
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Appendix 5.8: Sensitivity analyses: Association between 25(OH)D and standardised memory function score  
   Standardised memory function score 
   Model 1* Model 2† 
 25-hydroxyvitamin D, nmol/l N(%) Coefficient (95% CI) Coefficient (95% CI) 
1958BC      
 <25 267 (6.82) Reference Reference Reference Reference 
 25-49 1,359 (34.72) 0.04 (-0.10, 0.17) 0.04 (-0.10, 0.17) 
 50-74 1,443 (36.87) 0.10 (-0.04, 0.24) 0.10 (-0.04, 0.24) 
 ≥75 845 (21.59) 0.01 (-0.14, 0.17) 0.01 (-0.14, 0.17) 
   Ptrend = 0.85 Ptrend = 0.83 
   Pcurvature = 0.02 Pcurvature = 0.02 
PIVUS      
 <25 15 (2.38) Reference Reference Reference Reference 
 25-49 219 (34.82) 0.19 (-0.34, 0.73) 0.22 (-0.32,  0.75) 
 50-74 276 (43.88) 0.22 (-0.31, 0.75) 0.22 (-0.30,  0.75) 
 ≥75 119 (18.92) 0.30 (-0.25, 0.85) 0.32 (-0.25, 0.86) 
   Ptrend = 0.26 Ptrend = 0.29 
   Pcurvature = 0.37 Pcurvature = 0.32 
Beta-coefficient from linear regression model; 
* adjusted for age (PIVUS) gender, month of blood collection, region (in 1958BC), education and depressive symptoms (in 1958BC): n= 3,426 for 
1958BC, n=623for PIVUS. 
† 
adjusted for age (PIVUS), gender, month, region (in 1958BC), education and depressive symptoms (in 1958BC) and number of APOE ε4 alleles: 
n=3,426  for 1958BC, n=623 for PIVUS 
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Appendix 5.9: Sensitivity analyses: Association between APOE ε4 and naturally log-transformed 25(OH)D 
 25-Hydroxyvitamin D (nmol/l) 
  Model 1  Model 2  
 N(%) Coefficient (95% CI) Coefficient (95% CI) 
1958BC      
zero APOE  ε4 alleles 2,667 (68.14) Reference Reference Reference Reference 
one APOE  ε4 alleles 1,109 (28.33) -0.01 (-0.04, 0.02) -0.01   (-0.04,  0.02) 
two APOE  ε4 alleles 138 (3.53) 0.06 (-0.01,  0.13) 0.06  (-0.01,  0.13) 
 
 ptrend  = 0.56 ptrend  =0.55 
PIVUS      
zero APOE  ε4 alleles   433 (68.84) Reference Reference Reference Reference 
one APOE  ε4 alleles 178 (28.30) -0.03 (-0.09, 0.03) -0.02 (-0.09, 0.04) 
two APOE  ε4 alleles 18 (2.86) -0.06 (-0.23,  0.10) -0.06 (-0.22,  0.11) 
 
 ptrend  =0.27 ptrend  = 0.32 
Model 1 adjusted for age (in PIVUS), gender, month, region (for 1958BC):n= 3,913 for 1958BC, n= 629 for PIVUS; 
Model 2 adjusted for age (in PIVUS), gender, month, region (for 1958BC), standardised memory score: n= 3,913  for 
1958BC, n= 629 for PIVUS 
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Appendix 5.10: Sensitivity analyses: Association between APOE ε4 and memory score 
 Standardised memory scores 
  Model 1*  Model 2 
†
 
 N(%) Coefficient (95% CI) Coefficient (95% CI) 
1958BC      
zero APOE  ε4 alleles
‡
 2,667 (68.14) Reference Reference Reference  Reference 
one APOE  ε4 alleles 1,109 (28.33) -0.05 (-0.12, 0.02) -0.05 (-0.12, 0.02) 
two APOE  ε4 alleles 138 (3.53)  -0.05  ( -0.21, 0.12) -0.04  ( -0.21, 0.13) 
  ptrend  =  0.18 ptrend  =0.18 
PIVUS      
zero APOE  ε4 alleles
‡
   433 (68.84) Reference Reference Reference  Reference 
one APOE  ε4 alleles 178 (28.30) -0.25 (-0.42,  -0.08) -0.25 (-0.42,  -0.07) 
two APOE  ε4 alleles 18 (2.86) -0.45 (-0.92,   0.03) -0.45 (-0.92,   0.03) 
  ptrend  =0.001 ptrend  =0.001 
*adjusted for age (in PIVUS), gender, region (for 1958BC), education and depressive symptoms (in 1958BC):n= 3,426 for 
1958BC, n= 623 for PIVUS;
  
†
adjusted for age (in PIVUS), gender, region (for 1958BC), education, depressive symptoms (in 1958BC) and 25(OH)D 
concentrations: n= 3,426 for 1958BC, n= 623 for PIVUS 
‡
two ε3 alleles 
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Appendix 5.11: Sensitivity analyses: GxE interaction with restricted sample 
 
1958BC 
Three-way interaction between 25(OH)D, 25(OH)D2 and number of APOE ε4 
alleles was not significant (overall pinteraction=0.75).  However the curvature term 
(25(OH)D2) remained significant in this GxE model (p=0.02).  Therefore, a two-
way GxE model was examined, adjusting for the curvature term.  The two-way 
GxE, adjusting for the curvature term was significant (overall pinteraction=0.02). 
PIVUS 
There was no evidence of three-way interaction (overall pinteraction=0.87).  
Although the curvature term was not significant in this model (p=0.31), a two-
way GxE model, adjusting for the curvature term was applied to be comparable 
with GxE models of the 1958BC.  There was evidence of GxE interaction using 
the adjusted two-way interaction model (overall pinteraction=0.02). 
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Appendix 6: Additional information for Chapter 8 
Appendix 6.1: SNP quality checks 
Study SNP Gene Alleles Measured Call Rate MAF HWE p-value Imputed/Genotyped 
1958BC rs12785878 DHCR7 G/T 97.89 0.22 0.66 Genotyped 
 
rs12794714 CYP2R1 A/G 90.64 0.43 0.48 Genotyped 
ASPS rs12785878 DHCR7 G/T 100 0.29 0.11 Imputed from 1000G 
 
rs12794714 CYP2R1 A/G 100 0.44 0.72 Imputed from 1000G 
ELSA rs12785878 DHCR7 G/T 98.99 0.22 0.08 Genotyped 
 
rs12794714 CYP2R1 A/G 99.11 0.43 0.80 Genotyped 
ESTHER rs11603330 DHCR7 A/C 85.26 0.26 0.59 Genotyped 
 
rs12794714 CYP2R1 A/G 85.10 0.46 0.93 Genotyped 
HBCS rs7944926 DHCR7 A/G 89.95 0.27 0.38 Genotyped 
 
rs12794714 CYP2R1 G/A 90.01 0.39 0.64 Genotyped 
PIVUS rs12785878 DHCR7 C/A 97.62 0.35 0.29 Genotyped 
 
rs12794714 CYP2R1 G/A 89.21 0.40 0.78 Genotyped 
TROMSØ rs12785878 DHCR7 G/T 95.70 0.38 0.01 Genotyped 
 
rs12794714 CYP2R1 A/G 76.23 0.41 0.15 Genotyped 
ULSAM rs12785878 DHCR7 C/A 94.05 0.33 0.59 Genotyped 
 
rs7938266 CYP2R1 G/A 94.14 0.39 0.57 Genotyped 
WHII rs12785878 DHCR7 G/T 87.57 0.23 0.50 Genotyped 
 
rs12794714 CYP2R1 A/G 87.40 0.42 0.46 Genotyped 
G: Guanine; T: Thymine; A: Adenine; C: Cytosine; MAF: Minor allele frequency; HWE: Hardy-Weinberg equilibrium 
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Appendix 6.2: Distribution of 25(OH)D in each cohort 
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Appendix 6.3: Distribution of cognitive tests in each cohort 
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Appendix 6.4: Distribution of genetic variants in each cohort 
 DHCR7 per allele, %(N) CYP2R1 per allele, %(N) 
 0 1 2 0 1 2 
1958BC 60.7 (3,770) 34.6 (2,147) 4.8 (295) 32.2 (1,853) 49.5 (2,847) 18.3 (1,052) 
ASPS 48.56 (401) 44.0 (363) 7.5 (62) 31.1 (257) 50.0 (413) 18.9 (156) 
ELSA 60.8 (3,328) 33.8 (1,853) 5.4 (295) 32.4 (1,776) 48.9 (2,681) 18.7(1,026) 
ESTHER 55.0 (4,573) 38.5 (3,198) 6.5 (541) 29.0 (2,402) 49.8 (4,128) 21.3(1,766) 
HBCS 37.6 (613) 48.5 (790) 13.9 (226) 37.4 (609) 48.1 (783) 14.6 (238) 
PIVUS 43.3 (427) 43.8 (432) 12.9 (127) 36.4 (328) 47.5 (428) 16.1 (145) 
TROMSO 38.6 (4,555) 46.1 (5,439) 15.4 (1,812) 34.5 (3,246) 49.1 (4,616) 16.4 (1,542) 
ULSAM 44.8 (503) 43.7 (491) 11.5 (129) 36.2 (407) 48.7 (547) 15.1 (170) 
WHII 59.9 (2,700) 34.8 (1,569) 5.3 (241) 33.4 (1,504) 48.3 (2,175) 18.3 (822) 
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Appendix 6.5: Effect modification by gender on 25(OH)D and cognitive function 
 
375 
 
Appendix 6.6:  Effect modification by age-group (<65 versus ≥65 years) on 25(OH)D and cognitive function 
 
: 
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Appendix 6.7: Association between DHCR7 and 25(OH)D, stratified by 25(OH)D tertiles. 
 Beta reflects % change in 25(OH)D per vitamin D-increasing allele 
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Appendix 6.8: Association between CYP2R1 and naturally log-transformed 25(OH)D, stratified by 25(OH)D tertiles.  
Beta reflects % change in 25(OH)D per vitamin D-increasing allele 
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Appendix 6.9: Association between synthesis score and naturally log-transformed 25(OH)D, stratified by 25(OH)D tertiles.  
Beta reflects % change in 25(OH)D per vitamin D-increasing allele 
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Appendix 6.10: Association between genetic variants and cognitive function 
Cohort Outcome Exposure N Coefficient (se) p-value 
1958BC Global cognitive function DHCR7 5,304 -0.001 (0.02) 0.97 
  CYP2R1 4,900 0.01 (0.02) 0.67 
  Synthesis score 4,808 0.001 (0.02) 0.97 
 Memory cognitive function DHCR7 5,402 -0.0001 (0.02) 0.10 
  CYP2R1 4,995 0.03 (0.02) 0.12 
  Synthesis score 4,901 0.02 (0.02) 0.31 
ASPS Global cognitive function DHCR7 724 0.08 (0.05) 0.09 
  CYP2R1 724 0.04 (0.05) 0.40 
  Synthesis score 724 0.06 (0.04) 0.07 
 Memory cognitive function DHCR7 763 0.08 (0.05) 0.08 
  CYP2R1 763 0.03 (0.04) 0.57 
  Synthesis score 763 0.05 (0.03) 0.11 
ELSA Global cognitive function DHCR7 5,309 0.04 (0.02) 0.06 
  CYP2R1 5,315 -0.03 (0.02) 0.12 
  Synthesis score 5,270 0.002 (0.01) 0.87 
 Memory cognitive function DHCR7 5,421 0.03 (0.02) 0.23 
  CYP2R1 5,429 -0.04 (0.02) 0.05 
  Synthesis score 5,382 -0.01 (0.01) 0.50 
ESTHER Global cognitive function DHCR7 1,338 0.06 (0.04) 0.15 
  CYP2R1 1,339 0.03 (0.04) 0.46 
  Synthesis score 1,331 0.04 (0.03) 0.13 
 Memory cognitive function DHCR7 1,338 0.04 (0.04) 0.39 
  CYP2R1 1,339 0.02 (0.04) 0.58 
  Synthesis score 1,331 0.03 (0.03) 0.30 
HBCS Global cognitive function DHCR7 785 0.01 (0.05) 0.89 
  CYP2R1 786 -0.04 (0.05) 0.41 
  Synthesis score 785 -0.01 (0.04) 0.73 
 Memory cognitive function DHCR7 785 0.04 (0.05) 0.45 
  CYP2R1 786 -0.04 (0.05) 0.41 
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Cohort Outcome Exposure N Coefficient (se) p-value 
  Synthesis score 785 0.002 (0.04) 0.96 
PIVUS Global cognitive function DHCR7 743 -0.02 (0.05) 0.75 
  CYP2R1 684 -0.02 (0.06) 0.76 
  Synthesis score 676 -0.02 (0.04) 0.72 
 Memory cognitive function DHCR7 768 0.02 (0.05) 0.78 
  CYP2R1 705 -0.003 (0.06) 0.96 
  Synthesis score 697 0.01 (0.04) 0.73 
Tromsø Global cognitive function DHCR7 3,535 -0.0004 (0.02) 0.98 
  CYP2R1 2,275 -0.05 (0.02) 0.02 
  Synthesis score 2,253 -0.04 (0.02) 0.01 
 Memory cognitive function DHCR7 3,755 0.03 (0.02) 0.09 
  CYP2R1 2,407 -0.05 (0.03) 0.04 
  Synthesis score 2,385 -0.03 (0.02) 0.15 
ULSAM Global cognitive function DHCR7 833 0.04 (0.05) 0.48 
  CYP2R1 832 -0.09 (0.05) 0.07 
  Synthesis score 829 -0.03 (0.04) 0.44 
WHII Global cognitive function DHCR7 4,040 -0.01 (0.02) 0.64 
  CYP2R1 4,038 -0.002 (0.02) 0.91 
  Synthesis score 3,961 -0.01 (0.02) 0.58 
 Memory cognitive function DHCR7 4,062 -0.01 (0.03) 0.82 
  CYP2R1 4,060 -0.01 (0.02) 0.79 
  Synthesis score 3,983 -0.01 (0.02) 0.58 
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